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ABSTRACT  
Rapeseed pomace (RSP) is the waste/by-product obtained after edible oil 
production from Brassica napus and is currently used as animal feed. In an 
attempt to revalorize this by-product as a potential nutraceutical for the 
treatment or prevention of neurodegenerative disease, this project aimed to 
determine (i) a suitable extraction technique, (ii) the phytochemical composition 
and  in vitro activity of the extract, in relation to neuroprotective properties, (iii) 
the neuroprotective potential of the extract in a cellular model (SH-SY5Y 
neuroblastoma cells) and (iv) the extracts potential to prevent/treat 
neurodegenerative disease in one Machado-Joseph disease (MJD) and three 
Parkinson’s disease (PD) C. elegans (nematode) models.  
To achieve this aim at the start of the project, three extraction techniques i.e. 
Soxhlet, ultrasonic assisted and accelerated solvent extraction were employed 
using a solvent mixture of ethanol and water (95:5) on the RSP samples obtained 
from the north east of Scotland. Based on the chemical composition of the 
extracts and their antioxidant properties, Soxhlet extraction was revealed as the 
most promising and practical extraction technique. Bulk extraction was carried 
out, to obtain enough RSP extract that would last for the duration of the project. 
Thereafter, the composition of the extract was further investigated, to show 
sinapine to be the most abundant secondary metabolite, together with other 
phenolic acids, such as sinapic, ferulic, caffeic and syringic acid. The final extract 
showed in vitro antioxidant and acetylcholinesterase inhibition activity, the 
potential to protect plasmid DNA from oxidative damage, copper ion chelating 
potential and the inhibition of self-mediated β-amyloid (1–42) aggregation. The 
latter in vitro characteristics and properties could be beneficial for the protection 
of neurons from oxidative stress induced degeneration. 
In the SH-SY5Y neuroblastoma cell line, the RSP extract was found to be non-
toxic up to a concentration of 1.5 mg/mL. Subsequent cellular studies using 1 
mg/mL or less of the RSP extract, showed its ability to protect the cells from 
reactive oxygen species (ROS) and oxidative DNA strand breakage induced by 
hydrogen peroxide. In addition, using protein array technology, the RSP extract 
was able to down regulate cell stress associated proteins SIRT2 and SOD2. 
In the C. elegans nematode model, the RSP extract showed no toxicity up to 5 
mg/mL. The RSP extract was able to improve the disease phenotype in the MJD 
model (motility deficiency) as well as in all three PD models (dopaminergic 
neuronal loss). This improvement was at least partially dependent on the 
activation of the antioxidant gene glutathione-s-transferase (gst-4) in C. elegans. 
Overall, the RSP extract showed very positive in vitro characteristics and valuable 
in vivo effects in 4 disease C. elegans models, thus warranting further detailed 
studies on the use of RSP extract to help prevent and/or treat neurodegenerative 
diseases. 
 
Keywords: rapeseed pomace/cake/meal, canola, antioxidants, 
phenolics, neurodegeneration, C. elegans, SH-SY5Y, oxidative stress, 
acetylcholinesterase, β-amyloid, antioxidant pathways,  Machado-
Joseph disease, Parkinson’s disease, Alzheimer’s disease 
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extract 
Louis Watters (Artesis Plantijn Hogeschool, Antwerp, Belgium) 
- RGU project student, involved in the secondary HPLC-MS/MS analysis of e.g. 
sinapine under supervision of F. Pohl, K. Yates and P. Kong Thoo Lin, collaboration 
with F. Pohl on metal chelating assays and AChE inhibition activity of sinapine, 
conducted experiments comparing RSP extracts antioxidant activity to phenolic acid 
mixture and sinapine 
Sarah Wynants (Artesis Plantijn Hogeschool, Antwerp, Belgium) 
- RGU project student, set-up of 96-well plate antioxidant assays from cuvette assays 
using singe compounds (DPPH, FC, FRAP, ORAC and AChE inhibition Ellman) under 
supervision and in collaboration with F. Pohl and P. Kong Thoo Lin 
Lisa Leyser (Robert Gordon University, Aberdeen, Scotland & Hochschule Bonn 
Rhein Sieg, Rheinbach, Germany) 
- RGU project student, antioxidant analysis of single secondary metabolites  from 
RSP extract and their potential synergistic effect under supervision and in 
collaboration with F. Pohl and P. Kong Thoo Lin 
Maike Busch and Annika Mozer (Robert Gordon University, Aberdeen, Scotland & 
Hochschule Bonn Rhein Sieg, Rheinbach, Germany) 
- RGU project student, help with HPLC-MS/MS analysis set up at RGU used for 
following sinapine analysis, contribution to sinapine based paper under supervision 
and in collaboration with F. Pohl, K. Yates and P. Kong Thoo Lin 
Contributions from all collaborations are further highlighted in the result/discussion 
section of each chapter in the Figure/Table details. 
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This chapter will give a brief introduction to the general topics associated with this 
thesis, including waste products and their current use, rapeseed and rapeseed 
pomace production and research. Furthermore, the chapter will introduce topics on 
oxidative stress, direct/indirect antioxidants as well as neurodegenerative disease in 
general. Focus will be drawn to Alzheimer’s-, Parkinson’s- and Machado-Joseph 
disease, as these are of interest in subsequent chapters of this thesis. At the end, 
this chapter provides a summary of the overall aims of the project. 
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1.1 Natural products for medicinal use 
The plant kingdom has always offered a great variety of remedies1. The oldest 
so far found written evidence of plant exploitation for medical use was found 
in a Sumerian chunk of clay, dating back 5000 years2. Natural products (NPs) 
can be defined as substances produced and/or found in nature, more often 
referring to compounds with pharmacological effects3. These compounds 
have always played a significant role in the development of new drugs. This 
is still the case as shown in a recently published paper by Newman et al.4, 
covering “Natural products as Sources of New Drugs over the 30 Years from 
1981 to 2010”. Although synthetic drugs are still the main contributors for 
drug development, natural, biological or natural derived products are 
significantly contributing in numbers. Natural compounds can be obtained 
from plants, microbes, minerals as well as animals and are very often 
secondary metabolites (1.1.2 Secondary metabolites, p.5)5–7. Recent papers 
have reported on berry extracts8, nut extracts9 and extracts obtained from 
grape by-products in the wine making process10,11 indicating the great 
potential of NPs in drug development and  research. The active ingredients in 
these plant and plant by-products are phytochemicals (secondary 
metabolites) produced by the plants, non-essential for plant growth and 
developments but with important defensive activity. Plants and especially 
secondary metabolites have long served as an important resource for the 
development of small-molecule therapeutics, due to their mostly unique 
chemical characteristics and bioactivity. Historically a few of the best known 
natural products are aspirin (acetylsalicylic acid), from the parental 
compound salicin, which was first isolated from the bark of the willow tree 
(Salix alba), as well as morphine isolated from opium poppy (Papaver 
somniferum) and quinine isolated the bark of Cinchona spp.12. Interest has 
also increased in the extraction of biological active secondary metabolites 
from food sources, such as berries or fruits. However, this has certain 
disadvantages, as those foods are lost as food source for the ever growing 
world population. Also, the extraction from other plants is not ideal as they 
fulfil other ecological purposes in nature. However, food waste/by-products 
are ideal for the extraction of valuable phytochemicals.  
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1.1.1 Natural waste/by-products from food production 
The food processing industry is fast growing in most countries, due to the 
ever-increasing world population. Understanding population growth is very 
important when trying to achieve sustainable food production for the next 
generations. In 2017, the world reached a population of 7.6 billion. This 
number is expected to increase further to over 8 billion in 2030, and almost 
10  billion in 2050 (Figure 1.1), with Africa being expected to be the fastest-
growing continent in population numbers13.  
  
Figure 1.1| World population estimates from 1950-2015 
including medium-variant projection with 95 % confidence interval from 2015-2100, 
reproduced with copy right agreement from World Population Prospects: The 2017 
Revision13 
This means that within the next 82 years almost 1.5 times as many people 
will have to be sustained. Already in 2050 a 50% production increase will be 
necessary to feed the growing population14. The demand on producers as well 
as on food waste management will increase with this demand. The use of 
food waste and/or by-products for the extraction of phytochemicals could 
help to cope with the increased need for food while decreasing the amount of 
waste. Currently food waste and by-products are created but their potential 
is not exploited at all or not efficiently enough. Common by-products from 
the agricultural food industry are hulls, shells, husks, pods, stems, stalks, 
bran, seeds, washings, pulp refuse, stones, press cake/pomace15. All these 
are obtained after the production of nutritional valuable products, from 
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vegetables, oilseeds or fruit, and often considered to be waste products. Food 
waste is accumulated in all stages, in the food production industry, retail and 
on the side of the consumers. The extent and magnitude of the accumulated 
waste of some food products in the US is presented in Table 1.1.  
Table 1.1| Estimated food loss and wastage in the U.S. supply chain 
 
Note(s): Reprinted under the terms of the Creative Commons Attribution-
NonCommercial-No Derivatives License (CC BY NC ND) from Dou et al.16. 
acalculations from Dou et al.16 based on USDA ERS Loss Ajusted Food Availability 
(LAFA) databases;2012 data. bBuzby et al.17 based on USDA ERS LAFA 
databases;2010 data. c values in () represent percent of food entering each of the 
supply chain sectors that is lost and wasted in this sector. dfor some food groups, 
processing losses were 0 in the LAFA tables, see Food Availability tables for details 
(USDA-ERS, 2015a) 
The disposal of these waste products is presenting a continuously growing 
problem. Plant material for example is prone to microbial spoilage, which 
might limit further exploitation. Also, legal restrictions on disposing of by-
products present an issue. Hence, the interest in efficient, inexpensive and 
environmentally responsible utilization of these materials is raising in 
importance18,19. Some of the produced by-products such as brewers grains20, 
soybean meal and soy husks, wheat by-products such as middlings and bran, 
cotton seed meal and rapeseed pomace/meal are used as live stock or fish 
feed and so have some value21. One issue for the farmers producing the feed 
from those by-products is the constantly fluctuating sales value. A paper by 
Carré and Pouzet22, for example summarizes the meal prices for rapeseed 
meal from 1998 to 2013, showing prices below 100 €/t in 1998 up to over 
300 €/t in June 2013 with significant fluctuations in between. Similar changes 
in value were also seen for sunflower and soybean meals. This is due to the 
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fact that demand for feed varies and depends on agricultural yields2. To 
increase the commercial and ecological value of by-products, research has 
started to investigate the exploitation/utilization of these by-products for use 
apart from animal feed and to prevent them from going to waste treatment 
plants. This would add value to the by product, reducing strain on farmers 
selling the product and would give the product extra value. 
One potential option is the use of by-products for the extraction of fibres. The 
isolation of dietary fibre has risen in interest, due to its common availability 
in a significant number of food by-products, and because its use has shown 
success in the prevention and cure of a diverse range of common diseases, 
especially related to gut health23. Fibres have been extracted from a wide 
variety of food production left overs such as fruit pomace (e.g. apple); peel 
and pulp refuse (citrus fruits, potatoes and bananas); oil cakes (e.g. olive, 
rapeseed and cotton seed); as well as bran and other plant components15,23. 
A report by Sharma et al.15 provides an overview of the studies on fibres 
obtained from by-products. In addition, plant by-products have also been 
suggested as new sources of protein, e.g. cauliflower leaves and stems24, 
tomato seed meal25, flaxseed meal26, rapeseed stems27 and Kiwi fruit seeds28. 
One of the most researched areas in revalorisation of plant by-products 
however is the extraction of phytochemicals. Phytochemicals (from Greek 
phuton, “plant”) are biologically active compound found in different plant 
species. Most phytochemicals are secondary metabolites, which are not 
directly involved in plant growth, development, or reproduction. However, 
they are important for their defence against herbivores, pests and 
pathogens29. These secondary metabolites, including alkaloids, terpenes and 
phenolics, can be extracted from plant products but also from food production 
by-products.  
1.1.2 Secondary metabolites  
Plants produce a significant number of metabolites, which can be separated 
into two main groups, primary and secondary metabolites. Primary 
metabolites are the ones necessary for plant growth and development, 
without them the plant would not survive. In contrast, secondary metabolites 
are not involved in growth and development and their absence will not lead 
to instant plant death30. Initially secondary metabolites were considered plant 
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waste products, but in recent years they have been found to play a significant 
role in the plant’s survivability. A lack of secondary metabolites can for 
example cause a deficiency in the plants defence system (against herbivorous 
animals, viruses, microbes or competing plants). Whilst other organisms can 
flight or fight for defence, plants developed a different system i.e. the 
production of secondary metabolites29–31. They can fulfil a variety of different 
ecological roles apart from defence they also help them compete for water, 
light and nutrients.  In addition, they can also act as signalling compounds to 
attract pollinating and seed-dispersing animals, help to protect from external 
stress, such as UV light or physical harm or have selected physiological 
functions and hence provide advantage for survival32.  
Plants usually produce complex mixtures of secondary metabolites, often 
representing different classes. Because the structures of secondary 
metabolites have been shaped and optimized during more than 500 million 
years of evolution, many of them exert interesting biological and 
pharmacological properties which make them useful for medicine or as bio-
rational pesticides30. There are a number of factors that contribute to the 
secondary metabolite composition (qualitative and quantitative) of different 
plants, e.g. agronomic conditions (plant species, cultivar, developmental 
stage, plant part, plant competition, fertilization, pH), season, climatic 
factors, water availability, light (intensity, quality, duration) and carbon 
dioxide33. 
Plant secondary metabolites are a diverse group of compounds, which can be 
divided into three main groups, (i) terpenes, (ii) phenolics and (iii) 
alkaloids/nitrogen containing compounds. Different classes within these 
groups are often separated according to their biosynthetic pathways and 
certain classes are associated with certain set of species within a phylogenetic 
group and so can be used as taxonomic markers. In general plants will 
produce a mixture of different secondary metabolites from different classes, 
which can act additively or synergistically on different molecular targets29,30. 
The structure and shape of these compounds have been optimized throughout 
evolution and many of them show interesting biological and pharmacological 
characteristics, which can and have been employed in the pharmaceutical 
industries31. 
Chapter 1: Introduction 
Franziska Pohl           7 
The alkaloids represent a structurally diverse group of secondary metabolites 
containing nitrogen. They are one of the larger groups of secondary 
metabolites34. Most of these alkaloids are derivatives of amino acid 
precursors, such as ornithine, arginine, lysine, leucine, tyrosine, tryptophan 
or nicotinic or anthranilic acid. Depending on the precursor, these classes can 
be further separated into minor divisions35. The biosynthetic pathways of 
many alkaloids have already been elucidated on the enzyme and even at the 
gene level36. Well known alkaloids include morphine, nicotine and caffeine 
(Figure 1.2).  
 
Figure 1.2| Common alkaloids  
More than 20,000 different alkaloids have been discovered, with certain plant 
families being particularly rich in alkaloids, e.g. nightshades and amaryllis. 
Alkaloids represent an immense number of phytochemicals, with 
toxicological, pharmacological, nutritional and cosmetic interests. The 
alkaloids belong to a general group of nitrogen containing secondary 
metabolites, also non-protein amino acids, amines, cyanogenic glycosides, 
alkamides, lectins, peptides, polypeptides and glucosinolates all belong to this 
group. However, apart from the latter (3.1.1.2 Glucosinolates (GLSs) p. 136) 
no other nitrogen containing compounds were closely investigated in this 
project, hence they only get a brief mention here. Similar is true for the 
terpenes. The latter are hydrocarbons with a basic C5-unit (isopentenyl 
pyrophosphate or dimethylallyl pyrophosphate) as a building block and can 
be subdivided into hemiterpenes (C5H8), monoterpenes (C10H16), 
sesquiterpenes (C15H24), diterpenes (C20H32), triterpenes (C30H48), 
tetraterpenes (C40H64), and polyterpenes ((C5H8)n) such as rubber (Figure 
1.3, p. 8)37.  
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Figure 1.3| Subdivisions of terpenes 
Terpenoids are usually terpenes with additional functional groups. The latter 
are the largest group of secondary metabolites38. Most of the terpenes readily 
interact with cell components, such as biological membranes and proteins 
within them, changing their normal function, which can lead to cell death. 
This activity is mostly non-specific; which makes terpenes cytotoxic to a wide 
range of organisms. Due to structural similarity, some terpenes can also act 
as analogues to natural substrates such as hormones or neurotransmitters. 
Some of the most commonly known terpenes are eucalyptol, limonene and 
myrcene (Figure 1.4). 
 
 
Figure 1.4|Common terpenes 
All the above characteristics make them and the alkaloids/nitrogen containing 
compounds very interesting research material. However, these have not been 
widely reported in rapeseed by-products and were not part of this project. 
The third main group of secondary metabolites are the phenolics and in 
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contrast to terpenes and alkaloids, they are widely researched in rapeseed 
by-products and so are the focus of this work.  
1.1.3 Phenolic secondary metabolites 
Phenolics are secondary metabolites with at least one hydroxyl group 
attached to one or more aromatic rings. 
Currently, there are more than 8,000 known 
phenolic structures ranging from simple 
molecules to highly polymerized complex 
substances39,40. These phenolic compounds can again be further classified 
according to their chemical structure (Figure 1.6 p.10).   
The interest in phenolics has been increasing linearly over the last 20 years, 
as presented in Figure 1.5. This is mainly due to their interesting biological 
activities. 
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Figure 1.5| Number of publications on sciencedirect.com with the 
search word “phenolic” from 2000-2018 
The data for the year 2018 so far shows that the number of publications 
(29023) on phenolics has exceeded the number of publications in 2017 
(25047) by over 4000 papers. A total number of 5139 publications are already 
published for 2019 (as of December 2018).  
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Figure 1.6| Polyphenols sub-divisions and their basic chemical structure, adapted from Shahidi et al.41 and Firuzi 42 
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Amongst all the phenolics, flavonoids are the largest family with more than 
2000 individual natural compounds. Phenolics are produced in plants as 
secondary metabolites via the shikimic acid pathway40, an overview of which 
can be found in Maeda et al43. In general, plant genetics/cultivar, soil 
composition, growing conditions, maturity state, season of harvest and post-
harvest processes can effect quantity and quality of the phenolics present in 
plant foods and by-products44,45. Just like the phytochemicals in general, 
phenolics are particularly known for their biological activity and beneficial 
effects for human health and wellbeing. They have for example been 
associated with a number of valuable physiological properties, including anti-
inflammatory46, antimicrobial47,48, cardioprotective49,50 and anti-atherogenic51 
effects.  
In addition, the antioxidant properties of phenolics have been widely studied, 
in both, in vitro and in vivo systems producing very interesting data and 
making them potential candidates for the pharma-, food- and cosmetic-
industry52–54. Various studies have also shown that a diet rich in fruits and 
vegetables can contribute to the delay of aging and in particular reduce the 
risk of oxidative stress, associated with a number of chronic disorders (e.g., 
cardiovascular diseases, arteriosclerosis, cancer, diabetes and neurological 
diseases)55. On a molecular level, different mechanisms have been observed, 
for the action of secondary metabolites, which are responsible for their 
biological activity especially related to neuroprotection. For example green 
tea polyphenols such as (-)epigallocatechin-3-gallate (EGCG) have been 
found to exhibit antioxidant activity by chelating metal ions56. Tea extracts 
(green and black) have been shown to suppress lipid peroxidation and 
protected neuroblastoma cells (SH-SY5Y) from 6-hydroxydopamine induced 
neuronal death57 while EGCG also inhibits β-amyloid-induced cognitive 
function58. Lin et al.59 suggested that polyphenolic compounds from magnolia 
extracts (honokiol and magnolol) protect neurons (rat cerebellar granule 
cells) from hydrogen peroxide, glutamate and N-methyl-D-aspartic acid 
(NMDA) induced toxicity, suspecting neuroprotection to be related to their 
antioxidant properties. Similar results were also found for blueberry8,60–62, 
ginkgo bilboa63–65 and grape pomace10,66,67 extracts. These and other 
biological activities relevant for neuronal protection, have made phenolics 
very interesting compounds in the research for drugs to prevent or treat 
neurodegeneration associated diseases.  
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This project also connects food waste and the biological activity of phenolic 
compounds (both topics briefly discussed above) in a neurodegeneration 
associated study. To decrease the amount of food waste, or at least to 
improve the value of food waste, attention was focused on the rapeseed 
pomace (RSP). The latter is the leftover product after the production of 
rapeseed oil, with the aim of determining its chemical secondary metabolite 
composition as well as studying its biological activity related to 
neurodegenerative diseases. Food process by-and/or waste-products such as 
pomace are ideal for the search of new and interesting compounds. Pomace 
in general, is the waste product obtained after for example fruit juice, wine 
or oil production. It can comprise of only one or all of the following plant 
components: fruit skins, pulp or seeds, plant stems and leaves or any other 
solid or soft plant parts 1,11. A variety of different plant pomace such as grape 
10,11,68, apple 1,69, berry 70,71 and olive 72,73 had already been analysed and 
were found to contain significant amounts of phytochemicals. This project is 
based on determining the potential use of rapeseed pomace extracts and its 
functional ingredients in the treatment and/or prevention of 
neurodegenerative diseases. A brief introduction to both rapeseed/RSP and 
neurodegenerative disease will be provided following, to provide a 
background for the project (1.2 Rapeseed and Rapeseed pomace and 1.3 
Neurodegeneration). The section on rapeseed will give an overview of the 
plant as well as a literature review on the current knowledge of rapeseed 
pomace research, including its secondary metabolite composition. The section 
on neurodegenerative disease will entail a general introduction on the three 
neurodegenerative diseases investigated in this project i.e. Alzheimer’s 
disease, Parkinson’s disease and Machado-Joseph disease (Spinocerebellar 
Ataxia 3). 
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1.2 Rapeseed and Rapeseed pomace 
Rapeseed (Brassica napus) also known as oil rape, oilseed rape, swede rape, 
Argentine rape or colza belongs into the Brassicaceae family (formerly 
Cruciferae). Plants belonging to the Brassicaceae family are widely distributed 
in nature, with approximately 350 genera and 3500 species74, including 
amongst others a number of well known vegetables such as broccoli, 
cabbage, kale, turnip and horseradish. The bright-yellow flowering rapeseed 
cultivar (Figure 1.7 and Figure 1.8B) is believed to have originated through 
spontaneous hybridization between turnip rape (B. rapa L.) and cabbage (B. 
oleracea L.) genotypes75. The plant can grow between 50-200 cm in height76. 
 
Figure 1.7| Rapeseed field near St. Cyrus in Kincardineshire, Scotland 
(F. Pohl, May 2018)  
A species previously used as industrial lubricant is now one of the top three 
oilseeds worldwide, after palm and soybean oil production (Figure 1.8A)77,78.  
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World vegetable oil supply and distribution 2013/2014
34.81%  Palm
26.38%  Soybean
15.47%  Rapeseed
9.10%  Sunflowerseed
4.12%  Palm Kernel
3.28%  Peanut
3.03%  Cottonseed
1.98%  Coconut
1.82%  Olive
Total=170.57 million metric tons
 
Figure 1.8| A: World Vegetable Oil Production in 2012/2013 (adapted 
from USDA78) B: Rapeseed plant (F. Pohl, May 2018) 
Canola, a registered trade mark in Canada, is a different name for rapeseed 
mainly used in the USA and Canada. It describes the same plant, with some 
genetic modifications, obtained through traditional breeding in Canada 
starting in the 1970’s77. This species was created to decrease anti-nutritional 
components of rapeseed, namely glucosinolates and erucic acid. Both provide 
an unfavourable bitter taste. In Europe rapeseed oil in this form was 
introduced in 1977 as low-erucic acid rapeseed (LEAR) oil containing <5% 
erucic acid and low amounts of glucosinolates77. Today, the same breed used 
in the European Union, is still referred to as rapeseed.  In general, the oil 
which can be obtained from rapeseed seeds, contains little (<10%) saturated 
fatty acid and high concentrations of monounsaturated fatty acids (45-
75%)79. Furthermore it is high in α-linolenic acid (C18:3), giving it a low ratio 
(1.7-2.480) of omega − 6/omega − 3 fatty acids (essential fatty acids)  
making it better for human consumption than many other plant oils in this 
respective80–83. Increased intake of omega-6 polyunsaturated fatty acids 
(PUFA) and hence an increase in omega-6/omega-3 ratio, are associated with 
the increased risk of many disease including cardiovascular disease, cancer, 
inflammatory- and autoimmune diseases84. In contrast, increased levels of 
omega-3 PUFA (a low omega-6/omega-3 ratio) has shown to suppress these 
effects84. 
Rapeseed can be cultivated as winter (Europe), semi-winter (Asia) and 
spring-sown (Canada, China, Australia and northern European countries) 
crop75. The production of rapeseed crop and oil has seen a huge increase over 
the last 50 years across the world (bottom, Figure 1.9 p.16). But not only the 
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overall world production has increased, also the UKs rapeseed crop 
production has increased almost 180 times in over 30 years, from nearly 
nothing in 1972 (14000 t) to 2.46 million tonnes in 2014 (top, Figure 1.9 
p.16). With these values, the UK was 8th top producer in 2014 after Canada, 
China (mainland), India, Germany, France, Australia and Poland. The harvest 
of these almost 2.5 million tonnes of rapeseed crop lead to a production of 
about 831200 tonnes of rapeseed oil, giving a yield of about 34%. The total 
oil content of rapeseed is most times given as being around 40% which can 
also be seen in Figure 1.9 from the world production80,83,85,86. Differences 
between the general oil content and the percentage of oil produced in a single 
country (e.g. United Kingdom) can be explained by the potential processing 
of grown crops in other countries or the processing process itself (i.e. cold 
pressing and/or solvent extraction).
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Figure 1.9| United Kingdom/World production of Rapeseed, indicating harvest area and the amount of produced 
rapeseed and rapessed oil, adapted from FAOstat85,86 
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However, increasing production of rapeseed oil also accumulates a higher 
amount of solid rapeseed waste/by-product called rapeseed pomace (RSP) or 
rapeseed cake/meal. Depending on the process of oil production, cold pressed 
or heat/solvent aided, the RSP can still contain more or less amounts of oil 
respectively.  
Currently this by-product is used as an addition to livestock feed due to its 
high protein content83 and is sold for a considerable but fluctuating price22. 
However, there might be potential to improve the value of this material. As 
previously described, plants contain different phytochemicals, some of which 
have been found beneficial for human health. However, only small amounts 
of these are found in the rapeseed oil itself, most of them are left in the by-
products, after oil production. Options to improve the oils properties have 
been suggested: (i) developing rapeseed varieties, that apart from the low 
erucic acid and glucosinolates, have higher amounts of bioactive components, 
(ii) modification of rapeseed pre-treatment before the oil production process, 
(iii) the use of enzymes in the production process, and (iv) the potential 
supplementation of the rapeseed oil with phytochemical rich extracts80,87–90. 
The latter was taken into consideration by  Thiyam et al. 91, which in 2004 
reported the potential use of RSP extracts in preventing lipid oxidation in 
rapeseed oil, due to significant amount of phenolic compounds present in the 
extracts. Suggestions were not only made to use RSP extracts to stabilize 
oils, but also other food products. This utilization of rapeseed oil by-product 
would have a large contribution to the plant meal industry91. A review by 
Szydłowska-Czerniak75 on bioactive compounds from rapeseed and its 
products described the presence of many biologically active compounds such 
as tocols, phytosterols, phospholipids and phenolic compounds and their 
distribution in rapeseed, rapeseed oil or the pomace. Some of the compounds 
present have antioxidant properties, suggesting their potential use in the 
food, pharmaceutical or cosmetic industry75. 
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1.2.1 Phytochemicals in rapeseed/RSP 
The number of papers covering the composition of rapeseed oil and its 
importance for the food industry are significant. However, research related to 
the rapeseed oil production by-product rapeseed pomace/meal/cake, and its 
potential application in the food and pharma industry is less attainable. The 
total phenolic content of rapeseed is known to be higher than in any other 
oilseed flours/cakes as shown in Table 1.2.  
Table 1.2| Total amount of phenolics in oilseed flours 
MEAL Total Phenolics 
(mg/100g, dry weight) 
SOYBEAN FLOURA 23.4 
COTTON FLOURA 56.7 
PEANUT FLOURA 63.6 
RAPESEED/CANOLA FLOURA 639.9 
CANOLA MEALB 1540-1840 
SOYBEAN MEALB 460 
CANOLA SEED CAKE (DEFATTED)C ~2200 
HEMP SEED CKAE (DEFATTED)C ~900 
FLAX SEED CAKE (DEFATTED)C ~800 
Note(s): data adapted from A92, B93 and C94(in mg gallic acid equivalence/100 g, 
extraction techniques: Anot provided, Btwo phase solvent extraction (10% 
ammonia/methanol and methanol/5% water), Cultra sound assisted extraction 
Extracts of rapeseed mainly contain phenolic acid, flavonoid and condensed 
tannins derivatives95. Rapeseed and RSP have been found to contain high 
amounts of sinapic acid (SA) and SA derivatives (Figure 1.10) together 
between 6390 and 18370 μg/g RSP cake, depending on variety, growing 
conditions and pressing method. SA belongs to the group of naturally 
occurring hydroxycinnamic acids and makes up over 73% of the free phenolic 
acids in rapeseed cakes96. 
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Figure 1.10| Chemical structure of sinapic acid (SA) and SA 
derivatives common in rapeseed 
Sinapine (Figure 1.10), a choline ester of sinapic acid, is the most abundant 
phenolic ester in rapeseed extracts92. According to Thiyam et al.97 sinapine 
constitutes between 55-70% of rapeseed extract while sinapic acid 
constitutes between 6-14%. They also found significant amounts of sinapoyl 
glucose (14–27%, Figure 1.10) in the rapeseed extracts. All three of which 
showed antioxidant activity in the following order sinapic acid > sinapoyl 
glucose > sinapine97. A detailed overview of sinapic acid, its derivatives 
(including sinapine) their natural sources and biological activity is available 
from Nićiforović and Abramovič96. 
Furthermore, other phenolics such as caffeic, chlorogenic, ferulic, gallic, 
cinnamic, p-coumaric, p-hydroxybenzoic, protocatechuic and syringic acids  
have been found in some rapeseed varieties80,93. These  together with other 
phenolics, such as benzoic and cinnamic acid derivatives are present as free, 
insoluble bound form and as soluble esters (glycosides)95. Phenolics such as 
those named above are known for their radical scavenging activity, quenching 
of ROS, chelation of transition metals and their inhibition of oxidative 
enzymes98. Phenolics in rapeseed are thought to protect from ultraviolet-B 
(UV-B) stress99. 
Another group of compounds often found in rapeseed and RSP, are the 
glucosinolates, one of the nitrogen containing secondary metabolites. 
Identified glucosinolates in rapeseed include progoitrin,  epiprogoitrin, 
glucoraphanin, gluconapin and others99–101. Further details about 
glucosinolates can be found under 3.1.1.2 Glucosinolates (GLSs) (p. 136). 
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In addition, tocols have been identified in rapeseed. They can be classified 
into two groups, the  tocopherols and tocotrienols, with four isomers (α, β, , 
) in each group (Figure 1.11)75. The principal tocols in rapeseed are α and  
tocopherol but also plastochromanol-8 and tocotrienols can be found102–104. 
The latter are among some of the major antioxidants in food105. However, as 
they are lipid soluble compounds, most of the time either rapeseed seeds or 
rapeseed oil is analysed for their presence, not rapeseed pomace. An 
extensive list of references regarding the tocol content of rapeseed and 
rapeseed oil can be found in Szydłowska-Czerniak75. 
 
Figure 1.11|Different Tocols 
Also phytosterols (steroid alcohols), including plant sterols and stanols have 
been reported in rapeseed. Stanols are saturated (no double bond in the 
sterol ring structure) sterols.  Just like many other secondary metabolites, 
phytosterols can be free or bound to other compounds such as esters and 
glucosides. Phytosterols found in rapeseed include sitosterol, campesterol, 
brassicasterol, 5-avenasterol, stigmasterol and cholesterol (Figure 
1.12)75,106.  
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Figure 1.12|Phytosterols in rapeseed, adapted from75,106,107 
In contrast to phytosterols and tocopherols, which are mostly found in the 
oil, phenolics are often retained in the meal after pressing of the rapeseed 
seeds108. This had prompted researchers to investigate the leftover product 
rapeseed pomace/meal for the presence of phenolics. Research has shown 
that the previously mentioned phenolic compounds e.g. sinapic acid, 
sinapine, and ferulic acid are retained in the pomace/meal after oil extraction 
(cold press or solvent extraction). Hence, these can be extracted from the 
de-oiled pomace using different solvent systems, e.g. alcoholic solvents such 
as ethanol or methanol or water (2.1.1.2 Extraction solvents, p.69) in 
conjunction with different extraction methods (2.1.1.3 Extraction technique, 
p.70), e.g. Soxhlet, microwave, or ultrasonic assisted extraction91,109,110. In 
vitro studies of a number of different RSP extracts by e.g. Hassas-Roudsari 
et al.111, Wanasundara and Shahini87 and Szydłowska-Czerniak et al.90, have 
previously reported their antioxidant activity. An overview of the rapeseed 
metabolome was recently also provided by Misra112, which included a table 
that summarized all the so far detected secondary metabolites and their 
corresponding references, including compound class, their MS m/z ratio as 
well as MS/MS breakdown products. 
Although a lot of work has been done on the chemical composition of 
rapeseed and RSP, most of the work was done on seed/plants grown in 
Canada113, Korea110, Poland80,109, China114 Germany80,91,113 or France80, little 
literature is however available on rapeseed grown in Scotland/UK115. The 
rapeseed pomace obtained for this project was kindly provided by Gregor 
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Mackintosh, the owner of Mackintosh of Glendaveny. This family owned farm 
is located in Glendaveny, in Aberdeenshire, near the town of Peterhead 
(Figure 1.13). Mackintosh of Glendaveny was established in 2009 and since 
then produces cold pressed rapeseed oil. The rapeseed pomace is currently 
sold to surrounding farmers as animal feed. 
 
Figure 1.13| Location of rapeseed harvest/oil production by 
Mackintosh of Glendaveny 
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1.3 Neurodegeneration 
With the continual growth and improvement of medical services as well as 
the constant access to food and cleaner water, especially in the developed 
countries of the world, the average human longevity has been increasing 
continuously over the last decades116. In the United States for example, the 
average human life span has seen a rise of around 6 years over the last 
century, increasing the average expected age for men to 74 and for women 
to almost 80 years117. This increase in life expectancy is a consequence of the 
positive impact of medical research and development as well as easier access 
to basic human needs i.e. clean water, food and shelter. Although the 
increase in life expectancy is a great achievement for mankind, it presents 
itself as double-edged sword, because it also leads to an increase of age 
related diseases.79,117,118 
Age related diseases refer to those ailments that are closely associated with 
ageing and are known to increase in prevalence with rising age. In addition, 
factors such as advanced medical diagnostic tools and enhanced awareness 
of neurodegenerative disease markers have added to the raising numbers119. 
The problem is further exacerbated by the lack of treatment options for some 
of these medical conditions. Treatment is either unavailable, only partially 
effective or only treats the symptoms of the disease but does not impact on 
the actual origin of the diseases. Conspicuous is the fact, that there are a lot 
of neurodegenerative disease in that list of age related conditions, such as 
Alzheimer’s disease (AD), Huntington’s disease (HD) and Parkinson’s disease 
(PD).  
Neurodegenerative diseases are the consequence of the gradual and 
progressive degradation and loss of neurons, which inevitably leads to 
nervous system dysfunction120. The increasing rise in such debilitating chronic 
neurodegenerative disease is closely associated with the ageing population. 
This inevitably also intensifies the obligations of scientists and medical 
researchers to (i) acquire sophisticated knowledge of these 
neurodegenerative diseases and (ii) implement the necessary research to 
develop and find new therapeutics121. Increased research in this area and 
possible treatment will improve the elderly’s quality of life, by preventing, 
curing or at least delaying the onset of such disease. On the other hand, costs 
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related to the health system and the burden on carers will also be reduced, 
proving a great benefit to mankind. The treatment of neurodegenerative 
diseases is thought to cost the United States billions of dollars every year, 
the frontrunner being AD, with estimated costs of $100 billion alone120. 
Many neurodegenerative diseases share a common pathogenic mechanistic 
element, the aggregation and deposition of misfolded proteins in the central 
nervous system, although these proteins are expressed systemically in most 
cells122. AD, HD, PD, Creutzfeldt-Jakob disease, multiple system atrophy as 
well as many of the spinocerebellar ataxias (SCAs) are only some of the 
common and well known neurodegenerative diseases showing such protein 
misfolding. Although the type of protein aggregation, their location and the 
temporal and regional pattern of deposition pattern varies in all these 
diseases (Table 1.3), they are however thought to be linked by comparable 
protein aggregation pathways122. Furthermore, the patients’ innate response 
together with environmental factors can influence the aggregations123. 
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Table 1.3| Neurodegenerative disease with their respective 
microscopic lesions, location and aggregated proteins  
Disease Onset 
Microscopic 
lesion 
Location 
Aggregated 
Protein 
Alzheimer’s 
Disease (AD) 
Usually 6th 
decade or 
older 
Amyloid 
plaque 
Extracellular/ 
Intracellular 
Amyloid-β (Aβ) 
Neurofibrillary 
tangle 
Intracytoplasmic 
(neurons) 
Tau 
Lewy bodies 
Intracytoplasmic 
(neurons) 
α-synuclein 
Amyotrophic 
lateral 
sclerosis (ALS) 
About 60 
years of 
age 
Hyaline 
inclusions 
Intracytoplasmic 
(neurons) 
Superoxide 
dismutase-1 
(SOD1) 
Huntington 
disease (HD) 
Dependent 
on poly-Q 
repeats, 
usually 
30-50 
Neuronal 
inclusions 
Intranuclear 
(neurons) 
Huntingtin 
(containing 
polyglutamine 
repeats) 
Multiple system 
atrophy 
6th decade 
of life 
Glial 
cytoplasmic 
inclusions 
Intracytoplasmic 
(oligodendroglia) 
α-synuclein 
Parkinson’s 
disease (PD) 
Over the 
age of 50 
Lewy bodies 
Intracytoplasmic 
(neurons) 
α-synuclein 
Pick’s disease 
Typically, 
before the 
age of 60 
Prion plaques Extracellular 
Protease-
resistant prion 
protein 
Spinocerebellar 
ataxia (SCA) 
Dependent 
on poly-Q 
repeats, 
usually 
30-50 
Neuronal 
inclusions 
Intranuclear 
(neurons, 
plasma) 
Ataxin 
(containing 
polyQ repeat 
expansion) 
Note(s): adapted from116,122,124–128, as previously published in79 
Not only the type of aggregates and their position of occurrence, but also the 
disease symptoms can differ significantly amongst these diseases. Possible 
symptoms are dementia (AD), movement deficits (SCA’s and HD) and 
personality changes (HD, AD)120,129. Despite all their differences, all the 
aforementioned neuronal conditions can nevertheless be associated with the 
aggregation of proteins and a mostly adult onset of the disease. This has led 
to the idea that it might be possible to treat all these diseases by the same 
therapeutic approach/target130. Research, however, is still in its early stages 
and the reason behind the neurotoxicity in these diseases has not been fully 
elucidated. Much more effort and work are necessary to evaluate their 
mechanisms and the possibilities of treatment. On that account, in this 
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project RSP extract was employed to study its neuroprotective properties in 
vitro and in vivo.  
The work undertaken here was based on neurodegeneration and oxidative 
stress and in particular on three neurodegenerative diseases, Alzheimer’s-, 
Machado-Joseph- and Parkinson’s disease. For this reason, the following 
three neurodegenerative diseases will be introduced in more detail, followed 
by a section on the significance of oxidative stress in neurodegeneration (1.4 
Oxidative stress in neurodegeneration and the potential use of antioxidants 
to prevent neurological disorders p.51 ff.). 
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1.3.1 Alzheimer’s Disease (AD) 
Alzheimer’s disease (AD) is, a progressive neurodegenerative disease with a 
late onset in life. With 60-80% of cases, it is the most common form of 
dementia in the elderly131. Furthermore, statistics from 2016 show that it is 
the 5th leading cause of death, whilst in 2000 it was only the 14th 132. These 
numbers indicate the major increase of prevalence of AD, which is related to 
the general increase in life expectancy and better diagnosis. The risk of 
developing AD is increasing by a factor of two per 5 years, starting from the 
age of 65120. Alone the number of people with dementia in the UK, is over 
900,000. This is set to rise to just over 2 million by 2051. Of these 
approximately 62% are AD related133. The costs associated with the care of 
AD patients are tremendous, in 2014 the costs in the UK alone were estimated 
to about £26.3 billion, with an average yearly cost of £32,250 per patient133. 
This figure will have increased over the last 4 years and will probably double 
till 2051 with the doubling of patient numbers. Just like for most 
neurodegenerative disease, the main risk factor for AD is age134. 
1.3.1.1 Symptoms 
There are major problems giving a clinical definition for AD and it is hard to 
implement a uniform diagnosis, because of the many different symptoms and 
their severities. Usually AD can be diagnosed in patients with some or all the 
following symptoms at the beginning of onset: (i) slight memory loss, (ii) 
disorientation, (iii) restlessness, (iv) incoherent conversations and (v) 
occasional confusion. This is soon followed by severe mental impairment, 
which can even lead to personality changes of the patient120,128. Also the 
decrease in cognitive function and an impairment of daily living activities are 
common135. For example, even simple tasks can become confusing and more 
of a challenge with ongoing disease progression. In the later stages of the 
disease this might even become impossible. In the last years of the disease, 
symptoms will worsen and might even be followed with the patient being 
incontinent, bedridden and often mute and unresponsive136. In addition, AD 
patients have language difficulties that show early in the disease, usually with 
reduced verbal fluency and naming abilities137. 
Pathologically, AD is associated with a progressive degeneration of nerve cells 
(mainly cholinergic neurons) in the brain regions (especially hippocampus), 
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which are critically for memory, cognitive performance and personality, 
leading to the above mentioned recognizable symptoms in the patient119,136. 
All these symptoms are a reduction of life quality, for the patients as well as 
all the surrounding people associated with the patients. This in addition to the 
associated costs for the health care system, highlight the importance of a 
cure for AD. 
1.3.1.2 Mechanisms/pathophysiology associated with AD 
AD was first described by Alois Alzheimer in 1907, who identified salient 
clinical and pathological aspects of the disease. It was not till later however, 
that AD was discovered as being the most common cause for dementia in 
elderly people by Blessed et al.135,138.  
In general, Alzheimer’s disease can be characterized by the hallmark of 
abnormal aggregations of harmful proteins. The most common aggregated 
proteins include β-amyloid (Aβ) peptide and tau, leading to plaques and 
neurofibrillary tangles (NFTs) respectively, visualized in Figure 1.14139. 
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Figure 1.14| Neuropathology of Alzheimer’s disease 
(a) Microphotograph of amyloid plaques in the AD brain, visualized by immunostaining 
with anti-Aβ42 specific antibody; scale bar: 125 mm. (b) Microphotograph of 
neurofibrillary tangles, visualized by immunostaining with an anti-PHF1 specific 
antibody; scale bar: 62.5 mm. Reprinted with copyright permission from LaFerla and 
Oddo139 
The affected proteins have unrelated functions, but their aggregation is 
further downstream associated with oxidative stress and inflammatory 
damage that lead to energy failure and synaptic dysfunction and neuronal 
loss134. Both proteins will be further discussed following. 
  
The Potential Application of Rapeseed Pomace Extracts in the Prevention and 
Treatment of Neurodegenerative Diseases 
30  Franziska Pohl 
A Tau 
AD belongs into a group of tauopathies, with other disease such as Pick’s 
disease, frontotemporal dementia with parkinsonism and progressive supra 
nuclear palsy, due to the presence of aggregates formed by tau in patients’ 
brains. In AD patients, tau levels (total and phosphorylated tau) are increased 
in the brain as well as the cerebrospinal fluid (CSF). The mechanisms behind 
the increase in aggregated tau are still under investigation140. The tau protein 
normally binds to microtubules and is responsible for their stabilization and 
assembly as well as for vesicle transport. Tau is controlled by the level of 
phosphorylation122,134. When this stabilization process is no longer given, for 
example due to hyperphosphorylation of the protein (insoluble  and lacks 
affinity for microtubules), the formation of NFTs is possible, after its self-
association into paired helical filament structures134. Hyperphosphorylation is 
not the only explanation for the accumulation of NFTs and there are other 
factors that also modify the interaction of tau with microtubules or even with 
the cytoskeleton, leading to toxicity120. A paper published by Arriagada et 
al.141, suggests that the formation of NFTs by hyperphosphorylated forms of 
tau has a higher correlation with the progression and severity of AD, than the 
amyloid plaques (described below) and are also thought to be the main 
mechanism of neuronal death135. However, opinions on that are still divided. 
Tangles are preferentially situated in specific brain regions, for example areas 
of the hippocampus (correlating with some clinical features, such as memory 
loss) as well as nerve cells of the basal forebrain, leading to cholinergic 
neurotransmitter deficits135. The exact mechanisms of why these aggregates 
or previous intermediate stages lead to the outbreak of the disease are still 
under investigation. 
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B β-amyloid 
In addition to the tau tangles β-amyloid plaques can also be found in the 
brains of AD patients. Amyloid plaques are compact and spherical 
extracellular deposits mainly consisting of the amyloid β-peptide 
(Aβ)139.These usually start to assemble in the 5th decade of life and at the 8th 
decade about 75% of the population is thought to be affected. In general, the 
density of senile plaques is not assumed to increase slowly with age but 
thought to go from a plaque free status to a plaque-bearing status in a very 
short time. The mechanism and the reason for this behavior however, are not 
established so far135. They start developing as diffuse plaques first (mostly 
non-toxic β-amyloid), in some individuals thus they undergo changes and 
soon form senile neuritic plaques. The main constituent of these plaques is 
β-amyloid (Aβ) but they can also contain other proteins, metal ions and 
cholinesterase’s (Figure 1.15 p.32)142. Aβ is a heterogeneous group of small 
peptides containing between 38 or 43 amino acids (AAs) and is cleaved from 
the amyloid precursor protein (APP, Figure 1.15)140. This protein can be 
fragmented by different secretases, during proteolytic processing136, which 
will cleave at different locations of the protein (Figure 1.15). The left hand 
site of Figure 1.15 presents the “normal”, non-neurotoxic cleavage of the 
protein via α- and γ- secretase. β-amyloid (Aβ40 or Aβ42) thus is produced by 
cutting with γ-and β-secretase. In non-AD patients, the shorter, less 
aggregatory Aβ40 peptide is most prevalent. However, in sporadic and most 
cases of familial AD either the ratio of Aβ42 to Aβ40 is raised or the total 
concentration of Aβ42 is increased.   
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Figure 1.15| Fragmentation of amyloid precursor protein (APP) into 
toxic and non-toxic fragments 
Non-neurotoxic fragmentation on the left (a), neurotoxic cleavage on the right (b), 
schematic altered from135,142,143  
 
Chapter 1: Introduction 
Franziska Pohl         33 
Plaques form by aggregation of a number of Aβ monomers. Although plaques 
are closely associated with AD, more recent research has focused on the 
oligomers, as they seem more likely to be causing the neurotoxicity instead 
of the plaques. This was indicated by a few patients with visible plaques in 
the brain which failed to present symptoms of dementia. Also, other studies 
showed that learning defects do not require the presence of large visible 
plaques, suggesting that already small intracellular accumulations of Aβ are 
enough to lead to deficits in the learning process144. 
However, the aggregation of Aβ amyloid just like tau tangles are not the origin 
of AD, but a downstream effect. Research had shown, that there are usually 
at least a number of possible discrete genetic mutations or polymorphisms 
preceding and causing the aggregation and hence the accumulation of Aβ145. 
Although it was shown that the aggregation levels of Aβ have an effect on 
phenotypes, the aggregation rate and level alone does not determine the 
pathogenicity120. It is also known that some genetic mutations in the coding 
gene for β-APP on chromosome 21 might even lead to an early onset 
(autosomal dominated inherited) familial AD135 (see C Genetic implications 
p.34). 
Nevertheless, how exactly these Aβ plaques and Tau NFTs in AD lead to the 
progression and pathology of the disease is still unclear and controversial. 
Some people with AD brain pathology showing tau and β-amyloid aggregates 
e.g. sometimes stay dementia free146. It was also established, that 
environmental factors and the comorbid (co-occurring medical condition)  
brain pathology can have an important impact on the outbreak of the 
disease135. The relevance of environmental factors has been suggested by 
studies of monozygotic twins, which showed that not always both developed 
the disease147. 
  
The Potential Application of Rapeseed Pomace Extracts in the Prevention and 
Treatment of Neurodegenerative Diseases 
34  Franziska Pohl 
C Genetic implications 
AD can be classified into two types, early-onset, which typically develops 
before the age of 65 years, and late-onset which usually starts in those older 
than 65. Early-onset AD (familial AD)  is caused by rare and dominantly 
inherited mutations in APP, or the proteins cleaving APP, PSEN1 (component 
of the γ-secretase complex), and PSEN2 (component of the γ-secretase 
complex along with PSEN1) all of which are involved in β-amyloid42 
production139,148,149. But also late-onset AD (sporadic AD) can have genetic 
components, with high heritability, but genetic as well as environmental 
factors play a role in onset, progression, and severity of these cases148,150. 
One of the genes known to be involved in sporadic AD is APOE (ε4 allele). 
The APOE protein is responsible for cholesterol carriage in the brain and is 
also involved in control of inflammation, cholesterol metabolism, lipid 
transport, neurogenesis, or the generation and trafficking of APP and Aβ148. 
Due to the genome-wide association study researchers were able to identify 
a great number of other genes, which when mutated can increase the chance 
of AD later in life. A comprehensive summary of these was provided by Giri 
et al. in 2016148. 
Although both proteins (tau and Aβ42) have been positively associated with 
AD as well as some genetic mutations, AD is a multifactorial and complex 
disease, which is still not well understood. And researchers are still in the 
dark on the actual cause. Other factors might play a significant role in the 
disease origin or development, e.g. oxidative stress (1.4 Oxidative stress in 
neurodegeneration and the potential use of antioxidants to prevent 
neurological disorders), which is one of the main points of interests in this 
project. 
1.3.1.3 Treatment (current and future) 
Although there are some drugs currently available for the treatment of AD, 
which slowdown the progression of the disease, no treatment has been found 
to cure this neurodegenerative disease120. There are 2 classes of FDA (Food 
and Drug Administration) approved drugs which can be prescribed to AD 
patients, acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate  
(NMDA) receptor antagonist151 or a combination of both152. 
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A Acetylcholinesterase inhibitors 
As previously described, AD is caused by the death of neurons, in particular 
cholinergic neurons, which leads to a decrease in acetylcholine neuronal 
signaling. To alleviate this decrease, acetylcholinesterase (AChE) inhibitors 
are used, which as their name states, inhibit acetylcholinesterase, the 
enzyme responsible for the breakdown of acetylcholine in the synaptic cleft 
(Figure 3.10 p.147). By using AChE inhibitors, acetylcholine is retained in the 
synaptic cleft for neurotransmission. The three currently used AChE inhibitors 
are galantamine, rivastigmine and donepezil (Figure 1.16). 
 
Figure 1.16 | Chemical structure of donepezil, galantamine and 
rivastigmine, current treatments for symptoms of Alzheimer’s 
disease 
B N-methyl-D-aspartate receptor antagonists 
N-methyl-D-aspartate (NMDA) receptor antagonists inhibit NMDA receptors  
and fall into four categories, those that bind to and block the binding sites for 
either (i) glutamate or (ii) glycine or noncompetitive antagonists, which 
inhibit NMDA receptors by binding to (iii) the allosteric sites, (iv) those that 
block the ion channel by binding to a site within the channel (Figure 1.17 
left). Memantine, the currently approved NMDA receptor antagonist is a non-
competitive blocker of the NMDAR channel and prevents entry of excess 
calcium153 (lower level of noise Figure 1.17 p.36).  
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Figure 1.17| NMDA receptor antagonist memantine, adapted 
from153,154  
Nevertheless, there is currently no drug available that can cure the disease 
itself. All the introduced drugs only ease the symptoms and might delay 
further progression. However, research is in progress, as reported by 
Cummings et al.155, currently (stand May 2017) a total of 25 agents are in 29 
phase I trials, 52 agents are in 68 phase II trials and a total of 28 agents are 
in 42 phase III trials. The mechanism of action of all these agents are covering 
a wide area, including drugs which are (i) neurotransmitter based, (ii) anti-
tau, (iii) anti-amyloid, (iv) neuroprotective, (v) anti-inflammatory as well as 
(vi) antiviral and (vi) metabolic based. All the agents currently in trials are 
summarized and discussed by Cummings et al.155. The number of agents in 
clinical trials has increased over the last years. A similar review written by 
Cummings et al.156  in 2014 presented data on agents and their registration 
years, whilst there was only a total of 5 agents that were registered for clinical 
trials in 2002, this number increased to 12 in 2003, 14 in 2004, 32 in 2005 
till a maximum of 72 registrations in 2009. From then on (2010-2012) the 
number of registered agents was constantly around 50. 
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1.3.2 Machado-Joseph Disease (MJD) 
Machado-Joseph disease (MJD), also named spinocerebellar ataxia 3 (SCA3) 
is one of the types of spinocerebellar ataxias. There is a wide range of SCAs, 
such as SCA1, SCA2, SCA6 and SCA17, but SCA3 is by far the most prevalent 
worldwide157,158. In Portugal, for example, MJD covers 58% of all known 
dominant ataxias159. The prevalence however is strongly dependent on 
geographic places. The Flores Island, in the North Atlantic Ocean (one of the 
Azores Islands) is associated with the highest prevalence of MJD worldwide 
(1/239)79,160.  
This adult-onset neurodegenerative disease obtained its name from the 
affected families of Antone Joseph and William Machado, both originating 
from the Portuguese Azores Islands144. Due to the first mentioning of MJD 
symptoms in this family it was first named “Azorean disease of the nervous 
system”159. Initially, MJD was described as three independent clinical entities 
found in two other families (Thomas and Joseph), described between 1972 
and 1976. This indicates the immense differences in phenotypical symptoms, 
which can be observed in SCA3 patients. Only a paper published a couple 
years later proposes the presence of a single disease161. Although the 
condition was first reported in the mentioned families, it has since been found 
in families with different ethnical background and geographical origin79,162.  
1.3.2.1 Symptoms and Onset of MJD 
In general, the symptoms of MJD show a gradual progression, which 
subsequently leads to the death of the patient. Most obvious is the 
progressive neuron loss, which can be associated with a decline in motor and 
cognitive function. The usual onset of symptoms is relatively late in life 
(midlife, 3rd or 4th decade), with death occurring 10 to 30 years (with an 
average of 21 years159) after the first symptoms have been noticed. The age 
of onset and severity is also dependent on the number of CAG-repeats (Figure 
1.18) 158,163. The green line in this graph (highlighted with arrow) shows the 
decreased age for onset of SCA3 with increased number of CAG repeats164. 
In comparison to some of the other polyQ disease (e.g. SCA7 and HD) the 
slope for MJD is particularly steep, i.e. only slight changes in the number of 
repeats have a significant impact on the age of onset79.   
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Figure 1.18| Correlation between the number of CAG repeats and the 
age of onset of 8 polyglutamine disorders 
crosses heterozygous (indicated by arrow) and circles homozygous (indicated by arrow 
head) patients, reprinted with copyright permission from Gusella et al.164 
Even people with the same number of repeats, do not necessarily start 
showing symptoms at the same age. This demonstrates that there are also 
other factors that have an influence on the outbreak of the disease165. 
Although MJD has an average onset age of 40 years, extremes of 4 and 70 
years have been reported159. 
Since MJD is a dominantly inherited disorder, the onset, clinical features and 
progression should be similar in homozygote and heterozygote patients. 
Nevertheless, few homozygous affected patients were reported to present 
more severe phenotypes than what is observed in heterozygote individuals166. 
Also, from Figure 1.18 this conclusion can be drawn, where homozygote 
patients are depicted with green circles (highlighted with arrow head), 
showing an earlier onset for all MJD cases164. Very common for polyQ disease 
is also a decreasing age of onset in successive generations, also called 
anticipation, which results from paternal transmission79,167. 
 
Chapter 1: Introduction 
Franziska Pohl         39 
In general, ataxia is associated with problems to coordinate voluntary muscle 
movements, which usually can be seen in unsteady movement and staggering 
gait. Progressive ataxia also shows the following symptoms: cerebellar 
syndrome (uncoordinated gait), dysarthria (speech disorder), spasticity, 
nystagmus (involuntary eye movement), and oropharyngeal dysphagia 
(swallowing disorder)158,167. This however, is not a comprehensive catalogue 
of symptoms of MJD. These symptoms severely decrease life quality for 
patients and a cure is urgently needed, even though the number of affected 
patients in comparison to AD is low. 
1.3.2.2 Mechanisms/pathophysiology associated with MJD 
MJD is caused by an increased expansion of unstable CAG-repeats in the 
coding region of the gene encoding the protein ataxia-3 (Figure 1.19), a 
protein with ubiquitous expression in the body157,163. 
 
Figure 1.19|Mutant ataxin-3, caused by increased CAG repeats, 
leading to polyQ amino acid sequence and elongated and misfolded 
proteins 
The disease thus only occurs when a certain threshold of repeats is 
exceeded168 (Table 1.4, p.40). The three letter code CAG encodes the amino 
acid glutamine (Gln), which has the one letter code Q. Hence, SCA3 is also 
known to be one of at least 9 so far recognised polyglutamine diseases (polyQ 
disease, Table 1.4, p.40)79,168.
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Table 1.4|Collection of the 9 polyglutamine expansion disease and some of their characteristics79,157,169 
Disease 
 
Affected 
protein 
Gene 
location 
Regular 
CAG 
repeat 
Pathogenic 
CAG repeat 
Intracellular protein 
localization 
Intracellular 
localization of 
aggregates 
SBMA 
(Kennedy’s 
disease) 
Androgen 
receptor 
Xq11-12 9-36 38-65 Cytoplasm/ nucleus Nuclear 
HD Huntingtin 4p16.3 6-35 36-121 Cytoplasm/ nucleus 
Nuclear/ 
cytoplasmic 
DRPLA Atrophin-1 12p13 3-35 49-88 Cytoplasm/ nucleus Nuclear 
SCA1 Ataxin-1 6p23 6-38 39-83 Cytoplasm/ nucleus Nuclear 
SCA2 Ataxin-2 12q24.1 14-31 32-77 Cytoplasm Nuclear/cytoplasmic 
SCA3 Ataxin-3 14q32.1 10-51 55-87 Cytoplasm/ nucleus Nuclear/cytoplasmic 
SCA6 CACNA1A 19p13.1 4-19 20-33 Cytoplasm Nuclear/cytoplasmic 
SCA7 Ataxin-7 3p12-13.5 4-35 37-306 Cytoplasm/ nucleus Nuclear 
SCA17 TBP 6q27 47-55 47-55 Nucleus Nuclear 
   Note(s): SBMA- Spinal and bulbar muscular atrophy, HD-Huntington’s diesease, DRPLA- Dentatorubral-pallidoluysian  
                         atrophy, SCA-Spinocerebellar ataxia, TBP- gene, encoding the TATA-box-binding protein 
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MJD, like most other polyQ diseases, is an autosomal dominant inherited 
disorder. The precise numbers of repeats that cause MJD symptoms are open 
to interpretation. Although Table 1.4 provides the range of 55-87 repeats to 
show the abnormal phenotype157, other sources suggest, that only repeats 
above a number of 61 are associated with the condition159,160. This can be 
explained by the relative rarity of the occurrence of intermediate alleles. In 
addition, some people with an intermediate number of repeats show an 
abnormal phenotype, whilst others do not170,171. This again indicates that 
other, possible environmental, factors might have an influence on the 
disease’s outbreak and appearance.  
The increased number of CAG repeats is assumed to originate from a DNA 
strand slippage during the process of DNA replication or DNA repair, leading 
to a looping out of one or more repeats in the newly formed DNA strand. After 
a further replication these loops can be converted to expansions. These 
expandable repeats were shown to form unusual hair-pin-like structures, 
predisposing them to instability79,172.  
A MJD Associated Protein Ataxin-3  
The MJD associated gene encodes ataxin-3, a protein with a molecular weight 
of approximately 42kD, in its original form, it is the smallest of the known 
polyglutamine-containing proteins173. It belongs to a family of cysteine-
proteases, composed of 339 amino acids plus the variable polyQ part. An 
overview of the general protein structure is given in Figure 1.20. 
 
 
Figure 1.20| General structure associated with ataxin-3  
not showing possible isoforms, adapted from Costa et al.174 as presented in79 
The figure above shows the overall organisation of ataxin-3, containing a 
conserved N-terminal Josephin domain, which is followed by two Ubiquitin-
Interacting Motif (UIM) domains, the polyQ region and sometimes by another 
UIM domain. The existence of this protein in the nucleus and cytoplasm in 
 UIM1
1 
UIM2 polyQ UIM3     Josephin 
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various kinds of tissues, suggests its importance in eukaryotic cells. This is 
reinforced by findings of highly homologous sequences in other organism’s 
genes (mouse, chicken, C. elegans)79,174. 
Due to the UIM regions (short, conserved and 11 amino acids long) in ataxin-
3 (Figure 1.20, p.41), this protein is thought to bind polyubiquitin chains and 
play a role as deubiquinating enzyme in the ubiquitin-proteasome pathway 
(Figure 1.21), as shown in vitro159,168. In general these UIM regions are found 
in proteins taking part in ubiquitination and ubiquitin recognition157. 
 
Figure 1.21| Simple sketch of the ubiquitin-proteasome pathway 
adapted from Hochstrasser et al.175 
This pathway is responsible for the degradation of proteins, which are either 
regulatory (and not needed anymore), misfolded or otherwise abnormal 
proteins, which might lead to aggregation or toxicity, when not degraded168. 
Due to ubiquitin receptors associated with the proteasome (regulatory 
particle-RP in Figure 1.21), ubiquitinated substrates are recognised and will 
be degraded.  
On the other hand, ataxin-3 has also been linked to protein homeostasis 
maintenance176, cytoskeleton organisation177, transcription regulation178 as 
well as myogenesis174, thus its specific biological function is still not 
completely elucidated. This also limits the understanding, of why a mutation 
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in this protein leads selectively to the death of neurons in patients with 
MJD79,168. 
B Protein Aggregations and Inclusions found in neurons 
The CAG expansions cause glutamine repeats in the affected proteins, which 
then can lead to irregular protein conformations and polyglutamine 
aggregates or neuronal intranuclear inclusions (NIIs) in the brain157. If these 
aggregates cannot be degraded, they tend to build up into neuronal inclusion. 
Both the full-length ataxin-3 proteins and their polyQ fragments can act as 
an origin for aggregations. Misfolded proteins can undergo different 
mechanisms of degradation, including autophagy and degradation via 
proteasomes. If degradation does not occur, they can form oligomers that 
can lead to the formation of insoluble aggregates (Figure 1.22, p.45), which 
are observable in certain neurons in MJD patients. 
Conspicuous however is the fact that, although the proteins are expressed 
ubiquitously, it only leads to aggregations in neurons at certain regions of the 
brain (central nervous system, CNS), such as the deep cerebellar nuclei, 
substantia nigra, cranial nerve motor-, vestibular- and pontine nuclei and 
Clarkes’s columns. Hence, it is thought that there are specific cellular 
conditions only present in some neurons, which cause the discriminating 
cytotoxicity only in these cells. However, the presence of these aggregations 
is still an issue and widely controversial179. For example it is not clear whether 
the toxicity of polyQ disease is related to the presence of these inclusions or 
due to the intermediate species (oligomeric species such as protofibrils and 
microaggregates179), produced during the process of aggregation173. Hence, 
it could be that the inclusions are only a cellular strategy to trap pathogenic 
proteins, to prevent their toxic effect and thus might only be the end product 
of an upstream toxic event179. However, inclusions are usually found in the 
patients and progression of the disease can so far only be associated with the 
increasing amount of inclusions. This clearly shows that inclusions are still a 
good indicator for the presence and progression of the disease. 
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C Pathogenic Mechanism of MJD 
Although the genetic background is identified as discussed above, the 
molecular mechanism is still unclear and the question “How does the mutated 
protein trigger the pathogenic process?” still needs to be answered. Many 
different proposals about the mechanism of pathogenesis and the progressing 
neuronal death have been introduced, including a) alterations induced by the 
polyQ sequence, leading to functional changes and/or the generation of 
protein aggregations  and the formation of toxic oligomers, b) transcription 
dysregulation, c) decreased axonal transport, d) inhibition of ubiquitin-
proteasome system, e) synaptic and mitochondrial dysfunction and f) 
apoptotic cell death157 as well as others (Figure 1.22). However, due to the 
close relationship found between age of onset and the number of CAG-repeats 
a connection between the expanded polyQ sequence and the mechanism 
(leading to the disease) can be suspected79,168.  
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Figure 1.22| Problems associated with mutated ataxin-3 
top: pathogenic mechanism of mutant ataxin-3 , altered from180; bottom formation of 
oligomers and inclusions and their toxic effects, reprinted with copyright permission 
from Shao et al.181, adapted from Pohl79 
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1.3.2.3 Therapeutic Strategies for MJD 
There are two main categories in which the therapeutic strategies for MJD 
can be divided into: A) those having an impact on the downstream effect of 
the expanded polyQ protein and B) treatments targeting the mutant protein 
itself173. Possible pathways of treating MJD are shown in Figure 1.23. 
However, to date no cure or effective treatment has been found for MJD. 
 
Figure 1.23| Possible therapeutic drug targets associated with MJD 
highlighting the therapeutic target associated with this project (red box); adapted 
from79,180,181 
The importance of oxidative stress and the potential treatment with 
antioxidants in MJD or neurodegeneration in general is further highlighted in 
section “1.4 Oxidative stress in neurodegeneration and the potential use of 
antioxidants to prevent neurological disorders” p.51 ff. 
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1.3.3 Parkinson’s Disease (PD) 
PD is a progressive neurodegenerative disease with a combination of motor 
and non-motor symptoms.  After AD (in conjunction with other dementias), 
PD is the second highest cause of death for neurological disorders and the 
numbers are still increasing significantly. Whilst in the year 2000 the crude 
rate of death was 1.7 per 100,000 people globally, this number has almost 
doubled till 2016 to 2.9132. PD is slightly more prevalent in males and numbers 
significantly increase with rising age. The first descriptions of PD were made 
two centuries ago by James Parkinson in 1817. These findings were further 
refined and expanded by Jean-Martin Charcot in the mid 1800’s, including the 
separation from other disorders such as multiple sclerosis, although showing 
similar symptoms. Since then PD has become one of many complex 
neurological disorders under constant investigation182. Up until today the 
exact cause and path of the disease is still not fully understood. Both 
environmental and genetic causes have been investigated and associated 
with the disease. A complex interplay of both seem to cause complex cellular 
dysfunction in the brain.  The most common feature is the loss of 
dopaminergic (DAergic) neurons. 
1.3.3.1 Symptoms/clinical features 
The key symptoms of PD are rest tremor, rigid and stiff muscles, postural and 
gait impairment as well as bradykinesia (slowness of movement). However, 
these symptoms strongly differ from patient to patient (heterogeneous). Also, 
non-motor function related symptoms have been described, such as cognitive 
impairment, sleep disorders, pain, constipation, fatigue and olfactory 
dysfunction. Some of these non-motor symptoms can start before the onset 
of the PD classical motor symptoms182,183. 
The progression of the disease can be seen through the worsening of the 
bodily motor functions, which still can be managed with treatment (1.3.3.3 
Treatment, p.49). However, the long-time treatment of PD can lead to 
complications, which create challenges for the management of later stages of 
the disease. Treatment-resistant symptoms such as postural instability, 
freezing of gait, falls, dysphagia, and speech dysfunction become more 
pronounced about 17 years after disease onset. Common non-motor features 
at this age are urinary incontinence, constipation, and symptomatic postural 
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hypotension. Also dementia is a common clinical feature in the later stages 
of the disease182,183. PD symptoms, especially in the later stages significantly 
impair the patients’ normal living and most often need considerable care once 
treatment residence sets in. 
1.3.3.2 Mechanisms/pathophysiology associated with PD 
The most prevalent brain pathological feature in PD is the loss of DAergic 
neurons, especially in the substantia nigra pars compacta (SNpc). Loss of 
these DAergic neurons within this area leads to the previously introduced 
symptoms. Normally functioning dopamine (neurotransmitter) is responsible 
for excitatory and inhibitory synaptic transmission ensuring smooth directed 
movements184.  
Also, the presence of eosinophilic protein deposits (Lewy bodies) is a common 
hallmark of PD. As previously described in AD, many neurodegenerative 
diseases are associated with the abnormal formation of proteins, and PD is 
one of them. The aggregated protein in PD patients is α-synuclein, which in 
the misfolded state becomes insoluble and forms intracellular inclusions 
called Lewy bodies within the cells. These inclusions can also occur in 
neuronal processes and are then called Lewy neurites. α-synuclein is a 14-
kDa protein found in neuronal cells, belonging to a family of structural related 
proteins. Under non-disease physiological conditions, α-synuclein promotes 
the association of the SNARE machinery, a large protein complex responsible 
for vesicle fusion, in the presynaptic terminal. It has also been suggested to 
play a role in neurotransmitter release and protection of nerve terminals 
against injury185. However, under disease physiological conditions, inclusions 
are formed containing mainly misfolded α-synuclein. These inclusions were 
first described by F.J.H. Lewy in 1912 and were named after him by K.N. 
Tretiakoff in 1919186. Lewy body formation is hypothesised to be a biological 
maker for PD and some even give them a causal role in the disease 
development. However, PD is more complex, and neurodegeneration is most 
likely not only caused by Lewy bodies. Just like for AD and β-amyloid, other 
aggregation types have been revealed (e.g. oligomers), which might play an 
important role in the degeneration process185. Also, other misfolded proteins 
(e.g. tau and β-amyloid) have been found in PD patients brains182. 
Furthermore, also neuroinflammation and oxidative stress (1.4 Oxidative 
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stress in neurodegeneration and the potential use of antioxidants to prevent 
neurological disorders p.51 ff.) are common features in PD187,188.  
1.3.3.3 Treatment 
Initial treatment for PD has included venesection and other methods to divert 
blood and inflammatory pressure away from the brain and spinal cord 
(beginning of the 19th century). Later, anticholinergic drugs (e.g. belladonna 
alkaloids or hyoscyamine, a tropane alkaloid) were used as well as other 
compounds and apparati, which are summarised by Goetz189. It was not until 
the finding of the synthetic pathway of dopamine in 1910 and later the 
discovery of dopaminergic deficits in Parkinson's disease patients’ brains in 
the mid 1900’s that levodopa was introduced as treatment for PD. Levodopa 
was first administered to patients in 1961 with exceptionally good results190 
and remains the most used drug for the treatment of PD motor symptoms up 
until today. In the clinic, it slows the progression of motor disabilities 
(assessed by the Hoehn and Yahr staging system) and furthermore it reduces 
mortality. In addition, it is one of the better tolerated drugs for PD treatment 
particularly in the elderly population191. 
Levodopa is a prodrug which metabolizes after administration into the 
pharmacologically active compound, in this case to dopamine via L-aromatic 
amino acid decarboxylase (Figure 5.10, p.275). Levodopa can cross the blood 
brain barrier in contrast to dopamine and so can restore synaptic DA 
concentrations (Figure 1.24, p.50). 
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Figure 1.24| Mechanism of Levodopa 
Apart from levodopa there are other treatments (for motor-symptoms) 
available that effect the DA concentrations or excite the dopamine receptors 
and these include (i) dopamine agonists (Piribedil, Rotigotine and 
Bromocriptine), (ii) monoamine oxidase type B inhibitors (Rasagiline and 
Selegiline) (iii) catechol-O-methyltransferase inhibitors (Entacapone, 
Tolcapone) and others (Amantadine, Anticholinergics, clozapine)182. 
However, current treatment options still only treat the symptoms of the 
disease, not the origins of the disease. Current research is actively seeking 
to find drugs that stop or at least slow the neurodegenerative process 
associated with PD182. 
The three introduced neurodegenerative disease (AD, PD and MJD) covered 
here, have varying symptoms and backgrounds. However, they also have 
common features, such as the aggregation of proteins in neuronal cells. For 
all of them the exact pathology leading to the neuronal death has not been 
completely elucidated. They also share the notion that oxidative stress could 
be involved in the disease pathology. The medication with exogenous 
antioxidants could be a potential treatment or prevention not just for a certain 
neurodegenerative disease, but for all of them in general192,193. Thus, the 
following section will introduce oxidative stress and the potential of natural 
antioxidants in the fight against these conditions.
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1.4 Oxidative stress in neurodegeneration and the 
potential use of antioxidants to prevent 
neurological disorders 
Current research has been focusing on a wide variety of different potential 
drug targets. In AD these have included  for example N-Methyl-D-aspartate 
(NMDA) receptor antagonists 194,195, acetylcholinesterase inhibitors 195,196, 
radical scavengers 197, monoamine oxidase inhibitors 196 and Aβ and tau 
aggregation inhibitors/dissolver198. In PD, treatment is mainly based on 
levodopa. Currently there is no treatment specifically for MJD. Drugs 
employed for the treatment of neurodegenerative diseases have helped to 
alleviate some of the symptoms associated with the diseases, but they are 
currently neither a cure nor do they halt the progression of the disease in any 
way. The number of current and future drug targets under investigation, 
might potentially lead to a cure for many neurodegenerative diseases. Some 
of those targets are summarized in Figure 1.25, highlighting targets of 
interest in this study in red. 
 
Figure 1.25| Examples of drug targets for neurodegeneration 
highlighting the targets under investigation in this project (red outline) 
In this project, the focus is the prevention of oxidative stress, using phenolic 
antioxidants, and to determine their potential to decrease the 
neurodegenerative pathology. Furthermore, mitochondrial dysfunction is 
drug targets
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often associated with oxidative stress, hence this is partially highlighted in 
Figure 1.25 (p.52) together with protein aggregations, which are also part of 
this investigation. 
Aging, one of the main risk factors of many neurodegenerative disease has 
first been associated with free radicals (oxidative stress) by Harman “Aging: 
A theory based on free radical and radiation chemistry” in 1956199. Since then, 
reactive oxygen species (ROS) have shown to be the cause of oxidative 
stress, the latter has been linked to a range of neurological disorders such as 
AD, PD, ALS and MJD157,193. It is assumed, that reducing oxidative stress 
within the human body could at least be part of future treatment options; 
maybe in conjunction with other drugs, pursuing multiple drug targets 
simultaneously. This could be of advantage, as most neurodegenerative 
disease have been associated with a number of different pathways involved 
in the disease development200,201. 
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1.4.1 Oxidative stress 
Oxidative stress, a condition where the balance of reactive oxygen (ROS) and 
reactive nitrogen species (RNS) to antioxidants is in favour of ROS/RNS, is 
one of the causes associated with many neurodegenerative diseases. ROS, 
such as superoxide (O2●-), hydrogen peroxide (H2O2) and hydroxyl radical 
(OH●) are generated during normal aerobic respiration of the cells. Other 
sources of oxidants are bacteria or virus infected cells, which are destroyed 
by phagocytosis, generation of by-products in peroxisomes (lipid and fatty 
acid degradation) as well as by-products generated by cytochrome P450 
(enzyme responsible for metabolism of many medications (phase1)193.  
It is well known, that the production of ROS increases with age, whilst some 
of the endogenous defence mechanisms can decrease. If the balance between 
ROS and antioxidants is disturbed, the excessive amounts of ROS will damage 
the cells, by protein oxidation, DNA/RNA strand breakage, lipid peroxidation 
or the formation of advanced glycosylation end-products. These changes in 
the body with increased age lead to the aging phenotype that relates to the 
neurodegenerative disease. However, it is important to remember, that under 
normal conditions, a balance slightly on the pro-oxidant side (Figure 1.26)  is 
optimal for essential cellular processes, because ROS fulfil an important 
regulatory role, affecting a variety of cellular processes e.g. proliferation, 
metabolism, differentiation, apoptosis, antioxidant and anti- inflammatory 
responses, iron homeostasis as well as the adaptive stress response of cells54. 
Therefore, the antioxidant defence system should minimize the levels of 
harmful ROS, while enabling enough ROS to remain in the cell202.  
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Figure 1.26| Difference between the normal and the disease state of 
oxidative stress balance 
adapted from Poljsak et al.202 as presented in Pohl and Kong Thoo Lin203 
Redox dysregulation can be caused by the ineffectiveness of the endogenous 
antioxidant system to handle an increase in the production of free radicals 
(e.g. disease, mitochondrial dysfunction, exposure to environmental factors) 
or because of a decreased effectivity of the endogenous antioxidant system 
itself. The additional stress that relates damage to biological molecules can 
lead to a rapid cell death, which if occurring in the brain, this will result in 
neurodegeneration192,204.  
 
 
 
Figure 1.27| Causes of oxidative stress in neurodegeneration 
adapted from205,206 as presented in Pohl and Kong Thoo Lin203 
In addition, inflammation, protein aggregations (e.g. amyloid in AD) as well 
as excessive presence of metal ions such as iron (Fe2+) and copper (Cu2+) can 
lead to oxidative stress (Figure 1.27)205,206. ROS can damage cell components 
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like DNA/RNA, proteins and lipids. DNA damage can lead to mutations and 
possibly cancer, if the damage cannot be reversed by DNA repair mechanisms 
in time. Damage to the lipids in the cell can result in decline in physiological 
function and cell death, whereas protein damage can e.g. cause enzyme 
inhibition, denaturation or protein degradation, all of which cause a disruption 
of regular cellular mechanisms which can lead to cell 
death/neurodegeneration54. In general, eukaryotic cells control reactive 
compounds through an elaborate detoxification system in which lipophilic 
molecules are solubilized (cytochrome P450; phase 1), thereafter, reactive 
species, including ROS, and products of the phase 1 system are inactivated 
(phase 2) and can then be transported out of the cell (phase 3)207. 
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1.4.2 Antioxidants to counteract oxidative stress 
Antioxidant molecules are those that can prevent the oxidation of other 
molecules i.e. biomolecules (DNA/RNA, proteins or lipids) in the human body. 
Generally, the human body has its own in-built antioxidant system (Figure 
1.28), which ought to keep a balance between the production of ROS and the 
antioxidants defence system. Keeping this biological equilibrium is especially 
important for neurons. Due to their very high oxygen consumption, long life 
time and the additional formation of reactive nitrogen species and the 
prominent role of nitric oxide in the signalling processes, neuronal cells are 
even more susceptible to oxidative stress192,193,208. The natural human 
antioxidant system can be divided in two groups, enzymatic and non-
enzymatic193 (Figure 1.28). 
 
Figure 1.28| Natural antioxidants categorised with examples 
adapted from54,193,209,210; * further detailed in Table 1.5 
A number of the important enzymatic antioxidants and their functions are 
presented in Table 1.5. In addition to the enzymatic anti-oxidants, the body 
also produces non-enzymatic antioxidants. These can also be called metabolic 
antioxidants (endogenous), that are produced by metabolism in the body, 
such as α-lipoic acid, metal binding proteins (e.g. ferritin), glutathione (GSH), 
L-arginine, coenzyme Q10, melatonin and uric acid all of which are 
summarized by Mirończuk-Chodakowska et al.211. 
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derived from dietary sources
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Table 1.5|Cytoprotective enzymes and their antioxidant function54 
Enzyme/ Protein Function 
Catalase (CAT) Elimination of H2O2 
Glutathione peroxidase (GPx) Elimination of H2O2 
Glutathione reductase (GR) 
Reduces glutathione disulfide to the 
sulfhydryl form glutathione, which is an 
important cellular antioxidant 
Glutathione S-transferase (GST) Phase 2 enzyme (glutathionylation) 
Heme oxygenase-1 (HO-1) Heme catabolism, stress response 
Superoxide dismutase (SOD) Elimination of superoxide radical 
Thioredoxin (TXN) Cysteine thiol-disulfide exchange 
Thioredoxin reductase (TrxRs) Reduction of oxidants and oxidized thiols 
In addition to endogenous antioxidants the body also receives exogenous 
antioxidants e.g. ascorbic acid (vitamin C), tocopherols (vitamin E) and 
phenolics through dietary sources. The latter are the focus of this project 
(Figure 1.28, p.56). When the endogenous antioxidant system is not 
functioning well enough, an increased amount of exogenous antioxidants 
could reduce the cumulative effect of oxidative stress209, and hence prevent 
oxidative cell damage and neuron loss. Sources of exogenous antioxidants 
can either be synthetic or natural. There are a large variety of synthetic 
antioxidant compounds previously discussed by Augustyniak et al. 210 and 
Carocho and Ferreira212. However, these synthetic antioxidants are 
sometimes associated with a negative reputation e.g. toxicity212. For that 
reason, in most antioxidants studies nowadays, compounds from natural 
sources are employed. One source of natural antioxidants is in the human 
diet; especially plant products provide a good source of plant secondary 
metabolites of which many have previously demonstrated positive antioxidant 
activities in vitro213.  
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1.4.3  Exogenous antioxidants - natural products: 
direct and indirect antioxidant activity 
In drug discovery pipelines, natural products (mostly plant sources) have 
always been a rich source of antioxidant compounds (1.1 Natural products 
for medicinal use p.2 ff.) Even in the case of synthetic derivatives plant 
metabolites can be an inspiration for the drug development process214. 
Extracts from plants, animals, microbes and minerals were the only 
medication in hand before the 20th century and are still widely used in Asia6.  
In the last two decades however their use had decreased, due to technical 
barriers for screening natural products in high-throughput assays for specific 
molecular targets and with issues associated with the synthesis of natural 
compounds for the pharmaceutical industry215 as well as advances in 
metagenomics and combinational chemistry216. However, their importance 
has risen again in recent years. This is due to improved fractionation 
techniques and advanced NMR techniques for structural elucidation as well as 
profiling and isolation techniques such as HPLC-MS/MS, high-resolution 
Fourier-transform mass spectrometry  and photo-diode arrays for 
metabolomics; the use of natural extracts has become more attractive 
again203,215.  
Antioxidant activity detected in plant extracts or isolated compounds are 
mostly due to secondary metabolites, which occur in plants in high levels of 
structural diversity and number (1.1.2 Secondary metabolites, p.5 ff.). 
Although some secondary plant metabolites are thought to have disease-
protecting properties in vivo, they are non-essential nutrients for humans. 
Phytochemicals from plants were shown to exhibit different biological 
activities, such as anti-inflammatory9,76,217,218, anti-microbial83,219, anti-
carcinogenic219,220 and anti-diabetic properties10,221. Some of which, are due 
to the regulation of several cellular molecular pathways222. Hence, the in vitro 
and in vivo effects of phytochemicals have been shown intense interest as 
testified in the literature, including their ability to treat and prevent 
neurodegeneration6,10,83,203,223. 
Exogenous antioxidants can be further separated into direct and indirect 
antioxidants, based on their mode of action. Direct antioxidants on the one 
hand are compounds that are redox active and can directly scavenge ROS224. 
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Some well-known exogenous antioxidants are e.g. ascorbate (mineral salts 
of ascorbic acid), tocopherols as well as phenolics54. These direct antioxidants 
are short-lived because they are either consumed or chemically modified 
during the process of their redox action. To keep the system in balance, these 
direct antioxidants need to be replenished or regenerated224. The number of 
secondary metabolites in plants with direct antioxidant activity is huge, 
including phenolics (phenolic acids, flavonoids, anthocyanins, coumarins 
lignans and stilbenes (Figure 1.6, p.10), carotenoids (xanthophylls and 
carotenes) and vitamins (vitamin E and C)225,226. 
Indirect antioxidants on the other hand are not always redox active. Their 
mode of action is the activation of antioxidant regulatory pathways (e.g. 
Kelch-like ECH-associated protein 1- nuclear factor erythroid 2–related factor 
2- antioxidant response element (Keap1-Nrf2-ARE))54,227. Under normal 
circumstances Nrf2 is bound to Keap1 for maintaining normal (inactive) levels 
of Nrf2 and degraded via proteasome if not needed. However, compounds 
with e.g. an α,β-unsaturated carbonyl group (quercetin)54 or an isocyanate 
group (sulforaphane)228, which are highly reactive towards nucleophiles 
(electron donator), can be inducers of cytoprotective proteins (Figure 1.29). 
The reactive protein (e.g. Keap1 with cysteine thiols) within the cell act as 
nucleophile in the addition reaction. Through a nucleophilic attack of the thiol 
group by e.g. sulforaphane, a covalent bond can be formed  and so activate 
the Keap1-Nrf2-ARE regulatory pathway (Figure 1.29)54. This activation also 
occurs on the impact of oxidative or electrophilic stress (ROS)229.Once 
released Nrf2 moves into the nucleus to bind the ARE in the DNA, which 
upregulates the transcription of ARE-responsive genes i.e. a number of 
antioxidant and phase 2 detoxification enzymes, e.g. NAD(P)H:quinone 
acceptor oxidoreductases 1 (NQO1), heme oxygenase 1 (HO-1), catalase 
(CAT), glutathione peroxidase (GPx) and glutathione S-transferases 
(GSTs)230. 
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Figure 1.29| Activation of Nrf2-Keap1 pathway  
via oxidative stress and indirect antioxidant sulforaphane, adapted from54,228 
Sulforaphane and quercetin are not the only natural Nrf2-Keap1 pathway 
activator, also other compounds such as resveratrol (grape), curcumin 
(turmeric), naringenin, ferulic acid (cabbage) and diallyl sulphide (garlic) can 
induce the pathway (concentration dependent)231. The cytoprotective 
proteins (catalysts) induced during this process are not consumed during 
their reactions with ROS and have a longer half-life than direct antioxidants. 
This means they do not need to be replenished as quickly as direct 
antioxidants227.  That is why inducers for these pathways, which leads to the 
upregulation of genes for the production of these 
cytoprotective/detoxification proteins play an important role in the bodies 
protection from ROS54.  
In addition, there are a few other antioxidants, that are neither direct nor 
indirect antioxidants in the way described above e.g. metal chelators. 
Through their action the production of radicals can be inhibited due to a 
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decreased availability of redox active metals232. Antioxidant-based therapies 
or MJD/SCA3 have been scarcely researched, however the use of natural 
antioxidants has been shown more interest in AD and PD. Table 1.6 (p.62), 
highlights just a few of natural antioxidant extracts/compounds, which have 
shown neuroprotective properties in in vitro and in vivo models for those 
three diseases. Additional natural products with promising effects in 
neurodegeneration studies will be presented throughout the following 
chapters.  
This chapter gave an introduction on the main topics covered during this 
research, followed by the overall aim of the project. In the end of the 
introductions, provided for each of the following four experimental chapters, 
the objectives to achieve this aim will be further discussed. 
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Table 1.6| Plant, plant products and by-products and their preventative/medicinal properties in neurodegeneration 
  Disease/ 
condition 
Substance/plant 
Outcome Ref. 
Cell 
culture 
SH-SY5Y 
Oxidative 
stress 
Scutellaria 
baicalensis extracts 
- radical scavenging and antioxidative activity 
- nitric oxide and lipid peroxidation inhibition  
- protection against H2O2-induced cell injury 
233,23
4 
Neurodege
neration in 
general 
Vanillin 
- attenuated rotenone induced mitochondrial dysfunction, ROS 
generation, oxidative stress, and apoptosis 
235 
Primary 
human 
neurons 
PD 
Pomegranate Juice 
Extracts 
- ameliorate MPTP-induced neurotoxicity 236 
SK-N-SH-
MJD78 MJD/SCA3 
Caffeic Acid and 
Resveratrol 
- decreased reactive oxygen species (ROS), mutant ataxin-3 and 
apoptosis and increased autophagy in pro-oxidant tert-butyl 
hydroperoxide (tBH)-treated cells 
237 
Model 
Organism 
C. elegans 
AD 
Gingko biloba 
Extract EGb 761 
- alleviates Aβ-induced pathological behaviors 
- inhibits Aβ oligomerization and A deposits 
(not by reducing oxidative stress) 
- attenuated the basal as well as the induced levels of H2O2-
related reactive oxygen species 
64,65 
AD, aging 
Tea Seed Pomace 
(Camellia tenuifolia) 
- decreased intracellular reactive oxygen species 
- prolonged lifespan 
- reduced amyloid-β (Aβ) toxicity in transgenic C. elegans 
expressing human Aβ 
238 
Aging, 
oxidative 
stress 
Green Tea 
(epigallocatechin 
gallate) 
- EGCG decreased the formation of lipofuscin, an aging related 
pigment 
- EGCG reduced beta amyloid (A?) deposits and inhibited Aβ 
oligomerization 
239 
Drosophila 
MJD/SCA3 
Caffeic Acid and 
Resveratrol 
- improved survival and locomotor activity and decreased mutant 
ataxin-3 and ROS levels in tBH-treated SCA3 Drosophila 
237 
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PD 
Natural antioxidants 
of Decalepis 
Hamiltonii 
- significantly improved climbing ability and circadian rhythm of 
locomotor activity 
- reduced levels of ROS and LPO and enhanced catalase (CAT) and 
superoxide dismutase (SOD) activity 
240 
mice 
AD, 
dementia 
Sinapic acid, Sodium 
sinapate 
- rescued neuronal cell death and attenuated the increase of iNOS 
expression, glial cell activations and nitrotyrosine expressions 
induced by Aβ1–42 protein 
- attenuated memory impairment 
- cerebral protective and cognition-improving effects 
241,24
2 
AD 
Grape seed 
polyphenol extract 
- attenuated the development of tau neuropathology in a TMHT 
mouse model of AD through mechanisms associated with 
attenuation of extracellular signal-receptor kinase 1/2 signaling in 
the brain 
- interference with the assembly of tau peptides into neurotoxic 
aggregates 
67 
rats 
PD Ferulic acid 
- rescued dopamine neurons in substantia nigra pars compacta 
area and nerve terminals in the striatum from the rotenone insult 
- restored antioxidant enzymes, prevented depletion of 
glutathione, and inhibited lipid peroxidation 
- attenuation of microglial and astrocytic activation 
243 
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1.5 Overall Aim and thesis structure 
The overall aim of this study was to determine the potential use of the by-
product RSP, obtained after edible rapeseed oil production in Scotland, for 
the treatment or prevention of neurodegenerative disease in vitro and in vivo 
models. 
To achieve the aim several objectives were set out, leading to the following 
four chapters of this thesis: 
Chapter Title 
2 
Secondary Metabolite Composition and Antioxidant Activity of 
Rapeseed Pomace Extracts – comparison between 2 harvest 
years and 3 extraction techniques 
3 
Phytochemical Characterisation and Neuroprotective Properties 
of RSP Extract in vitro Phytochemical Characterisation and 
Neuroprotective Properties of RSP Extract 
4 
Cell Protective Properties of RSP Extract in SH-SY5Y 
Neuroblastoma Cell Line 
5 
An in vivo Study of the Antioxidant and Neuroprotective 
Properties of RSP Extract in C. elegans Nematode Models 
 
Each chapter will have its own introduction, including the objectives and 
general information covering techniques as well as background information 
necessary for the chapter. Materials and methods, results and discussion as 
well as a conclusion, summarizing the found results in context and leading to 
the following chapter, will follow the introduction. All the results obtained will 
be drawn together in an overall conclusion at the end of the thesis (Chapter 
6). References (Chapter 7) and supplementary data (Appendices) follow there 
after.
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2 SECONDARY METABOLITE 
COMPOSITION AND 
ANTIOXIDANT ACTIVITY OF 
RAPESEED POMACE EXTRACTS – 
COMPARISON BETWEEN 2 
HARVEST YEARS AND 3 
EXTRACTION TECHNIQUES 
Contents 
2.1 Introduction       66 
2.1.1 Extraction         
2.1.2 Determination of secondary metabolites in extracts 
2.1.3 Antioxidant/Reducing capacity assays 
2.1.4 Objectives 
2.2 Materials and Methods      88 
2.2.1 Chemicals and Equipment 
2.2.2 Methods 
2.3 Results and Discussion      98 
2.3.1 Secondary metabolite composition of RSP from free, alkali-labile 
and acid-labile fractions 
2.3.2 Comparison of SOX, UAE and ASE extraction techniques 
2.3.3 Folin-Ciocalteu (FC) assay 
2.3.4 HPLC-MS/MS 
2.3.5 FRAP assay 
2.3.6 DPPH assay 
2.3.7 Correlation of the data from FC, FRAP and DPPH 
2.3.8 Partial least squares analysis of data from the DPPH, FC and FRAP 
2.3.9 ORAC assay 
2.3.10 Partial least squares analysis (ORAC) 
2.3.11 Determination of antioxidant activity of single compounds within 
the extract as well as their mixtures     
2.4 Conclusion/Future work     131 
This chapter will cover the analysis of free and bound secondary metabolites of the 
RSP as well as RSP extracts obtained via three different extraction techniques. All 
three extractions were done using two harvest years of rapeseed (2012 and 2014). 
These extracts were compared regarding their secondary metabolite composition, 
antioxidant and radical scavenging activity as well as their ease of handling, to select 
a viable extraction technique for further in vitro and in vivo experiments.
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2.1 Introduction 
2.1.1 Extraction  
The use of plants and their secondary metabolites has gained much interest 
over the last few years (as described in chapter 1  Introduction”). However, 
to determine their potential activity, their active ingredients are required to 
be extracted from the starting material. This can then be followed by their 
chemical characterisation and assessment of their in vitro and in vivo 
biological activities. Extraction is necessary as most activity experiments are 
undertaken in solution and applied to multi well formats; whole plant leaves, 
stems, seeds or by-products are difficult to assess. The use of organic 
solvents is the most popular process of extraction from solid matter. 
Extraction also leads to the concentration of the compounds in question, 
opening the possibilities to test the extract from high to very low 
concentrations in all assays. To extract the secondary metabolites of interest 
it is important to pick the right extraction technique and conditions, as well 
as extraction solvent/solvents (2.1.1.2 Extraction solvents, p.69/2.1.1.3 
Extraction technique, p.70) for the sample matrix244. Parameters such as 
solvent polarity, temperature and pressure of the solvent can influence the 
extracts composition. There is not one general extraction technique for all 
plant material; hence, the experimental set up is unique for each project.  
2.1.1.1 Pre- extraction preparations 
Before the start of extraction, the pre-extraction preparations of samples 
need to be considered. Pre-extraction preparations are important, to preserve 
the molecules of interest within the plant sample245.  
A. Dry or fresh samples 
Plant material can be utilized either fresh or dried, both having certain 
advantages and disadvantages. Analysing fresh samples gives the advantage 
of being representative for what is in the plant when consumed immediately 
as fresh product. However, being of organic content, plant material will not 
stay fresh for long and would need to be analysed within a few hours of 
harvesting246. In comparison, when drying or freezing samples, they can be 
preserved for much longer without affecting the contents of the sample. 
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Dry materials allow the expression of components from the sample on a dry 
mass basis and thus remove the problems associated with water content in 
crude samples247. There are a number of drying processes available and these 
include air-, microwave-, oven- and freeze-drying (lyophilisation) all of which 
are described in more detail in a review by Azwanida245. Using different drying 
techniques and temperatures can lead to materials with different 
characteristics, which might affect the subsequent extraction process248. In 
general, the drying process can change the plant composition, and 
consequently does not present a reliable comparison of the plants initial 
composition. However, since dried samples can nowadays be effectively 
stored, they are used more regularly than fresh ones. Vongsak et al.249 
studied different extraction techniques such as decoction and maceration on 
fresh and dry samples of drumstick tree (Moringa oleifera) leaves. Their 
findings showed no significant differences in phenolic contents, between the 
fresh and dried samples when extracting using decoction. In general, their 
results show that the extraction technique and solvent composition are more 
important than the decision on whether to use fresh or dry samples. In 
contrast, a study by Vaidya et al.250, on the “Antioxidant Capacity of Fresh 
and Dry Leaf Extracts of Sixteen Scutellaria Species” demonstrated significant 
differences of total polyphenol content, Trolox equivalent antioxidant capacity 
(TEAC) as well as total flavonoid content. The found differences are not 
consistently better for one or the other, the outcome was dependent on the 
species as well as the analysis method. 
Mulinacci et al.251 published a paper on the effects of pre-extraction 
preparations, comparing fresh rosemary sample to frozen, freeze-dried and 
room temperature died samples. Freezing of the fresh material was not 
appropriate for rosemary, due to a loss of rosmarinic acid. Freeze-drying gave 
better results than drying at room temperature, for total flavonoids, 
terpenoids and phenols content. Overall, fresh samples still showed the 
highest results for all the analysed characteristics. 
The deciding factor on whether to use dried, frozen or fresh samples depends 
on the experimental procedure as well as the project length, the questions of 
interest as well as the source material available for analysis. 
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B. Whole plant versus ground samples 
As part of the extraction process one has to decide whether to use whole 
plant parts or ground/powdered samples. Grinding can be accomplished with 
a conventional pestle and mortar or electric grinders and mills. By grinding 
the sample, the particle size is lowered, resulting in an increased surface area 
between sample and extraction solvent. Theoretically, the smaller the particle 
size, the bigger the surface contact area, the better the extraction efficiency 
due to a better mass transfer of active particles from plant material to 
solvent252. However, in practice this does not always seem to be the case. In 
a study by Makanjuola253 for example it was shown, that for the aqueous 
extracts the smallest particle size always showed the highest antioxidant 
properties. However, for both ethanoic and aqueous ethanoic extracts no 
single particle size (0.425, 0.710 and 1.180 mm) was able to show significant 
different results in any of the antioxidant assays253. This led to the conclusion, 
that (i) the optimal particle size depends on the solvent; (ii) the optimal 
particle size depends on the antioxidant properties measured (assay type) 
and (iii) not always the smallest particle size yields the best antioxidant 
properties. In a different study, by Kossah et al.254, it was shown, that with 
decreasing particle size, the extracted phenolic content increased. However, 
no significant difference was observed between the smallest particle sizes 0.5 
and 1 mm. This leads to the conclusion that the difference between particle 
size, below a certain size (such as 1 mm), potentially has a smaller or no 
impact on the extraction efficiency. Although grinding seems to positively 
affect the extraction efficiency in most cases, it also adds an additional step 
to the process, costing time and money. Khan et al.255 provide one example, 
where a decreased particle size reduced the extraction efficacy of polyphenols 
from orange peel. A range of five particle sizes (0.5, 1.0, 1.5, 2.0 and 2.5 
cm2) was tested and polyphenol yields of 3.44%, 3.65%, 4.32%, 4.41% and 
4.38% were found respectively. In this case, the highest concentration of 
polyphenols was reached with particles of 2.0 cm2. One suggested 
explanation for this observation was that smaller particle sizes of orange peel 
float at the top of the extraction solvent, leading to less efficient extraction. 
Considering the examples provided here, the decision on whether to grind 
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samples and if so to which size must be made with economic reasoning and 
considering the sample characteristics and the extraction technique. 
2.1.1.2 Extraction solvents 
A very important factor to consider for the extraction of phytochemicals apart 
from the extraction technique (2.1.1.3 Extraction technique p.70) is the 
solvent. There is a large number of solvents available for the different 
extraction techniques. The choice on what solvent to use depends on the 
following factors: (i) used extraction technique, (ii) compounds of interest, 
(iii) environmental impact, (iv) costs, (v) safety and (vi) ease of use, e.g. low 
boiling point for solvent removal. The table below provides an overview of 
which liquid solvents to use, when interested in a particular group of 
secondary metabolites. 
Table 2.1| Solvents used for extraction of specific plant secondary 
metabolite groups (adapted from256–258) 
solvent Water Methanol Ethanol Acetone Chloroform Ether 
Extraction 
of: 
Tannins Anthocyanin   Tannins Flavonoids Terpenoids Alkaloids 
Saponins Terpenoids Polyphenols  Flavonoids Terpenoids 
Terpenoids Saponins Flavonol  
 
coumarins 
Lectins Tannins Terpenoids  
 
Fatty acids 
Poly- 
peptides 
Flavones Alkaloids  
  
Antho- 
cyanins 
Polyphenols Poly- 
acetylenes 
 
  
 Quassinoids Sterols    
  Ethanol    
polarity 
polar                                                                                             non-polar 
 
By mixing two or more of the solvents, presented above, for extraction, 
different compounds can be extracted. In a recent study by Ngo259, four 
different pure solvents (acetone, methanol, ethanol and water) together with 
water mixtures (50% v/v) were used for extraction. Mixtures of the solvents 
showed higher results for most of the measured parameters e.g. total 
phenolics and flavonoids, radical scavenging activity, ferric ion reducing 
capacity and cupric reducing antioxidant capacity. 
Apart from the solvent or mixture of solvent of choice, also the solid to solvent 
ratio plays a role in the extraction efficiency. In a study by Wong et al.261 it 
was shown, that a 1:5 solid to liquid ratio showed lower results in the activity 
assays (Folin-Ciocalteu(FC), total flavonoid content (TFC),  ABTS and DPPH) 
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than for example a 1:15 or 1:20 ratio. The difference between the 1:15 and 
the 1:20 ratio only showed significant differences for one of the assays (FC). 
It can be assumed that a further increase of the ratio would show less of an 
effect in extraction efficiency. Also in Radojković et al.244,  a higher solvent to 
sample mixture showed better results, which is consistent with the mass 
transfer principle. The transfer of compounds into the solvent is dependent 
on a concentration gradient between solid and solvent, meaning higher 
solvent to solid ratio shows better extraction.  
2.1.1.3 Extraction technique 
Extraction is the process of separating compounds of interest from a solid or 
liquid starting material using selected individual or a mixture of solvents. The 
extraction of phytochemicals from plant and plant by-products has always 
been of interest, especially in Asia, where herbal remedies have commonly 
been used throughout the centuries. Also, in the western world, the interest 
in extracting active compounds from plants and plant by-products has seen 
a significant increase over the last few years. Extraction is the process  used 
to separate the soluble metabolites from the plants. The procedure leaves 
behind the insoluble residue (cellular marc)245,252. The plant extracts can 
contain various secondary plant metabolites such as phenolics, flavonoids, 
alkaloids, glycosides and terpenes. Products obtained through extraction of 
for example medicinal plants are usually impure liquids, semisolids or 
powders (depending on post-extraction procedures). They can be used for 
oral administration or external application. Some of the common extraction 
techniques are explained briefly in Table A1 (appendix, p.424 ff.), including 
some advantages and disadvantages as well as examples of papers where 
they were used for the extraction of plant metabolites. 
For the extraction of RSP in this project, three different extraction techniques, 
Soxhlet (SOX)-, ultrasonic assisted (UAE)- and accelerated solvent (ASE) 
extraction were initially evaluated and the extracts compared in vitro. These 
three extraction techniques are described in more detail below. 
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Figure 2.1| Extraction of phytochemicals from RSP  
 
A. Soxhlet Extraction (SOX) 
One of the working extracts was obtained via automated Soxhlet extraction, 
a technique often used for lipid extractions262,263. However, this user friendly 
method of extraction has previously also been used for the extraction of 
phytochemicals264,265. For automated Soxhlet extraction, the sample is 
weighed into a cellulose thimble, which is inserted into a metal wire holder 
and then introduced to the solvent in the extraction beaker. In most 
automated systems a number of these beakers (2-6) can be run in the same 
machine and sometimes a number of machines can be run at the same time 
all managed by one controller (multistat)266. The extraction starts with the 
heating of the solvent to a set temperature (hot extraction, see Figure 2.2 A, 
p.72).  
 
SOX UAE ASE 
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Figure 2.2| Automated Soxhlet extraction apparatus 
adapted from Gerhardt instruction manual266  
The cellulose thimble lets the solvent pass through, and the sample is in direct 
contact with the solvent throughout the whole extraction time (Figure 2.2 A). 
The extraction can be set to any desired time between 0 and 99 minutes266.  
Leakage of the sample into the beaker is prevented by using glass wool in 
the top of the thimble. After a period of extraction, the first evaporation 
process starts, to allow the solvent, to reach levels below the cellulose 
thimble. For this, the outlet at the top of the beaker is opened, to let the 
solvent evaporate. The evaporated solvent is cooled down and then collected 
in a recovery tank in the back (Figure 2.2 B). This makes it possible to recycle 
the solvent for a considerably lower environmental impact. After the solvent 
has evaporated below the level of the thimble/sample, the rinsing process 
starts, by closing the outlet at the top. This way the evaporating solvent 
condenses just above the beaker and can drop back down through the sample 
and rinse out further compounds of interest with the condensed solvent 
(Figure 2.2 C). The rinsing time can also be set to any desired time between 
0-99 minutes266. There after the final evaporation takes place to lower the 
Hot extraction
The sovent 
surrounds the 
material and 
extractable 
comounds are 
liberated into 
the solvent. 
Evaporation A
Evaporation of 
solvent below 
extraction 
thimble. Solvent 
is collected in 
recovery tank.
Rinsing
The material is 
extracted 
further via 
refluxed and 
condensed 
solvent 
dripping from 
the top 
through the 
thimble.
Evaporation B
Most of the 
solvent is 
evaporated, to 
concentrate 
extract.
A B C D 
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amount of solvent in the extract, to shorten the post-extraction preparations 
needed (Figure 2.2 D). After the extraction finished, necessary modifications 
can be applied during post –extraction processing (2.1.1.4). 
Previously extractions of the rapeseed pomace involving two step extractions 
with petroleum ether (40-60°C) and an ethanol/water (95/5%, v/v) mixture 
showed high levels of phenolic compounds. In addition those extracts 
exhibited radical scavenging activity, ferric ion reducing antioxidant power 
and partial rescue of a MJD C. elegans disease strain79,267. Due to these 
positive results, the same extraction method will be undertaken, and the 
extracts tested to confirm the previously observed results.  
 
B. Ultrasound Assisted Extraction (UAE) 
An additional extraction method used is conventional solvent liquid 
extraction, assisted by ultra sound (UAE) as previously undertaken by for 
example Londoño-Londoño et al. and Khan et al. 255,268. When using UAE, two 
different ultrasound options can be used, either ultrasonic baths (indirect 
sonication) or ultrasound probes. Ultrasonic baths are common laboratory 
equipment and were used for this project. For the extraction process, the 
sample and solvent are mixed in glass jars and immersed in the ultrasound 
bath for the desired time. The solvent is in constant contact with the sample. 
When the ultrasound passes through the solvent, small vacuum filled bubbles, 
also called cavitations are created. These can implode with further 
rarefraction and compression cycles (Figure 2.3, p.74). When they burst an 
area of increased temperature and pressure is created, which improves the 
extraction because of the higher mass transfer269,270. A review recently 
published in Ultrasonics Sonochemistry by Chemat et al.271 provides details 
on recent advances on the use of UAE for food and natural products and 
references other papers for more detailed background literature. 
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Figure 2.3| Schematic of UAE using a ultrasound water bath 
description on cavitation adapted from272,273 
Extractions from RSP had been undertaken using UAE before with promising 
results. The obtained extraction product showed phenolic content, radical 
scavenging activity, ferric ion reducing antioxidant power as well as the 
partial rescue of a C. elegans model of MJD79,267. Research published by Yu et 
al.27 demonstrated the positive effect of UAE (ultrasonic probe) in the 
extraction of protein and polyphenols from rapeseed green biomass. Also 
other publications have shown successful use of UAE for plants and plant by-
products255,274, including rapeseed52. 
 
C. Accelerated Solvent Extraction (ASE) 
Both above methods use a large amount of solvent. In case of the Soxhlet 
extraction the sample is also heated up to the boiling point of the solvent 
(140°C-260°C) which might decompose some of the phytochemicals275. For 
those reasons, a third extraction method is employed for comparison 
purposes. Accelerated solvent extraction (ASE), also known as pressurized 
fluid/liquid extraction10, is an extraction technique working with smaller 
volumes of solvents. To avoid the use of very high temperatures, which might 
decompose the secondary meatbolites of interest in the sample, high 
pressure is applied, enhancing the extraction kinetics at lower temperatures 
and shortening the extraction time. The equipment available allows the user 
to run multiple sample cells at the same time without human intervention. 
The solvent is pumped into the extraction cell, which is located in an oven 
and the extract solution collected in as separate vessel (Figure 2.4).  
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Figure 2.4| Schematic of ASE equipment  
(adapted from Shahid et al.39) 
Parameter such as extraction time and cycle number, solvent mixture and 
temperature can be adapted. Vergara-Salinas et al.11 successfully used ASE 
for the extraction of phenolics from deodorized thyme (Thymus vulgaris). 
Their results showed the best phenolics extraction was with a 5-minute 
extraction at 100°C, using water. However, the highest antioxidant activity 
was obtained with extracts from a higher temperature (200°C) and longer 
extraction time (30 minutes)11. Similarly, Hossain et al.276 found that extracts 
obtained with higher extraction temperatures (129°C) exhibited better 
antioxidant activity than extracts from lower extraction temperatures (66°C). 
They also compared different mixtures of methanol (32-88%) and water as 
extraction solvent on three plants of the Lamiaceae family. Their findings 
showed, that for different plant species different methanol/water mixtures 
were optimal276.  
2.1.1.4 Post-extraction preparations 
In post extraction methodology most extracts are liquid, consisting of the 
extracted compounds dissolved in the utilized solvent/s. The extract solution 
can be analysed as it comes, as long as the solvent does not interfere with 
the subsequent experiments. Long-time storage of extracts in this condition 
however, can have a strong impact on their activity in vitro as well as their 
phenolic and anthocyanins contents as reported by Srivastava et al.277. When 
storing blueberry extracts in their liquid form in glass bottles, a significant 
decrease in phenolic and anthocyanin content and antioxidant activity trolox 
equivalent antioxidant capacity (TEAC) assay was found within the first 
Collection vessel 
valve pump 
solvent/s 
 
nitrogen 
Oven,  
with extraction cell 
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month of storage at 23±1°C and 35±1°C. Even storage at temperatures of 
6±1°C and -20±1°C showed a significant decrease in phenolic and 
anthocyanin content after 60 days. The antioxidant activity (TEAC) was not 
significantly changed at -20°C277. These significant changes for phenolic and 
anthocyanin content even at -20°C (60 days) when stored as liquid extracts 
must be borne in mind when planning long-term projects. Therefore, the 
solvent is usually evaporated using rotary evaporation and/or a vacuum 
drying oven. Leftover water/moisture can be evaporated by freeze-drying 
(lyophilisation).  
Thus, a solid final product provides a material, that is easy to handle 
(homogeneous sample taking), more stable for storage and less prone to 
degradation. In a study by Maisuthisakul et al.278 the antioxidant activity of 
freeze dried Thai mango seed kernels was tested over a period of 0-182 days 
under different storage temperatures. DPPH radical scavenging as well as 
antioxidant efficiency decreased significantly at room (28-32°C) and fridge 
(7°C) temperatures. The appropriate storage temperature was found to be -
20°C, as the extracts activity did not change (aluminium foil packaging)278.  
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2.1.2 Determination of secondary metabolites in 
extracts 
To determine the chemical composition of extracts several methods are 
available. Simple chemical reactions can be used for qualitative analysis, e.g. 
Mayer’s and Wagner’s test for the determination of alkaloid279, froth test for 
saponins280, Salkowski’s and Libermann Buchard’s test for 
steroids/triterpenoids281 and the gelatine test for the presence of tannins282. 
For a general overview of total amounts of certain groups of secondary 
metabolites, UV-VIS spectrophotometric methods have successfully been 
used for qualitative and quantitative analysis. A few examples are detailed in 
Table 2.2 (p.78).
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Table 2.2| UV-VIS methods for the detection of secondary metabolites in plant extracts 
Secondary 
metabolite UV-VIS detection chromatography 
 specific 
Chemical test/reaction 
chemicals used 
Example, with 
reference 
method 
Example, with 
reference 
Alkaloids Total alkaloids 
reaction between alkaloid and 
bromocresol green (BCG) 
Chitrakadivati283, 
Sankezhen (roots of 
Berberis plant) 284 
HPLC 
Sankezhen (roots of 
Berberis plant) 284 
Glucosinolates Total glucosinolates sodium tetrachloropalladate 
Mustard cake (de-
oiled)285, cruciferous 
seeds286 
HPLC-DAD Rapeseed meal115 
Terpenoids Total triterpenoids 
vanillin-acetic solution, sulfuric 
acid/perchloric acid and acetic 
acid 
Jatropha curcas 
leaves287, medicinal 
plants288 
GC-MS 
Plant leaves (Ocimum 
basilicum and 
Nicotiana 
langsdorffii)289 
Fast-GC Pine290 
LC-MS/MS Ginko291 
Phenolics 
Total phenolics 
Folin-Ciocalteu reagent 
(2.1.3.1 Folin-Ciocalteu- (FC) 
Assay) 
medicinal plants288, 
oil cake extracts292, 
Root of Salacia 
chinensis L.259 
HPLC/LC-MS fruits293 
HPLC-DAD Trochuda cabbage294 
Total flavonoids 
NaNO2, AlCl3*6H2O solution and 
NaOH 
medicinal plants288 LC-MS/MS Ginko291 
Total anthocyanins 
pH differential method (0 Total 
Monomeric Anthocyanin Pigment 
Content) 
Juices, wine, food 
colorants295, 
Chilean berry 
extracts296 
HPLC-ESI-
MS 
 
Acai species275 
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Apart from spectroscopy other methods such as indirect desorption 
electrospray ionization imaging mass spectrometry297, GC-MS298, thin layer 
chromatography (TLC) and high performance thin layer chromatography 
(HPTLC)299, infrared spectroscopy (IR)300 , NMR246, capillary electrophoresis 
(CE)280 and others can be used for the isolation and determination of 
secondary metabolites. However, the most common method for the 
qualitative/quantitative determination of single secondary metabolites in 
plant, plant components or plant extracts are high performance liquid 
chromatograph (HPLC), liquid chromatography coupled to mass spectrometry 
(LC-MS or LC-MS/MS), gas chromatograph (GC) or gas chromatography mass 
spectrometry (GC-MS). Secondary profiling of different groups of secondary 
metabolites can be undertaken and the present metabolites can be qualified 
and quantified (Table 2.2).  
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2.1.3 Antioxidant/Reducing capacity assays 
There are a number of assays available to analyse in vitro 
antioxidant/reducing capacity. These chemical assays are based on different 
mechanisms and hence provide distinct information on the interactions of the 
antioxidant and the respective ROS/RNS species created/used301. Depending 
on the reaction involved, these can be broadly divided into hydrogen atom- 
(HAT) and electron transfer (ET) reactions as described by Huang et al.302. As 
previously reported by  Apak et al.303, HAT-based assays measure the 
capability of substances to quench free radicals by donation of hydrogen 
atoms, like demonstrated in the following reaction (Equation 2.1), where the 
H-atom of e.g. the phenol (Ar-OH) is transferred to a peroxyl radical (ROO●). 
Equation 2.1 
The aryloxy radical (ArO●) formed in the reaction is stabilized and non-
reactive, due to resonance, hydrogen bonds and conjugation303–305. To protect 
biomolecules (BioH) effectively, the antioxidants need to react faster with the 
free radicals than the biomolecules themselves. This mechanism of 
competitive reaction is reflected in HAT-based assays such as the total 
peroxyl radical-trapping antioxidant parameter (TRAP)306 and the crocin 
bleaching307 assay both of which use the peroxyl radical generator 2,2'-
Azobis(2-amidinopropane) dihydrochloride (AAPH) as radical source. The 
latter measures the inhibition capacity of compounds to prevent the bleaching 
of crocin (natural carotenoid) by AAPH302, whereas the TRAP assay employs 
R-phycoerythrin as fluorescence probe and analyses the lag time of 
fluorescence decay induced by antioxidants308. The oxygen radical 
absorbance capacity (ORAC, 2.1.3.4) assay is another example for a HAT 
based reaction, whereas the Folin-Ciocalteu (FC, 2.1.3.1) assay and the ferric 
ion reducing antioxidant power (FRAP, 2.1.3.2) assay are ET based302. The 
latter reactions are based on the ability of antioxidants to transfer one of their 
electrons (e-) to either free radicals, carbonyls or for example metals232,309 
(Equation 2.2) 
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Equation 2.2 
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay in contrast has been found 
to be based on both, electron and hydrogen atom transfer310. Depending on 
the solvent of choice and the pH, one or the other can be favoured. Although 
most often it is referred to as an ET reaction302.  A summary of a number of 
common assays to determine antioxidants from natural sources is provided 
in Ndhlala et al.311, where the mechanism, advantages and disadvantages are 
described. None of the above in vitro assays can accurately reflect all the 
radical sources and reaction characteristics/mechanisms involved, within 
living organisms, alone. That is why for most studies two to four different 
assays are often undertaken90,312,313.  
Following, a brief summary and the reaction mechanism behind all four 
assays, used in this study, together with their advantages are explained in 
detail. Limitations of each technique will follow in results and discussion (2.3 
Results and Discussion, p.98). 
2.1.3.1 Folin-Ciocalteu- (FC) Assay 
This assay, often referred to as “total phenolic assay” or “Gallic acid 
equivalence method”, measures the samples reducing capacity and not total 
phenolic content of samples. A variation of this assay was described as early 
as 1912 in a paper published by Folin and Denis314. Later in 1927 Folin and 
Ciocalteu then described the reagent for the detection of tyrosine (containing 
phenol group) and tryptophan302,315. As early as 1965 Singleton and Rossi 
described the use of Folin-Ciocalteu reagent, in favour over the original Folin-
Denis reagent, for the determination of phenolics in wine samples using gallic 
acid as standard316.  The method was even adopted by the European 
Communities for the analysis of wine in 1990317 but is also described in more 
recent publications318. Although the reagent can be prepared, as described by 
Huang et al.302 and the European commission317,318, most often is just bought 
as ready to use reagent from chemical suppliers. The reagent is a mixture of 
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tungstate (W6+) and molybdate (Mo6+)319, when in contact with phenolics 
changes its colour from yellow to blue in an alkaline environment (sodium 
carbonate). It is assumed, that the molybdenum in the complex is easier to 
reduce and electron transfer occurs between reductants and Mo6+ (Figure 
2.5). 
 
Figure 2.5| FC reagent reaction with phenolic compound 
The intensity of the blue colour relates to the concentration of phenolics as 
described by Singleton and Rossi316. Gallic acid is used as phenolic standard 
and the final results are given as mg gallic acid equivalence (GAE)/g sample 
or per mL of a solution/extract. The analysis is quick and does not require 
excessive amounts of preparations, when using prepared FC reagent directly. 
It is usually one of the first experiments undertaken when analysing samples 
of unknown phenolic composition such as plant extracts244,276, fruit juice/ 
beverages236,320 or extracts from plant waste/by-products68,113,292. 
 
2.1.3.2 Ferric Reducing Antioxidant Power (FRAP) assay 
As with the FC assay, the FRAP assay is based on an ET reaction. The ferric 
salt, Fe (III)(TPTZ)2Cl3 (Figure 2.6) is the oxidant; the antioxidant provides 
FC reagent 
(Mo6+, W6+) 
Reduced FC 
reagent (Mo5+) 
e- 
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an electron, which leads to the reduction of Fe (III) to Fe (II), yielding an 
intense blue colour, which can be measured at 593 nm.  
 
Figure 2.6| FRAP reaction mechanism 
This assay was first described by Benzie and Strain321,322 for the measurement 
of reducing power in plasma but it was quickly adapted for the determination 
of antioxidants in botanicals323,324. The redox potential of Fe (III) salt (⁓ 0.7 
V) is close to the one of ABTS●- (⁓ 0.68 V) the oxidant used in an additional 
antioxidant assay called Trolox Equivalent Antioxidant Capacity Assay 
(TEAC), the only difference being the pH which they are run at. The FRAP is 
conducted under acidic aqueous conditions (pH 3.6), whereas the TEAC is 
carried out at a neutral pH. These two assays usually show good positive 
linear correlation325,326, warranting the use of only the FRAP assay in this 
project. The FRAP is a rapid method for the determination of reducing power 
of unknown samples. Although the preparation of the FRAP reagent is slightly 
more time consuming than the ready to use solution in the FC assay, the 
assay is still quick and easily conductible with common laboratory equipment. 
2.1.3.3 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay 
DPPH, a stable radical was first suggested for the determination of antioxidant 
content by Blois in 1958327, since then it has be adapted and is mostly used 
to determine radical scavenging activity of samples with antioxidant property. 
The experiment is simple and can be undertaken even in laboratories 
equipped with little instrumentation. As previously mentioned, the reaction 
(Figure 2.7, p.84) can be based on electron or hydrogen atom transfer 
depending on the chemical environment of the experiment, making the DPPH 
assay a bit more complexin determining reaction mechanisms310,328.  
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Figure 2.7| DPPH reaction with radical scavenger (H-AO) 
example of HAT based reaction 
Once the DPPH radical, with an unpaired valence electron at the atom of the 
nitrogen bridge (dissolved in methanol purple), reacts with a radical 
scavenging compound, it is converted into the reduced DPPH2, resulting in a 
colour change from purple to yellow, as indicated in Figure 2.7. In this 
reaction DPPH acts as both, the radical and the probe329. 
This assay has been used for a wide variety of antioxidants, such as the 
radical scavenging of different plant extracts249,330–332, food by-products292,333, 
beverages320,329 as well as single compounds310,328. 
2.1.3.4 ORAC 
The ORAC assay is based on early work by Glazer334 and was further 
developed by Cao et al.335. In this assay AAPH is used to create peroxyl 
radicals, which react with the fluorescent probe, causing oxidation of the 
latter, to produce a non-fluorescent product. The initial fluorescence probe 
introduced by Cao et al.335 was B-phycoerythrin (B-PE), an isolated protein 
from red alga (Porphyridium cruentum). This probe was replaced in 2001 with 
fluorescein, due to its advantages over B-PE, such as decreased experimental 
costs, less interaction with other compounds and higher stability in the 
absence of AAPH305.  The kinetics of the reaction between fluorescein and 
AAPH (Figure 2.8) can be monitored using fluorescence spectroscopy, over a 
set period of time323. 
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Figure 2.8| Reaction mechanism of reaction between fluorescein and 
AAPH  
(adapted from305,336) 
This HAT-based reaction uses a competitive reaction scheme between the 
antioxidant and the fluorescein probe for the constantly generated peroxyl 
radical (hydrophilic). These are created by AAPH, via spontaneous thermal 
decomposition337. The stronger the antioxidant activity of the compound in 
question the better the elimination of the created radical and hence the better 
protection of the fluorescence probe (Figure 2.9, p.86).  
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Figure 2.9| Graphical representation of the ORAC assay 
comparing a blank to a weak and strong antioxidant in the reaction mix 
The results are presented using fluorescence decay curves, determining 
inhibition time and degree305. Since its introduction this assay has widely been 
used for the determination of antioxidant capacity of beverages329, 
plants/plant extracts338–340 as well as biological samples e.g. urine or 
serum305.  
Compared to the FRAP assay that follows a single electron transfer 
mechanism and measures the specific oxidant –reducing power, ORAC 
measures chain-breaking antioxidants that interrupt the radical chain 
reaction. More specifically, the ORAC assay determines the hydrophilic 
(aqueous  condition) antioxidant activity for the AAPH created peroxyl 
radicals305,319. Use of the peroxyl radical offers advantages over some of the 
other assays, providing a better model for ROS in food and in vivo than for 
example DPPH radicals. Also, the continuous production of radicals, caused 
by the temperature of the assay (37°C), in a timely manner are closely 
associated with in situ reactions341. 
Determination of antioxidant activity of the different RSP extracts together 
with their secondary metabolite composition, will aid to determine a 
favourable extraction technique for further investigations. This and the other 
objectives set out for this part of the project are highlighted next.  
blank 
weak 
antioxidant 
strong 
antioxidant 
+ fluorescein + AAPH 
short term  long term  
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2.1.4 Objectives 
The list below describes the objectives set out for this chapter: 
- Determine the secondary metabolite composition of the RSP (free and 
bound fraction) 
- Compare three different extraction techniques and determine the most 
suitable using antioxidant activity assays as well as LC-MS/MS analysis 
of secondary metabolites 
- Compare pomace samples from two harvest years and decide on most 
appropriate using antioxidant activity assays as well as LC-MS/MS 
analysis of secondary metabolites 
- Determine secondary metabolites responsible for the shown activity 
via partial least squares analysis (PLS) analysis 
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2.2 Materials and Methods 
2.2.1 Chemicals and Equipment 
For the experiments discussed in this chapter, the following chemicals (Table 
2.3) and equipment (Table 2.4) were used. 
Table 2.3| Chemicals, reagents and kits 
Chemicals Provider 
1,1-Diphenyl-2-picryl-hydrazyl 
(DPPH) 
Sigma-Aldrich 
Methanol (HPLC grade) Sigma-Aldrich 
Gallic acid Sigma-Aldrich 
Trolox Sigma-Aldrich 
Folin & Ciocalteu’s phenol 
reagent 
Sigma-Aldrich 
Sodium acetate trihydrate Sigma-Aldrich 
2,4,6-Tris(2-pyridyl)-s-triazine 
(TPTZ) 
Sigma-Aldrich 
Hydrochloric acid (HCl) Sigma-Aldrich 
Ferric chloride Sigma-Aldrich 
Sodium carbonate (Na2CO3) Sigma-Aldrich 
Sodium hydroxide (NaOH) Sigma-Aldrich 
2,2'-Azobis(2-amidinopropane) 
dihydrochloride (AAPH) 
Sigma-Aldrich 
Monopotassium phosphate 
(KH2PO4) 
Sigma-Aldrich 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma-Aldrich 
Sodium fluorescein Sigma-Aldrich 
Sinapic acid (SA) Sigma-Aldrich 
Glacial acetic acid (CH3CO2H) Fisher Scientific 
Ethanol Fisher Scientific 
Tris-base Fisher Scientific 
Petroleum ether, extra pure 
(C6H14; boiling point 40-60°C) 
Fisher Scientific 
Naringenin Sigma-Aldrich 
Syringic acid (SyA) Sigma-Aldrich 
Ferulic acid (FA) Sigma-Aldrich 
Caffeic acid (CA) Sigma-Aldrich 
Vanillic acid (VA) Sigma-Aldrich 
Vanillin (V) Sigma-Aldrich 
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Table 2.4| Equipment 
Equipment Manufacturer/Details 
Freeze Dryer  Modulyo Edwards 
Coffee grinder De Longhi KG39 
Freeze-mill Spex 6700, Edison 
LC MS/MS (Rowett) Agilent 1100 
Automatic Soxhlet Gerhardt; Soxtherm SE 416 
Plate reader BioTek µQuant 
Ultrasonic bath (extraction) Fisher Scientific FB15060 
Evaporator gene vac (EZ-2) 
Accelerated solvent extractor Dionex ASE 350 
Rotary evaporator  Büchi Rotavapor R-114 
Oven Techne Hybridiser HB-10 
Fridge DEAWOO 
Freezer -20°C Blomberg 
Freezer -80°C New Brunswick Scientific U725 
pH meter Denver Instruments Basic 
Balance OHAUS Pioneer™PA114 
Ultrasonic bath Ultrawave SFE5901 
Balance Mettler BB1200 
Centrifuge (molecular) Heraeus Multifuge 1 L-R 
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2.2.2 Methods 
The methods described in this chapter were employed to determine the best 
possible extraction technique for further investigations. The chapter aims to 
determine a quick and reliable extraction method for the RSP and to 
determine any significant differences between the two harvest years/breeds. 
Figure 2.10 gives a general overview of the methods used. 
 
Figure 2.10| Overview of in vitro methods used in the assessment of 
RSP and RSP extracts 
2.2.2.1 Plant Material 
The RSP utilized throughout this project was provided by Gregor Mackintosh 
of Glendaveny (Mains of Buthlaw, Glendaveny, Peterhead), Scotland.  Two 
RSP samples were obtained, one breed harvested in 2012 and a second breed 
harvested in 2014 and stored in plastic bags at -80°C upon arrival. The 
pomace from the 2014 harvest was freeze dried (Edwards, Freeze Dryer 
Modulyo) prior storage at -80°C.  
Before extraction the pomace samples were individually ground in a coffee 
grinder (De Longhi KG39) to a particle size between 710 and 125 µm and 
then freeze dried (Edwards, Freeze Dryer Modulyo). Ground dried samples 
Rapeseed 
pomace (RSP) 
2012 and 2014
grinding/freeze 
drying
extraction with 
ethyl acetate 
free fraction 
bound fraction
(alkali- & acid 
labile)
LC-MS/MS 
analysis
Soxhlet 
extraction
freeze drying
LC-MS/MS 
analysis
antioxidant 
activity 
assays
FRAP assay DPPH assay ORAC assay
reducing 
capacity FC 
assay
Ultrasonic 
assisted 
extraction
Accelerated 
solvent 
extraction
 
 
RSP analysis 
(2.2.2.2)  
RSP extract analysis 
(2.2.2.3) 
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were kept at -20°C until extraction (short time storage). For long-term 
storage, the pomace was kept at -80°C. 
2.2.2.2 Secondary Metabolite Analysis of Rapeseed Pomace 
To characterise the major secondary metabolites (free and bound fractions) 
in the RSP three extractions on freeze-milled (Spex 6700, Edison) pomace 
samples were performed, to determining free (FA) and bound (alkali (ALK)- 
and acid labile (ACD)) secondary metabolites, using extraction processes 
previously described by Russell et al.293. 
Free Acids  
In brief, RSP sample (0.1 g dry weight) was suspended in HCl (0.2 M; 3 mL) 
followed by the addition of ethyl acetate (EtOAc; 5 mL). The mixture was 
shaken, vortexed and sonicated for 5 mins, followed by centrifugation (1800 
x g; 5 mins; 18C). The EtOAc layer was collected and filtered into a round 
bottom flask (50 mL), by passing through Whatman No 1 filter paper 
containing a small amount of sodium sulphate (anhydrous). This process was 
repeated two more times, with a final centrifugation (3200 x g; 10 mins; 
18C). The solvent in the round bottom flask was removed via a rotary 
evaporator at temperatures not exceeding 40C. Samples were stored in a 
desiccator until preparation for analysis. The remaining aqueous fraction 
(obtained after the EtOAc extraction) was neutralised (pH 6.5-7.0) using 
NaOH (4 M), frozen and then freeze dried.  
Alkali-labile Phenolic Acids  
To the freeze dried aqueous fractions, NaOH (1 M; 3 mL) was added and 
stirred at room temperature for 4 hours under nitrogen, then the pH was 
reduced to pH 2 with HCl (10 M). The fraction was then extracted with EtOAc 
(5 mL), shaken, vortexed and sonicated (5 mins). The solvent (EtOAc) layers 
was separated by centrifugation (1800 x g; 5 mins; 18C), and then 
processed as above.  
Acid-labile Phenolic Acids  
To the freeze dried aqueous fractions, HCl (2 M; 3 mL) was added and the 
sample incubated at 95C for 30 mins with intermittent mixing, then cooled 
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to room temperature and extracted with EtOAc (5 mL), shaken, vortexed and 
sonicated (5 mins). The solvent (EtOAc) layers was separated by 
centrifugation (1800 x g; 5 mins; 18C), and then processed as above.  
Chemical Analysis of the free and bound phenolic Extracts (HPLC-
MS/MS) 
The three RSP extract fractions (free, alkali- and acid- labile) were subject to 
LC-MS/MS analysis, to determine their phytochemical profile. The freeze-
dried extracts were dissolved in 0.5 mL methanol. For analysis, each sample 
(100 µL) was mixed with an internal standard (400 µL) and then analysed as 
previously described by Russell and Neacsu et al.342,343 on an Agilent 1100 
HPLC system, fitted with a Zorbax Eclipse 5 µm, 150 mm x 4 mm column 
(both Agilent Technologies, Wokingham, UK). This analysis was kindly 
undertaken by Garry Duncan as a service of the Rowett Institute of Nutrition 
and Health, Aberdeen University. 
 
2.2.2.3 Rapeseed Pomace Extraction techniques 
Soxhlet Extraction (SOX) 
For the Soxhlet (Gerhardt; Soxtherm SE 416) extraction both RSP samples 
from 2012 and 2014 (dissimilar breeds) were used; these will be referred to 
as SOX2012 and SOX2014 respectively. First, both pomace samples were 
defatted according to Wanasundara et al.344 and Sagdic et al.345 with some 
modifications. Ground pomace (6.0 g) was transferred into cellulose thimbles 
(Fioroni S.A X25 Extraction thimble 33x80mm) for the Soxhlet extraction. 
The lipids were extracted with petroleum ether (140 mL) as previously 
described by Qin Liu et al. 346, in a shorter procedure with the settings shown 
in Table 2.5. The de-fatted pomace filled thimbles were left to dry overnight 
in a fume hood, to remove any traces of solvent.  
After 16 hours, a second extraction with an ethanol/water mixture (95:5, 140 
mL, pH 7.9) according to Sagdic et al.345 was undertaken, with minor 
modifications (Table 2.5). The total ethanol/water extraction lasted three 
hours. The final evaporation (B) was aborted before complete dryness, to 
avoid charring of the extracts. Extracts from the 6 extraction beakers were 
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pool into one pre-weight round bottom flasks (150 mL), evaporated on a 
rotary evaporator (Büchi Rotavapor R-114), frozen and freeze dried 
(Edwards, Freeze Dryer Modulyo) to yield a powdered dry product. The 
extraction yield was determined by weight. 
Table 2.5|Petroleum ether and ethanol/water (95:5) Soxhlet 
extraction parameters 
step  petroleum ether  ethanol/water 
Extraction 45 mins, 150°C 45 mins, 240°C 
Evaporation A 4 x interval 4 x interval 
Rinsing 45 mins 45 mins 
Evaporation B 1 x interval 1 x interval 
 
Ultrasound Assisted Extraction (UAE) 
Rapeseed pomace, from both harvest years (3 g), and extraction solvent 
(95:5(v/v) ethanol/water, 70 mL, pH 7.9) were transferred into brown glass 
jars and then placed in an ultrasonic bath (Fisher Scientific FB15060) for 45 
min. Following extraction, the extracts were transferred in falcon tubes (50 
mL) and centrifuged at 2600 x g for 15 minutes. The supernatant was then 
transferred into a pre-weight round bottom flasks, evaporated on the rotary 
evaporator (Büchi Rotavapor R-114), frozen (-20°C), freeze dried (Edwards, 
Freeze Dryer Modulyo) and the extraction yield determined. Following, these 
two extracts will be referred to as UAE2012 and UAE2014 respectively. 
Accelerated Solvent Extraction (ASE) 
For the accelerated solvent extraction, the sample cells were prepared, by 
weighing 6 g Ottawa sand and 0.5 g sample (2012 and 2014 pomace) into 
an extraction cell. The latter was then packed with Ottawa sand. Cellulose 
filter (27 mm) were fitted at the bottom and top of the extraction cell. The 
extraction method was set up, to run 4 extraction cycles, using the same 
ethanol/water mixture as previously described for SOX and UAE (5 mL), at 
80°C with a static time of 5 min and a purge time of 300 s. The extract was 
collected in pre-weight brown glass vials and evaporated in the Genevac (EZ-
2), frozen (-20°C), freeze died (Edwards, Freeze Dryer Modulyo) and the 
extraction yield determined. Following these two extracts are referred to as 
ASE2012 and ASE2014 respectively. 
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2.2.2.4 Folin-Ciocalteu-(FC) Assay  
The FC assay was conducted according to Waterhouse et al.347 with minor 
modifications. Gallic acid was prepared to give final concentrations from 0.01 
to 0.20 mg/mL. The extracts were dissolved (ethanol:water, 4:10) and 
further diluted with deionised water. For the reaction to occur, test solutions 
(25 µL) were mixed with distilled water (200 µL) and FC reagent (20 µL) (n 
= 3, technical replicates in plate). After a short incubation time (3 mins at 
room temperature), 20% Na2CO3 solution (25 µL) was added. After a second 
incubation (37°C; 30 mins), the absorbance was read at 750 nm (BioTek 
µQuant). Sinapic acid (SA), as most abundant phenolic acid, was analysed 
for comparison in the FC assay. The results are expressed as mg GAE/ g dry 
RSP extract (C) by using the following formula, where c equals the found 
concentration from the gallic acid calibration graph (mg/mL), V is the used 
volume (mL) of the extract and M is the total mass (g) of extract used in one 
well (Equation 2.3). 
𝑪(𝒎𝒈𝑮𝑨𝑬/𝟏𝒈) = 𝒄(𝒎𝒈/𝒎𝑳) ∗ (
𝑽(𝒎𝑳)
𝑴(𝒈)
 ) Equation 2.3 
2.2.2.5 Chemical Analysis of the RSP Extracts (HPLC-MS/MS) 
The extracts obtained from the three extraction techniques (SOX, UAE, ASE) 
were subject to LC-MS/MS analysis, to determine their phytochemical profile. 
Solutions of the freeze-dried extracts with a concentration of 1 mg/mL were 
prepared (methanol/deionized water, 95/5 (v/v)). For analysis, each sample 
(100 µL) was mixed with a standard (400 µL) and then analysed as previously 
described by Russell et al.342,343  on an Agilent 1100 HPLC system using a 
Zorbax Eclipse 5 µm, 150 mm x 4 mm column (both Agilent Technologies, 
Wokingham, UK). Garry Duncan kindly undertook this analysis, as a service 
of the Rowett Institute of Nutrition and Health, Aberdeen University. 
 
2.2.2.6 In vitro antioxidant activity 
Ferric Reducing/Antioxidant Power (Plasma)- (FRAP) Assay 
The FRAP assay was performed according to Arya et al.348. To freshly prepare 
FRAP reagent, acetate buffer (25 mL; 300 mM; pH 3.6), TPTZ (2.5 mL; 10 
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mM in 40 mM HCL) and FeCl3*6H2O (2.5 mL; 20 mM in dH2O) were mixed 
and incubated (37˚C) until use. Trolox was prepared with concentrations 
ranging from 31.20 to 312.5 µg/mL. The samples were prepared in 
ethanol:water (4:10) and diluted further with water to obtainabsorbance 
values in the range of the calibration curve. Sample/blank/standard (10 µL) 
were mixed with the FRAP reagent (190 µl) and the absorbance at 593 nm 
(BioTek µQuant) was read after incubation (30 mins, at room temperature, 
in the dark). The results are given as mg TE/g dry extract (C) by using the 
following formula (Equation 2.4), where c is the concentration obtained from 
the Trolox calibration graph (mg/mL), V is the volume (mL) of extract and M 
is the total mass (g) of extract used in each well (Equation 2.4). 
𝑪(𝒎𝒈𝑻𝑬/𝟏𝒈) = 𝒄(𝒎𝒈/𝒎𝑳) ∗ (
𝑽(𝒎𝑳)
𝑴(𝒈)
) Equation 2.4 
 
2,2-Diphenyl-1-picrylhydrazyl- (DPPH) Assay 
The radical scavenging activity of the samples was measured using the 
method by Sagdic et al.345 with minor modifications. Serial dilutions of all the 
extracts (3.9-1000 µg/mL) were prepared in methanol and 50 µL mixed with 
freshly prepared DPPH solution (100 µL; 0.1 mM in methanol) for final extract 
concentrations between 1.3 and 333.3 µg/mL. The 96-well plates were 
incubated in the dark (30 mins; at room temperature) and the absorbance 
was read at 517 nm (BioTek µQuant). The percentage of present radicals was 
calculated as below (Equation 2.5), where A is the absorbance. The linear 
part (including the 50% mark) of the obtained curve was used to determine 
the IC50 value, by plotting a linear graph and using the trend line for IC50 
calculations.  
% 𝒐𝒇 𝒑𝒓𝒆𝒔𝒆𝒏𝒕 𝒓𝒂𝒅𝒊𝒄𝒂𝒍𝒔 =
(𝟏𝟎𝟎∗𝑨𝒔𝒂𝒎𝒑𝒍𝒆)
𝑨𝒃𝒍𝒂𝒏𝒌
  Equation 2.5 
Oxygen Radical Absorbance Capacity (ORAC) Assay 
Samples were analysed according to Roy et al.329 and Huang et al.349 with 
minor modifications. From a Trolox stock solution, a series of dilutions (10 to 
125 µM) was made in PBS (75 mM; pH 7.4). To start the ORAC reaction, 
Trolox (25 µL) and sodium fluorescein (150 µL; 25 nM) were incubated (30 
mins, 37 °C). After the incubation, 2,2'-Azobis (2-amidnopropane) 
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dihydrochloride (AAPH, 25 µL, 150 mM) was added and the reaction was 
monitored (over 2 hours at 2 mins intervals) at an excitation and emission 
wavelengths of 485/20 and 525/20 nm respectively (BioTek Synergy HT). 
RSP extract solutions were prepared (1 to 50 µg/mL) in PBS, giving final well 
concentrations of 0.125 to 6.25 µg/mL. RSP extract samples were treated in 
the same way as the Trolox standard solutions described above. The Trolox 
standard series was run with all samples to determine µmol Trolox 
equivalents (TE)/g of dry extract (C) from the net AUC calibration curve (see 
calculations below Equation 2.6-2.8). AUC is the area under the curve, fxmin 
the fluorescence measurement at the respective minute, c is the 
concentration obtained from the Trolox calibration graph (µmol/L), V is the 
volume (L) of extract and M is the total mass (g) of extract used in one well. 
 
𝑨𝑼𝑪 = 𝟎. 𝟓 +
𝒇𝟐𝒎𝒊𝒏 
𝒇𝟎𝒎𝒊𝒏
+
𝒇𝟒𝒎𝒊𝒏 
𝒇𝟎𝒎𝒊𝒏
+  
𝒇𝟔𝒎𝒊𝒏 
𝒇𝟎𝒎𝒊𝒏
+ ⋯
𝒇𝟏𝟏𝟖𝒎𝒊𝒏 
𝒇𝟎𝒎𝒊𝒏
+ 𝟎. 𝟓(
𝒇𝟏𝟐𝟎𝒎𝒊𝒏 
𝒇𝟎𝒎𝒊𝒏
) 
𝒏𝒆𝒕 𝑨𝑼𝑪 = 𝑨𝑼𝑪𝒔𝒂𝒎𝒑𝒍𝒆 − 𝑨𝑼𝑪𝒏𝒆𝒈 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 
𝑪(µ𝒎𝒐𝒍𝑻𝑬/𝟏𝒈) = 𝒄(µ𝒎𝒐𝒍/𝑳) ∗ (
𝑽(𝑳)
𝑴(𝒈)
) 
Equation 2.6-2.7-2.8 
 
2.2.2.7 In vitro antioxidant activity of single compounds in RSP 
extract/PLS 
To see if it is possible to determine the compounds responsible for the 
antioxidant activity in the RSP extract, seven different compounds were 
selected, using the following criteria: 
i. Highest concentration in extract 
ii. Most likely responsible for DPPH, FC, FRAP activity 
iii. Most likely responsible for ORAC activity 
The first criteria (i) was determined using the results obtained from HPLC-
MS/MS analysis, (ii) and (iii) were determined after PLS analysis of the data 
obtained above, using the 6 extracts, their secondary metabolite profile as 
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well as their in vitro activity from results obtained in the DPPH, FC, FRAP and 
ORAC assay.  
The overall activity of these seven compounds was tested as well as their 
activity at the extract specific (SOX2014) concentration at 1 mg/mL using the 
same methods as described in 2.2.2.4 Folin-Ciocalteu-(FC) Assay (p.94) and 
2.2.2.6 In vitro antioxidant activity (p.94 ff.)  
 
2.2.2.8 Statistical analysis 
Statistical analysis was carried out using GraphPad Prisim 7 and Umetrics 
software. Specific methods used for statistical comparison and correlation 
analysis for each experiment are detailed in the results section. P-values 
below 0.05 were considered to be significant.  All experiments were repeated 
at least three times unless otherwise stated and results shown as 
mean±standard deviation.
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2.3 Results and Discussion 
2.3.1 Secondary metabolite composition of RSP 
from free, alkali-labile and acid-labile fractions 
To determine the secondary metabolite composition of the starting RSP 
material, a number of extractions were undertaken. The reasoning of applying 
three different ethyl acetate extractions was to analyse which secondary 
metabolites would be available should RSP be used directly for human 
consumption. Since free phenolic acids are easily absorbed in the small 
intestine350, these compounds can be measured by simple solvent extraction 
into ethyl acetate (free) (Table 2.6, Table A2 p.429 ff.).  
Table 2.6| Concentrations (mg/kg pomace) of the most abundant 
secondary metabolites found in both RSP samples after free, alkali-
labile and acid-labile extractions 
Secondary 
metabolite extraction 
RSP 2012 
(mg/kg 
pomace) 
RSP 2014 
(mg/kg pomace) 
Significant 
difference 
sinapic acid 
free 224.24 ± 3.58 161.40 ± 25.55 * 
alkali-labile 917.650± 43.78 1072.14 ± 32.38 ** 
acid-labile 11.31 ± 1.38 10.54 ± 1.25  
indol-3-
pyruvic acid 
free 3.04 ± 0.39 53.54 ± 87.11  
alkali-labile 76.17 ± 131.93 197.68 ± 37.96  
acid-labile 381.40 ± 71.97 223.58 ± 123.48  
kaempferol 
free 0.19 ± 0.01 0.75 ± 0.53  
alkali-labile 0.11 ± 0.01 0.20 ± 0.01 *** 
acid-labile 141.30 ± 6.77 152.62 ± 5.54  
ferulic acid 
free 12.25 ± 0.30 9.570± 1.63 * 
alkali-labile 64.55 ± 39.37 38.65 ± 2.07  
acid-labile 1.53 ± 0.17 1.23 ± 0.06 * 
protocatechuic 
acid 
free 2.52 ± 0.04 5.40 ± 0.81 ** 
alkali-labile 16.54 ± 3.76 24.12 ± 1.20 * 
acid-labile 17.14 ± 0.53 17.42 ± 0.94  
Note(s): Further metabolites can be found in Table A2 (p.429 ff.), statistical analysis 
was performed using multiple t-tests without correction for multiple comparison in 
Graph Pad Prism6 (statistical significance with alpha=5.000%, p<0.05*, p<0.01**, 
p<0.001***), HPLC-MS/MS analysis conducted by Garry Duncan (Rowett) 
However, most of the secondary metabolites were found to be esterified to 
other plant components, like sugars and complex carbohydrates. When bound 
to cell wall components, such as polysaccharides and lignin, they are unlikely 
to be absorbed in the small intestine and will only be available after microbial 
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release and metabolism in the colon351,352. Bound metabolites were measured 
after alkali (ALK) and acid (ACD) extraction. Although this does not allow the 
determination of the conjugate, it allows for a more accurate phenolics 
quantification353.  
Table 2.6 shows the five most abundant secondary metabolites found. The 
table distinguishes among the three extraction techniques (free, ALK, ACD) 
used for total metabolite analysis. A part of the results presented here have 
previously been published in F. Pohl et al.353 in 2018. A more detailed list of 
all the analysed metabolites is presented in Table A2 in the appendix (p.429 
ff.), including compounds analysed for, but not present in the extracts. 
There are significant differences between the two harvest years, when 
comparing the results found for the metabolites from the different 
extractions. Sinapic acid shows significantly higher (p<0.5) results in the free 
metabolite fraction for 2012, but for the alkali labile fraction concentrations 
were found to be significantly higher in the 2014 pomace. Whereas there is 
no significant difference for the acid-labile fraction. In general, there is no 
trend visible for both samples/years and the extraction techniques studied.  
As expected, most metabolites were found following alkali and/or acid 
extractions e.g. approximately 80% of sinapic acid was extracted after alkali 
treatment, while most of the kaempferol (more than 99%) was obtained after 
acid treatment. Only for a small number of compounds such as m-
hydroxybenzoic acid and chlorogenic acid as well as cinnamic acid and 
phenyllactic acid no/or smaller concentrations were extracted during 
alkali/acid-labile extraction respectively (Table A2, p.429 ff.). In general, only 
few studies have been carried out on the accessible secondary metabolites 
after ethyl acetate extraction of rapeseed pomace/meal. Most times the 
solvents of choice are methanol, ethanol, water or mixtures of these91,338. 
Similar free phenolic acids were found previously by Krygier et al.354, in 3 
different defatted rapeseed cultivars (flour), showing the presence of p-
hydroxybenzoic, vanillic, gentisic, protocatechuic, syringic, p-coumaric, 
ferulic, sinapic, and chlorogenic acid at different concentrations depending on 
the cultivar. Sinapic acid was found to be the most abundant in all 3 samples 
(Table 2.7, p.100). The analysis of RSP itself gives a very good idea on what 
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can be extracted when using different extraction methods such as SOX, UAE 
and ASE. 
A series of papers by Krygier et al. and Sosulski  et al.354–356 looked into free 
and bound fractions of phenolic acids in defatted rapeseed and other 
vegetable flours. Their method of extraction was slightly different to the one 
used here, e.g. no acid labile extraction was undertaken. However, it gives a 
good indication about free and bound fractions in the three varieties of 
rapeseed (Yellow Sarson, Indian; Candle and Tower, Canadian) studied. They 
found trans-sinapic acid to be the most abundant phenolic acid in both, the 
free (37 mg/kg-801 mg/kg, Table 2.7) and from esters liberated fraction 
7123-11162 mg/kg. 
Table 2.7| Comparison of free phenolic acids detected from rapeseed 
flour in Krygier  et al.354 to the two harvests in this study (2012, 2014)  
Phenolic acid Yellow 
Sarsona 
Candlea Towera Scottish Rapeseed 
pomace 
  2012 2014 
p-hydroxybenzoic 1 5 trace 3.8 5.2 
Vanillic trace 3 8 1.8 2.6 
Gentisic  4 trace Not analysed 
Protocatechuic 3 6  2.5 5.4 
Syringic 11 6 15 2.4 5.7 
p-coumaric  11 31 2.2 1.9 
cis-ferulic  trace 0.6 
12.3b 9.6b 
trans-ferulic 8 68 27 
Caffeic 1 3 4 5.5 7.5 
cis-sinapic trace 7 90 
224.2 b 161.4 b 
trans-sinapic 37 732 801 
Chlorogenic  trace trace 1.0 1.0 
Total 61 845 982 254.7 200.3 
Notes(s): All concentrations given as mg/kg dry pomace/flour  
a values adapted from publication354 transferred from mg/100g to mg/kg 
b not distinguished between cis- and trans-forms 
HPLC-MS/MS analysis of Scottish Rapeseed pomace conducted by Garry Duncan 
(Rowett) 
When comparing the concentrations oof free phenolic acids measured by 
Krygier et al.354 with ours (Table 2.7), similar results were obtained for most 
phenolics. Surprisingly, the amount of total sinapic acid was very low for their 
Yellow Sarson variety (37 mg/kg) compared with Candle (739 mg/kg) and 
Tower (891 mg/kg) cultivar. However, our Scottish RSP gave concentrations 
within the minimum and maximum values obtained. 
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Some differences can be explained by the pre-extraction preparations. In our 
study, the pomace was obtained from a family farm that obtains oil purely by 
cold pressing357. In contrast, the samples used in Krygier’s study were first 
defatted using hexane as solvent. The defatting process makes the starting 
material lighter implying that more flour/pomace was initially weighed in for 
further extraction when compared to this project. Furthermore, the difference 
in extraction solvent and the different growing conditions can have an impact 
on the results. Unfortunately, the alkali/acid-labile extraction in our work 
cannot be compared with Krygier’s paper, due to differences between the 
methods.  
Other publications also suggest the usage of acid and alkali extractions to find 
the bound fractions of secondary metabolites358,359. The same alkali/acid-
labile extraction undertaken in this project, have previously been undertaken 
to determine bound secondary metabolites in different fruits in Russell et 
al.293  and cereals in Neacsu et al.343 . For better comparison in the same plant 
family (Brassica), selected secondary metabolite compositions of e.g. 
cabbage, kale, broccoli and cauliflower are provided in Table A3 (p. 440, 
unpublished data360). This set of data was provided by Wendy Russell from 
the Rowett Institute, where they form part of a study on secondary metabolite 
composition of different plants. The table shows, that the RSP shows a similar 
secondary metabolite composition to the other Brassica plants. The sinapic 
acid concentration of the RSP for example is less than in red cabbage and 
kale, but more than in white cabbage, broccoli and cauliflower. A similar 
distribution is true for other metabolites such as coumaric acid, ferulic acid 
and p-hydroxybenzoic acid. For some of the metabolites the RSP has the 
highest content e.g. indole-3-pyruvic acid (IPA), kaempferol and benzoic acid. 
For both kaempferol and IPA the higher concentrations were obtained from 
the acid-labile fraction353, meaning these might have been bound to other 
plant components. Different kaempferol derivatives have previously been 
identified in rapeseed, e.g. kaempferol-3-O-β-D-glucopyranosyl-(1→2)-β-D-
glucopyranoside-7-O-β-D-glucopyranoside and kaempferol-3-O-(2-O-
sinapoyl)-β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside-7-O-β-D-
glucopyranoside99, from which kaempferol could have been liberated during 
the acid labile extraction. IPA is part of the IPA pathway for the production of 
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indole-3-acetic acid (IAA) from tryptophan in plants, where it acts as 
regulator of growth and development361. 
The analysis of free and bound secondary metabolites in the RSP was 
undertaken to analyse the starting material to get a general overview in 
metabolite distribution. The extraction technique used to obtain the three 
fractions are not amenable for commercial application due to the time 
consuming extraction. For this reason, here three extraction different 
techniques were chosen for the secondary metabolite extraction of RSP. The 
final chosen technique should provide an extract with easy handling for 
further experiments.  
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2.3.2 Comparison of SOX, UAE and ASE extraction 
techniques 
For the SOX and UAE extraction techniques a solid to solvent ratio of 1:18.8 
(g/g) or 1:23.3 (g/mL) was used. The ratio for ASE was 1:10 for 4 extractions 
in sequence (total of 1:40). Kankara et al.362, Wong et al. 261  and Muñiz-
Márquez et al.274 had previously demonstrated, that the solid to solvent ratio 
can have an impact on the extraction efficiency (Table 2.8, p.103). 
Table 2.8|Impact of solid to solvent ratio on antioxidant activity of 
extracts 
reference Ratios 
tested 
Antioxidant 
assays 
outcome 
Kankara et 
al.362 
1:10, 
1:15 or 
1:20 
FC, DPPH or 
FRAP 
No sig. difference 
1:30 FC, DPPH Slightly less active than the 
above 
Wong et al.261 1:5 FC, ABTS, DPPH, 
total flavonoids 
Significant less active than 
1:10, 1:15 and 1:20 
1:10 FC, ABTS, DPPH, 
total flavonoids 
Better than 1:5 in FC, ABTS 
and DPPH  
1:15 and 
1:20 
FC, ABTS, DPPH, 
total flavonoids 
Both significantly better than 
1:10 in FC, total flavonoid and 
DPPH 1:20 only sig. better 
activity in FC assay 
Muñiz-Márquez 
et al.274 
1:12, 1:8 
and 1:4 
FC 1:12 sig. better than 1:4 and 
1:8 
 
The solvent of choice for the secondary metabolite extraction in this project 
was an ethanol water mixture (95:5, v/v) for all three extraction techniques. 
Considering Table 2.1 (p.69), this should provide a wide variety of secondary 
metabolites. This solvent mixture was also chosen due to positive preliminary 
results267 and the smaller environmental impact of ethanol compared to other 
organic solvents363. 
 
2.3.2.1 Yield of extraction 
The amount of extract obtained after the extraction is very important, 
especially if the product is made commercially viable, then the higher the 
yield the higher the earnings on the product. Furthermore, the physical 
characteristics of the extracts are important for ease of handling.  
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The most efficient extraction technique during this project was found to be 
accelerated solvent extraction (ASE), followed by ultrasonic assisted 
extraction (UAE) and Soxhlet (SOX) respectively (Table 2.9).   
Table 2.9| Extraction yields in mg per g pomace and in percent, 
subdivided by extraction technique and harvest year 
extraction year yield [mg/g pomace] yield [%] 
SOX 
2012 79.55 7.96 
2014 75.59 7.56 
UAE 
2012 158.59 15.86 
2014 175.46 17.55 
ASE 
2012 362.31 36.23 
2014 344.67 34.47 
 
However, due to the nature of the techniques higher yields in overall mass 
were obtained for SOX and UAE, because higher amounts of pomace can be 
used as starting material. In comparison, for the ASE only 0.5 g were 
employed per extraction cell, while 6 or 12 times more starting material was 
used for UAE and SOX respectively. An advantage of SOX, over the other two 
extraction techniques, was that a dry extract was obtained after extraction 
followed by freeze drying. Extracts from both UAE and ASE yielded oilier 
extracts in nature, which were difficult to handle. Homogeneous sample 
taking was challenging for the latter ones.  The difference in the physical state 
of the extract is most likely due to the additional defatting step undertaken 
during the SOX extraction, which is a common step with Soxhlet extraction. 
However, previous results presented by Wagener267 had shown positive 
antioxidant activity for both the SOX and the UAE, which is why the extraction 
parameters were kept very similar. ASE was added as an additional extraction 
technique for comparison and due to its ease of use and lower solvent 
consumption. 
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2.3.3 Folin-Ciocalteu (FC) assay 
The first step in determining whether there is a difference in phenolic content 
in the 6 different extracts (three extraction methods of two harvest years 
(2012/2014) each), the Folin-Ciocalteu (FC) method was chosen. As 
previously mentioned, this method is often referred to as analysing the 
phenolic content but is actually measuring the samples reducing capacity 
(2.1.3.1 Folin-Ciocalteu- (FC) Assay, p.81). The results obtained for the FC 
assay performed on the six RSP extracts are presented in Figure 2.11.  
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Figure 2.11| FC assay results, comparing the three extraction 
techniques together with the two harvest years/breeds 
Results are given as mg gallic acid equivalence (GAE) per g dry weight of RSP extract. 
Significant difference via Two-way ANOVA (box) and Bonferroni’s multiple comparisons 
test between years for each extraction technique; p≤ 0.01**, p≤0.001***  
The highest reducing capacity was found for the SOX extract (51.92 ± 4.91 
(2012) and 55.84 ± 2.83 (2014) mg GAE per g dry weight of RSP extract), 
followed by UAE (39.03 ± 4.28 and 37.61 ± 1.79 mg GAE per g dry weight 
of RSP extract for 2012 and 2014 respectively) and ASE (24.63 ± 0.83 and 
31.17 ± 3.91 mg GAE per g dry weight of RSP extract for 2012 and 2014 
respectively). Two-way ANOVA showed that the extraction technique 
(p<0.001) had a higher significant difference than the harvest years (p<0.01) 
on the reducing capacity. However, an interaction was found which makes 
the interpretation of the results more complex. For example, the extract 
obtained from the 2014 harvest did not show better results in the FC assay 
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for all three extraction techniques. Whereas, better results were exhibited 
after SOX and ASE extraction, the 2012 extract was found to show slightly 
better results after UAE. Additional multiple comparison analysis 
(Bonferroni’s) revealed, that only ASE extraction showed significant 
differences between the two harvest years.  
The FC results especially for the SOX extracts are in close agreement with 
previous reports. Cvjetko et al364. reported: 51.7 (80% ethanol), 54.0 (60% 
ethanol) and 55.7 (70% methanol) mg GAE/g using defatted rapeseed 
pomace/meal and ultrasonic assisted extraction at 45°C for 40 minutes. Data 
on the reducing capacity of rapeseed oil itself is not readily available, except 
in one publication  it was shown that cold pressed rapeseed oil had polyphenol  
equivalents to 1.56 mg GAE/g365. This implies that the extract from our RSP 
has about 35 times (SOX) more reducing capacity than the oil itself. 
Although the FC method has widely been used68,113,244, due to its fast and 
easy procedure, it has its limitations. The resulting colour change is due to 
the oxidation of the phenolics and the reduction of molybdenum, which leads 
to the blue colour. However, this oxidation can also be found for non-
phenolics, such as aromatic amines, sugars and ascorbic acid311, which is why 
the assay should be referred to as measuring the samples reducing capacity. 
An issue one encounters when analysing samples with this technique, is the 
lack of a standard method for solid samples. Although the European 
commissions have a method for the analysis of wine a standard method for 
solid samples is not available. This has led to a vast amount of results that 
are not comparable with other laboratories unless the same operating 
procedure is used. A further problem is the use of different phenolics as 
standard, whereas most papers show their results as GAE, such as Cvjetko 
et al.364 others choose to give results as sinapic acid equivalence, as in the 
case of Szydłowska-Czerniak and Tułodziecka52. In their study sinapic acid 
was chosen, because it is known to be one of the most common phenolic 
acids in rapeseed. Testing strongly coloured substances in this assay can lead 
to interferences, if they absorb at the FC specific wavelength (750 nm). 
Although the extract is yellow, once dissolved, the tested concentrations are 
faint enough not to interfere with the 750 nm wavelengths. However, for a 
better qualitative and quantitative overview of present secondary 
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metabolites, HPLC-MS/MS analysis was applied to analyse for the present of 
e.g.  phenolics, indoles, amines, flavonoids and coumarins.  
2.3.4 HPLC-MS/MS  
The most abundant phenolic found during HPLC-MS/MS analysis of all the 
extracts (SOX, UAE, ASE) is sinapic acid (Table 2.10, p.108). This confirms 
previously found results in the literature80,366 as well as results obtained 
during the analysis of the pomace starting material using the same HPLC-
MS/MS method (2.3.1 Secondary metabolite composition of RSP from free, 
alkali-labile and acid-labile fractions, p.98 ff.).  
Other phenolics with high concentrations are ferulic acid, caffeic acid, syringic 
acid and 4-hydroxyphenylpyruvic acid (Table 2.10, p.108). Surprising were 
the high amounts of spermidine (amine) and indole-3-pyruvic acid (indole) 
found in the extracts. These could be present due to the degradation of 
protein, particularly through fermentation or storage360. The most abundant 
flavonoids/coumarins are kaempferol (SOX14; UAE12) and luteolin (SOX12; 
UAE14; ASE12,14). Additional found phenolics, indoles, amines, flavonoids 
and coumarins are presented in Table 2.10, excluding the metabolites not 
found in either of the six extracts.  
In general, the total amount of phenolic compounds found, appears to mirror 
the results obtained by the FC assay, showing the following general order 
SOX>UAE>ASE. However, when comparing the total concentrations, the 
order considering the extraction technique and year 
(SOX12>SOX14>UAE12> UAE14>ASE12>ASE14, Table 2.10) slightly 
deviates from the results found in the FC assay 
(SOX14>SOX12>UAE12>UAE14>ASE14>ASE12, Figure 2.11, p.105) as for 
the ASE and SOX the years are switched. This shows that simple chemical 
reaction assays with spectroscopically measurement, such as the FC assay, 
can give a general overview of the phenolic content; however, they are not 
as accurate as separation techniques, such as HPLC analysis.  
The phenolics, sinapic and ferulic acid found in the RSP extracts are well 
known antioxidants and they have shown interesting chemical and biological 
activity in previous research. Sinapic acid (SA) for example has shown DPPH 
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radical scavenging97, superoxide O2●-, hydroxyl (●OH), nitric oxide (●NO), and  
peroxyl nitrite (ONOO-) scavenging as well as the suppression of lipid 
peroxidation367. In further studies using rodent models, SA was found to 
protect rats from arsenic induced toxicity368, exhibited neuroprotective effects 
in a amyloid β(1-42) protein-induced Alzheimer's disease mouse mode 241 
and attenuated kainic acid-induced hippocampal neuronal damage in mice369. 
Other phenolics such as ferulic acid have also been found to show 
neuroprotective potential in e.g. a rotenone model of Parkinson’s disease243. 
In a oxidative stress induced (Aβ42) sea urchin (Paracentrotus lividus) embryo 
model, ferulic acid neutralized ROS, blocked apoptotic pathways and 
recovered mitochondrial membrane potential370. For others phenolics such as 
syringic acid and 4-hydroxyphenylpyruvic acid not much research on their 
biological availability and potential activity are available. 
Also the flavonoids luteolin, kaempferol and naringenin, previously found in 
the pollen of Brassica napus371, exhibit interesting biological activity. For 
example luteolin has shown to have cancer chemopreventive and 
chemotherapeutic potential as well as antioxidant, anti-inflammatory and 
antimicrobial activity372. Kaempferol was shown to exhibit similar activity 
(anti-inflammatory, cardio-protective, antitumor and antioxidant)373,374.  
Table 2.10| Phenolics, Amines and Flavanoids/Coumarins found in 
RSP extracts  
Extraction 
technique 
SOX UAE ASE 
Harvest year 2012 2014 2012 2014 2012 2014 
Benzoic Acids 
p-hydroxybenzoic 
acid 
48.90 
± 1.82 
74.89 
±  
9.51 
27.23 
± 
 1.56 
36.37 
±  
1.90 
12.08 
±   
1.65 
17.46     
±       
0.64 
syringic acid 
44.82 
± 2.45 
224.2  
± 
16.54 
20.35 
±  
0.71 
113.3
7 ±  
8.78 
7.52   
±   
6.52 
73.59     
±       
4.22 
vanillic acid 
41.85 
± 0.79 
44.72 
±  
2.61 
18.29 
± 
 1.08 
16.39 
± 
14.21 
3.63   
±   
6.29 
- 
protocatechuic acid 
32.27 
± 1.51 
72.59 
±   
1.14 
14.66 
±  
1.02 
35.75 
±  
2.15 
9.17    
±   
1.26 
24.20      
±       
2.04 
salicylic acid 
11.47 
± 1.82 
14.99 
±  
1.72 
10.81 
±  
0.66 
8.24   
±   
1.27 
7.01   
±   
2.58 
13.99      
±       
1.58 
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p-anisic acid - 
28.11 
±  
3.94 
- - - - 
Benzaldehydes 
syringin 
64.30   
±    
4.19 
33.58 
±  
3.15 
10.20 
±  
0.87 
8.16  
±  
0.61 
8.23  
±  
1.72 
8.04        
±         
0.60 
protocatachaldehyde 
54.46 
±  
3.56 
48.83 
±  
1.38 
- - 
6.52   
±   
0.85 
9.65        
±         
0.82 
vanillin 
17.26 
±  
1.60 
15.08 
±  
1.34 
- - - - 
Cinnamic Acids 
sinapic acid 
7496.
7 ± 
198.8
9 
4896.
9 ± 
281.6
8 
4610.
2 ± 
61.59 
2769.
3 ± 
79.64 
2682.
1 ± 
58.02 
1923.
3     ±      
18.45 
ferulic acid 
226.5
4 ±  
8.37 
182.7
0 ±  
9.82 
126.4
8 ±  
7.13 
91.28 
±  
3.85 
70.97 
±  
2.40 
60.92       
±        
1.76 
cinnamic acid 
107.9
4 ± 
11.67 
69.59 
±  
3.35 
68.41 
± 
11.10 
56.05 
±  
2.25 
55.41 
±  
3.81 
84.96       
±         
3.24 
caffeic acid 
97.28 
±  
7.26 
110.8
2 ±  
9.57 
50.00 
±  
2.13 
61.12 
±  
2.61 
30.08 
±  
0.91 
41.24  
±  
1.65 
p-coumaric acid 
46.97 
± 0.89 
32.10 
± 2.94 
15.69 
± 1.18 
15.87 
± 0.45 
8.97 ± 
0.84 
- 
Phenypyruvic Acids 
4-
hydroxyphenylpyruvi
c acid 
172.7
4 ± 
43.61 
149.7
7 ± 
39.56 
160.3
5 ± 
14.50 
128.5
7 ±  
5.23 
117.8
8 ±  
8.36 
161.3
1     ±   
    
13.54 
Other Phenolics 
4-hydroxy 3-
methoxy benzyl 
alcohol 
- 
0.76 ± 
1.32 
- - - - 
Indoles 
indole-3-pyruvic acid 
480.8
1 ± 
80.64 
336.0
5 ± 
89.09 
630.3
8 ± 
46.73 
351.6
3 ± 
33.77 
270.9
7 ± 
31.69 
311.7
3  
±  
17.77 
indole-3-carboxylic 
acid 
17.36 
±  
0.23 
11.78 
±  
0.59 
6.01  
±  
0.91 
4.81  
±  
0.20 
4.96  
±  
0.24 
4.42    
±  
0.90 
Amines 
spermidine 
524.9
3 ± 
12.38 
433.5
6 ± 
41.44 
389.5
2 ± 
22.87 
345.3
0 ± 
20.72 
408.3
9 ± 
55.54 
456.1
4  
±  
82.34 
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spermine 
2.68  
±  
0.57 
1.82  
±  
0.05 
1.97  
±  
0.18 
1.50  
±  
0.21 
1.80  
±  
0.42 
2.21  
± 
 0.20 
Flavanoids/Coumarins 
Kaempferol 
123.6
9 ± 
100.8
8 
22.32 
±  
6.92 
12.26 
±  
3.32 
- - - 
Isorhamnetin 
27.89 
± 
12.97 
7.85  
±  
1.30 
6.41  
±  
0.67 
1.26  
±  
1.13 
4.46  
±  
0.19 
- 
Luteolin 
18.75 
±  
1.49 
44.66 
±  
3.43 
7.07  
±  
0.55 
3.16  
±  
0.17 
4.68  
±  
0.45 
4.35        
±        
0.03 
Apigenin 
4.78  
±  
0.30 
2.31  
±  
0.42 
2.78  
±  
0.29 
0.19  
±  
0.33 
0.89  
±  
0.09 
0.95  
±  
0.15 
Naringenin 
3.53  
±  
0.24 
2.58  
±  
0.25 
- - 
0.85  
±  
0.13 
- 
Tangeretin 
1.09  
±  
0.04 
0.93  
±  
0.10 
0.75  
±  
0.19 
0.75  
±  
0.05 
0.61  
±  
0.16 
0.85  
±  
0.12 
Quercetin-3-
Glucoside 
- 
6.72  
±  
0.81 
- 
2.44  
±  
0.34 
2.62  
±  
4.53 
- 
Phloridzin - 
2.09  
±  
0.29 
- - - - 
e-lac - - - 
0.51  
±  
0.05 
0.51  
±  
0.05 
1.12  
±  
0.23 
total 9669 6872 6190 4052 3720 3200 
  Note(s): determined using HPLC-MS/MS analysis, in mg/kg extract (mean) ± standard 
deviation, excluding compounds found in neither of the samples, HPLC-MS/MS analysis 
conducted by Garry Duncan (Rowett) 
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2.3.5 FRAP assay 
This assay determines the antioxidant power by the extracts potential of 
reducing the ferric-tripyridyl triazine complex to the ferrous-tripyridyl triazine 
complex by electron transfer reaction (Figure 2.6, p.83). This reduction leads 
to a colour change of the solution, measured at 593 nm302. To verify this 
absorbance maximum suggested by other papers the absorbance spectrum 
of different concentration of Trolox, a common reducing agent, as well as a 
negative control (no reducing agent) were recorded. The results of this study 
are presented in Figure A1 (p.440); verifying that the absorption maximum 
is at 593 nm.  
Figure 2.12 shows an example of one of the calibration curves obtained for 
the FRAP assay, using Trolox as standard, because following results of the 
extracts will be expressed as Trolox equivalents (TE). For all the experiments 
similar curves were obtained, with R2 values above 0.999 for all experiments. 
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Figure 2.12| Calibration graph example for FRAP assay using 1.56-
15.6 µg/mL Trolox 
Using the Trolox calibration curves, the FRAP activity in mg TE/g dw RSP 
extract can be calculated for each of the six extracts. The order of reducing 
activity in the FRAP assay for all the extracts is similar to the FC assay results 
obtained previously. SOX gave the best ferric reducing antioxidant power 
along all the extracts with values of 163.4 ± 3.8 and 172.4 ± 3.8 mg TE/g 
per dry weight for the 2012 and 2014 sample respectively (Figure 2.13, p. 
112).  
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Figure 2.13| FRAP results in Trolox equivalence per g RSP extract 
Dry weight, significant difference via Two-way ANOVA (box), Bonferroni’s multiple 
comparisons test between years for each extraction technique; p≤0.05*, p≤ 0.001*** 
The extraction technique applied showed higher significant differences 
(p<0.0001) than the harvest year (p=0.0002). However, a significant 
interaction (p<0.001) is present too as previously seen in the FC assay. The 
post hoc Bonferroni’s multiple comparison test showed that the differences 
between the years are highly significant (p<0.0001)) for the ASE. A smaller 
significant difference (p=0.0314) between the two years is present for SOX, 
whereas UAE does not show any significant difference between the years. In 
general, the outcomes from the FRAP assay are similar to the FC assay giving 
the following order of ferric ion reducing antioxidant power potential: SOX 
14>SOX12>UAE12>UAE14>ASE14>ASE12 (Figure 2.13). 
In the FRAP assay (as in the FC assay) not the SOX 2012 extract, with the 
highest total amount of phenolics (Table 2.10, p.108), but SOX 2014 showed 
the best reducing capacity. This has led to the assumption that maybe not 
sinapic acid, the main secondary metabolite, but one of the compounds with 
higher concentration in SOX 2014 is contributing more to the FRAP and FC 
activity. Potentially compounds such as p-hydroxybenzoic acid, syringic acid, 
protocatechuic acid, caffeic acid or luteolin (higher in SOX14) have a more 
significant impact on the in vitro antioxidant activity assays. 
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When comparing results from the FRAP assay with the methanol extracts of 
waste and by-products of other plants reported by Wijngaard et al.375, the 
RSP extracts showed very promising results. For example, the SOX extracts 
showed antioxidant activity 10 times higher than for example kiwifruit, pink 
grapefruit and apple pomace extracts.  Furthermore up to 20 times higher 
results were obtained when compared to vegetable by-products such as  
white cabbage cut-offs, cauliflower cut-offs and broccoli stems (methanol 
extracts)375. In a paper by Szydłowska-Czerniak et al.90 it was shown that the 
FRAP and DPPH activity as well as the concentrations of erucic acid and total 
glucosinolates were dependent on the breed/variety and their origin. Here in 
our study, the origin for both samples (2012 and 2014) was the same. The 
rapeseed used in the production of the Mackintosh of Glendaveny rapeseed 
oil is harvested in the north east of Scotland. However, the breed and the 
year of harvest were different for both samples and either could have 
contributed the difference in the FRAP activity. 
One disadvantage about using the FRAP assay is the requirement of an acidic 
pH (3.6) environment; this is far from physiological conditions. A similar 
assay to the FRAP assay is the CUPRAC, this is done at pH 7.0 and emulates 
normal physiological conditions better301. Just like for the FC assay the FRAP 
reaction is nonspecific, any compound will cause the reduction of the Fe(III)-
TPTZ, if they have a suitable redox potential319. 
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2.3.6 DPPH assay 
For the DPPH assay, the IC50 values were determined for each sample. The 
latter is the concentration of the sample required to scavenge half of the 
number of initial radicals. The lower the concentration needed to scavenge 
these, the better the scavenging activity of the sample. To verify the 
absorbance maximum for DPPH at 517 nm327, absorbance spectra were 
recorded for the DPPH solution and DPPH reacted with sinapic acid, a well-
known antioxidant found in the RSP extracts. The results are presented in 
Figure A2 (p.440), verifying the absorption maximum at 517 nm.   
This wavelength was then used to determine the radical scavenging activity 
of different concentrations of RSP extract, when in contact with the free 
radicals of the DPPH solution. Concentrations between 1.3 and 333.33 µg/mL 
of the extract (e.g. SOX14) showed the decay course of absorbance 
presented in Figure 2.14 (A). The straight part of this curve, including the 
50% mark, was used to determine the IC50 via linear regression (B). 
 
Figure 2.14| DPPH assay IC50 determination  
A) representative example of the course of the curve for the scavenging potential of 
one of the RSP extracts (SOX14)  from 333.3 µg/mL down till 1.3 µg/mL B) linear 
regressing of A) including 50% mark for determination of IC50, Graph Pad Prism  
When considering all three extraction techniques, the order of activity 
determined from the previous antioxidant assays (FC, FRAP) is maintained. 
A 
B 
Chapter 2: Secondary Metabolite Composition and Antioxidant Activity of Rapeseed 
Pomace Extracts – comparison between 2 harvest years and 3 extraction techniques 
Franziska Pohl   115 
SOX is the extraction technique that gave the extract with the best radical 
scavenging activity, followed by UAE and ASE (Figure 2.15). The trend related 
to the harvest year for each extraction technique is also the same as 
previously identified via FC and FRAP assay, given the following order of 
activity: SOX14 (49.23 ±14.01 µg/mL) > SOX12 (60.09±1.343 µg/mL) > 
UAE12 (100.9±0.8049 µg/mL) > UAE14 (109.1±2.601) > ASE14 
(131.4±4.659 µg/mL) > ASE12 (180.3±16.16 µg/mL).  
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Figure 2.15| DPPH results as IC50 (µg/mL)  
Significant difference via Two-way ANOVA (box), Bonferroni’s multiple comparisons test 
between years for each extraction technique; p≤ 0.001*** 
Although this assay is commonly used in many laboratories interested in 
radical scavenging activity, a lack of (i) standarization of the experimental 
procedures, (ii) sample and DPPH solutions preparation, (iii) reaction 
conditions and (iv) the expression of the results in different ways makes it 
difficult to compare results obtained from different laboratories and different 
plant materials310,376. Szydłowska-Czerniak and Tułodziecka52 for example 
test RS extracts (UAE) in the DPPH assay, but decided to show their results 
as mmol TE/100g. Radojković et al.244 determined IC50 values for the radical 
scavenging activity of black mulberry leave extracts showing a range between 
10 and 60 µg/mL244. When comparing rapeseed pomace extracts to mulberry 
leaf extracts, the latter showed better radical scavenging activity than the 
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RSP extracts. However, the slight differences in experimental set up need to 
be taken into consideration when comparing results with other research 
papers.  For example in their method description an incubation time of 60 
minutes was used, comapared to 30 minutes in this project. Although a 
steady state is expected to be reached after 30 minutes, slight changes could 
significantly influence the IC50 value determination. Furthermore the authors 
fail to mention the concentration of DPPH used and also, how the IC50 value 
was obtained. Another DPPH method, described in  more detail by Phani 
Kumar et al.377, uses a similar experimental setup as in this project (30 
minutes incubation, 0.1 mM DPPH in methanol). For extracts from Terminalia 
arjuna bark (Indian traditional medicine) they found higher IC50 values 
ranging between 270±12 µg/mL and more than 500 µg/mL for different 
extraction solvents. The enitial alcoholic extract (ethanol) was carried out 
using Soxhlet extraction (72h), therafter the extract was further partitioned 
using additional solvents377. Having a mixture of solvents might have 
increased the chances of extracting other groups of secondary metabolites 
(Table 2.1, p.69), which decreased the concentration necessary to scavenge 
DPPH radicals. 
Another draw back of this assay is that although determination of the IC50 
provides valuable input on the stoichiometry of the reaction, it does not 
provide any information on the kinetics of the reaction, as measurements are 
undertaken after the steady state is reached (measurement after 30 
minutes). Compared to the DPPH radicals that are stable in solution for hours, 
most physiologically relevant radicals have liftimes of milliseconds or 
seconds, only some ROS/RNS e.g. non radicals such as organic peroxides 
(ROOH), hypochlorous acid (HOCl) or peroxynitrous acid (ONOOH) are 
slightly more stable310,378. So for the positive activity of radical scavengers 
within the living system, the number of reactive groups is not as important 
as the velocity of the reaction. To better understand the reaction kinetics, 
measurements should be taken continiously starting right after the addition 
of DPPH to the compound/s of interest. However, not many papers show 
kinetic analysis and so comparison between different 
compounds/lab/research projects is not possible. Interestingly, Sharma and 
Bhat376 reported a kinetic comparison between common antioxidants, 
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demonstrating an instantant reaction of ascorbic acid. BHT however, reacted 
relatively slowly. Although they might show a similar absorbance after 30 
minutes, their reaction kinetics for the first 30 minutes can be very different 
(e.g. Figure 2.16)376.  
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Figure 2.16| Hypothetical reaction kinetic comparison  
Compounds A, B and C, with same absorbance at 30 minutes but different rection times 
(adapted from Sharma et al.376) 
For better explanation a graph is presented in Figure 2.16 above, comparing 
the reaction kinetics for three hypothetical compounds A, B and C. Although 
these compounds show the same absorbance at 30 minutes their initial 
reaction kinetics are very different. Whilst compound A reacts immediately 
after reaction initiation with DPPH radicals. Compound C in comparison has a 
slightly delayed reaction but reaches the same absorbance as compound A 
after about 20 minutes. In contrast, compound B reacts even slower within 
the first 30 minutes, before reaching the same absorbance as compound A 
and C. As described before, the reaction velocity however is important, 
considering the very short lifetime of some radicals. For better comparison of 
compounds, both reaction kinetics as well as concentration dependent 
reaction curves should be obtained. In addition, Sharma and Bhat376 also 
highlighted the lack of standard operation procedures. Unequal DPPH 
concentration, reaction media and incubation times are used within 
laboratories, leading to different IC50 values for the same compounds. For 
better intra and inter laboratory comparison of results, standard operating 
procedures are necessary, not just for DPPH but also for the FC and FRAP 
assay. 
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2.3.7 Correlation of the data from FC, FRAP and 
DPPH assay 
To determine whether there is a relationship between two variables 
(numerical, continuous) correlation analysis is used. Having a positive value 
close to 1.0, demonstrates a positive relationship between these two 
variables. The fact, that the data from the three antioxidnat experiments 
show the same trend in activity of all the samples, would suggest a strong 
correlation among the three assays used. This was confirmed using 
correlation analysis as shown in Table 2.11. 
Table 2.11| Correlation between FC, FRAP and DPPH assay  
 FC FRAP DPPH# 
FC - 0.9987 0.9798 
FRAP 0.9987 - 0.9756 
DPPH# 0.9798 0.9756 - 
Note(s): using the mean activity values for all six extracts via Pearson correlation in 
GraphPad Prism; #to address the inverted values of the DPPH assay, 1/IC50 values 
were used for correlation 
Obtaining a very high correlation for all the six extracts would suggest that 
in our case, not all three experiments were necessary to determine the 
extracts order of antioxidant activity. Similar high correlations were reported 
by Dudonné et al.330, DPPH and FRAP (R=0.822) followed by FRAP and FC 
(R=0.906) and DPPH to FC (R=0.939). Here in our case, the correlation 
between DPPH and FRAP is the smallest with R=0.9756, followed by 
R=0.9798 (DPPH/FC) and highest for FRAP and FC with R=0.9987. Similar to 
Dudonné et al.330,  also Vergara-Sallinas et al.339 found high correlation 
among DPPH, ORAC and FRAP, when analysing effect of different 
temperatures and times of the extraction towards the antioxidant activity of 
thyme. The high correlation obtained in this project is probably due to the 
fact that our results are from (i) the same plant species, (ii) are grown in the 
same region and (iii) involved only a small sample number (n=6). Figure 2.17 
shows an example graph for the correlation of FRAP and DPPH, including the 
equation and the R2-value obtained from the linear regression analysis.  
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Figure 2.17| Correlation between FRAP and DPPH assays 
Correlation coefficient R= 0.9756 (Pearson) and linear regression analysis using 
GraphPad Prism 
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2.3.8 Partial least squares analysis of data from 
the DPPH, FC and FRAP assay 
Data review using partial least squares (PLS) analysis was undertaken 
including secondary metabolite composition and antioxidant activity results 
(FC, FRAP, DPPH) for both harvest years (2012 and 2014) and the three 
extraction techniques (SOX, UAE and ASE). A Lodings Bi-plot was created 
with umetrics software (Figure 2.18). The plot displays similarity and 
dissimilarity among observations by creating a model of the data (extraction 
technique (observation), phenolic analysis (variable x) and in vitro 
antioxidant tests (variable y). The closer the data points, the more likely 
these variables are affecting each other. 
All the results from the three assays (FC, FRAP, DPPH) are in close proximity 
to SOX2014, showing similarity, with better activity. SOX2014 is closely 
followed by SOX2012 in proximity to the activity assays. When measuring the 
distances the following order concerning activity can be classified: 
SOX14>SOX12>UAE12>UAE14>ASE14>ASE12, thus confirming the order 
previously determined (2.3.3 Folin-Ciocalteu (FC) assay p.105 ff., 2.3.5 FRAP 
assay p.111 ff. and 2.3.6 DPPH assay p.114 ff.). 
In addition, the secondary metabolites found in the extracts were included in 
the created model. As a result, it is possible to determine metabolites that 
might be responsible for the activity found for the extracts. Both, vanillic acid 
and caffeic acid are in close proximity to FC, FRAP and DPPH assay, 
suggesting their importance for activities found in the extract.  
Furthermore, the proximity of metabolites to extracts shows which 
compounds are found in higher concentrations in certain extracts, e.g. 
protocatechuic acid is most prevalent in SOX14, whereas the flavonoids 
apigenin and kaempferol are at the highest concentration in SOX12 (Table 
2.10, p.90). In brief the PLS plot creates an overview of the data obtained so 
far and displays them in connectivity manner. However, it is noteworthy to 
mention that this is only a statistical theoretical model and the information 
provided must be used with caution. Just because caffeic acid is found the 
closest to the antioxidant activity, does not meant that caffeic acid is causing 
the most activity in practice. An additional draw back it that this model only 
considers parameters entered into the software, unknown secondary 
metabolites are not included. 
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Figure 2.18| PLS plot including the six extracts and their secondary metabolite composition, in relation to their  
found FC, FRAP and DPPH activity 
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2.3.9 ORAC assay 
After concluding that ASE showed the lowest activity in all antioxidant assays 
carried out, experiments using these extracts were discontinued and only 
SOX and UAE extracts were taken further for ORAC analysis. 
The ORAC analysis gave mean values of 2825 ± 87 and 2607 ± 212 μmol 
TE/g dry weight for SOX12 and SOX14 respectively. Lower values of 1729 ± 
91 (2012) and 1618 ± 327 (2014) µmol TE/g dry weight were found for both 
UAEs (Figure 2.19).  
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Figure 2.19| ORAC results in µmol Trolox equivalence per g RSP 
extract  
Dry weight, significant difference via Two-way ANOVA (box), Bonferroni’s multiple 
comparisons test between years for each extraction technique; p≤ 0.001*** 
Two-way ANOVA analysis showed a significant difference between the 
extraction techniques. However, the harvest year had no effect on the 
activity. Multiple comparison analysis also showed insignificant differences 
between the breeds/harvest years (Figure 2.19). All four extracts inhibit 
and/or delay the probes (fluorescein) oxidation caused by the free radical-
generating azo compound AAPH. The latter produces a peroxyl free radical 
upon thermal decomposition (Figure 2.8, p.85) which is commonly found in 
the body, making this reaction more relevant to biological systems than for 
example the FRAP or DPPH assay379.  
Figure 2.20 shows the kinetic curves obtained for the SOX 2012 extract at 
different concentrations (0.25-6.25 µg/mL), showing clear protection 
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properties over time, when compared to control ( 0 µg/mL). Even at low 
concentration ( 0.25 µg/mL) of the extract partial protection of the 
fluorescence probe, fluorescein, from the damaged caused by AAPH, is 
observed (Figure 2.20  vs.  curve).  
SOX 2012
Time (min)
fl
u
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
0 50 100
0
2000
4000
6000
8000
no AAPH
0 g/mL
6.25 g/mL
2.5 g/mL
1.25 g/mL
0.75 g/mL
0.25 g/mL
 
Figure 2.20| Example of ORAC absorbance measurement for 
SOX2012 
Concentrations between 0 and 6.25 µg/mL (final concentration) compared to the 
fluorescein control (120 min) 
The ORAC results obtained for the SOX extraction (>2500 µmol TE/g RSP 
extract) are about eight times higher than those obtained by Chandrasekara 
et al.338. The latter reported values between 0.24 ± 0.02 mmol TE/g dw and 
0.37 ± 0.06 mmol TE/g dw for canola extracts, extracted using an 
ethanol/water mix (80:20) and 4 different extraction techniques at 
temperatures of 60°C or less. The conditions together with the origin of the 
rapeseed, could have contributed to their lower ORAC activity values. 
Although the ORAC assay employs a biological relevant radical source 
(peroxyl radical, ROO•)10, it cannot be considered a total antioxidant activity 
assay. It measures the hydrophilic antioxidant activity of the extracts 
specifically against peroxyl radicals. To determine the overall antioxidant 
activity of a sample they would need to be tested against various ROS/RNS 
in different environments305. A limitation of this experiment is also the need 
of a more sophisticated plate reader, which can undertake thermostated 
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fluorescence measurement, compared to the previously described antioxidant 
assays. Although this assay is mostly seen as more biological relevant due to 
the radical source created by AAPH, its nutritional relevance has recently been 
questioned319. Seeing the kinetics of the measurement however is very useful 
to understand the reaction, as shown in Figure 2.20. Amarati and Valgimigli319 
suggest that determining the AUC mixes both the duration and the efficacy 
of protection, giving more weight to the former, which might lead to 
misleading interpretations of the AUC results319. 
ORAC data collected on food, mostly provided by Wu et al.380,381 were 
provided in a data base by the United States Department of Agriculture 
(USDA) in 2007. However, after the release of a second version, the database 
was deleted by the USDA due to a couple of reasons described on the USDA 
web page (http://www.ars.usda.gov/Services/ docs.htm?docid=15866)309: 
 i) evidence indicates that the antioxidant capacity values have no relevance 
to the effects of the tested compounds, including polyphenols on human 
health 
ii) the metabolic pathways associated with antioxidants are not completely 
understood and potential non-antioxidant mechanisms (undefined) might be 
responsible for the activity 
iii) misused of ORAC values by the food and dietary supplement industry to 
promote products 
iv) lack of evidence that the positive effects of polyphenol-rich foods are 
caused by the antioxidant properties 
Never the less, new ways of potentially using a number of different reactive 
oxygen species (ORAC using multiple radical, ORACMR) are suggested by Prior 
and Prior et al.309,382.  These might increase the knowledge obtained from this 
in vitro assay. The potential use of more relevant probes might influence the 
current opinion on antioxidant assays. Schaich et al.341 also suggested the 
replacement of fluorescein with a probe, which does not interact with itself or 
phenols by non-radical mechanisms. Unfortunately, they fail to provide 
potential options.  
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2.3.10 Partial least squares analysis (ORAC) 
From the ORAC results of all four extracts (SOX2012/2014 and 
UAE2012/2014), an additional PLS plot was created, including the secondary 
metabolites and the ORAC activity (Figure 2.21). In this plot, as well as the 
last one (Figure 2.18, p.121), SOX extracts are closer to the ORAC activity, 
suggesting better activity. However, the order of the harvest years is different 
to the previous three assays (FC, FRAP and DPPH). SOX12 is closer to ORAC 
than SOX14, followed by UAE12 and then UAE14. This order of activity was 
also shown in the ORAC results (Figure 2.19, p.122). In contrast to the 
previous PLS plot (Figure 2.18, p.121) the secondary metabolites closest 
associated with the ORAC activity are naringenin, vanillin and 
protocatachaldehyde, followed by vanillic acid and p-coumaric acid. As 
previously highlighted, this theoretical model only shows indications of 
potential relation of secondary metabolites to activity in the respective 
assays. However, it is only a model and any assumptions taken need to be 
experimentally proven. 
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Figure 2.21| PLS plot including the SOX and UAE extracts and their secondary metabolite composition, in relation  
to their found ORAC activity
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2.3.11 Determination of antioxidant activity of 
single compounds within the extract as well as 
their mixtures  
To determine whether the theoretical models created during PLS analysis are 
representative for the activity caused by the individual compounds in the in 
vitro assays, seven compounds were chosen and analysed using ORAC, FRAP 
and DPPH assay, to determine their activity as single compound and to 
determine whether a synergistic effect contributes to the activity among 
those chosen compounds. 
Two compounds, caffeic acid (CA) and vanillic acid (VA), were selected 
because they showed close proximity to the FC, FRAP and DPPH activity in 
the PLS plot (Figure 2.18 p.121). The phenolic aldehyde vanillin (V) and the 
flavanone naringenin (N) were chosen since they showed more relevance to 
the ORAC activity in the second PLS graph (Figure 2.21, p.126). Three further 
metabolites (sinapic-(SA), syringic- (SyA) and ferulic acid (FA)) were also 
analysed due to their high concentration in the RSP extracts. The RSP extract 
was analysed in parallel as control. For comparison purposes, initially the 
single compounds activity, in the FRAP and DPPH assay, was analysed and 
compared to the RSP extract (Table 2.12)383. 
Table 2.12| Seven single compounds and their FRAP and DPPH 
activity383  
 
The DPPH and FRAP results for the different secondary metabolites showed 
to be diverse. The three compounds selected due to their high abundance in 
High abundance in RSP 
extract (Table 2.10) 
FC, FRAP, DPPH PLS plot  
(Figure 2.18) 
ORAC PLS plot  
(Figure 2.21) 
Note(s): results obtained in collaboration with Lisa Leyer 
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the extract (SA, SyA, FA) showed high activity in both FRAP and DPPH assay. 
Although they are situated further away from the activity assays in the PLS 
plot than CA and VA. CA, which showed the second best activity of the tested 
compounds in the FRAP and the best results in the DPPH, was suggested to 
be an active compound by its close proximity to the assays (Figure 2.18, 
p.121). However, VA, also suggested to have the potential for high activity in 
the PCA plot, showed to be less active than SA, SyA and FA in both assays. 
In a similar study, Mudnic et al.384 looked at FRAP activity of hydroxybenzoic 
acids (HBA); p-hydroxybenzoic-, protocatechuic-,vanillic-, gallic- and syringic 
acid as well as hydroxycinnamic acids (HCA); p-coumaric- caffeic-, ferulic- 
and sinapic acid (Figure 2.22). 
 
Figure 2.22| HBA and HCA analysed in Mudnic et al.384 for their FRAP 
activity 
For comparison of results, compounds analysed in both studies are shown in 
Table 2.13 with their respective order determined in both studies. Included 
in this table are the allocations of the compounds to their respective HCA/HBA 
group. Comparing both, no general conclusion can be drawn on whether HBA 
or HCA perform better in this assay. More important seems to be the number 
of –OH or –OCH3 groups present in HBA and HCA. Gallic-, syringic- and sinapic 
acid which all have three –OH or OCH3 groups show the best activity. This is 
followed by caffeic-, protocatechuic-, ferulic- and vanillic acid which have two 
of these sidechains, whereas both p-coumaric- and p-hydroxybenzoic acid 
Order of FRAP  
activity: 
9. 
5. 
7. 
1. 
2. 
8. 
4. 
6. 
3. 
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each only have one. Although both groups impact the activity, when 
comparing compounds with the same number of R’s, the ones with a higher 
number of –OH groups are better than the ones with more –OCH3 e.g. gallic 
acid compared to syringic acid. Already in 1996 Rice-Evans et al385. suggested 
the importance of hydroxyl groups in phenolics and flavonoids antioxidant 
activity. However, Mudnic et al.384 as well as this study shows that the number 
of hydroxyl as well as the number of methoxy groups are important, e.g. 
syringic vs. protocatechuic acid. 
Table 2.13| Comparison of FRAP activity of single phenolics found in 
this study and Mudnic et al.384 
compound HBA/HCA Mudnic et al.  
[mmol/L TE] 
Order in Mudnic 
et al. 
Leyer and Pohl 
(Table 2.12) 
Syringic 
acid 
HBA 1.47 1. 1. = 
Sinapic acid HCA 1.26 2. 3. ↓ 
Caffeic acid HCA 1.11 3. 2.↑ 
Ferulic acid HCA 0.99 4. 4. = 
Vanillic acid HBA 0.37 5. 5. = 
 
Sevgi et al.386 also analyses a number of selected phenolic acids, including 
caffeic-, ferulic-, syringic- and vanillic acid. Their order of activity for both 
DPPH radical scavenging and reducing power deviate from this study and 
Mudnic et al.’s384 results. In their study caffeic acid shows the best activity in 
both assays. Variations found between their activities are very minor in Sevgi 
et al.386 Differences between their and this study could be due to the different 
ways of calculating results and experimental set up.  
During our study we also analysed V and N due to their proximity to the ORAC 
assay in the PLS plot (Figure 2.21, p.126). V, thus much closer situated to 
the activity in the plots than e.g. SyA, showed lower activity. Also, N showed 
very little or no activity in either assay, although close in proximity to e.g. FA 
in the PLS plot (Figure 2.18, p.121). Out of the seven individual compounds 
tested, only naringenin did not exhibit any activity in the FRAP assay. This 
was also observed by Csepregi et al.328 who reported a value of 0 myricetin-
3-Oglucoside equivalents. Those results show that the PLS analysis can give 
an initial indication of potentially active compounds, as found with caffeic acid 
however it is advised to verify theoretical models like the PLS analysis using 
the same in vitro experiment. 
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To assess the contribution of these compound to the extracts activity the 
concentrations present in the extract were measured in FRAP, DPPH and 
ORAC. At the test concentrations, none of the compounds showed any 
significant activity. To investigate a potential synergistic effect, mixtures were 
prepared (Table 2.14), containing the same concentrations of metabolites 
found in the extract. 
Table 2.14| Mixtures of secondary metabolites created for analysis of 
their antioxidant and radical scavenging activity and the 
determination of potential synergistic effects383 
MIXTURE COMPOSITION 
A SA, SyA, FA, CA, VA, V, N 
B SA, SyA, FA, CA, VA, V 
C SA, SyA, FA, CA, VA 
D SA, SyA, FA, CA 
E SA, SyA, FA 
F SA, SyA 
G SA 
Note(s): results obtained in collaboration with Lisa Leyer 
The six mixtures and SA were then analysed using FC, FRAP and DPPH assay 
to determine their activity and potential synergistic effects. The results 
obtained for the absorbance/fluorescence were very close the negative 
control. No significant contribution of these mixtures of compounds at the 
extract specific concentration was observable383. 
These results suggested, that the secondary metabolites tested here are not 
responsible for the in vitro antioxidant activity observed in the RSP extract. 
There are a few potential reasons for this outcome: 
(i) One of the other known compounds of lesser concentration (Table 
2.10, p.108) is responsible 
(ii) A number of other known compounds (Table 2.10, p.108) work in 
synergy with either the tested compounds (Table 2.14, p.130) or 
other unknown compounds to cause the activity 
(iii) There are other secondary metabolites in the extract, which have 
not yet been identified responsible for the activity, either by 
themselves or in synergy with known/unknown compounds  
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2.4 Conclusion/Future work 
All six RSP extracts obtained throughout this initial study of extraction 
techniques and antioxidant activity, have shown to be active in the FC, FRAP 
and the DPPH assay. However, taking all six extracts further in this study was 
not possible. Thus, the results obtained in this chapter, allowed the selection 
of SOX extraction as the method of choice for subsequent experiments 
discussed in later chapters of this thesis. All the in vitro assays show that the 
SOX extraction method demonstrated the best antioxidant activity that was 
substantiated in both PLS plots. In addition, the SOX extracts also 
demonstrated better activity in the ORAC antioxidant assay. Using a 
preliminary defatting step during this extraction method created an easily 
workable starting material for further investigation. The results obtained for 
the Soxhlet extraction for both years (2012 and 2014) were published in Pohl 
et al. 2018353. 
The decision of the harvest year was reached after detailed observations of 
the results obtained as well as considering handling and storage 
circumstances. SOX2014 showed significantly higher results for the FRAP 
assay as well as slightly better results for the FC and DPPH assay. The lower 
activity of the SOX2014 extract for the ORAC assay was found to be non-
significant. In addition, the HPLC-MS/MS analysis demonstrated a similar 
general secondary metabolite composition for both harvest years.  
Furthermore, the 2014 pomace was obtained within the first couple of months 
of this project. On arrival, the pomace was freeze dried and stored at -80°C 
(long term storage). The process after the arrival of the 2012 harvest was 
not clear. The impact of the longer storage time of the 2012 harvest was also 
considered. All these factors led to the decision to continue research with the 
RSP from 2014. 
Besides, the study showed, that the compounds suggested to be responsible 
for the extract’s in vitro activity by the PLS plots were not responsible for the 
found activity of the RSP extract. Further research into the extract’s 
composition could lead to the identification of the responsible compounds. 
Literature research suggests the presence of e.g. sinapine and other phenolic 
compounds88,110, canolol108, glucosinolates99, tocols102, phytosterols106 and 
phospholipids387.  That is why the following chapter will focus on determining 
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the reproducibility of the SOX extraction technique and the further 
characterisation of the final extract, including glucosinolate, anthocyanin and 
sinapine analysis. In addition, further in vitro studies looking into the extract’s 
potential in the prevention or treatment of neurodegenerative disease will be 
shown. 
To optimise the extraction of phytochemicals on the one hand other extraction 
techniques could be tested such as described in Table A1 (p.424). On the 
other hand different solvent combinations and ratios338, extraction 
temperature and time388 and the solid to solvent ratio261 will have an effect 
on the extraction efficiency as well as the composition of the extract and 
should be optimised for the RSP. Further research into the Soxhlet extraction 
technique should consider eliminating the petroleum ether extraction, as the 
latter solvent is not environmentally friendly. However, this might lead to as 
less dry end product, such as seen for the UAE and the ASE extraction, where 
no de-oiling was undertaken. Hence, if the elimination of this de-oiling is not 
possible, the Soxhlet equipment should be used to its capacity and the solvent 
collected at the end of the run reused, after verifying that this has no impact 
on the de-oiling procedure. By re-using the solvent, the environmental impact 
of the Soxhlet extraction could be decreased. When changing the extraction 
technique or the solvent composition, a parameter for optimization of 
extraction needs to be chosen. Here we used the in vitro antioxidant activity 
as a read out, however this might not be the optimal read out, other 
parameters, such as in vivo activity or the concentration of a certain 
secondary metabolite might be more appropriate depending on the further 
use of the extract. In addition, further research should also consider the 
analysis of the leftover product after the initial Soxhlet extraction. This 
powdery material might still contain valuable components e.g. proteins which 
can add additional value to the product. 
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3  PHYTOCHEMICAL 
CHARACTERISATION AND 
NEUROPROTECTIVE PROPERTIES 
OF RSP EXTRACT IN VITRO 
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This chapter will cover the characterisation of the final extract (SOX2014), 
determining a number of different secondary metabolite groups, including phenolics, 
glucosinolates and anthocyanins. In addition, results for in vitro chemical activities, 
such as antioxidant-, metal chelating-, acetylcholinesterase inhibition–, self-
mediated β-amyloid (1-42) aggregation inhibition and plasmid DNA protective 
activities will be presented. 
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3.1 Introduction 
The following chapter is focused on the chemical characterisation of the final 
chosen RSP pomace extract. As determined in the previous chapter, SOX 
extraction was the chosen extraction technique and the RSP from 2014 was 
used for the extraction. Initially the repeatability of the extraction technique 
was assessed on three independent extracts based on their in vitro activity 
(FC, FRAP and DPPH). This helped to determine whether a bulk extraction of 
the RSP would be necessary for a more homogeneous extract. A final 
characterisation using DPPH, FC, FRAP, ORAC and LC-MS/MS (chapter 2) 
analysis, for the previously analysed secondary metabolites, was undertaken, 
to characterise the final extract. 
3.1.1 Determination of additional secondary 
metabolites in the RSP extract 
For the last decade, interest in rapeseed secondary metabolites has 
increased. A large number of papers recently reported the analysis of 
secondary metabolites81,112,353 and biological/chemical activity of rapeseed, 
RSP, RSP extracts or respective single metabolites found in 
rapeseed76,111,353,366,389. Those reports suggested the presence of phenolics, 
such as sinapic acid, caffeic acid, ferulic acid and others which agree with our 
data described in chapter 2. Furthermore, other secondary metabolites have 
been reported in the Brassica plant, these include sinapine (a choline ester of 
sinapic acid), sinapic acid derivatives, other phenolics99,110,113,390 and 
glucosinolates99,391. The characterisation of these metabolites from the RSP 
extract formed the basis of this chapter (3.1.1.1 Sinapine and additional 
phenolic derivatives, p.135 and 3.1.1.2 Glucosinolates (GLSs), p.136 ). A 
further group of secondary metabolites often cited for their positive 
antioxidant activity is the anthocyanins. The latter are flavonoids, mostly 
associated with causing red/blue colours in fruits, vegetables and other 
plants/plant parts. As RSP does not show the indicative colour, the 
anthocyanin content has not been of great interest so far but will however be 
part of this investigation (3.1.1.3 Anthocyanins, p.140). 
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3.1.1.1 Sinapine and additional phenolic derivatives  
In the last few years, sinapic acid and its derivatives such as syringaldehyde, 
sinapoyl ester, 4-vinylsyriingol and sinapine have received increase attention 
due to their various biological activities96. Sinapine (sinapoyl choline) for 
example is known to be present in the Brassicaceas/Cruciferae plant family, 
to which rapeseed/canola belongs to.  It was first isolated by Henry, Fils and 
Garot in 1825392 from black mustard seeds and named sinapine, but its 
chemical structure was not proposed till 1897393. Sinapine has been reported 
to be the most abundant phenolic ester in rapeseed92,110. It is produced in the 
plants through the shikimate/phenylpropanoid pathway and accumulates in 
brassicaceous plants together with a number of sinapate esters of flavonol 
glycosides, glucose and gentiobios40,110,394,395. In the past, breeding programs 
had aimed to decrease the content of these metabolites in Brassica napus, 
due to their associated anti-nutritive properties395. 
In many Asian countries research on sinapine has received much attention 
due to its significant biological activity. Brassica plants such as turnip 
(Brassica rapa var.rapa L.) and mustard (Brassica juncea), or parts of these, 
contain significant amounts of sinapine396,397 and are known to be used in 
Tibetan or Traditional Chinese Medicine396. Sinapine is also considered an 
acetylcholinesterase inhibitor due to structural similarity to acetylcholine 
(Figure 3.1)398. 
 
Figure 3.1| Chemical structure of sinapine in comparison to 
acetylcholine 
The patent “Use of sinapine in preparing medicine for preventing and curing 
senile dementia” (CN1259045C, language Chinese), granted in June 2006, 
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demonstrated the AChE inhibiting potential of sinapine399. Another Chinese 
patent application (CN105732402A) described the preparation of sinapine 
thiocyanate from rapeseed cakes and suggested its application in AD, due to 
its AChE inhibition activity400. He et al.401 (only abstract available in English) 
reports the compounds activity in cerebral homogenate and blood serum of 
rats with IC50 values of 3.66 and 22.1 µmol/L respectively and suggests 
sinapine’s potential for the prevention and cure of Alzheimer's disease401. 
Apart from AChE inhibition activity, sinapine present in Brassica rapa var. 
rapa L., had shown hepatoprotection in CCl4-induced hepatotoxicity mice 
models396. In a PC12 (rat pheochromocytoma) hypoxia damage model, 
sinapine showed protection from Na2S2O4-induced apoptosis and 
mitochondrial transmembrane potential disruption. Furthermore, it decreased 
malonaldehyde (MDA) production and lactate dehydrogenase (LDH) 
leakage402. Sinapine was also able to increase maximum, average and median 
life spans of Drosophila melanogaster at 10 and 50 mg/L concentrations403. 
The immense research undertaken in the Asian countries shows the potential 
importance of sinapine to human health.  
Other secondary metabolites of interest are for example 1-O-β-D-
glucopyranosyl sinapate as this was found to be the most active antioxidant 
metabolite in canola meal344. A vast number of other phytochemicals have 
also been identified in rapeseed; including derivatives of some of the 
secondary metabolites determined in the rapeseed as described in Chapter 2 
e.g. kaempferol, quercetin and ferulic acid101,110,404–406. To analyse the 
additional secondary metabolites in the RSP extract, LC-MS/MS analysis will 
be employed. 
3.1.1.2 Glucosinolates (GLSs) 
Glucosinolates (GLSs), sulphur-containing secondary-metabolites are 
characteristic for Brassica plants such as rapeseed/canola. They all share a 
β-thioglucoside N-hydroxysulfate configuration with a variable side-chain 
derived from amino acids101. Glucosinolates are known to be present in at 
least 15 botanical families of the order Capparales including Brassicaceae407. 
When GLSs are exposed to hydrolytic enzymes such as myrosinase (β-
thioglucosidase) after tissue disruption, such as cutting, processing 
(pressing) or chewing, their breakdown leads to products such as 
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isothiocyanates, thiocyanates or nitriles that act as repellents towards 
generalist herbivores (Figure 3.2)407–409. 
 
Figure 3.2| Glucosinolates basic structure  
Side chain -R depending on specific glucosinolate and their products after myrosinase 
hydrolysis (adapted from409,410) 
The content of GLSs in rapeseed depends on the presence of certain nutrients 
(nitrogen and sulphur) in the growing environment411. In general, they 
account for between 3-8% of rapeseed meal in conventional cultivars, or 0.5-
1.0%, in low-GLS cultivars99. Just like sinapine, GLSs were undesirable due 
to their anti-nutritional properties, which prompted the creation of low-GLS 
cultivars90. However, positive biological activities have been identified for 
some isothiocyanates. Sulforaphane for example, which is produced in 
Brassica plants by the enzymatic reaction between glucoraphanin (GRa, 
Figure 3.3, p.139) and myrosinase, was shown to activate Nrf2 (redox 
sensitive transcription factor) that once activated, induces a number of phase 
II drug metabolising enzymes (Figure 1.29 p.60)412. A review by Giacoppo et 
al.413 presents further data on the neuroprotective effects of isothiocyanates 
for the treatment of neurodegenerative disease. Hence, in recent years, 
researchers have attempted to selectively  increase certain GLSs in rapeseed 
such as glucoraphanin, the precursor for the isothiocyanate sulforophane407.  
Although myrosinase is a plant specific enzyme, GLSs can be hydrolysed at a 
much lower rate by thioglucosidase enzymes414 or bacteria found in the gut 
flora415,416, which can lead to the presence of isothiocyanates in the gut, even 
in the absence of myrosinase. 
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The glucosinolate-myrosinase system, in conjunction with the break down 
products, found in rape and other Brassica species is a well-studied chemical 
defence systems against herbivores and fungi99. However, very little has been 
reported about the biological activities and advantages of GLSs themselves. 
A review by Vig et al.417 summarised their biocidal, bioherbicidal, 
antimutagenic, antiproliferative and indirect antioxidant activity caused by 
their hydrolysis products. A number of different glucosinolates have 
previously been identified in the seeds of the rapeseed plant, and these 
include (i) progoitrin; (ii) epiprogoitrin; (iii) glucoraphanin; (iv) 
gluconapoleiferin; (v) glucoalyssin; (iv) gluconapin; (vii) 4-
hydroxyglucobrassicin; (viii) glucobrassicanapin; (ix) glucoerucin; (x) 
glucoberteroin; (xi) gluconasturtiin and (xii) neoglucobrassicin99–101. Figure 
3.3 shows structures of the 11 GLSs analysed in this study. HPLC analysis 
with external GLS standards will be used to detect and quantify GLSs present 
in the RSP extract. 
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Figure 3.3| 11 glucosinolates commonly present in Brassica plants 
analysed in this study  
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3.1.1.3 Anthocyanins 
Anthocyanins (Figure 3.4), a subclass of flavonoids, can be found in 27 plant 
families, including the Brassicaceae family and the Brassica genera. They are 
most abundant in red/purple/blue coloured flowering plants as well as 
coloured vegetables and fruit, such as berries, black grapes and red 
cabbage418. The disease preventing properties of anthocyanin-rich extracts 
have been well documented for both in vitro and in vivo models and they are 
as follows: (i) antioxidant; (ii) anti-mutagenic; (iii) anti-inflammatory; (iv) 
anti-neurodegenerative and (v) anti-aging419,420. The most common 
anthocyanins in plants are pelargonidin, peonidin, cyanidin, malvidin, 
petunidin and delphinidin418.  
 
Figure 3.4| General structure of anthocyanins (flavylium cation) 
R1 and R2 can be H, OH or OCH3; R3 a glycosyl or H and R4 a glycosyl or OH, adapted 
from Kong et al.418 
Anthocyanins have been reported in many different Brassica plants such as 
Brassica oleracea var capitata (red cabbage)420, Brassica campestris var. 
chinensis (Beninabana)421, B. oleracea L. var. botrytis (violet cauliflower)422 
and Brassica juncea Coss variety (red mustard greens)423. However, 
anthocyanin content in Brassica napus has not been widely published. The 
only papers available were those investigating the potential increase of 
anthocyanin content in genetically modified rapeseed. Those papers showed 
an insignificant amount of anthocyanin in the unmodified plants. However, 
those analysis were done on the leaves rather than the seeds424,425. Limited 
data on the anthocyanin content of RSP extracts had therefore prompted us 
to analyse the anthocyanin content of RSP extract in this project. The analysis 
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of the presence of anthocyanin can initially be undertaken spectroscopically 
using the pH differential method. The latter method was first proposed by 
Fuleki and Francis in 1968426. It is based on a pH dependent colour change of 
anthocyanins (Figure 3.5). At a low pH of 1.0, anthocyanin pigments are 
brightly coloured (oxonium form, pink). In contrast, at pH 4.5 these pigments 
turn colourless (hemiketal form).  In the presence of any anthocyanins in the 
extract, a colour change from colourless to pink is anticipated at pH 1.0, with 
a maximum absorbance at a wavelength of 520 nm295. 
 
Figure 3.5| Chemical reaction of the colour change expected for the 
anthocyanin Pelargonidin (adapted from295) 
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3.1.2 Metal chelating properties 
Redox-active metals, such as Iron (Fe2+) and Copper (Cu2+) have important 
functions within the human body. Iron for example participates in several 
biochemical reactions, such as DNA, RNA and protein synthesis. It is also a 
co-factor for certain enzyme reactions (e.g. heme synthesis) and contributes 
to the synthesis of myelin which is necessary for normal brain function427. 
Copper on the other hand is just as important; it is a co-factor and structural 
component of numerous enzymes involved  in essential cellular processes 
including energy metabolism, antioxidative defence, iron metabolism, 
neuropeptide and neurotransmitter synthesis428,429. Dis-homeostasis of iron 
and copper can lead to severe disorders e.g. Copper: Menkes disease, 
Wilson’s disease428; Iron: Iron deficiency430. Impaired metal homeostasis has 
also been associated with a number of neurodegenerative diseases, such as 
PD, AD and ALS431. An increase in either Fe2+ or Cu 2+ can lead to higher 
oxidative stress caused by the generation of free radicals in vivo via the 
Fenton (Equation 3.1) and Haber-Weiss reactions (Equation 3.2) 
Equation 3.1 
 
Equation 3.2 
Metal chelators have shown improvements in in vitro and in vivo models of 
neurodegenerative disease. In an AD mouse model for example the metal 
chelators clioquinol reduced the amount of amyloid deposits in the brain432. 
Desferrioxamine, one of the earliest iron chelators has shown promising 
results in PD animal model studies, using MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) as inducer of neurodegeneration, by inhibiting iron 
accumulation while elevating dopamine to normal levels433. Metal chelating 
activity together with the known antioxidant activity of the extract could add 
to the extract’s potential to prevent neurodegeneration.  
In a paper by Santos et al.232 high-throughput assays for the determination 
of iron and copper chelating properties were proposed. The iron chelating 
activity assay employs ferrozine (3-(2-pyridyl)-5,6-diphenyl-1,2,4- triazine-
p,p’-disulfonic acid monosodium salt hydrate) for the detection of chelating 
properties, which was first introduced by Carter434. In this assay, the 
𝐹𝑒2+ + 𝐻2𝑂2 →  𝐹𝑒
3+ + 𝐻𝑂● + 𝐻𝑂− 
𝐹𝑒3+ + 𝐻2𝑂2 →  𝐹𝑒
2+ + 𝐻𝑂𝑂● + 𝐻+ 
𝑂2
●− + 𝐻2𝑂2  ↔  𝑂2 + 𝐻𝑂
● + 𝑂𝐻− 
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compounds/extracts in question are in competition with ferrozine, to bind 
Fe2+ ions provided by iron(II)sulfate (Figure 3.6; e.g. caffeic acid). The 
stronger the binding of the tested compound, the smaller the amount of Fe2+ 
that can bind to ferrozine. When ferrozine binds to iron ions, a colour change 
from clear to blue is observed232. 
  
 
Figure 3.6| Reaction mechnism for the in vitro iron chelating assay 
The intensity of the observed blue colour depends on this chelating ability of 
the tested compounds, i.e. the better the binding, the less intense the blue 
colour (Figure 3.7). This change in absorbance is measured at a wavelength 
of 562 nm. No change in the absorbance compared to the control (solvent 
instead of tested compounds) suggests no chelating activity. 
 
Figure 3.7| Reaction colour scheme for the iron(II) chelating activity 
assay   
control 
weak Fe2+ 
chelator 
strong Fe2+ 
chelator 
 
no Fe
2+
 
chelator ferrozine 
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The copper (II) chelating assay employs pyrocatechol violet (3,3’,4-
trihydroxyfuchsone-2’’-sulfonic acid) for the determination of Cu2+ chelating 
potential. Similar to the iron chelating assay, the compounds/extracts of 
interest are in a competitive relationship with pyrocatechol violet for the 
binding of copper(II) ions. An example for the reaction mechanism is depicted 
below using quercetin as example phenolic (Figure 3.8). 
   
 
Figure 3.8| Reaction mechanism for the in vitro copper chelating 
assay 
When pyrocatechol violet binds Cu2+ the absorbance increases at a 
wavelength of 632 nm due to the brown/blue coloured complex formation. In 
contrast, if this complex formation is inhibited by copper chelating agents, 
the reaction mix is yellow. 
 
Figure 3.9| Reaction colour scheme for the copper (II) ion chelating 
activity assay   
blank 
weak Cu2+ 
chelator 
no Cu
2+
 
chelator 
Pyrocatechol 
violet 
strong Cu2+ 
chelator 
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Both assays are easy to perform and can be applied in any laboratory. As 
described previously for the ORAC, FC and FRAP assay, these experiments 
use EDTA as standard and the extracts’ activity are given as EDTA 
equivalence. In Santos et al.232 the technique was tested on coffee extracts 
found to have good reproducibility and repeatability and a mean recoveries 
of over 96%. 
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3.1.3 Acetylcholinesterase 
(AChE)/Acetylcholinesterase inhibitors 
Current treatments for AD are mostly acetylcholinesterase inhibitors (AChE) 
such as Donepezil (synthetic), Rivastigmine (semi-synthetic derivative of 
physostigmine) and Galantamine (alkaloid present in plants e.g. members of 
the family Amaryllidaceae or synthetic production). All of which are reversible 
AChE inhibitors435. AChE is an enzyme (serine-protease), responsible for the 
breakdown of the neurotransmitter acetylcholine (ACh), via the hydrolysis of 
carboxylic ester of Ach in the synaptic cleft436 (Figure 3.10). The endogenous 
neurotransmitter ACh was first discovered by Otto Loewi (German-born 
pharmacologist), who received the Nobel Prize in Physiology or Medicine in 
1936 for his discovery of the first known neurotransmitter. Systematic 
biochemical investigations of AD patients, to elucidate the cause for AD and 
to find potential drug targets started in the 1960s and early 1970s. In the 
mid-1970s, low levels of choline acetyltransferase (ChAT), the enzyme 
responsible for the production of ACh were found437,438. Later studies 
confirmed the deficiency in presynaptic ACh. This together with the known 
importance of ACh in learning and memory led to the cholinergic hypothesis 
of Alzheimer’s disease437,439, which initiated the use of AChE inhibitors for the 
treatment of AD. Figure 3.10, shows a schematic of ACh transmission in 
untreated AD patients and those treated with AChE inhibitors. AChE 
inhibitors, apart from the ones currently used in clinic, are continuously being 
discovered, especially in plant extracts such as from Globularia alypum218, 
Solanum leucocarpum Dunal and Witheringia coccoloboides (Damm) 
(Solanaceae family)440 as well as Hypericum undulatum and Sanguisorba 
minor332.
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Figure 3.10| Acetylcholine levels and neurotransmission in AD patients with and without acetylcholinesterase 
inhibitors 
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3.1.3.1 Ellman method for AChE inhibition studies 
To determine the acetylcholinesterase inhibition activity of the RSP extract 
initially the Ellman method441 was applied. In this assay acetylthiocholine 
iodide is used as substrate which is hydrolysed by acetylcholinesterase to 
thiocholine and acetic acid, thereafter thiocholine reacts with the oxidizing 
agent 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) to form 5-thio-2-
nitrobenzoate as a yellow coloured product with an absorption maximum at 
412 nm (Figure 3.11).  
 
Figure 3.11| Reaction mechanism of the Ellman method for the 
detection of AChE inhibition, adapted from Badawy and El-Aswad442 
In the presence of AChE inhibitors, 5-thio-2-nitrobenzoate will not be formed, 
showing no increase in absorbance, thus differentiating between inhibitors 
and non-inhibitors. 
3.1.3.2 Amplex Red Assay kit for AChE inhibition studies 
A second method for the determination of AChE inhibition activity is a 
fluorescent based assay known as the Amplex Red AChE kit. It is more 
sensitive and less prone to interference than the Ellman assay (UV/VIS-
absorbance based). In this assay the AChE activity is measured indirectly 
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through 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent), which 
reacts with H2O2 and acts as fluorogenic probe. Acetylcholine chloride, used 
as acetylcholine substrate, is converted to choline by AChE (Figure 3.12). 
Thereafter, choline is oxidized by choline oxidase, which leads to the 
formation of betaine and H2O2. The fluorogenic probe Amplex red reacts with 
the formed H2O2 (in the presence of horseradish peroxidase) in a 1:1 
stoichiometric ratio to form the fluorescent end-product resorufin, with an 
excitation and emission wavelength of 530-560 nm and ~590 nm 
respectively443.  
 
Figure 3.12| Amplex® Red Acetylcholine/Acetylcholinesterase Assay 
reaction scheme 
By using a fluorescence-based assay, potential absorbance interferences can 
be avoided. The increased sensitivity is also of significant advantage, 
especially for compounds showing little AChE inhibition activity. 
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3.1.4 Inhibition of self-mediated β-amyloid (1–42) 
aggregation 
The progressive deposition of misfolded and aggregated proteins is a hallmark 
of a number of different neurodegenerative disease e.g. AD (β-amyloid 
peptide, tau), PD (α-synuclein), HD (Huntingtin), SCA3 (ataxin-3) and ALS 
(superoxide dismutase) (1.3 Neurodegeneration, p.23 ff.). These misfolded 
proteins are fundamental for the progressive development of 
neurodegenerative disease. The question on which form of mutated protein 
(monomers, oligomers or insoluble aggregates) is causing the disease is still 
unknown. Also, the fact on whether the aggregations are causing the disease 
or are a downstream effect of it is still unclear. Although protein aggregates 
are a common target for drug treatments, the issue of missing knowledge 
about protein aggregations is generating a unique challenge for the drug 
development process444.   
In AD for example, the prevention of self-mediated β-amyloid aggregation is 
a well-studied potential mechanism of disease prevention. A number of 
natural compounds such as curcumin, caffeic acid, ferulic acid, β-carotene 
and sulforaphane have been identified as peptide aggregation inhibitors445. 
However, although these compounds have been found to inhibit the 
aggregation formation, their specific target and chemical mechanisms 
underlying this prevention is still unclear. Research has shown different 
covalent and non-covalent inhibition mechanisms445.  
Some of the above stated compounds, i.e. caffeic acid and ferulic acid have 
been positively identified in the RSP extract (Table A2, p.429). To assess the 
extracts ability to inhibit self-mediated β-amyloid aggregation, the thioflavin 
T (ThT) fluorescence method was used (Figure 3.13). The use of ThT for the 
detection of β-amyloid aggregations was first described by Vassar and Cullin 
in 1959446.  
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Figure 3.13| ThT assay 
Increase of fluorescence reading during the formation of β-amyloid fibril formation 
adapted from Wallin et al.447 
The fluorescence intensity of ThT increases when bound to protein fibrils. A 
smaller increase of fluorescence intensity suggests the inhibition of 
aggregation.  
A positive outcome of this study would supplement the extracts known 
antioxidant activity and support further investigation into the extracts 
potential to prevent or treat neurodegenerative disease. Extracts from plant 
material such as Mulberry leafs448, grape seeds449 and maple syrup450 have 
previously shown prevention of β-amyloid aggregation. 
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3.1.5 DNA protection 
Cells in the human body are under constant stress from chemicals produced 
in vivo during normal cellular metabolism or from external factors, such as 
environmental chemicals or radiation. This stress, mostly oxidative, can cause 
DNA damage (Figure 1.27, p. 54). Damage to DNA is exceptionally harmful, 
as DNA builds the basis for the formation of proteins necessary for cellular 
function. This is especially worrying for neurons, as these are not like for 
example epithelial cells, lining the intestine, replaced every five days, but are 
retained for life. This increases the importance of protecting neurons from 
DNA damage451. 
To determine the DNA protection potential of the RSP extract 
a simple in vitro assay using plasmid DNA will be employed. 
Plasmid DNA such as pBR322, created in 1977 by 
postdoctoral researchers (Bolivar and Rodriguez) in Herbert 
Boyers lab at the University of California, San Francisco is 
used as DNA source. The pBR322 plasmid is circular DNA 
consisting of 4361 base pairs. In its native state pBR322 plasmid DNA is 
mostly super coiled (over- and under- wind). However, once it is exposed to 
ROS (e.g. peroxyl- or hydroxyl radicals) the supercoiled form is broken into 
an open circular or even linear formation (Figure 3.14). ROS can be 
introduced in vitro via e.g. AAPH, a peroxyl radical producer (2.1.3.4 ORAC, 
p.84 ff.), or the Fenton reaction, leading to the formation of hydroxyl radicals. 
 
Figure 3.14| Reaction of pBR322 plasmid DNA with AAPH 
AAPH 
O2 
2ROO● + N2 
+ 2ROO
●
  
or  
Super coiled Circular Linear 
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This change is associated with a conformational change of the plasmid DNA, 
which leads to a delay of movement; in e.g. agarose gels, compared to the 
supercoiled form. This assay has previously been used to determine DNA 
protective properties for various extracts and single compounds, e.g. 
polyphenols extracted from green tea452 and Terminalia arjuna bark 
extracts377, with promising results. The same experiment using pUC19 
plasmid DNA showed protecting properties for onion extracts (allium cepa 
L.)453. These and other plasmids (pMK 3454, pUC18455) have previously been 
used  to determine the protection of DNA from oxidative stress in vitro. 
The plasmid DNA protection assay together with the other anticipated 
experiments described in this introduction will enhance our knowledge of the 
composition an in vitro activity of the RSP extract regarding neuroprotective 
potential. All the set out objectives for this chapter are briefly summarised 
following. 
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3.1.6 Objectives 
The list below describes the objectives set out for this chapter: 
- Determine repeatability of Soxhlet extraction technique, to assess 
whether bulk extraction is necessary 
- Analyse antioxidant activity of the final extract 
- Determine secondary metabolite composition of final extract, including 
previously shown method as well as additional LC-MS/MS, HPLC and 
spectroscopic methods 
- Establish the extracts metal chelating (Fe(II) and Cu(II))-, DNA 
protecting-, β-amyloid (1-42) self-mediated aggregation inhibiting- 
and AChE inhibiting properties
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3.2 Materials and Methods 
3.2.1 Chemicals and Equipment 
For the experiments discussed in this chapter, the following chemicals/kits 
(Table 3.1) and equipment (Table 3.2) were used. 
Table 3.1| Chemicals, reagents and kits 
Chemicals Provider 
1,1-diphenyl-2-picryl-hydrazyl 
(DPPH) 
Sigma-Aldrich 
Methanol (HPLC grade) Fisher Scientific/Sigma-Aldrich 
Gallic acid Sigma-Aldrich 
Trolox Sigma-Aldrich 
Folin & Ciocalteu’s phenol 
reagent 
Sigma-Aldrich 
Sodium acetate trihydrate Sigma-Aldrich 
2,4,6-tris(2-pyridyl)-s-triazine 
(TPTZ) 
Sigma-Aldrich 
Hydrochloric acid (HCl) Sigma-Aldrich 
Ferric chloride (FeCl3*6H2O) Sigma-Aldrich 
Sodium carbonate (Na2CO3) Sigma-Aldrich 
Sodium hydroxide (NaOH) Sigma-Aldrich 
2,2'-azobis(2-amidinopropane) 
dihydrochloride (AAPH) 
Sigma-Aldrich 
Monopotassium phosphate 
(KH2PO4) 
Sigma-Aldrich 
Ethylenediaminetetraacetic 
acid (EDTA) 
Sigma-Aldrich/Alfa Aesar 
Sodium fluorescein Sigma-Aldrich 
Sinapic acid Sigma-Aldrich 
Glacial acetic acid (CH3CO2H) Fisher Scientific 
Ethanol Fisher Scientific 
Tris-base Fisher Scientific 
Petroleum ether (C6H14; boiling 
point 40-60°C) 
Fisher Scientific 
Syringic acid Sigma-Aldrich 
Ferulic acid Sigma-Aldrich 
Caffeic acid Sigma-Aldrich 
Acetonitrile Fisher Scientific 
Glacial acetic acid Fisher Scientific 
Trifluoroacetic acid (TFA) Fisher Scientific 
FeSO4*5H2O Sigma-Aldrich 
Ferrozin Sigma-Aldrich 
CuSO4*5H2O Sigma-Aldrich 
Penicillamine Sigma-Aldrich 
Pyrocatechhol Sigma-Aldrich 
Green tea Meßmer, Kaufland, Germany 
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Grapeseed pomace 
Portugal, Brancellao red 
grapes 
Plasmid DNA pBR322 Fisher Scientific 
GelRed dye Fisher Scientific 
Agarose Fisher Scientific 
β-amyloid peptide (1-42) calbiochem 
Na2HPO4 Fisher Scientific 
NaH2PO4 BDH (The British Drug Houses) 
Sodium chloride (NaCl) Fisher Scientific 
Glycine Fisher Scientific 
Thioflavin T Acros Organic 
DMSO Fisher Scientific 
Curcumin Sigma-Aldrich 
PBS OXOID 
Amplex® Acetylcholine 
/ Acetylcholinesterase Assay 
Kit 
Fisher Scientific 
Sinapine thiocyanate ChemFaces 
pBR322 plasmid DNA  Fisher Scientific 
Choline chloride Sigma-Aldrich 
DTNB Sigma-Aldrich 
Gel Red™ (10000x in water) VWR 
AChE (electric eel) Sigma-Aldrich 
Hepes Sigma-Aldrich 
Acetylthiocholine iodide Sigma-Aldrich 
Table 3.2| Equipment 
Equipment Manufacturer/Details 
Freeze Dryer  Modulyo Edwards 
Coffee grinder De Longhi KG39 
LC-MS/MS 
Agilent MassHunter 6420 
Triple Quad 
LC MS/MS (Rowett) Agilent 1100 
Gel tank Life Technologies Horizon®58 
Automatic Soxhlet Gerhardt; Soxtherm SE 416 
Plate reader BioTek µQuant 
Fluorescence 
spectrophotometer 
Perkin Elmer LS55 
Rotary evaporator  Büchi Rotavapor R-114 
Oven Techne Hybridiser HB-10 
Fridge DEAWOO 
Freezer -20°C Blomberg 
Freezer -80°C New Brunswick Scientific U725 
pH-meter Denver Instruments Basic 
Balance OHAUS Pioneer™PA114 
Balance Mettler BB1200 
Ultrasonic bath Ultrawave SFE5901 
Power pack 
E-C Apparatus Corporation EC 
105 
Plate shaker (molecular) Heidolph Polymax 1040 
Microwave Panasonic NN-E255W 
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3.2.2 Methods  
The methods in this chapter (Figure 3.15) were applied to further elucidate 
the chemical composition of the RSP extracts and to determine which 
compounds within the extract were responsible for antioxidant activity. 
Furthermore, the RSP extracts neuronal protection potential, was evaluated 
in vitro, in order to evaluate the extracts’ potential in preventing or treating 
neurodegenerative disease. 
 
Figure 3.15| Overview of methods used in the assessment of the RSP 
extract for its chemical composition and in vitro neuroprotective 
properties  
 
3.2.2.1 Determination of repeatability of Soxhlet extraction 
In this chapter repeatability of the extraction technique was determined for 
three independent extracts (2.2.2.3 Rapeseed Pomace Extraction techniques, 
Soxhlet, p.92 ff.), by determining their antioxidant activity using the DPPH, 
FC, FRAP assays (2.2.2.4 Folin-Ciocalteu-(FC) Assay, p.94/2.2.2.6 In vitro 
antioxidant activity, p.94 f.). 
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3.2.2.2 Production of final RSP extract and antioxidant activity and 
secondary metabolite analysis 
A final RSP extract was obtained by carefully mixing the extracts from nine 
separate extractions together to obtain one homogeneous mixture. In the 
following chapters this will be called RSP extract. Dried RSP extract aliquots 
(1-3 g) were sealed into plastic packages using a vacuum sealer and stored 
at -80°C until further use. The extract package in use at the time of 
experiments was stored at -20°C in 25 mL tubes in the presence silica gel as 
desiccant, to avoid moisture. That final extract was further characterised 
using the previously described antioxidant assays ((2.2.2.4 Folin-Ciocalteu-
(FC) Assay, p.94/2.2.2.6 In vitro antioxidant activity, p.94)). In addition, the 
final extract was submitted to LC-MS/MS analysis at the Rowett Institute, as 
previously described (2.2.2.5 Chemical Analysis of the RSP Extracts (HPLC-
MS/MS), p.94). 
3.2.2.3 Determination of additional secondary metabolites in the 
extract   
Additional secondary metabolites in the RSP extract were determine using 
different analytical techniques. Sinapine and other phenolic derivatives were 
determined using LC-MS/MS, glucosinolates using HPLC and total monomeric 
anthocyanin content was determined in a simple colorimetric reaction (UV-
VIS spectroscopy). 
Sinapine and similar 
Chromatographic separation was performed as previously described by Yates 
et al.456, according to Neacsu et al.343 with minor modifications, on an Agilent 
1200 Infinity Series HPLC (Cheshire, UK) using a Zorbax Eclipse Plus C18 
Rapid Resolution column (100 x 4.6 mm; 3.5 µm) maintained at 25°C. The 
mobile phase consisted of 0.1% acetic acid in water (A) and 0.1% acetic acid 
in acetonitrile (B) operated under gradient conditions at a flow rate of 0.4 
mL/min over 69 min with an injection volume of 10 µL. The gradient 
programme was: 90% A – 10% B initially, changed to 45% A – 55% B over 
45 min, then to 20% A – 80% B over 15 min and held for 3 min. Thereafter, 
conditions were changed back to the starting conditions of 90% A – 10% B 
in 1 min and kept for a final 5 min. The HPLC system was allowed to 
equilibrate after each run. The HPLC was coupled to an Agilent 6420 MS/MS 
Chapter 3: Phytochemical Characterisation and Neuroprotective Properties of RSP 
Extract in vitro 
Franziska Pohl   159 
triple quadrupole.  Electro-spray ionization (ESI) was utilised in both negative 
and positive ionisation modes.  The capillary voltage for both negative and 
positive ionisation modes was set to 4 kV.  The desolvation temperature was 
kept at 350°C with a gas flow rate of 12 L/min and nebulising pressure of 50 
psi. Nitrogen gas was used as the nebulising, desolvation and collision gas.  
Full-scan MS spectra were obtained by scanning from 40 – 1000 m/z. 
Retention times and two multiple reaction monitoring (MRM) transitions were 
monitored for each analyte for quantification and confirmation purposes457.   
Linearity was established via a six point calibration curve ranging in 
concentration from 0.05 to 1 µg/mL sinapine in mobile phase (90:10% 
acetonitrile:water). Intra-day and inter-day precision and accuracy was 
determined by triplicate injection of 0.1 and 1 µg/mL (0.8 µg/mL for sinapine) 
standards over two different days, respectively456. 
Antioxidant activity of sinapine in comparison to a mixture of phenolic acids 
(sinapic acid, caffeic acid, ferulic acid and syringic acid) and the RSP extract 
was tested as previously described (2.2.2.4 Folin-Ciocalteu-(FC) Assay, p.94, 
2.2.2.6 In vitro antioxidant activity, p.94 ff.). 
Glucosinolates (GLSs) analysis 
For the determination of GLSs in the rapeseed pomace as well as in the final 
RSP extract the procedure by Raikos et al.115 was followed with minor 
modifications. In brief, 50 mg of sample (RSP and RSP extract) were weighed 
in triplicate into 15 mL falcon tubes. A water bath was set to 100°C and a 
bottle containing milliQ water heated to the same temperature. Once the 
water reached the required temperature, all samples were made up to 25 
mg/mL, with hot water, vortexed, and placed into the water bath for 
extraction. The samples were vortexed regularly every 5 minutes. After 15 
minutes, the tubes were left to cool to room temperature and centrifuged 
(4000 rpm, 10 min, rt). The supernatant was collected into 5 mL Eppendorf 
tubes. Then filtered into two separate Eppendorf tubes (1.5 mL), collecting 
the initial and the final filtrate in one and the middle filtrate in the other one. 
The latter one was used for HPLC analysis. Samples were stored at -70°C 
until analysis. A serial dilution of all tested standards (external) was prepared 
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for external calibration and the limit of detection and quantification 
calculated. 
Table 3.3| External Glucosinolate Standards for HPLC 
• (-)-Sinigrin Hydrate • Gluconapin • Progoitrin • Glucobrassicin 
• Glucobrassicanapin • Glucoraphanin • Glucoiberin • Glucoerucin 
• Glucotropaeolin • Gluconasturtiin • Glucoraphenin  
 Note(s): for chemical structure of GLSs see Figure 3.3 p.139 
The analysis was undertaken on an Agilent 1260 Infinity HPLC with a diode 
array detector (DAD), using a Phenomenex Synergi 4 µm Hydro-RP 80A HPLC 
column (250 x 4.6 mm) with Phenomenex Synergi Polar-RP pre-column. DAD 
spectra were recorded between 190-700 nm and chromatograms monitored 
at 229 nm wavelength due to high absorption of glucosinolates at this 
wavelength. A gradient programme was used with mobile phase A, 0.05 M 
KH2PO4 buffer (pH 2.3), filtered (0.2 µm) and purged with nitrogen for 36 
hours protected from light and mobile phase B was HPLC grade acetonitrile.  
The column temperature was set to 25°C and the auto sampler thermostat 
to 4°C. Samples (20 µL) were injected and a flowrate of 1 mL/min was 
applied. The injection needle was washed with 100% acetonitrile between 
injections. 
Table 3.4| Mobile phase HPLC gradient for the detection of 
glucosinolates 
Time (min) %A %B 
0-6 100 0 
6-35 67 33 
35-36 67-30 33-70 
36-42 30 70 
42-43 30-100 70-0 
43-55 100 0 
 
Limit of detection (LOD) and quantification (LOQ) were calculated based on 
the standard deviation of the response (Sy) and the slope of the calibration 
curve (S) (Equation 3.3): 
𝑳𝑶𝑫 = 𝟑. 𝟑 ∗
𝑺𝒚
𝑺
   𝑳𝑶𝑸 = 𝟏𝟎 ∗
𝑺𝒚
𝑺
        Equation 3.3 
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Total Monomeric Anthocyanin Pigment Content 
The pH differential method was applied according to Lee et al.295 with minor 
modifications. Briefly, RSP extract (final extract) was made up in methanol to 
a final concentration of 1 mg/mL. This solution was diluted with two buffers 
(i) potassium chloride (0.025 M) buffer, pH 1.0 (ii) sodium acetate (0.4 M) 
buffer, pH 4.5, to give final concentrations of 200 µg/mL.  
The absorbance was measured at 520 nm. To correct for the presence of 
turbidity a measurement is also taken at 700 nm and subtracted from the 
520 nm reading. The measurements were taken 30 min after the preparation 
of solutions and the results are given as anthocyanin pigment cyanidin-3-
glucoside (cyn-3-glu) equivalents in mg/L (Equation 3.4) 
𝐚𝐧𝐭𝐡𝐨𝐜𝐲𝐚𝐧𝐢𝐧 𝐩𝐢𝐠𝐦𝐞𝐧𝐭 𝐜𝐲𝐧 − 𝟑 − 𝐠𝐥𝐮 𝐞𝐪𝐮𝐢𝐯𝐚𝐥𝐞𝐧𝐭𝐬 𝐢𝐧 𝐦𝐠/𝐋 =
𝑨 ∗ 𝑴𝑾 ∗ 𝑫𝑭 ∗ 𝟏𝟎𝟑
𝜺 ∗ 𝒍
 
Equation 3.4 
Where A= (A520 nm – A700 nm) pH 1.0 – (A520 nm – A700 nm) pH 4.5; 
MW (molecular weight) = 449.2 g/mol for cyanidin-3-glucoside (cyd-3-glu); 
DF = dilution factor; l = pathlength in cm; ε = 26900 molar extinction 
coefficient, in (L/(mol*cm), for cyd-3-glu; and 103 = factor for conversion 
from g to mg. 
As this method is measuring mg of anthocyanin pigment cyanidin-3-glucoside 
equivalents in liquids, the obtained results are for the starting solution of 1 
mg/mL. To obtain more useful results, this was transferred to mg of 
anthocyanin pigment cyanidin-3-glucoside equivalents per g extract. As 
positive control, grape pomace (GP) extract was prepared as described 
previously for the RSP (2.2.2.3 Rapeseed Pomace Extraction techniques, 
p.92) and analysed simultaneously. Wine production by-products have 
previously shown to contain anthocyanins340. 
3.2.2.4 Metal chelating properties (Iron and copper) 
Iron (Fe2+) chelating  
The iron chelating activity of the extracts was assessed according to Santos 
et al.232. EDTA was used as a standard and concentration between 5-50 
µg/mL prepared in deionized water. Both, the extract and sinapine were 
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similarly prepared in deionized water (1 mg/mL and 120 µg/mL respectively). 
Green tea was used as positive control458. A 96-well plate set-up was used, 
and wells filled with 50 µL sample/EDTA/negative control and 160 µL 
deionized water followed by 20 µL of Fe2SO4 (0.3 mM in deionized water). 
After a 5-minute reaction time, 30 µL ferrozine (0.8 mM in deionized water) 
were added and plates incubated for 15 minutes (rt). Thereafter, the 
absorbance was recorded at 562 nm. EDTA calibration curves were created 
and mg EDTA equivalence (equ.)/g RSP extract calculated (Equation 3.5). 
𝑪(𝒎𝒈 𝑬𝑫𝑻𝑨 𝒆𝒒𝒖𝒊𝒗𝒂𝒍𝒆𝒏𝒄𝒆/𝟏𝒈 𝑹𝑺𝑷 ) = 𝒄(𝐦𝐠/𝒎𝑳) ∗ (
𝑽(𝒎𝑳)
𝑴(𝒈)
) Equation 3.5 
Limit of detection (LOD) and quantification (LOQ) were calculated as 
previously described based on the standard deviation of the response (Sy) 
and the slope of the calibration curve (S) (Equation 3.3, p. 160). 
Copper (Cu2+) chelating 
The extracts ability to chelate copper ions was assessed following the method 
by Santos et al.232 using pyrocatechol violet as indicator. EDTA was used as 
a standard and concentration between 5-75 µg/mL were prepared in 
deionized water. Both, the extract and sinapine were similarly prepared in 
deionized water (1 mg/mL and 120 µg/mL respectively). As positive control 
Penicillamine was employed429. Briefly, 30 µL of sample/EDTA/negative and 
positive control were mixed with 200 µL sodium acetate buffer (50 mM, pH 
6.0) and 30 µL CuSO4* 5H2O (0.4 M) and were left to react for 2 min. To 
initiate the reaction, 8.5 µL pyrocatechol violet (2 mM) were added and the 
96-well plate shaken for 10 minutes followed by an additional 10 minutes 
reaction (25°C) thereafter, the absorbance was recorded at 632 nm. EDTA 
calibration curves were made and mg EDTA equivalence/g RSP extract 
calculated using the same formula (Equation 3.5) as for the iron chelating 
properties. Limit of detection (LOD) and quantification (LOQ) were calculated 
based on the standard deviation of the response (Sy) and the slope of the 
calibration curve (S) (Equation 3.3).  
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3.2.2.5 Acetylcholinesterase inhibition potential 
Ellman acetylcholinesterase (AChE) inhibition assay 
To determine AChE inhibition activity, the procedure detailed by Khlifi et al.218 
based on the Ellman method441 was used with slight modifications. For this, 
a 22 U/mL stock solution of acetylcholinesterase was prepared in Tris-HCl 
buffer (20 mM, pH 7.5). Prior to starting the experiment this solution was 
again diluted 1/100. The extract as well as the positive control neostigmine 
were dissolved in methanol, to obtain stock solutions of 1 mg/mL, which were 
further diluted in methanol to receive a serial dilution, to determine the IC50 
value. In a 96-well plate 125 µL DTNB (3 mM) are mixed with 25 µL sample 
or positive/negative control and 25 µL of the diluted AChE and the plate 
incubated for 10 minutes at room temperature. Thereafter 25 µL 
Acetylthiocholine iodide (15 mM) were added and the plate incubated for 10 
minutes at 37°C. Absorbance readings were recorded at 412 nm. IC50 values 
were calculated, using the linear part of the curve created after determining 
% of AChE inhibition (Equation 3.6). 
% 𝒐𝒇 𝑨𝑪𝒉𝑬 𝒊𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 =
(𝟏𝟎𝟎∗𝑨𝒔𝒂𝒎𝒑𝒍𝒆)
𝑨𝒃𝒍𝒂𝒏𝒌
    Equation 3.6 
 
Amplex® Red Acetylcholine/Acetylcholinesterase Assay Kit (A12217) 
For this assay, the instructions given by Molecular Probes443 were followed. 
All stock solutions were prepared as per instructions. Briefly, a ~20 mM stock 
solution of Amplex red reagent was prepared by dissolving one vial of the 
Amplex Red reagent (1 mg) in 200 µL DMSO. A 1X working solution of the 
reaction buffer was prepared by diluting the provided 5X stock solution 1:5 
in deionized water. The 200 U/mL stock solution of horse radish peroxidase 
(HRP) was prepared by adding 1 mL 1X reaction buffer to the vial of HRP. A 
20 mM H2O2 working solution was prepared daily by diluting the 3.6% stock 
solution with 1X buffer. The choline oxidase stock solution (20 U/mL) was 
prepared by dissolving the content of the provided vial (12 U) in 600 µL 1X 
buffer, which was aliquoted for the following experiments. To prepare 100 
mM acetylcholine, 5 mg of acetylcholine chloride was dissolved in 275 µL 
deionized water. This solution was made daily before each new set of 
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experiments. By dissolving the provided 60 U acetylcholinesterase (from 
electric eel) in 600 µL 1X reaction buffer a 100 U/mL stock solution was 
prepared. All prepared stock solutions, 5X buffer, H2O2 as well 
acetylcholinchloride were contained in the freezer (-20°C) until needed for 
the experiment. 
There after the instructions for the Acetylcholinesterase Assay443 were follow 
with minor modifications, to allow for the determination of 
acetylcholinesterase inhibition. The extract was dissolved in 1X reaction 
buffer and diluted to give a concentration gradient from 4 to 0.04 mg/mL with 
final well concentrations ranging from 1-0.001 mg/mL. As positive control, 
neostigmine was dissolved and diluted in 1X reaction buffer to 0.02 mg/mL 
giving a final well concentration of 0.005 mg/mL (22.39 µM). The 100 U/mL 
acetylcholinesterase stock solution was diluted to 0.2 U/mL (in 1X reaction 
buffer), of which 50 µL were used in each well, together with 50 µL RSP 
extract/neostigmine/1Xreaction (neg. control) buffer to determine the 
inhibition activity of the samples. A second positive control was prepared by 
diluting the 20 mM H2O2 working solution to 10 µM in 1X reaction buffer. For 
this reaction control instead of 50 µL AChE and 50 µL sample 100 µL H2O2 
were pipetted into the well. To all the wells, 100 µL of Amplex Red reagent 
(400 µM Amplex Red, containing 2 U/mL HRP, 0.2 U/mL choline oxidise and 
100 µM acetylcholine), were added to start the reaction. After addition of the 
Amplex Red reagent, the plate was immediately transferred into a preheated 
(37°C) fluorescence plate reader, running a program with the following 
settings, excitation wave length 530/25 nm and emission wave length 590/35 
nm and a gain of 35 for 150 minutes. 
In addition, after determination of the sinapine concentration in the extract, 
the extract (0.25 mg/mL) in comparison with the respective sinapine 
concentration as well as mixture of four phenolic acids (SA, SyrA, FA, CA) 
were analysed for AChE inhibition activity. 
3.2.2.6 Inhibition of self-mediated β-amyloid (1–42) aggregation 
The assessment of the extracts ability to inhibit self-mediated β-amyloid (1-
42) aggregation was done according to Bolognesi et al.459, with minor 
modifications. The amyloid peptide (0.25 mg) was dissolved in DMSO (110 
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µL) to prepare a 500 µM (2.27 mg/mL) stock solution. Curcumin (2.27 
mg/mL) and the extract (2.27 and 22.7 mg/mL) were similarly prepared in 
DMSO. For the reaction mix, 2 µL of peptide and 2 µL of the compounds were 
added to 96 µL of Phosphate/NaCl buffer (10 mM, pH 8.0). For the negative 
control, the extract was exchanged for 2 µL of DMSO. After 24 hours 
incubation, 300 µL of glycine/NaOH buffer (50 mM, pH 8.5) containing 5 µM 
ThT were added to each reaction mix. The resulting solutions were analysed 
using fluorescence spectroscopy (Perkin Elmer LS55) with an excitation 
wavelength of 446 nm and an emission of 490 nm, the values were averaged 
after subtracting the fluorescence background reading of the blank ThT 
solution. In addition, also extract controls were analysed, where the 2 µL 
peptide in the reaction mix were exchanged for DMSO. 
3.2.2.7 Inhibition of Supercoiled Plasmid DNA Strand Breakage 
The inhibition of supercoiled plasmid DNA strand breakage was performed 
according to Camargo et al.460  and Shahidi et al.312, 1 µL pBR322 plasmid 
DNA (0.5 µg/µL) was incubated with 6 µL PBS, 8 µL AAPH (10 mM, final 
concentration 3.48 mM) and 8 µL RSP extract (60-10 µg/mL, final 
concentration 20.9-3.5 µg/mL) or 8 µL sinapic acid (60-0.29 µg/mL, final 
concentration 20.9-0.102 µg/mL) for comparison. AAPH and/or 
extracts/sinapic acid were substituted with PBS for controls. The mixture was 
vortexed, centrifuged briefly (10000rcf, Eppendorf centrifuge 5415D) and 
incubated in the dark (37°C, 60 mins). Thereafter, 2 µL loading dye (500 µL 
glycerol; 500 µL dH20; 5 mg bromophenol blue) were added, the sample 
vortexed and loaded (10 µL) onto a 0.7% agarose gel, prepared with TAE 
buffer (40 mM Tris acetate, 1mM EDTA), stained with gel red dye (0.01%) 
and electrophoresed (70 mins; 80 V (Life Technologies Horizon 58 gel tank 
and Thermo EC 105 power pack) in TAE buffer. The gels were visualized and 
photographed using Peqlab Fusion FX7 (Fusion 15.11 software) under UV-
light. ImageJ software (v1.51) was used to analyse the band intensity. 
Inhibition of DNA strand breakage (%) was calculated (Equation 3.7). 
𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐃𝐍𝐀 𝐬𝐭𝐫𝐚𝐧𝐝 𝐛𝐫𝐞𝐚𝐤𝐚𝐠𝐞 (%) =
𝐃𝐍𝐀 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐨𝐱𝐢𝐝𝐚𝐭𝐢𝐯𝐞 𝐫𝐚𝐝𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐞𝐱𝐭𝐫𝐚𝐜𝐭 (𝐛𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲)
𝐃𝐍𝐀 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐰𝐢𝐭𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐨𝐱𝐢𝐝𝐚𝐭𝐢𝐯𝐞 𝐫𝐚𝐝𝐢𝐜𝐚𝐥 (𝐛𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲)
∗ 𝟏𝟎𝟎%     Equation  3.7 
After the sinapine concentration in the extract was determined (3.1.1.1 
Sinapine and additional phenolic derivatives ), the extract (20 µg/mL) in 
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comparison with the respective sinapine concentration as well as mixture of 
four phenolic acids (SA, SyrA, FA, CA) were analysed for DNA protective 
properties, along with two additional sinapine concentrations (20 and 0.2 
µg/mL). 
3.2.2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7. Specific methods 
used for statistical comparison of each experiment are detailed in the results 
section. P-values below 0.05 were considered significant and results shown 
as mean ± standard deviation. 
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3.3 Results and Discussion 
3.3.1 Extraction replicates differences in FC, FRAP 
and DPPH 
To determine the reliability of the 95% ethanoic extraction technique (SOX), 
three independent extractions were undertaken, and their antioxidant 
activities were determined via the DPPH, FC and FRAP assays. Among the 
three extracts significant differences were found only in the DPPH assay. In 
contrast, the FC and FRAP assays showed no significant differences among 
the samples studied (Figure 3.16).  
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Figure 3.16| DPPH, FC and FRAP results obtained from 3 extraction 
replicates 
Significant difference via One-way ANOVA (box), Bonferroni’s multiple comparisons test 
between extractions; p≤ 0.01**) 
Apart from the very small differences for the DPPH assay (only extract  
number 2), the results suggest that the extraction technique is reproducible, 
when using the same RSP harvest/breed (2014). However, to reduce the 
differences among the extractions, several extractions were undertaken in 
succession. Then, after freeze drying the extracts from all these extractions, 
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they were pooled together and mixed, to yield a homogeneous RSP extract. 
Subsequently, the extract was proportioned into smaller samples (1-3 g), 
which were vacuum packed and stored at -80°C. This procedure provided a 
homogeneous RSP extract that was used in all the experiments for the rest 
of the project. Of note, working RSP extract samples were stored at -20°C. 
All subsequent experiments were based on this extract, which will be referred 
to as RSP extract from now on. 
3.3.2 Antioxidant activity of final RSP extract 
To verify the homogeneity of the final extract in terms of its antioxidant 
properties, DPPH, FC, FRAP and ORAC assays were applied. Three 
independent samples from the mixture of the different extractions were taken 
and analysed. The results obtained clearly showed that the three independent 
samples taken from the final extract show no significant difference in all the 
assays (Figure 3.17). Therefore, samples used for further analysis should 
exhibit the same activity throughout the project. 
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Figure 3.17| DPPH, FC and FRAP and ORAC results obtained from 
three extraction replicates 
Indicating mean and standard deviation (technical replicates), significant difference via 
One-way ANOVA (box), Bonferroni’s multiple comparisons test between samples, ns-
not significant 
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3.3.3 LC-MS/MS analysis of final RSP extract 
In addition to the antioxidant assays, the secondary metabolite analysis was 
repeated, to determine the final extracts composition and to compare it to 
the previous SOX 2014 extract (Table A2, p.429 ff.). Most of the secondary 
metabolites initially found in the SOX extract from the 2014 harvest were also 
present in the final RSP extract (Table 3.5). The most abundant compounds 
in the final extract are sinapic acid, indole-3-pyruvic acid, syringic acid, 4-
hydroxyphenylpyruvic acid and ferulic acid. Multiple t-test was carried out 
between the two extracts (SOX2014 from Chapter 2 and the new SOX2014 
extract from chapter 3) and they showed significant differences for some of 
the compounds present. These differences might occur due to the way the 
original sample is processed and stored. The pomace itself is a biological 
sample and not completely homogeneous and can contain left over plant 
particles from leaves and stems as well as the seed pomace. Samples taken 
for the extraction are not necessarily completely homogeneous. Hence, when 
comparing the initial extract SOX2014 from chapter 2 (2.3.4 HPLC-MS/MS 
p.107 ff., first extract Table 3.5) to the final extract here in chapter 3 (final 
extract; Table 3.5), differences between the composition were expected.  
Sinapic acid, the most abundant compound with 3993 ± 49.89 mg/kg only 
represents about 0.4% of the extract. As described in chapter 2 (2.3.11 
Determination of antioxidant activity of single compounds within the extract 
as well as their mixtures, p.127 ff.) these low concentrations of phenolics do 
not contribute a great deal towards the antioxidant activity of the extract. 
Therefore, these results have led to further investigations in finding other 
abundant secondary metabolites in the extract which might be responsible 
for the observed antioxidant activity (3.3.4 Additional secondary metabolite 
analysis, p.175 ff.). Although most of the secondary metabolites found so far 
are present in small concentrations and do not contribute significantly to the 
antioxidant activity of the extract; they might have different activity in vitro 
or in vivo for which smaller concentrations are sufficient. Table 3.5 below, 
lists some of these additional activities for the secondary metabolites found 
in the RSP extract. Some of these activities have been closely associated with 
the potential treatment of neurodegenerative diseases. 
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Table 3.5| Concentration of secondary metabolites in First and Final 
RSP extract and published biological activities 
Extraction technique 
SOX [mg/kg RSP 
extract] 
 
 
Harvest year 
2014  
(first 
extrac) 
2014  
(final 
extract) 
t-
test activity 
Benzoic Acids (in mg/kg extract) 
benzoic acid - 21.59 ± 
7.21 
ns 
 
p-hydroxybenzoic acid 74.89 ± 
9.51 
71.20 ± 
9.07 
ns -AChE/BChE 
inhibition461 
-metal chelating 
and DNA protection 
in vitro386 
syringic acid 224.23 
± 16.54 
317.77 
± 16.15 
* -metal chelating 
and DNA protection 
in vitro386 
- neuro protection, 
elevation of SOD 
activity reduction of 
oxidative stress462 
vanillic acid 44.72 ± 
2.61 
12.83 ± 
6.94 
* -metal chelating 
and DNA protection 
in vitro386 
protocatechuic acid 72.59 ± 
1.14 
98.78 ± 
4.70 
* -metal chelating 
and DNA protection 
in vitro386 
-nerve regeneration 
potential463 
- inhibition of 
Aβ42445 
salicylic acid 14.99± 
1.72 
5.59 ± 
0.30 
* -antioxidant 
activity462 
p-anisic acid 28.11 ± 
3.94 
- ** 
 
gallic acid - 48.67 ± 
2.34 
*** -metal chelating 
and DNA protection 
in vitro386 
-inhibition of Aβ42445 
Benzaldehydes 
syringin 
33.58 ± 
3.15 
14.19 ± 
8.53 
ns -protects Aβ (25-
35)-induced toxicity 
in neuronal cells464 
protocatechualdehyde 
48.83 ± 
1.38 
21.87 ± 
2.49 
** - decreased 
reactive oxygen 
species (ROS) 
production and 
increased Nrf2/HO-
1 expression465  
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vanillin 
15.08 ± 
1.34 
- 
** -neurosupportive 
role on rotenone 
induced 
neurotoxicity (SH-
SY5Y)235 
Cinnamic Acids 
sinapic acid 4896.91 
± 
281.68 
3993.67 
± 49.89 
ns -AChE/BChE 
inhibition461 
-neuroprotection 
AD model (in 
vivo)241  
ferulic acid 182.70 
± 9.82 
199.84 
± 1.62 
ns -AChE/BChE 
inhibition461 
-neuroprotection243  
-metal chelating 
and DNA protection 
in vitro386 
-inhibition of Aβ42445 
cinnamic acid 69.59 ± 
3.35 
19.35 ± 
0.23 
*** -metal chelating 
and DNA protection 
in vitro386 
caffeic acid 110.82 
± 9.57 
94.48 ± 
8.00 
ns -anti dementia 
activity466    
-metal chelating 
and DNA protection 
in vitro386 
-inhibition of Aβ42445 
 
p-coumaric acid 32.10 ± 
2.94 
26.87 ± 
0.48 
ns -AChE/BChE 
inhibition461 
Phenylpyruvic Acids 
4-hydroxyphenylpyruvic 
acid 
149.77 
± 39.56 
249.62 
± 20.34 
ns 
-AChE inhibition467 
phenylpyruvic acid -  15.39 ± 
0.42 
*** 
 
Acetophones 
3,4,5-
trimethoxyacetophenone 
- 2.23 ± 
0.52 
* 
 
Phenyllactic Acids 
phenyllactic acid - 5.82 ± 
0.31 
*** 
 
Other Phenolics 
4-hydroxy 3-
methoxybenzyl alcohol 
0.76 ± 
1.32 
6.49 ± 
0.40 
* -antioxidant 
activity468 
anthranilic acid - 3.09 ± 
0.06 
*** 
 
chlorogenic acid - 19.46 ± 
2.90 
** -metal chelating 
and DNA protection 
in vitro386 
-antioxidant 
activity462 
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hydroxytyrosol - 10.12 ± 
0.13 
*** -neuroprotective 
effect in rat brain 
slices469 
Indoles 
Indole - 13.34 ± 
1.10 
** 
 
indole-3-pyruvic acid 336.05 
± 89.09 
412.36 
± 72.43 
ns 
 
indole-3-carboxylic acid 11.78 ± 
0.59 
9.57 ± 
2.01 
ns 
 
Amines 
Spermidine 433.56 
± 41.44 
- ** -protects against a-
synuclein 
neurotoxicity470 
Spermine 1.82 ± 
0.05 
13.61 ± 
0.74 
*** -neuroprotective by 
induction of 
autophagy471 
 
 
Flavanoids/Coumarins 
8-methylpsoralen - 2.06 ± 
0.25 
** 
 
Bergapten - 1.86 ± 
0.55 
ns 
 
Kaempferol 22.32 ± 
6.92 
3.09 ± 
0.50 
ns 
-inhibition of Aβ42445 
Isorhamnetin 7.85 ± 
1.30 
- * -protective effects 
against amyloid β-
induced cytotoxicity 
and amyloid β 
aggregation472 
Luteolin 44.66 ± 
3.43 
67.59 ± 
1.34 
* 
-inhibition of Aβ42473 
Apigenin 2.31 ± 
0.42 
11.31 ± 
0.21 
*** 
-inhibition of Aβ42445 
Glycitein - 1.26 ± 
0.18 
** -suppress Aβ 
toxicity through 
combined 
antioxidative 
activity and 
inhibition of Aβ 
deposition (in vivo 
C. elegans) 
Epicatechin - 22.50 ± 
0.32 
*** 
-inhibition of Aβ42445 
Phloretin - 0.50 ± 
0.03 
*** -neuroprotective 
via ROS 
scavenging, 
normalizing 
mitochondrial 
transmembrane 
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potential and 
consequently 
avoiding energy 
depletion474 
Imperatorin - 3.63 ± 
0.29 
*** -anti-inflammatory 
and antioxidant 
activities475 
Naringenin 2.58 ± 
0.25 
2.00 ± 
0.18 
ns -neuroprotective 
effect through 
suppression of NF-
κB signalling 
pathway and 
upregulates the 
antioxidant 
status476 
Tangeretin 0.93 ± 
0.10 
4.82 ± 
0.53 
** -antioxidant and 
anti-inflammatory 
effects, attenuate 
cholinergic deficits 
and reduction of 
abnormal 
accumulation of 
neurotoxic amyloid-
beta peptides477 
Quercetin - 30.61 ± 
0.54 
*** 
-inhibition of Aβ42445 
Quercetin-3-Glucoside 6.72 ± 
0.81 
3.24 ± 
0.28 
* 
 
Quercitrin - 0.61 ± 
0.03 
*** -attenuated Aβ (25-
35)-induced 
neurotoxicity478 
Hesperidin - 1.24 ± 
0.21 
* -antioxidant, 
inhibiting lipid 
peroxidation479 
Taxifolin - 1.17 ± 
0.06 
*** 
-inhibition of Aβ42445 
Phloridzin 2.09 ± 
0.29 
2.92 ± 
0.30 
Ns -neuroprotective 
effect through 
activation of Nrf2 
defence pathway 
(in vivo, rats)480 
I3-carboxaldehyde Not 
analysed 
19.38 ± 
1.80 
- 
 
total 6902.27 5887.60   
Note(s): Statistical significance determined using the Holm-Sidak method, with alpha 
= 0.05. Each row was analysed individually, without assuming a consistent SD.  ns-
not significant, *p≤0.05, ** p≤0.01, *** p≤0.001, given from adjusted p-values; 
HPLC-MS/MS analysis conducted by Garry Duncan (Rowett)
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3.3.4 Additional secondary metabolite analysis 
3.3.4.1 Sinapine 
The secondary metabolite composition of the extract described in Table 3.5, 
(p.171 ff.) was provided by the Rowett Institute. This service only determines 
concentrations of secondary metabolites that already exist in their reference 
library. Therefore, this prompted further HPLC analyses of the RSP extract, 
using similar parameters as described in the methods by Russell and Neacsu 
et al.342,343. This extended analysis was carried at RGU using LC-MS/MS 
methodology and was published in Yates et al.456. 
Initially the extract was analysed to obtain a chromatogram in the positive as 
well as negative ion mode (Figure 3.18). The chromatogram shows several, 
differently sized peaks. As published in Yates et al.456, standards of previously 
found secondary metabolites (sinapic acid RT=17.3 min, caffeic acid RT=12.0 
min, ferulic acid RT=17.5 min and syringic acid RT=12.1 min, highlighted 
with arrows in Figure 3.18, p.176) were analysed separately and their 
concentration determined in 5 mg/mL RSP extract samples. Their retention 
times are highlighted in the negative ion mode chromatogram (Figure 3.18, 
p.176). The peak sizes for caffeic, ferulic and syringic acid are relatively small 
compared to some of the other peaks observed for example at a RT of 2.5, 3 
and 8.8 mins. This initiated further analysis of those and a number of other 
peaks (Figure 3.22, p.181). 
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Figure 3.18| RSP extract (at 1 mg/mL) chromatogram in 
both/positive/negative ion mode after LC-MS analysis  
Results obtained in collaboration with Louis Watter and Kyari Yates 
The most significant peak found in the extract is eluting between 8.1 – 9.0 
minute retention time. This peak was most prominent in the positive ion mode 
(Figure 3.18). When conducting MS/MS analysis of this peak with a m/z ratio 
of 310.1 the following fragmantation peaks (m/z ratio) were found: 251.0, 
206.8 and 174.9 (Figure 3.19). These are the same MS/MS  break down 
products suggested by Yang et al. as being sinapine, a secondary metabolite 
very common in rapeseed110.  
sinapic acid 
RT=17.3 min 
ferulic acid 
RT=17.5 min 
caffeic acid 
RT=12.0 min 
syringic acid 
RT=12.1 min 
sinapine 
RT=8.5 min 
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Figure 3.19| MS/MS data obtained for the breakdown of the m/z 
310.1 peak 
Results obtained in collaboration with Louis Watter and Kyari Yates 
 
The Potential Application of Rapeseed Pomace Extracts in the Prevention and 
Treatment of Neurodegenerative Diseases 
178  Franziska Pohl 
This result was compared with a commercially available sinapine thiocyanate 
standard (chemface). Equal break down products and a similar retention time 
were found, corresponding to those found for the extract (comparison of 
Figure 3.18, p.176 with Figure 3.20). By creating a sinapine calibration curve, 
using the sinapine thiocyanate standard, the concentration of sinapine in the 
RSP extract was determined to be 109.1 mg/g RSP extract (10.9 %). Further 
details on the analysis of sinapine and the four phenolic acids (sinapic-, 
ferulic-, syringic- and caffeic acid) can be found in Yates et al.456. 
 
Figure 3.20| Chromatogram of sinapine  
Results obtained in collaboration with Louis Watter and Kyari Yates 
It is noteworthy to mention that direct comparison with other published data 
can be difficult. This is due to the fact that most papers express sinapine 
content in mg/g dry weight meal/cake. Here the concentration of sinapine is 
given per g RSP extract. The calculation of sinapine per g meal/pomace can 
be made by using the previously obtained extraction yields (Table 2.9, p.104) 
of about 76 mg extract/g RSP. A concentration of 109.1 µg sinapine per 1 mg 
of extract would mean a concentration of 8291.6 µg/g of pomace or 8.3 mg/g 
RSP. Zago et al.108 found a concentration of 9.80 ± 1.27 mg/g in their (un-
oiled) methanol extracted rapeseed cake. This is comparable to results found 
here, although our results are presented for the cold pressed RSP, still 
containing certain amounts of oil. Much higher values of sinapine were shown 
by Yang et al.110, ranging from 29.74 ± 4.81 to 52.24 ± 3.64 mg/g RSP meal. 
The extraction in the latter was carried out on de-oiled rapeseed meal, using 
10% methanol and 0.1% phosphoric acid. The extraction technique along 
with the different crop growing conditions and potentially different processing 
for the de-oiling steps (no details given in Yang et al.110) could have led to 
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these high values. Another explanation is the potential of additional sinapine 
in the leftover product after the first aqueous ethanol extraction, because the 
determination of extraction efficiency was not part of this project. 
In that case, the current value of 8.3 mg/g dry RSP (cold pressed) would not 
be the maximum concentration of sinapine in the RSP used in this study. 
Antioxidant activity of Sinapine  
To determine whether sinapine is responsible for the antioxidant activity of 
the RSP extract, the following samples at the extract concentration were put 
through a few antioxidant assays: (i) sinapine, (ii) a mixture of phenolic acids 
(sinapic acid, caffeic acid, ferulic acid and syringic acid) (iii) a mixture of 
sinapine and the phenolic acids. The results obtained for the FC, FRAP, DPPH 
and ORAC assay are presented in Figure 3.21 (p.180). The results show that 
sinapine is the main contributor to the antioxidant activity observed in the 
extract. Together with the phenolic acid mixture, less than 50% of the activity 
for the extract is unexplained (Figure 3.21 ). Furthermore, the mixing of 
sinapine with the phenolic acids leads to an addition effect in all four 
experiments (Figure 3.21 ). No synergistic or antagonistic effect was 
observed. This can be seen when comparing the height of the bars for the 
phenolic acid and sinapine mixture ( ) to sinapine ( ) and the phenolic 
acid mix ( ). 
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Figure 3.21| Antioxidant activity of sinapine and phenolic acids and 
their mixture compared to the RSP extract activity, determining 
unknown activity in the extract, adapted from Yates et al.456 
Results obtained in collaboration with Louis Watter  
The FC assay shows that sinapine is responsible for about 47% of the phenolic 
content (Figure A3, p.442). Slightly higher results were obtained by Thiyam 
et al.97, where sinapine alone, was found to be responsible for between 55-
70% of the phenolic content. In contrast, for the DPPH assay, they found 
sinapine to be responsible for only between 25-50% of the radical scavenging 
activity. Whereas in our study sinapine is responsible for more than 70% at 
the tested extract concentration (Figure A3, p.442). A comparison of sinapic 
acid (SA), sinapine (Sin) and sinapoyl glucose (SG) in the DPPH assay showed 
the following order of scavenging activity in their study SA>SG>Sin97. 
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However, they did not investigate the activity of sinapine in the FRAP or ORAC 
assay.  
The results in Figure 3.21 show that sinapine appears to exhibit a better 
radical scavenging activity (DPPH) than reducing capacity (FRAP/FC). The 
ORAC activity was found to be even lower and demonstrated that not all of 
the extract’s activity can be explained using sinapine and some of the 
phenolic acids found within the extract. Figure 3.18 (p.176) however 
indicated the presence of other compounds within the extract, which have 
not been identified yet. Some of the peaks have a larger peak area compared 
to the phenolic acids, these were investigated using MS/MS analysis following. 
3.3.4.2 Additional phenolic derivatives and other secondary 
metabolites identified via LC-MS/MS 
To determine some of the unknown peaks (1-7) within the chromatogram 
(Figure 3.22), MS/MS analysis was employed. The found m/z ratios for the 
molecular ion and the fragmentations are shown in Table 3.6 (p.182). 
 
Figure 3.22| +/- ESI total ion chromatogram of a 1 mg/mL RSP 
extract  
Showing additional peaks, some of which have been identified from existing literature 
(Table 3.6), adapted from Yates et al.456; results obtained in collaboration with Louis 
Watter and Kyari Yates 
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Table 3.6| MS/MS fragmentations of unknown peaks within the chromatogram 
Peak 
# 
Compound name 
Rt 
(min) 
quasi-
molecular ion 
MS-MS 
fragments 
following CID 
References used in identification 
type m/z   
1 Benzoylcholine 7.5 [M+H]+ 208 149.1, 105.1 Clauß et al. (2011)404 
2 
Kaempferol-3-O-
(sinapoyl)-diglucoside-
7-O-glucoside 
10.7 [M-H]- 977 815.2 Ferreres et al. (2009)398 
3 Sinapoyl glucoside 11.2 [M-H]- 385 
325.1, 265.2, 247, 
223, 205 
Ferreres et al. (2009)398, 
Thiyam et al. (2009)405, 
Oszmianski et al. 
(2013)406 
4 
Sinapine (4-O-8’) 
guaiacyl 
12.3 [M+H]+ 506 
446.9, 251, 207, 
175, 147 
Clauß et al. (2011)404 
5 
Cyclic spermidine 
conjugate (alkaloid) 
12.9 [M+H]+ 496 
478, 425, 408.2, 
381.9, 351, 324.9, 
280.8, 231.9, 198, 
191, 175 
Clauß et al. (2011)404, 
Yang et al. (2015)110 
6 
Feruloyl choline (5-8’) 
guaiacyl 
16.0 [M+H]+ 458 399, 381, 369.1 
Clauß et al. (2011)404, 
Yang et al. (2015)110 
7 
1,2-disinapoyl 
glucoside 
23.1 [M-H]- 591 367, 223, 205 
Ferreres et al (2009) 398, 
Yang et al. (2015)110 
Note(s): Including suspected names after literature comparison, adapted from Yates et al.456; results obtained in collaboration with Louis Watter 
and Kyari Yates 
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The identification of these metabolites was based on their mass spectra 
results and hence the proposed identity of each peak is not absolute. To verify 
their identity and determine concentrations found within the extract, 
standards are required. To date, these metabolites are not commercially 
available. However, these secondary metabolites have previously been 
identified in Brassica species110,398,404–406, which made identification using 
MS/MS spectra analysis possible. There are no reports on the antioxidant 
activity of these secondary metabolites, but they could contribute to the 
unknown antioxidant activity of the RSP extract (Figure 3.21 , p.180). Due 
to the lack of standards, one other way to positively identify these compounds 
and determine their activity would be the use of preparative/semi-preparative 
HPLC, to isolate and collect each individual peak followed by their subsequent 
NMR and antioxidant analysis. 
3.3.4.3 Glucosinolate (GLS) analysis 
To determine the presence of GLSs in the RSP extract HPLC methodology was 
utilized. Eleven GLSs were used as external standards (Figure 3.3, p.139). A 
chromatogram of this mixture is presented in Figure 3.23.  
 
Figure 3.23| Glucosinolate standard mixture HPLC chromatogram 
When overlaying the chromatogram obtained from the standard mix with the 
chromatogram from the extract (Figure 3.24, p.184), a number of peak 
retention times, match those from the standards, implying that the extract 
could contain these GLSs (Figure 3.24, indicated by blue and red arrows, 
p.184). 
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Figure 3.24| HPLC glucosinolates chromatorgram for standard mixture and RSP extract (overlay) 
Standard mixture of glucosinolates (0.091 mg/mL) and their retention times (red)  overlaid with the chromatogram obtained for the RSP 
extract (blue, 25 mg/mL), highlighting potential glucosinolate peaks (red and blue arrows) 
 
minutes 
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To confirm the presence of the GLS at these specific retention times, 
absorbance spectra of each standard was compared to the extract at the 
specific retention time (e.g. GLS progoitrin Figure 3.25). If it was possible to 
overlay the extract absorbance spectra with the spectra obtained from the 
respective standard, as seen with progoitrin (Figure 3.25), the GLS was 
considered for concentration calculations in the extract. A small difference in 
the DAD spectra (GLS standard vs. RSP extract) can be explained by a 
potential co-elution of the GLS with other compounds (Figure A4, p. 442 ff.). 
Thus, their determination in the RSP extract is not conclusive. 
 
Figure 3.25| Absorbance spectra for progoitrin Standard and RSP 
extract (190-360 nm) 
Calibration curves were obtained for each GLS and concentrations in the 
extract calculated if the obtained peak area was above the limit of 
quantification, as demonstrated in Figure 3.26 on the example of progoitrin. 
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Figure 3.26| Calibration curve obtained for progoitrin (0.005-0.5 
mg/mL) 
progoitrin standard RSP extract 
nm nm 
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The concentrations obtained in mg/mL were then transformed into mg GLS/g 
extract, giving progoitrin concentrations of 2.20 ± 0.05 mg/g RSP extract, 
making it the most abundant GLS in the extract. Other GLSs found above the 
LOD and LOQ were gluconapin and gluconasturtin (Table 3.7). 
Glucobrassicanapin was detected but the peak area was below the LOQ, so 
no concentration was calculated. Similarly, the spectra at 20.6 minutes 
retention time can be matched with the spectra of glucobrassicin (Figure A4, 
p.442 ff.) however, the detected peak area is below the LOD. 
Table 3.7| GLS found in RS extract (blue arrows in Figure 3.24) 
 
concentration [mg/mL] 
RSP [mg/g 
extract] 
GLS LOD LOQ mean std 
PROGOITRIN 0.005148 0.01560 2.197 0.04759 
GLUCONAPIN# 0.005781 0.01752 1.959 0.04021 
GLUCOBRASSICANAPIN# 0.009727 0.02948 below LOQ 
GLUCOBRASSICIN# 0.02899 0.08784 below LOD 
GLUCONASTURTIIN# 0.01546 0.04685 1.899 0.03623 
Note(s): #compounds potentially co-eluting with other compounds, absorption 
spectra inconclusive (Figure A4, p.442 ff.) 
Progoitrin has previously been shown to be the main GLS in RSP from 
Scotland, followed by gluconapin and glucobrassicanapin115. These three 
GLSs were also detected in our RSP extract. In a different study by Millán et 
al.481 a wider variety of GLS was found. Samples for their study were obtained 
from a field experiment studying the effect of different nitrogen and sulphur 
fertilizer on the level of GLS; the most abundant GLSs were also progoitrin, 
gluconapin and glucobrassicanapin. In addition, they also found high amounts 
of 4-hydroxiglucobrassicin as well as epiprogoitrin and gluconapoleiferin 
which were not analysed in this study; and glucobrassicin, gluconasturtiin. 
The total amount of GLSs present in rapeseed are known to be dependent on 
the nitrogen and sulphur content411. Other factors affecting the GLS 
concentrations in rapeseed are the cultivar, physiological age, health, and 
environmental factors (e.g. climate condition). The production process of the 
rapeseed also has a big impact on the GLS content of RSP sample, due to the 
activity of the enzyme myrosinase. The latter can act upon GLSs once the 
plant tissue is harmed (e.g. cutting, milling, chewing). In the study by Millán 
et al.481 harvested seeds were dried, then crushed and immediately extracted, 
giving the myrosinase little time to hydrolyse the GLSs. This could be the 
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reason for the additionally found GLSs. For this research project however, 
RSP was obtained, which was cold pressed and transported later to RGUs 
research facility. The exact storage condition at the farm as well as the time 
the RSP was store, before it was brought to RGU are unclear. The 
concentration of GLSs however is strongly dependent on storage time410,482. 
This uncertainty in storage time and environment suggests, that myrosinase 
might have had much longer time to act upon the glucosinolates in our 
samples. The action of myrosinase, at least partially, could have transformed 
the GLSs into GLS hydrolysis products (3.1.1.2 Glucosinolates (GLSs), 
p.136). An overview, summarizing parameters influencing the formation of 
different hydrolysis products are discussed in Holst et al.407.   
It is difficult to compare the quantitative results obtained in this study to 
other studies, because in most research papers concentrations are given in 
mg or µmol per gram or kg dry seed or de-oiled pomace. In contrast, the 
concentrations in this study are given per gram of extract, since the latter is 
the end-product of interest here.  
For better comparison with the literature, also the RSP itself was extracted 
with boiling water and analysed according the same method (3.2.2.3 
Determination of additional secondary metabolites in the extract, p.158 ff.). 
However, the peak areas obtained through HPLC analysis were much smaller 
or not visible for the GLSs studied (Figure A5, p. 445). No concentrations 
could be determined for any of the positively identified compounds via spectra 
comparison. However, GLS concentrations can be back calculated (Figure A6, 
p.445) to the cold pressed RSP by using the extraction yield of 76 mg RSP 
extract/g RSP (Table 2.9, p.104), leading to values of: progoitrin:0.167 g/kg 
RSP, gluconapin:0.149 g/kg RSP and gluconasturtiin:0.144 g/kg RSP which 
are much lower than the results found by for example Raikos et al.115  for 
cold-pressed rapeseed pomace (progoitrin: 2.52 ± 0.16 g/kg; gluconapin: 
0.68 ± 0.12 g/kg; glucobrassicanapin 0.45 ± 0.02 g/kg). 
Since GLSs have not been reported to have significant direct antioxidant 
activity483, their presence most probably does not contribute to the unknown 
antioxidant activity found for the extract (Figure 3.21, p.180). However, GLS 
hydrolysis products (Figure 3.2, p.137) can be indirect antioxidants, by 
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inducing phase II enzymes, responsible for the antioxidant and xenobiotic 
metabolizing response pathway involving e.g. heme oxygenase 1 (HO-1) or 
glutathione S transferases (GSTs) through Keap1-Nrf-2-ARE signalling (1.4.3 
Exogenous antioxidants - natural products: direct and indirect antioxidant 
activity, p.58 ff.)409,484. Their presence in vivo or in a cell system could induce 
an oxidative stress response pathway and aid in metabolising endogenous 
compounds and xenobiotics. A variety of isothiocyanines have previously 
been identified in rapeseed and rapeseed pomace, e.g. butenyl-, butenyl- and 
pentenyl- isothiocyanates485,486. Their analysis was unfortunately not part of 
this project due to time restrictions.  
 
3.3.4.4 Determination of total monomeric anthocyanin pigment 
content  
A further group of secondary metabolites often associated with positive 
biological activity are the anthocyanins, which belong to the flavonoid group 
of secondary metabolites (Figure 1.6, p.10). Anthocyanins are well known 
antioxidants and if present in the RSP extract, might play a role in the extracts 
antioxidant activity487. Here, the pH differential method was employed to 
confirm or preclude the presence of any anthocyanin. 
No colour change was visible, when mixing a stock solution of the RSP extract 
(1 mg/mL) with the highly acidic buffer (pH 1.0) 1:5. A slight turbidity 
occurred once the extract was introduced to the pH 1.0 buffer. In contrast, 
the grape pomace (GP) extract at the same concentration, showed a 
significant colour change, suggesting the presence of anthocyanins (Figure 
3.27). 
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Figure 3.27| pH differential method 
Visual observation of colour change, comparing RSP (left) with GP (right) 
When measuring the absorbance for the solution, a clear difference between 
peak intensity (520 nm) can be seen between the pH 4.5 and pH 1.0 solution 
for the GP extract (Figure 3.28,  and  line respectively). For the RSP 
extract however, no peak is visible. The slight overall increase of the curve 
(Figure 3.28,  compared to ) between 390 and 800 nm is most likely 
caused by the increased turbidity of the sample (Figure 3.27). 
 
 
Figure 3.28| Absorbance spectra for RSP and GP extracts at pH 4.5 
and pH 1.0 for the determination of total anthocyanins 
The calculation of the anthocyanin content showed the presence of 31.4±1.1 
mg total monomeric anthocyanin pigment content per g GP extract. The value 
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obtained for the RSP extract was much lower with 1.28±0.35 mg/g. However, 
this value is not arising from an actual peak but from the general absorbance 
increase (turbidity of sample at pH 1.0) over the 390-800 nm range. Hence, 
the obtained anthocyanin concentration is most likely not the actual value for 
the anthocyanin content. Even the correction using a reading at 700 nm was 
not able to correct for the turbidity caused increase of absorbance. However, 
the fact that there is no peak visible at 520 nm suggests the lack of 
anthocyanins in the RSP extract. 
Searching the literature for the presence of anthocyanins in rapeseed seeds 
or pomace, was unsuccessful. No papers were found showing anthocyanin 
content in RSP but neither did papers show the negative outcome of 
anthocyanin analysis. Anthocyanins most often cause a plant to be strongly 
coloured (red, blue or purple; e.g. red grapes). As rapeseed does not show 
any sign of this colouration, the assumption might have formed, that no 
anthocyanins are present in rapeseed seeds, which was confirmed, after 
determination using the pH differential method. Interestingly, a paper 
published by Li et al.425 used genetic manipulation to significantly increase 
the amount of anthocyanins in the leaves of Brassica napus with the aims to 
(i) improve the plants potential to produce pharmaceutical antioxidants and 
(ii)  provide protection against potential disease425. A paper by Dai et al.488 
also suggests the potential for (iii) increased resistance to droughts and cold 
stress. However, neither failed to show data for anthocyanin content in the 
seeds. 
This pH differential method gives an indication of total anthocyanin content 
but is not very sensitive to low amounts of anthocyanins. For a 100% 
exclusion of their presence, techniques that are more sophisticated should be 
used, such as HPLC-MS/MS methods. In a paper by Lee et al.489 for example, 
both methods showed good correlation. However, the HPLC results gave 
higher values than the pH differential values, in most of their samples. 
Because the pH differential method showed no indication for the presence of 
anthocyanins, it was decided to not look further into the HPLC analysis of 
anthocyanins within the RSP extract, due to time limitations. 
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3.3.5 Metal chelating potential 
The in vitro analysis of the metal (iron and copper) chelating activity of the 
extract, showed no significant iron chelating properties. The absorbance 
showed no significant differences to the negative control and values were 
outside the LOD and LOQ (Figure A8, p. 447). There is currently no research 
into the iron chelating properties of RSP extracts. However, the results are in 
contradiction to findings by Andjelković et al.490 who found iron chelating 
ability for both benzoic (weaker) and cinnamic acids (stronger) such as 
protocatechuic acid, gallic acid and caffeic acid, which are present in the RSP 
extract (Table 3.5, p.171). Sevgi et al.386 also found ferrous iron chelating 
properties for caffeic-, chlorogenic-, cinnamic-, ferulic-, gallic-, p-
hydroxybenzoic-, protocatechuic-, syringic- and vanillic acid, all of which are 
present in the RSP extract (Table 3.5, p.171). An explanation for the negative 
results in the iron chelating assay in this study could be the low 
concentrations of those single phenolic acids within the extract. An extract 
concentration of 1 mg/mL was prepared, however within the assay final 
extract concentrations only reach 0.19 mg/mL (3.2.2.4 Metal chelating 
properties (Iron and copper), p.161). In comparison, Sevgi et al.386 run final 
concentrations of 0.89 mg/mL of the phenolic acids. The highest 
concentration of the phenolic acids tested by Sevgi et al. in the RSP extract 
is syringic acid with 318 mg/kg (Table 3.5, p.171). In 0.19 mg of extract 
there are only about 0.06 µg of syringic acid, which is much lower than the 
tested concentrations in Sevgi et al.386. 
In contrast, the copper chelating activity assay showed the extracts potential 
to chelate Cu2+ ions, absorbance values measured were within the LOD and 
LOQ. The copper chelating activity was calculated and expressed as 29.23 mg 
EDTA equivalents/1 g RSP extract (Figure 3.29, p.192). This shows that only 
very high concentrations of the extract can chelate copper, meaning the 
extract is not as efficient as EDTA.  
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Figure 3.29| Copper chelating properties of the RSP extract 
Results obtained in collaboration with Louis Watters 
To determine whether sinapine is responsible for the copper chelating 
activity, the extract specific concentration of sinapine* was analysed in the 
same experiment, no change in absorbance compared to the negative control 
was observed. This leads to the conclusion, that sinapine is not acting as 
copper chelating agent in the RSP extract. The observed activity for the 
extract must therefore, be from other compounds within the extract. For 
example, Řiha et al.491  found copper chelating properties for a number of 
flavonoids, using two different methods, the hematoxylin assay (for less 
competitive compounds) and the bathocuproinedisulfonic acid disodium salt 
(BCS) assay (for more competitive compounds). In the hematoxylin assay 24 
out of a tested 26 compounds, including kaempferol, luteolin, apigenin, 
epicatechin and quercetin, all of which were found in the extract (Table 3.5, 
p.171 ff.). In the more competitive BCS assay, all the previous except 
epicatechin showed copper ion chelating properties491.  
Although the copper chelating properties are weak, they can add a positive 
attribute to the extract. In addition to the antioxidant properties found, the 
copper chelating activity, might further contribute to its potential activity in 
vitro and in vivo, as copper dis-homeostasis has been associated with a 
number of neurodegenerative diseases431. The outcome from this experiment 
also suggests that sinapine, although responsible for a significant amount of 
* 120 µg/mg RSP extract, exact concentration (109.1 µg/mg RSP extract) was still unknown at time of 
experiment 
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the antioxidant activity, is not accountable for all the different activities found 
for the RSP extract. Outcomes like this imply that the use of extracts might 
be preferable over the use of a single secondary metabolite, such as sinapine, 
from the plant extracts for further in vitro and in vivo studies. 
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3.3.6 AChE inhibition potential 
Initially AChE inhibition activity was analysed using the Ellman method, for 
which the absorption of 5-thio-2-nitrobenzoate (yellow solution) with an 
absorption maximum at 412 nm is measured (Figure 3.30). 
 
Figure 3.30| Absorbance spectra and reaction of DTNB to 5-thio-2-
nitrobenzoate (adapted from442,492) 
However, when dissolving the extract, a similar colour (yellow) to the reaction 
product 5-thio-2-nitobenzoate can be observed. To reveal potential 
interference of the extracts colour, when using the Ellman method for the 
determination of AChE inhibition activity, a complete spectrum (400-900 nm) 
for the extract was obtained (0.156-2.5 mg/mL) and compared to the 
absorbance spectra of 5-thio-2-nitrobenzoate (Figure 3.31). 
 
Figure 3.31| Absorbance spectra overlay of 5-thio-2-nitrobenzoate 
and the RSP extract 
Demonstrating the interference with the Ellman assay 
The results obtained therefore confirm issues with interference, since the 
extract absorbs at 412 nm. Furthermore, the formation of turbidity at high 
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extract concentrations showed absorbance at higher wavelengths (500-900 
nm). However, turbidity interference can be corrected by subtracting the 
absorbance obtained at 700 nm from the wavelength of interest (412 nm) as 
done in the anthocyanin assay. Despite this, the presence of much higher 
absorbance readings at 412 nm (Figure 3.31), makes this method unreliable 
to use for the determination of the extracts AChE inhibition potential. 
Instead, the fluorescent Amplex Red assay kit was used. The results obtained 
from this in vitro assay showed the extracts potential to inhibit AChE in a 
concentration and time dependent manner. As a positive control for the assay 
neostigmine (5 µg/mL ) showed significant inhibition throughout the full 
150 minutes the assay was conducted. Very similar inhibition results were 
found for 1.00 ( ) and 0.75 ( ) mg/mL RSP extract. With decreasing 
concentrations of the extract and increasing time however, the inhibition of 
AChE activity of was reduced (Figure 3.32). 
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Figure 3.32| Time dependent AChE activity 
Showing one of the three replicates, including the AChE positive control, co-incubation 
with the RSP extract (0.001-1.00 mg/mL) and neostigmine (0.005 mg/mL) as positive 
control for AChE inhibition  
At 0.001 mg/mL ( ) no significant inhibition activity was detected. Whereas 
at 0.1 mg/mL ( ) of RSP extract significant AChE inhibition activity was 
observed at 30 minutes (p<0.0001, Figure 3.33, p.196). This inhibition 
decreased after 60 minutes (p=0.0214) and after 90 minutes, the significance 
had disappeared  
 
The Potential Application of Rapeseed Pomace Extracts in the Prevention and 
Treatment of Neurodegenerative Diseases 
196  Franziska Pohl 
completely (Figure 3.33). Extract concentrations over 0.1 mg/mL of RSP 
extract, show a significantly decreased AChE activity at all time points. 
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Figure 3.33| AChE activity inhibition by RSP extract (0.001-1.00 
mg/mL) and neostigmine (5 µg/mL) 
Significant difference via One-way ANOVA and Bonferroni’s multiple comparisons test 
with AChE control (ns-not significant, p≤0.05*, p≤ 0.001***) 
Calculating the IC50 (50% inhibition of AChE activity) gave results ranging 
from 0.055 mg/mL at 30 minutes to 0.13 mg/mL at 150 minutes. IC50 values 
were calculated as previously demonstrated for the DPPH assay (Figure 2.14, 
p.114) for individual time points of the assay. The concentration needed to 
show significant AChE inhibition throughout the whole experiment (0.1 
mg/mL and higher) are much higher than for neostigmine, which shows 
significant inhibition at 0.005 mg/mL throughout the whole assay. This was 
to be expected due to the nature of the extract. The extract contains a 
number of components, only some of which might be AChE inhibitors, in 
contrast, neostigmine is a pure compound known to inhibit AChE. However, 
the fact that most often higher concentrations of plant extracts are tolerated 
in cell systems or in vivo compared to single compounds, the higher 
concentration of extract necessary to inhibit AChE are not concerning. Other 
plant extracts have previously shown AChE inhibition activity in vitro and in 
vivo, such as black chokeberry and lemon juice493, mulberry flavonols494 and 
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poly-phenol rich blueberry extracts495. Comparisons are difficult to make, as 
they all use the Ellman method for AChE inhibition potential. 
A review published by Chen389 in 2015 suggested the AChE inhibition potential 
of sinapine, by referring to two other papers published by He et al.401 and 
Ferreres et al.398. These indications had led us to the analyse the AChE 
inhibition properties of sinapine alone together with the extract, the phenolic 
acid mixture (sinapic-, ferulic, caffeic and syringic acid) and the phenolic acids 
and sinapine in one mixture. Results obtained from this analysis, showed 
strong AChE inhibition activity for sinapine (  Figure 3.34, p.198). 
Interestingly the phenolic acids mixture also exhibits weak AChE inhibition 
activity. The activity of both sinapine and the phenolic acids mixture together 
( ) showed a stronger AChE inhibition activity than sinapine on its own. 
However, the extract still shows better activity than the mixture of sinapine 
and the phenolic acids which is only observable after 90 minutes (  Figure 
3.34). The result obtained for the extract here (Figure 3.34, p.198), gave 
similar curve as the previous results for the extract at 0.25 mg/mL (Figure 
3.32 p.195), suggesting the experiments repeatability. The same analysis 
was undertaken using 1 mg/mL of the extract and the respective 
concentrations for sinapine and the phenolic acids. Increasing the sinapine 
concentration 4 times, to 109.1 µg/mL (present in 1 mg/mL of the RSP 
extract) led to complete inhibition of AChE for 150 minutes (Figure A7, 
p.446).  
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Figure 3.34| Time dependent AChE inhibition study of RSP extract 
secondary metabolites 
Including the AChE positive control, co-incubation with the RSP extract (0.25 mg/mL), 
phenolic acid, sinapine and a mixture of sinapine and phenolic acids at the extract 
specific concentration and neostigmine (5 µg/mL) as positive control for AChE 
inhibition, showing one of the three replicates. Results obtained in collaboration with 
Louis Watters. 
A Chinese patent, suggests the use of sinapine in the treatment of AD 
(CN1259045C399). A further Chinese patent application “Method for preparing 
sinapine thiocyanate from rapeseed cakes and application” (CN105732402A) 
even describes the isolation of sinapine thiocyanate from rapeseed400. In 
comparison, no such patents were found in the American or European patent 
offices. The results obtained for the AChE inhibition activity for the extract as 
well as for sinapine in this study are promising indicators in addition to the 
patents for sinapine’s potential as AChE inhibitors in the clinic.  
In addition to the in vitro AChE inhibition activity, molecular docking studies 
on sinapine were performed by Andrej Shiryaev, from the chemistry 
department at Samara State Technical University, Russia.  The in silico results 
are presented in Yates et al.456. 
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3.3.7 Inhibition of self-mediated β-amyloid (1–42) 
aggregation 
To test for the inhibition of self-mediated β-amyloid aggregation the ThT 
assay was used. Curcumin, a natural phenolic found in e.g. turmeric, had 
previously showed aggregation inhibition496 and was used as positive control 
in our study. Statistical analysis of the obtained data shows a significantly 
(p≤0.001) reduced formation of β-amyloid aggregations while co-incubated 
with curcumin (Figure 3.35 , 0.0455 mg/mL). At the same concentration 
as the peptide (0.0455 mg/mL) the extract also shows a significant (p≤0.05) 
inhibition of peptide aggregation. However, the ability of the RSP extract to 
inhibit the self-mediated β-amyloid aggregation, is lower than curcumins 
(Figure 3.35  vs. ). 
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Figure 3.35| β- amyloid self-mediated aggregation inhibition study  
Comparing co-incubation with curcumin (peptide concentration) and the RSP extract 
(peptide and 10x peptide concentration). Statistical significant difference analysis via 
One-way ANOVA and Bonferroni’s multiple comparisons analysis between the β-amyloid 
control and treatments, p≤0.05*, P≤0.01**, p≤0.001*** 
When increasing the concentration of the extract 10-fold (0.455 mg/mL), the 
RSP extract control (no β-amyloid peptide) showed a significant increase in 
fluorescence at the emission wavelength (490 nm). This could be due to the 
wide variety of compounds present in the RSP extract one or a few of which 
might show fluorescence at the specific excitation (446 nm) and emission 
wavelength. That is why Figure 3.35 above shows the results for both, the 
ThT buffer control ( ) as well as the RSP extract control ( ) corrected 
emission (see determined emission values in Table A4, p.445). Both show a 
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significant decrease in aggregation formation i.e. lower emission readings. 
When correcting for the RSP extract control, the significance (p≤0.001) is 
bigger than that for the buffer (ThT) control corrected sample. A similar but 
much stronger interference was observed by Weinberg et al.497, when trying 
to determine the aggregation inhibition of β-amyloid by oil palm phenolics. 
To overcome this issue, they used the Congo Red dye binding assay. 
In general, the results showed that the extract can inhibit the self-mediated 
aggregation of β-amyloid, but to a lesser extent than curcumin. This result is 
not surprising, as curcumin was tested at a much higher concentration than 
any single compound in the extract (3.3.4 Additional secondary metabolite 
analysis, p.175 ff.). When testing the extract at the peptide specific 
concentration, the most abundant known metabolite is sinapine, with only 
about 0.005 mg/mL. For the other determined compounds within the extract, 
their respective concentration is even less. At the higher concentration of the 
extract (0.455 mg/mL), a better inhibition was observed. At this 
concentration, the amount of sinapine (0.0496 mg/mL) is similar to the 
concentration of the peptide (0.0455 mg/mL). Literature research into the 
inhibition of amyloid aggregation by sinapine did not show any previous 
research in this direction. However, other compounds found in the extract 
(Table 3.8) have previously been identified to prevent or modulate amyloid 
aggregations445,473. These components could be responsible for the extract’s 
Aβ peptide aggregation preventative properties. Further in depth analysis of 
these compounds at the extract specific concentrations either by themselves 
or in a mixture could shed light on this subject. 
Table 3.8| Secondary metabolites preventing or modulating β-
amyloid aggregation 
Flavonoids Other phenolics 
Apigenin Caffeic acid 
Epicatechin Ferulic acid 
Kaempferol Gallic acid 
Quercetin  
Taxifolin  
Luteolin  
Note(s): adapted from445,473 
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3.3.8 Inhibition of supercoiled plasmid DNA strand 
breakage 
As previously demonstrated in the ORAC assay (2.3.9 ORAC assay p.122 ff.), 
AAPH is able to decrease the fluorescence intensity of the fluorescence probe, 
by radical generation. AAPH is also able to cause oxidative DNA stand 
breakage in pBR322 plasmids452, from the supercoiled to both an opened 
circular and linear form of the plasmid DNA (lane 2 Figure 3.36 A+B)353. 
Previous research had shown that certain natural compounds, such as green 
tea polyphenols452, Terminalia arjuna bark extracts377 and phenolic extracts 
from Sphallerocarpus gracilis seeds 498 are able to prevent this AAPH induced 
plasmid DNA strand breakage.  
Similar observations were made, for the RSP extract in the present study353. 
Concentrations of the RSP extract between 13.9 and 20.9 µg/mL showed 
almost complete protection from the AAPH induced oxidative damage (Figure 
3.36/Figure 3.37, p.202). Lower RSP extract concentrations, e.g. 7.0 and 
10.4 µg/mL, still showed partial DNA protection. However, no visible DNA 
protection was observed at a RSP extract concentration 3.5 µg/mL353. 
 
Figure 3.36| Protection of pBR322 plasmid DNA  
Plasmid DNA control(lane 1), AAPH (3.48 mM) induced damage (lane 2) protection by 
A: RSP extract (3.5-20.9 µg/mL, lane 3-8) and B: sinapic acid (0.102-20.9 µg/mL, lane 
3-8)353 
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To investigate whether the presence of the most abundant phenolic acid, 
sinapic acid, in the RSP extract, is contributing to the DNA protection, the 
respective concentrations found in 20.9 µg/mL of the two RSP extracts 
obtained in chapter 2* (Ext. SOX 2012: 0.157 and SOX 2014: 0.102 µg/mL, 
Table 2.10, p.108) were tested. In addition, concentrations of SA between 
0.35 and 20.9 µg/mL were assessed. While the three highest tested 
concentrations (20.9, 10.4 and 3.5 µg/mL) of sinapic acid show very good 
protective properties, lower sinapic acid concentrations i.e. 0.35 µg/mL and 
the relevant extract concentrations (SOX 2012: 0.157 and SOX 2014: 0.102 
µg/mL in 20.9 µg/mL extract*) showed little or no visible protection 
respectively (Figure 3.37).  
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Figure 3.37| Quantification of the plasmid DNA protection effect 
Protection of pBR322 plasmid DNA from AAPH (3.48 mM) induced damage by (A) RSP 
extract and (B) sinapic acid. Statistical significant difference analysis via One-way 
ANOVA and Bonferroni’s multiple comparisons analysis in comparison to DNA control 
column, p≤0.05*, p≤0.001***, n=3353 
The above results confirm that although SA is the most abundant phenolic 
acid present in the extracts, it is not the main contributor to the DNA 
protective activity of the RSP extract.  
To determine whether sinapine and/or the mixture of phenolic acid (3.1.1.1 
Sinapine and additional phenolic derivatives  p.135 ff.) could be responsible 
for the found DNA protective properties of the RSP extract, they were also 
tested in this assay. For this experiment RSP extract was analysed at 20 
µg/mL along with the respective concentrations of the 4 phenolic acids (PA) 
mixed, sinapine (Sin) and a mixture of the phenolic acids and sinapine. The 
AAPH converts supercoiled plasmid DNA into open circular DNA, as previously 
* experiment was undertaken before the production of final extract (sinapic acid conc.= 0.083µg/mL) 
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seen (Figure 3.36, p.201). Co-incubation of the extract (20 µg/mL) with AAPH 
can prevent this DNA damage (Figure 3.38). When testing the phenolic acid 
mixture, no DNA protection was observed. Similar to SA (Figure 3.37 B) the 
concentration of phenolic acids present in the extract are not high enough to 
demonstrate DNA protective properties (Figure 3.38). 
 
 
Figure 3.38| DNA protective properties of the RSP extract secondary 
metabolites 
Including phenolic acid mixture, sinapine (0.2-20 µg/mL) and a mixture containing 
sinapine and phenolic acids (*concentration present in 20 µg/mL extract). Statistical 
analysis via One-way ANOVA and Bonferroni’s multiple comparisons analysis between 
DNA control and AAPH treated samples, ***p≤0.05, n=3); results obtained in 
collaboration with Louis Watters. 
 
In comparison, sinapine, at the extract specific concentration (2.18 µg/mL), 
is showing protective properties. Statistical analysis showed no significant 
differences between the DNA control and samples incubated with AAPH and 
the extract ( ), sinapine ( , at extract concentration) and the 
sinapine/phenolic acids mixture (  extract concentration). Also, 20 µg/mL 
sinapine ( ) shows DNA protective properties, with no significant difference 
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to the DNA control. However, when diluting sinapine to 0.2 µg/mL no 
protective properties were observed (Figure 3.38, p.203).   
This is the only known study so far looking into the protection of plasmid DNA 
from AAPH induced oxidative damage by RSP extract and sinapine. No papers 
showing similar rapeseed related research were found in the literature.  
Compared to the copper chelating properties (3.3.5 Copper (Cu2+) chelating, 
p.191 f.), where sinapine was not responsible for the activity; or the 
antioxidant activity, where it was causing between 35-73% of the activity 
(3.3.4.1 Antioxidant activity of Sinapine, p.175 ff.); in the plasmid DNA 
protection assay it seems to be responsible for most if not all of the DNA 
protection. 
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3.4 Conclusion/Future Work 
The final extract obtained through bulk extraction (Soxhlet) from RSP showed 
a similar antioxidant activity and LC-MS/MS secondary metabolite profile to 
the preliminary extract (SOX 2014) characterised in chapter 2. For further 
phytochemical characterisation of the extract, additional LC-MS/MS analysis 
was undertaken to determine additional secondary metabolites. This 
investigation demonstrated a significant presence of sinapine, as well as 
additional phenolic derivatives in the RSP extract. Sinapine contributed 
mostly to the antioxidant activity (35-73%, depending on assay) of the RSP 
extract. These results were published in Yates et al. 2019499. In addition, the 
presence of three glucosinolates (progoitrin, gluconapin* and 
gluconasturtiin*) was confirmed, while no indication for the presence of 
anthocyanins was observed. Although some peaks found during the additional 
LC-MS/MS analysis (Figure 3.22 p.181) are still unknown, less than 50% of 
the extracts antioxidant activity is of unknown origin (Figure A3, p. 442), 
because the phenolic acids and sinapine explain the majority of the activity. 
The further identified compounds, e.g. sinapoyl glucoside or feruloyl choline 
(5-8’) guaiacyl (Table 3.6 p.182), but not with standards verified metabolites, 
could explain some of the additional activity. Potentially in conjunction with 
some of the undetermined peaks. 
Metal chelating properties of the extract were studied for copper(II) and 
iron(II) ions. The extract only demonstrated positive chelating ability for 
copper and this was not associated with the sinapine present in the extract. 
Additional investigations are needed to determine whether the other present 
secondary metabolites or unknown compounds in the RSP extract are 
responsible for the copper chelating activity. Furthermore, it was found that 
a major part of the AChE inhibition activity of the extract, is due to the 
presence of sinapine and some of the phenolic acids present in the extract. 
However, a small fraction of the AChE inhibition activity is still unexplained 
and requires further investigation. The RSP extract also inhibited self-
mediated β-amyloid (1-42) aggregation although inhibition observed was less 
than that with positive control curcumin but significant when compared with 
the untreated β-amyloid control. The RSP extract also demonstrates in vitro 
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plasmid DNA protective properties in the presence of radical initiator AAPH. 
In this case the activity was mainly attributed to the concentration of sinapine 
within the extract. The DNA protective properties of the RSP extract in 
comparison to sinapine and the mixture of phenolic acids formed part of the 
publication Yates et al.499. Metal chelating properties, inhibition of AChE as 
well as the inhibition of protein aggregations are all positive characteristics 
important for the potential treatment of neurodegenerative disease, because 
metal dis-homeostasis206,431,500, Ach levels501 as well as protein 
aggregations122,157,444,502 have all been associated with neurodegeneration. 
Overall, the extract demonstrates several positive in vitro activities, some of 
which can be explained by the presence of sinapine in the RSP extract. 
Extracts with similar activities have previously gone on to show very good 
results in different cellular or in vivo models of neurodegenerative disease. 
The AChE inhibition activity of the extract for example although much lower 
than for example neostigmine is promising, since it would provide a natural 
alternative to the commonly used AD drugs. Especially with the additional 
antioxidant and copper chelating properties, it could be advantageous (multi-
target) over compounds purely inhibiting AChE. More and more researchers 
explore the use of a mixture of drugs or extracts for the treatment of 
neurodegenerative disease, due to their complex and multifactorial nature 
(1.3 Neurodegeneration, p.23 ff.). The one drug one disease theory might 
not be applicable for this type of disease. Extracts showing multiple positive 
characteristics might show the long sought effects for the treatment or 
prevention of neurodegenerative disease.  
However, as raised by López-Alarcón and Denicola301 in vitro methods are not 
sufficient to assess compounds activity in vivo, due to the complexity involved 
in their mechanism of action. Most of these simple in vitro assays also ignore 
important parameters in biological environments, such as pH, bioavailability 
and the blood-brain barrier. Particularly the induction of antioxidant pathways 
within model systems is ignored using these in vitro methods. In conclusion, 
the in vitro assays presented in this chapter, only verify chemical activity. For 
the extract to be of biological relevance, similar activity in cell systems and/or 
in vivo is crucial for the potential use of the extract in health and wellbeing. 
Thus, the next two chapters will focus on exploring the biological activity of 
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the extracts in vitro (SH-SY5Y cells, Chapter 4) and in vivo (C. elegans, 
chapter 5).  
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4  CELL PROTECTIVE 
PROPERTIES OF RSP EXTRACT IN 
SH-SY5Y NEUROBLASTOMA 
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This chapter will cover experiments designed to study the antioxidant properties of 
RSP extract activity in a cell-based system. The SH SY-5Y neuroblastoma cell line 
was employed to determine the extracts toxicity and its potential to (i) reduce the 
production of reactive oxygen species and (ii) to prevent DNA damage induced by 
hydrogen peroxide. Furthermore, the effect of the RSP extracts on oxidative stress 
related protein makers and the  enzyme acetylcholinesterase at cellular level were 
explored.  
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4.1 Introduction 
4.1.1 Neuronal cell culture 
When undertaking research to study the effect of plant extracts in the field of 
neurodegeneration the best option for cell-based research is the use of 
primary neurons. Primary mammalian neurons can be derived from 
embryonic central nervous system tissue. However, they do come with 
certain limitations.  Once terminally differentiated into neurons, these cells 
will no longer propagate and so the number of cells available for experiments 
is limited503,504. In addition, recent developments in stem cell research have 
made it possible to generate induced pluripotent stem cells, from 
differentiated patient-derived cells, which have the capacity to self-renew by 
dividing and to develop into all cells of the adult body e.g. neurons,  in the 
laboratory505. Advancing this research even further has led to the creation of 
3D cell models using human stem cells506–508. These and further advances in 
cell based research, could lead to new experiments and future discoveries in 
neuroscience. 
To overcome the issue of non-propagating neuronal cells, very often 
secondary cell lines, derived from neuronal tumours, which have become 
immortalized, are used. Advantages of these include (i) unlimited number of 
cells which, grow easily under cell culture conditions (ii) less variability (iii) 
less challenging preparation (iv) approval from ethics committees is easier 
and (v) facile transfection.  There are  several cell lines currently being used 
for the search of potential neurodegenerative treatment from natural 
antioxidants. These include the neuroblastoma cell line SH-SY5Y, the human 
neuronally committed teratocarcinoma cell line NT2 or NTera as well as the 
PC12 cell line derived from rat pheochromocytoma of the adrenal 
medulla503,504. However, there are disadvantages in using these neuron like 
cell lines, for example they bear more physiological differences to mature 
neurons, thus  making them less likely to exhibit similar properties as 
neurons in vivo504. Depending on the field of interest, the right cell line/type 
needs to be chosen carefully. To study the effect of RSP extracts in neuronal 
like cells, the SH-SY5Y neuroblastoma is the cell line of choice in this study, 
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since this cell line is commonly used, as testified by their presence in the 
literature. Thus, this also will facilitate comparison of results. 
4.1.1.1 Background on SH-SY5Y cells 
The neuroblastoma cell line SH-SY5Y was created by subcloning the original 
cell line SK-N-SH three times. The SK-N-SH cell line (first reported in 1973509) 
was isolated from a bone marrow biopsy from a four-year old female patient 
with neuroblastoma, a cancer that is formed in immature nerve tissue mostly 
in children. The initial cell line SK-N-SH, first cultured in 1970, was subcloned 
to SH-SY, followed by SH-SY5, to the final cell line SH-SY5Y504,510.  
Since SH-SY5Y cells were derived from human, they express a number of 
human-specific proteins, which would not be present in rodent culture, giving 
them an advantage over for example the PC12 cell line mentioned before. 
SH-SY5Y cells are commonly used in vitro, for experiments requiring neuron-
like cells such as for research in PD, AD and ALS511–514. Advantages for the 
use of this cell line include its human origin, catecholaminergic neuronal 
properties and easy maintainance512. In the nervous system 
catecholaminergic neurons synthesise and release neurotransmitters 
dopamine and noradrenaline. In addition SH-SY5Y cells express tyrosine 
hydroxylase (rate-limiting enzyme for the production of dopamine) and 
exhibit, noradrenaline specific, moderate levels of dopamine-β-hydroxylase 
activity, which is part of the synthetic pathway of noradrenaline in neurons515. 
 
Both the use of differentiated and undifferentiated SH-ST5Y cells has been 
reported in the search for treatment of neurodegenerative disease. Similar to 
working with primary neurons, differentiated cells (e.g. with retinoic acid) 
cannot further propagate, due to cell population growth inhibition516. 
Differentiation of the cells in every experiment is time and work intensive and 
thus it was decided against in this project. Also the higher number of papers 
using undifferentiated SH-SY5Y (Figure 4.1, p.212) cells in for example PD 
research (81.5%)512, aided the decision to use undifferentiated cell for better 
comparison with previous research. Also Cheung et al.517 suggests the use of 
undeifferentiated SH-SY5Y cells in research related to neurotoxicity or 
neuroprotection, due to the changes, e.g. reduced susceptibility to 6-
hydroxydopamine or MPP+(inducer of PD), induced by for example retinoic 
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acid as  differentiating agent. In general undifferentiated SH-SY5Y cells lack 
long neurite outgrowth and tend to grow in clusters as demonstrated in Figure 
4.1516. 
 
Figure 4.1| Undifferentiated SH-SY5Y cells in DMEM media (40x 
magnification)  
SH-SY5Y cell lines have been maintained in several different basal media with 
various types of serum and other cell culture supplements. In a systematic 
review by Xicoy et al.512 on the use of this cell line in PD research the most 
common culture media in articles was Dulbecco’s Modified Eagle Medium 
(DMEM, 434 articles) with 10% foetal bovine serum (FBS, 770 articles). In 
addition, several articles also showed the supplementation of the culture 
media with antibiotics (631), glutamine (230), non-essential amino acids (94) 
and sodium pyruvate (61). 
In the field of natural products and neurodegeneration this cell line was used 
extensively. Hu et al.518 for example, tested 3,6’-disinapoyl sucrose (DISS) 
from Radix Polygala (root of Polygala tenuifolia) in association with the cell 
line, Seoposengwe et al.519 demonstrated the potential of four medical plants 
from Africa (Lannea schweinfurthii, Zanthoxylum capense, Scadoxus 
puniceus and Crinum bulbispermum) against rotenone-induced toxicity and 
many others520–523. 
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4.1.2 Cell toxicity/viability assays 
Cell viability assays are fundamental in the field of cell biology and drug 
discovery524. To work with compounds/natural extracts within a cell system, 
their initial toxicity needs to be determined. This information provides 
knowledge on safe working concentrations for further investigation. These 
working concentrations strongly depend on the aim of the research, for cancer 
research for example a certain amount of cell death is desirable. In contrast, 
when studying neuroprotection, concentrations must be chosen that are not 
harmful to the cells. The toxicity of compounds towards cell lines can be 
determined using a number of different assays, with each one of them having 
their own advantages and disadvantages. In general these assays either look 
into the viability of cell populations or individual cells525. One of the earliest 
methods to determine cell viability was trypan blue, the latter cannot cross 
intact cell membranes, so only dead cells will take up the dye. Viable versus 
non-viable cells can be counted manually (e.g. using a haemocytometer) or 
using automated systems, such as automated cell counters or flow cytometry. 
However, manual counting is labour intensive while sophisticated equipment 
in the case of automation is associated with high costs. Alternatives are the 
use of radiolabelled nucleotides (e.g. 3H-thymidine) and monitoring the rate 
of their incorporation into the DNA, which can be correlated to the rate of 
proliferation. This approach is sensitive but requires operation and safe 
handling of radio isotopic waste525,526. 
Nowadays the use of dyes in toxicity assays is more common. The dyes are 
transformed in the presence of metabolically active cells. Most of these assays 
can be performed on adherent cells in multi-well format and are evaluated 
using plate readers. The use of plate readers increases the number of samples 
and replicates that can be analysed at the same time. Tetrazolium salts are 
the most common dyes, the latter form colourless or weakly coloured 
aqueous solutions. They are converted to brightly coloured formazan 
compound by the reduction of the tetrazole ring in the presence of 
metabolically active cells527 (4.1.2.1 MTT assay, p.215). Both water soluble 
(sulfonated) and water insoluble formazans can be formed, depending on the 
starting compound (Table 4.1, p.214). The formation of aqueous insoluble 
formazans is used in endpoint assays, whereas soluble formazans, can be 
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used for continuous real time assays527. An overview of some commonly used 
dyes is given in Table 4.1. More specific details on these can be found in 
reviews by Berridge et al.527 and Stockert et al.528. 
Table 4.1| Tetrazolium based cell viability assays (adapted 
from525,527,528) 
Compound Full name 
Tetrazolium 
salt 
Formazan-
water 
MTT* 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
mono insoluble 
MTS 
5-[3-(carboxymethoxy)phenyl]-3-(4,5-
dimethyl-2-thiazolyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt 
mono soluble 
CTC 
5-cyano-2,3-di-(p-tolyl) tetrazolium 
chloride 
mono insoluble 
NBT nitroblue tetrazolium chloride di insoluble 
XTT 
sodium 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)- 
carbonyl]-2H-tetrazolium inner salt 
mono soluble 
WST 
sodium 5-(2,4-disulfophenyl)-2-(4-
iodophenyl)-3-(4-nitrophenyl)-
2Htetrazolium inner salt 
mono soluble 
Note(s): * used in this project 
These methods are cost effective and easy to undertake. However, they do 
lack high sensitivity and potential interactions with reducing groups from 
drugs are possible, limiting their use for certain experiments524. 
Fluorescence based assays such as Alamar Blue (resazurin, see 4.1.2.2 
Resazurin assay, p.215) can overcome the issue of low sensitivity and 
interference. These are increasingly being used for the determination of cell 
viability. Other methods such as using cellular ATP production or real-time 
methods, such as engineered luciferase and a small molecule pro-substrate 
are used. In the case of the luciferase assay, the pro-substrate is reduced by 
the cells with active metabolism and diffuses into the culture media to react 
with the luciferase yielding a luminescent signal. Even multiplex assays using 
the continuous viability data in conjunction with other cell based downstream 
effects can be undertaken, as long as reagents used for either do not interfere 
with each other525,529. These and other possibilities for viability measurements 
are reviewed in the book “Mammalian Cell Viability” by Stoddart525. Both, the 
MTT and the resazurin, assays used in this project are further discussed 
following. 
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4.1.2.1 MTT assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay is a colorimetric assay that assesses cell viability via their metabolic 
activity. It was first introduced in 1957 by Pearse for the detection of 
dehydrogenase activity530. For this assay the MTT solution is added to the 
adherent cells in a well plate format and incubated for a set amount of time 
(between 2-4 hours). If the cells are metabolic active, the MTT will be reduced 
to the purple formazan forming water insoluble crystals (Figure 4.2). These 
can be dissolved by the addition of e.g. dimethyl sulfoxide (DMSO) after 
removal of the culture media. The reduction takes place due to the presence 
of the coenzyme NAD(P)H and glycolytic enzymes within the cell. 
 
Figure 4.2| MTT reaction in metabolic active cells 
The higher number of the metabolically active cells present, the more 
formazan crystals will be formed giving higher absorbance at 560 nm after 
dissolving the formazan crystals. The MTT assay is one of the most widely 
used assays for cell viability, cytotoxicity, proliferation and chemo- and radio 
sensitivity analysis in vitro528. It is simple and less time consuming compared 
to for example trypan blue cell counting methods, since it can be undertaken 
in a multi-well plate format, testing several drugs or drug concentrations at 
the same time by using plate readers for detection. 
4.1.2.2 Resazurin assay 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide), first introduced as 
alamarBlue®, is a blue dye with weak fluorescence. In viable cells resazurin 
(an oxazone chromophore) is irreversibly reduced to the pink coloured 
resorufin  due to the electron transfer from NADH/H+ to resazurin (Figure 4.3, 
p.216)528. Resorufin can be detected either using colourimetry or fluorimetry. 
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The fluorescence measurement shows better sensitivity, as little as 80 cells 
can give reproducible signals531,532.  
 
Figure 4.3| Reduction of resazurin to resorufin within cells 
Being able to add resazurin straight to the culture media and the formation 
of the aqueous soluble resorufin eliminates certain steps necessary for e.g. 
the MTT assay. Resazurin has also been found to be less toxic than the 
former. As cells are not killed in the process of toxicity assessment, further 
analysis can be undertaken with the same set of cells532. However, incubation 
times suggested by the manufacturer need to be adhered to otherwise cell 
toxicity might be observed533. A disadvantage is also that further reduction of 
resorufin can gives a final colourless/non-fluorescent product called 
hydroresorufin528,532, again suggesting to adhere to manufacturers incubation 
times. Furthermore, to determine potential interference issues, wells without 
cells with the compound in question should be analysed simultaneously. 
Interference in this assay can occur if the compound/extract in question 
shows similar absorbance/fluorescent signalling. 
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4.1.3 ROS in the cell system 
Indications on the importance of ROS production in the neurodegenerative 
disease development has been described in “1.4 Oxidative stress in 
neurodegeneration and the potential use of antioxidants to prevent 
neurological disorders” (p. 51 ff.). This makes the detection of ROS within cell 
systems and the potential prevention of ROS production very important. The 
dye H2DCFDA (2',7' –dichlorofluorescin diacetate, (Figure 4.4, top) is widely 
used to measure the production of hydroxyl-, peroxyl- and other ROS activity 
in cells. In general, H2DCFDA is resistant to oxidation, but once taken up by 
cells, it is deacetylated by intracellular esterases to form the more hydrophilic 
non-fluorescent dye 2’,7’–dichlorhydrofluorescin DCFH, which is retained in 
the cells534. In the presence of oxidizing species, it is rapidly oxidized to form 
the highly fluorescent DCF (2’, 7’ –dichlorofluorescein)535. 
 
Figure 4.4| H2DCFDA in vitro reaction in the presence of ROS/RNS 
(adapted from Eruslanov and Kusmartsev535)  
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The occurring fluorescent signal can be detected by using (i) a multi-well plate 
system and a fluorescence plate readers, (ii) fluorescence microscopy, (iii) 
fluorimeter or (iv) flow cytometry with excitation sources and emission filters 
appropriate for fluorescein (Ex: ~492–495 nm; Em: ~517–527 nm). 
Although plate readers bring the advantage of being quick and easy, they are 
only able to measure total fluorescence, since intra- and extracellular 
fluorescence cannot be distinguished from each other. In contrast, flow 
cytometry provides the possibility to measures the intracellular fluorescence 
of cells as well as optical cell characteristics. Total number of cells emitting 
fluorescence can be determined, compared to relative fluorescence units in 
the plate reader535,536. During flow cytometry analysis (Figure 4.5), cells are 
transported from the sampling tube into the flow cell system and cells are 
surrounded by sheath fluid (physiological buffer).  
 
Figure 4.5| Schematic of flow cytometry in the presence of 
fluorescent and non-fluorescent cells 
The fluidic system, consisting of the sheath fluid and pressurized lines, 
funnels the cells into single file, where they will eventually pass through the 
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excitation laser (interrogation point).  Detectors can collect data on forward 
scattered (FSC), side scattered (SSC) and fluorescent emissions. The 
scattered light is related to structural and morphological properties (FSC: size 
and SSC:internal complexity) of the cells under investigation. The 
fluorescence emission is directly proportional to the quantity of fluorescent 
probe (e.g. DCF) within a cell. For further information on the principles and 
applications of flow cytometry can be found in a review published by Adan et 
al.536 gives a detailed overview. By using the number of detected events 
(cells) and their respective fluorescence, the level of ROS within a cell sample 
can be measured and compared with different samples, e.g. H2O2 stressed 
cells or cells treated with other compounds of interest. 
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4.1.4 Cellular DNA damage/ Comet assay 
Oxidative stress (1.4 Oxidative stress in neurodegeneration and the potential 
use of antioxidants to prevent neurological disorders p. 51 ff.), amongst 
others factors can lead to DNA damage, which together with protein and lipid 
damage is associated with neurodegeneration. The question of whether DNA 
damage is a cause or a consequence (or both) of the neurodegenerative 
process is still unclear537. Already in 1994 Mecocci et al.538 observed a 
significant increase in oxidative DNA damage marker, 8-hydroxy-2'-
deoxyguanosine (using HPLC), in the mitochondrial and nuclear DNA, of post-
mortem brain tissue from AD patients. Furthermore DNA stand breaks have 
previously been detected in samples from e.g. AD539 and PD540 patients. 
Here, to determine the potential of the extract to protect nuclear DNA from 
H2O2 induced stand breakage in SH-SY5Y cells, the comet assay was 
employed. The comet assay, also known as single cell gel electrophoresis 
(SCGE), is one common technique available to measure nuclear DNA 
breakage and repair in individual eukaryotic cells541. Ostling and Johanson542 
first introduced the use of microgel electrophoresis in 1984 for the detection 
of radiation-induced DNA damage in mammalian cells. This method was 
modified by Singh et al.543 in 1988 using alkaline conditions544. The comet 
assay has successfully been employed in genotoxicity testing, ecologic 
monitoring and human studies541. The modified alkaline version of the assay 
was used in this project, to detect single and double strand breakage as well 
as alkali-labile sites. There are a few variants of the assay which are briefly 
described in Table 4.2. 
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Table 4.2| Comet assay types and some examples of their usage541,545,546 
Un-/ 
common 
Type Short description Examples of application 
Common 
Alkaline# 
Detection of double and single DNA strand breaks, including 
alkali-labile sites such as base or phosphate alkylations and 
intermediates in base excision repair, the base-less sugars left by 
glycosylase action, which are transformed into strand breaks by 
high pH 
- Potential mutagenic/carcinogenic action of 
inhalation anaesthetics547 
- Evaluation of sperm DNA quality548 
- Oxidative DNA damage protection and 
repair by polyphenolic compounds in PC12 
cells549 
Neutral 
Detection of double and single strand breaks predominantly 
facilitates the detection of double strand breaks  
- Environmental exposures to phthalates 
(industrial chemicals) and DNA damage in 
human sperm550 
Lesion-specific 
enzymes 
Convert altered bases to strand breaks e.g.  
- Endonuclease III converts oxidised pyrimidines 
- Formamidopyrimidine DNA glycosylase (FPG) converts 8-
oxoguanine and some other oxidised purines 
- 3-methyladenine DNA glycosylase II (AlkA) converts alkylated 
bases to AP (apurinic/apyrimidinic) sites 
- T4 endonuclease V converts cyclobutane pyrimidine dimers 
- UDG detects uracil misincorporated in DNA 
- Evaluate the genotoxicity of oregano 
essential oil in rats 
- Genotoxicity of the herbicide551 
DNA repair 
a) Cells are given time, after removal of stressor, for DNA 
repair, thereafter one of the above techniques is used to 
determine the DNA repair efficiency of the cells or 
b) Comet-based in vitro assay: DNA nucleoids containing a 
specific lesion  are incubated with a cell extract containing a 
certain amount of repair enzymes; enzymes, as a part of the 
repair process, produce breaks at the sites of the lesions in the 
DNA that are measured using the alkaline comet assay protocol; 
the capacity of the cell extract to carry out the incisions, is 
considered to be the rate-limiting step of the repair process and 
is taken as an indicator of the DNA repair activity of those cells 
a) Assessment of DNA repair efficiency in 
drug naïve schizophrenia patients552 
b) Oxidative DNA damage protection and 
repair by polyphenolic compounds in PC12 
cells549 
Un- 
common 
Bromodeoxy- 
uridine labelling 
Identification of replicating DNA 
- Cancer research, Detection of Maturation of 
Recently Replicated DNA553 
Fluorescence in situ 
hybridization (FISH) 
 comets 
Detection of damage on specific chromosomes 
- Test for radio sensitivity of specific genes: 
compare DNA damage and repair in p53 and 
hTERT genes554 
Note(s): # version of comet assay used in this project 
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Cultured cells, primary cells or tissue samples can be employed for the comet 
assay546. When studying the protection of DNA by compounds/extracts from 
oxidative stress induced DNA strand breakage, cells can be exposed to e.g. 
H2O2. This exposure can take place before cell collection, in the culture flasks 
or after cell collection in Eppendorf tubes. To determine whether certain 
compounds can prevent DNA damage, pre-treatment for a chosen time occurs 
just before the introduction of the stressor. Once cells are harvested, cell 
pellets are obtained via centrifugation and cells are resuspended in low-
melting point agarose gel (1% in PBS (#2 Figure 4.6). The cells in the agarose 
suspension are then evenly distributed (#3 Figure 4.6) onto squares of thin 
agarose layers (1% standard melting point agarose in PBS), prepared on top 
of microscopy slides (frosted or agarose coated, #1 Figure 4.6), and covered 
with cover slides for an even dispersal of cells in the gel layer. The cells on 
the slides are then lysed, using detergent and a high salt solution to remove 
membranes, cytoplasm and nucleoplasm and to dissolve the nucleosome, 
leaving only the DNA (supercoiled in a negative sense) in the nucleoids (#4  
Figure 4.6). Subsequent alkali treatment leads to supercoil unwinding and 
unzipping of the double DNA strands (#5 Figure 4.6). During the process of 
electrophoresis, DNA with strand breakages, is more likely traveling towards 
the positive electrode of the electrophoresis tank (comet tail). DNA without 
strand breakage, lacks free ends and so the large size prevents the migration, 
and the DNA stays in place, forming the comet head (#6 Figure 4.6). The 
difference in number of DNA strand breakages leads to different shapes of 
the comets. After electrophoresis, the slides are immersed into neutralisation 
buffer, which leads to the joining of the unzipped DNA strands (#7 Figure 
4.6). This prepares the DNA for DAPI staining. DAPI is a DNA intercalating 
dye which binds to adenine–thymine rich regions of double stranded DNA. 
This staining makes the observation of the comets possible, using 
fluorescence microscopy (#8 Figure 4.6). The comets are then scored (#9 
Figure 4.6) according their head/tail size and intensity, given an arbitrary 
number between 0 (no DNA strand breaks, circular comets) and 4 (high 
number of DNA strand breaks, comets with a small head and big tail, Table 
4.5, p.234). 
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Figure 4.6| Comet assay overview 
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4.1.5 Cell stress related proteins 
Oxidative stress can have an impact on many cellular components such as 
DNA (see capter 4.1.4), lipids and protein. Cellular stress can activate a 
number of cell stress related proteins within the cell system (e.g. Nrf2 
pathway, Figure 1.29, p.60. The most common technique to study the 
expression levels of certain proteins is western blotting. With these, 
expression levels of proteins can be detected. When investigating several 
different proteins, this technique becomes laborious and very time 
consuming. To address this, protein micro array technology has been 
developed and is now commonly used in many laboratories. With this system, 
the expression levels of several different proteins can be determined at the 
same time, thus making this method extremely time efficient555. 
These protein arrays are membrane-based antibody arrays for the detection 
of selected human proteins. Cell as well as tissue lysates have been validated 
for detection in these assays. Initially cell/tissue lysates are usually incubated 
with the biotinylated detection antibodies (#1 Figure 4.7), in the presence of 
the protein in question, the latter will bind to the antibodies. The mixture of 
the cell lysate and the antibodies is thereafter added to the array membrane 
(#2 Figure 4.7)556.  
1
2
2a
3
 
Figure 4.7| Principle of protein micro arrays  
(HRP-horse radish peroxidase) 
After overnight incubation, the membranes are washed. If the protein/s in 
question are not present in the cell lysate, the biotinylated detection 
antibodies are washed off (#2a Figure 4.7). Thereafter, streptavidin-HRP and 
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chemiluminescent detection reagents are added to make the detection 
possible (#3 Figure 4.7). In the case of absent proteins in the cell lysate, no 
signal is produced.  
To determine whether the RSP extract induces cell stress, the Proteome 
Profiler Human Cell Stress Array Kit (R&D systems) was employed. This kit 
contains 4 membranes, which are spotted in duplicate with 26 cell stress 
related capture antibodies and allows the detection of relative levels of these 
proteins. Amongst other the kit determines protein levels for (i) heat shock 
proteins (HSPs), induced in response to environmental, physical and chemical 
stresses557, (ii) superoxide dismutase (SOD), an enzyme responsible for the 
catalysis of the superoxide (O2−) anion to molecular oxygen (O2) or hydrogen 
peroxide (H2O2) (4.3.1 Study into the cell stress related protein expression 
induced by RSP extract using micro array technology p.250), (iii) Serum 
paraoxonase/arylesterases (PONs), which are enzymes responsible for 
hydrolysing exogenous toxic organophosphate compounds558, (iv) hypoxia-
inducible factors (HIFs), induced under a lack of oxygen (hypoxia)559 as well 
as (v) transcription factor NFκB1, which can activate a vast number of genes 
related to cell survival and death, inflammation and immunological 
responses560. 
A similar human cell stress array kit had previously been used to determine 
the effect of marine oils, digested with human fluids, on human intestinal 
Caco-2 cells, which showed down regulation of certain cell stress proteins 
(e.g. HSP-70 and SOD2)561.  
The determination of stress related protein levels in the SH-SY5Y cells, after 
RSP extract treatment, together with the other experiments set out for this 
part of the project will aid to elucidate the RSP extract’s potential to prevent 
or treat neurodegeneration associated with oxidative stress. Following the 
objectives for this chapter, used to assess the overall aim of the project (1.5 
Overall Aim and thesis structure, p.64), are introduced. 
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4.1.6 Objectives 
The list below describes the objectives set out for this chapter: 
- Examine the RSP extracts cytotoxic effects in SH-SY5Y neuroblastoma 
cells 
- Assess the extracts potential to prevent ROS production within the cell 
system 
- Analyse the extracts DNA damaging and protective properties in the 
cellular model 
- Inspect the extracts activity on cell stress specific proteins 
- Determine the extracts AChE inhibition activity in SH-SY5Y cells 
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4.2 Materials and Methods 
4.2.1 Chemicals and Equipment 
The following chemicals/kits (Table 4.3) and equipment (Table 4.4) was used 
in the aid of the experiments in this chapter. 
Table 4.3| Chemicals, reagents and kits 
Chemicals Provider 
MTT Sigma-Aldrich 
Resazurin R&D systems 
DMEM, high glucose, pyruvate Fisher Scientific 
FBS Fisher Scientific 
Pen/Strep Sigma-Aldrich 
NEAA Sigma-Aldrich 
Trypsin-EDTA solution Sigma-Aldrich 
H2DCFDA 
Invitogen, Life Technologies by 
Fisher Scientific 
Sheath buffer Beckman Coulter Inc. 
DMSO Fisher Scientific 
PBS OXOID, Fisher Scientific 
Amplex® Acetylcholine/ 
Assay Kit 
Fisher Scientific 
Proteome Profiler Human Cell 
Stress Array Kit 
R&D systems 
H2O2 Sigma-Aldrich 
AAPH Sigma-Aldrich 
agarose gel (high melting 
point) 
Fisher Scientific 
agarose gel (low melting 
point) 
Sigma-Aldrich 
EDTA Alfa Aesar 
Triton-X100 Acros Organics 
NaOH Fisher Scientific 
Tris base Fisher Scientific 
Developer and Fixer  
(RP X-OMAT LO) 
KODAK, Carestream 
DCTM Protein Assay Kit Bio-Rad 
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Table 4.4| Equipment 
Equipment Manufacturer/Details 
Plate reader BioTek µQuant 
Oven Techne Hybridiser HB-10 
Fridge DEAWOO 
Freezer -20°C Blomberg 
Freezer -80°C New Brunswick Scientific U725 
pH-meter Denver Instruments Basic 
Balance OHAUS Pioneer™PA114 
Balance Mettler BB1200 
Ultrasonic bath Ultrawave SFE5901 
Incubator (cells) Nuaire™ DH Autoflow 
Incubator (media) Stuart Scientific co.LTD SI50 
Fridge (cell culture) Zanussi 
Flow chamber 
Thermo Electron Corporation Hera 
safe 
Freezer (cell culture) AEG Öko_ARCTIS 
Flow cytometer Coulter Epics XL-MCL 
Scanner Canon 4225i 
Centrifuge (cell culture) MSE centaur 2 
Centrifuge (molecular) Heraeus Multifuge 1 L-R 
Microscope (cell culture) Leica DMIL 
Microscope (comet assay) Leica DMRB 
microwave Panasonic NN-E255W 
Comet electrophoresis tank Anachem 3003 
Power source Consort E831 
Plate shaker (molecular) Heidolph Polymax 1040 
CL-XPosure X-ray film Thermoscientific 
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4.2.2 Methods 
The methods employed in this chapter (Figure 4.8) were used to study the 
effect of RSP extract on neuronal like cells. The results from these methods 
also aid the evaluation of the potential application of RSP extract as treatment 
or prevention of neurodegenerative diseases. 
 
Figure 4.8| Overview of methods used to determine the extracts 
activity in SH-SY5Y neuroblastoma cells 
4.2.2.1 General cell culture techniques 
Maintenance 
SH-SY5Y cells were cultured as previously described562 with minor 
modifications, using DMEM media (Gibco™ DMEM, high glucose, pyruvate) 
supplemented with 10% FBS, 1% non-essential amino acids (NEAA) and 1% 
Penicillin/Streptomycin (Pen/Strep). Maintenance cell culture flasks and 
experimental plates/flasks were maintained in a 5 % CO2 humidified incubator 
at 37°C. Cells were passaged once 80% to 90% confluence levels were 
reached. For passage or cells collection, old media was discarded, cells were 
washed with PBS and then trypsinized for 2-5 minutes (37°C). Trypsin activity 
was stopped by addition of fresh supplemented media and cells centrifuged 
(1500 rpm, 5 minutes). Then the media/trypsin supernatant was discarded, 
and cells suspended in fresh media for passage or in experimental buffer for 
further analysis. When necessary, cells were counted using a 
haemocytometer and cell numbers adjusted with media/ experimental buffer 
depending on cell density needed for experiment and/or stock of cells.  
 
SH-SY5Y 
cell culture
RSP extract 
toxcicity
Protection from 
ROS, induced by 
H2O2
Protection from 
DNA strand 
breakage, induced 
by H2O2
Cell stress protein 
experession
AChE inhibition 
potential
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Cell lysis 
Cell pellets were collected by centrifuging of the cell suspensions for 5 
minutes at 2000 rpm (4°C) and the supernatant discarded. Collected cell 
pellets were suspended in lysis buffer (~200 µL, 150 mM NaCl, 50 mM Tris 
pH 8.0, 1.0% Triton-X100) for 30 minutes on ice and then sonicated for an 
additional 15 minutes (4°C). Thereafter cell lysates were centrifuged for 10 
minutes at 14,000 g and the supernatant transferred into new Eppendorf 
tubes for protein analysis.  
Protein determination 
Both, the Bradford and the DC protein assays were applied, to determine the 
appropriate assay compatible with the lysis buffer. Since the Bradford assay 
showed strong interferences with the used lysis buffer (1% Triton-X100), it 
was not use for protein determination. However, the DC protein assay (BIO-
RAD) showed no interferences and was used for protein determinations, using 
the protocol provided by the “DC Protein Assay Instruction Manual”563. Briefly, 
a working reagent A’ was prepared fresh daily by adding 20 µL reagent S per 
1 mL reagent A. A bovine serum albumin (BSA) standard was prepared (25 
mg/mL) and further diluted (2.5 mg/mL) with cold deionized water. Standard 
solutions of this BSA stock were prepared ranging from 0.125-1.5 mg/mL. 
Cell lysate samples were diluted 1:10 in deionized water. The BSA standard 
solutions as well as the diluted samples (5 µL) were pipetted into a clear flat 
bottom 96-well plate in triplicates. Thereafter 25 µL of reagent A’ followed by 
200 µL reagent B were added to each well. The plate was incubated on a 
shaking platform for 15 minutes and then analysed at 750 nm in a plate 
reader. The BSA standards were employed to create a standard curve, which 
was used to calculate the protein amount in the 10-fold diluted sample, which 
was converted into the concentration of the actual sample. Protein 
concentrations for each sample were adjusted with deionized water or 
experimental buffer to required concentration in each of the experiments. 
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4.2.2.2 Cell viability 
MTT assay  
The MTT assay was carried out according to Barron et al. 564. Briefly, 104 cells 
(100 µL) were seeded in 96-well plates and left to attach for 24 hours. 
Thereafter, 100 µL of the RSP extracts (concentrations as specified in 4.3.1, 
p.250) or other compounds under investigation (diluted with media) were 
added and cells incubated for an additional 24 hours. On the following day 
cells were observed under the microscope (DMIL Leica) before the cell culture 
medium was removed and 100 µL of freshly made and sterile-filtered (0.22 
µm) MTT solution (1 mg/mL, in serum free media) were added. After 4 hours 
incubation (37°C), the MTT solution was carefully removed and 200 µL DMSO 
were added to each well and the plate shaken to dissolve the metabolised 
MTT product. After 20 minutes, the absorbance was measured at 560 nm. 
IC50 concentrations were determined, normalising to the media control mean 
(Equation 4.1).  
 
% 𝒐𝒇 𝒗𝒊𝒂𝒃𝒍𝒆 𝒄𝒆𝒍𝒍𝒔 =
(𝟏𝟎𝟎∗𝑨𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕)
𝑨𝒄𝒐𝒏𝒕𝒓𝒐𝒍
  Equation 4.1 
 
All experiments contained at least three technical replicates per plate and 
statistical analysis was done on at least 3 independent experiments. 
 
Resazurin assay  
For the resazurin assay, 104 cells, in 100 µL media were seeded in 96-well 
plates (white, clear bottom) and left to attach for 24 hours. Thereafter the 
RSP extract was added at final concentrations between 0.1-5 mg/mL (in 100 
µL media) and cells incubated for an additional 24 hours. The next day cells 
were observed under the microscope (DMIL Leica) before the addition of 20 
µL of resazurin (ready to use buffered solution, 0.2 μm filtered; R&D systems) 
to each well and incubation for 4 hours. The fluorescence intensity was read 
at wavelengths of 530/25 nm and 590/35 nm for excitation and emission 
respectively. IC50 concentrations were determined, as described for the DPPH 
assay before (Figure 2.14, p.114). All experiments had three technical 
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replicates per plate, statistical analysis was done on at least 3 independent 
experiments. 
4.2.2.3 Measurement of intracellular ROS accumulation 
To determine the ROS production in SH SY-5Y cells, 2,7’-dichlorofluorescin 
diacetate (H2DCFDA) was used. Cells (7x105) were cultured in T25 culture 
flasks (in duplicate), 24 hours later cells were treated with RSP extract/media 
(control cells) and cells incubated for an additional 24 hours. The next day, 
H2O2 (1mM) was added in 5 mL fresh media, to avoiding co-incubation of 
H2O2 with the RSP extract, removed after 30 minutes and H2DCFDA dye (5 
µL, 0.58 µg/µL) added (in 5 mL fresh media). After 4 hours incubation, the 
cells were washed twice with PBS, trypsinized and collected using PBS. The 
supernatant was removed after centrifugation (1500 rpm, 5 min) and cells 
re-suspended in fresh PBS for flow cytometer analysis. Duplicates of every 
condition were run in each independent experiment. A total number of 4 
independent experiments were carried out.   
4.2.2.4 Comet assay (alkaline) 
For the comet assay, cells were seeded (105 in 800 µL media) in 12 well 
plates. After 24 h, the RSP extract (5 mg/mL in 200 µL) or media (control 
cells) was added and left for an additional 24 h. All conditions were run in 
duplicate wells. The next day, the culture media was replaced with 1 mL fresh 
media (control) or media containing H2O2 (concentration depending on 
experiment, 4.3.3 Protection of SH-SY5Y cells by RSP extract from H2O2-
induced DNA strand breakage-Comet assay, p.244) and left to incubate for 
30 minutes respectively. Thereafter cells were washed with PBS and detached 
using 100 µL trypsin per well. To inactivate the trypsin 900 µL supplemented 
media were added after detachment and cells were collected in Eppendorf 
tubes and counted using a haemocytometer (cell numbers usually between 
2x105 and 2.7 x105). Cells were centrifuged for 5 minutes (4°C, 2000 rpm), 
and the supernatant carefully removed, without disturbing the pellet. The 
pellets were kept on ice until further use. 
The comet assay was run according to Duthie et al.565 with minor 
modifications (Figure 4.6, p.223). First the bottom 1% (w/v) agarose gels 
(standard melting point, SMP) was prepared on frosted microscopy slides 
(Richardson Supply Ltd). For this, a 1% (w/v) standard melting point SMP 
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agarose was prepared and kept in a 40°C water bath, to avoid solidification. 
The SMP agarose (85 µL) was pipetted onto frosted microscopy slides and 
covered carefully with 18x18 mm microscope coverslips (#1 0.13-0.16 mm; 
Fisher Scientific) to form an even square agarose layer. Two slides were 
prepared per experimental condition, with two gels on each slide. After 
preparation of the gel layer, the slides were left to solidify (4°C for 5-10 
minutes). A 1% (w/v) low melting point (LMP) agarose was prepared, and 
the cell pellet carefully suspended in an appropriate amount of LMP agarose 
to achieve about 2-5x104 cells in 85 µL agarose. The latter were then added 
on top of the SMP agarose layer, after removing the coverslip. This second 
layer of agarose containing the cells was also covered with 18x18 mm cover 
slips and left to solidify as before. Then the coverslips were removed, and the 
slides suspended in lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris and 4% 
TritonX-100, pH 10) for one hour (4°C protected from light). Thereafter slides 
were place into the electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, ~pH 13) 
in the electrophoresis tank. After 40 minutes incubation, the electrophoresis 
was started using 25V. For both the alkaline treatment and the 
electrophoresis, the tank was kept protected from light (4°C). After 40 
minutes of electrophoresis, slides were washed for 5 minutes using 
neutralisation buffer (0.4 M Tris, pH 7.5) in microscopy slide boxes. This was 
repeated 2 more times (fresh buffer (4°C)). Thereafter gels were covered 
using 22x22 mm microscope coverslips (#1.5 0.16-0.19 mm; Fisher 
Scientific) and stored protected from light (4°C, up to 3 days) until comet 
scoring. For the comet scoring, coverslips were removed, 20 µL DAPI staining 
solution (1 µg/mL in distilled H2O) added and slides covered again with 22x22 
mm coverslips.  Comets were scored manually according to Heuser et al.566 
using a fluorescence microscope with an excitation wavelength from 340-380 
nm and an emission wavelength of 425 nm (Leica DMRB 200x magnification). 
Comet scores and criteria for moving to the next level of comet are detailed 
in Table 4.5, p.234. In case not all the criteria for the next level were present, 
comets were scored into the lower number category. A total number of 100 
comets were scored leading to arbitrary numbers between 0-400 for each 
scored gel. For each condition three gels were scored, and their mean value 
determined. Statistical analysis was done on at least three independent 
experiments.    
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Table 4.5| Comet scoring criteria  
Comet 
score 
Schematic Criteria 
0 
 
• Bright big circular comet head  
• No indication of tail 
1 
 
• Big and bright circular comet 
head (same as 0) 
• Sparkle like tail visible; at least 
the length of the head 
2 
 
• Bright circular comet head, 
same size as 0 and 1 
• Comets show significant tail 
• Tail is less bright than head 
• Head still has a sharp outer 
contour 
3 
 
• Big head, but fainter in 
brightness, similar to tail 
brightness 
• Tail and head begin to merge in 
shape 
• Head loses sharp circular 
contour 
4 
 
• Small head with decreased 
brightness 
• Head is smaller in diameter 
than tail and looks separated 
from tail 
 
4.2.2.5 Proteome Profiler (Human Cell Stress Array Kit) 
To determine the relative levels of selected human cell stress related proteins 
the proteome profiler was used according the manufacturer’s instructions556 
with minor modifications. Cells were grown and treated (1 mg/mL RSP 
extract) in T25 culture flasks in duplicates (as described in 4.2.2.3, p.232). 
After 48 hours, the cells were harvested as previously described and treated 
with Lysis Buffer 6 (1x107 cells/mL) for 30 minutes, after which the 
 head 
tail 
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suspension was centrifuged at 14000 x g for 5 minutes and the supernatant 
transferred into a clean Eppendorf tube. The protein content was determined 
as described before (4.2.2.1 General cell culture techniques, p.229). To 
prepare the membranes, 2 mL of Array Buffer 6 were dispensed into each 
well of the 4-well multi-dish provided with the kit and membranes were 
immersed into the solution (one well each, 2 for each condition) for 1 hour 
on a rocking platform (rt). The samples were prepared in Array Buffer 6 to a 
total of 1 mL (300 µg protein each) and 0.5 mL of Array Buffer 4 were added. 
To each sample in addition 20 µL detection antibody cocktail (reconstituted 
in 100 µL deionized water) were added and samples mixed and incubated for 
one hour (rt). 
After blocking of the membranes with Array Buffer 6, the buffer was removed 
from the 4-well plate and prepared samples with antibody mixture added to 
each membrane. The samples were incubated with the membranes overnight 
on a rocking platform shaker (rt). 
The next day membranes were carefully removed and placed into individual 
plastic containers containing 20 mL of 1x washing buffer, prepared from the 
25x washing buffer provided. Membranes were washed individually for 10 
minutes three times. Streptavidin-HRP was diluted in Array Buffer 6 (1:1000) 
and 2 mL pipetted into each well of the 4-well plate. Membranes were added 
to the Streptavidin-HRP solution after draining the wash buffer and incubated 
on a rocking platform shaker for 30 minutes (rt). After incubation each 
membrane was washed individually in wash buffer 3 times as previously 
described. Before placing the membranes on foil (saran film), each membrane 
was drained by blotting the lower edge onto paper towel. Once membranes 
were placed on the foil 1 mL of Chemi Reagent Mix (1:1 mixture of chemi 
reagents 1 and 2) was pipetted onto each membrane and covered with more 
foil and incubated for 1 minute. The membranes were placed into an 
autoradiography film cassette and exposed to X-ray  film (CL-Xposure, 
Thermoscientific) for 15 minutes. Thereafter, the film was developed, 
washed, fixed (Kodak), rinsed and air dried. To determine the spot intensity 
of photocopied images of the films, Image J software with an in build protein 
array analyser was used. Due to limited resources, only one independent 
experiment was undertaken (two technical replicates; two membranes per  
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condition). Statistical analysis was undertaken with the limited number of 
technical replicates obtained (n=2).  
4.2.2.6 Amplex® Red Acetylcholinesterase Assay 
For the determination of cellular AChE activity, cells were grown and treated 
as previously described for the comet assay (4.2.2.4 Comet assay (alkaline), 
p.232). To determine whether the extract decreases AChE in vitro in SH SY-
5Y cells, the Amplex® Red kit previously used for the AChE inhibition activity, 
was used, with minor modifications. Neostigmine (100 µM) was used as a 
positive control (known AChE inhibitor) after determining its non-toxic 
concentrations via MTT assay (4.2.2.2 Cell viability, p.231). 
The protein content of the samples was determined as previously described 
(4.2.2.1 General cell culture techniques, p.229 ff.) and diluted to 3000 
µg/mL. 100 µL of protein sample as well as AChE (positive control), 1x 
reaction buffer (negative control) and H2O2 (10 µM, positive control) were 
pipetted in triplicates into a black 96 well plate, with clear flat bottoms. To 
the controls and the samples 100 µL of the reaction mix (previously described 
in 3.2.2.5 Acetylcholinesterase inhibition potential, p.163) were added and 
the plate immediately placed into the plate reader. The reaction was 
monitored over a period of 150 minutes. Four independently grown cell 
culture samples were collected for this experiment and analysed in the same 
96-well assay plate. 
4.2.2.7 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 7. Specific methods 
used for statistical comparison of each experiment are detailed in the results 
section. At least 3 independent experiments (n) were analysed per assay, 
unless otherwise stated and results shown as mean ± standard deviation. P-
values below 0.05 were considered significant.  
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4.3 Results and Discussion 
4.3.1 Cellular toxicity of RSP extract 
4.3.1.1 MTT assay 
Initial experiments using MTT for the toxicity determination of the RSP 
extract, showed questionable and varying results for three independent 
experiments (Figure 4.9). From the absorbance measurements taken at 560 
nm the results appear to show an increase of proliferation when treated with 
e.g. 5 mg/mL RSP extract. However, morphological observation of the cells 
under the microscope before addition of the MTT solution after 24 hours 
treatment showed extensive cell toxicity (rounded up cells and decrease in 
cell number, Figure A10, p.449) compared to the media control. The results 
from the MTT assay contradict these observations. 
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%
 o
f 
A
b
s
o
rb
a
n
c
e
 i
n
c
re
a
s
e
/d
e
c
re
a
s
e
(m
e
d
ia
 c
o
n
tr
o
l 
s
e
t 
to
 1
0
0
%
)
m
ed
ia 5.
0
4.
0
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0
100
200
300
1. trial
2. trial
3. trial
RSP extract (mg/mL)
 
Figure 4.9| MTT-assay results from SH-SY5Y cells incubated with RSP 
extract (24 h treatment) 
Literature research into this issue revealed the potential of interference of the 
extract with the MTT solution. In Bruggisser et al.567 for example flavonoids 
kaempferol and resveratrol as well as antioxidant substances such as ascorbic 
acid sodium salt, vitamin E and N-acetylcysteine were able to reduce the 
tetrazolium ring of MTT (Figure 2.7, p.84). Also, some of the tested plant 
(Hypericum) extracts showed similar effects. The observed interference was 
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not due to the extract’s absorption at the measured wavelength but due to 
an active reduction of MTT to formazan567. To determine whether this could 
be the case sinapic acid as one of the present phenolic acids was tested in a 
cell free system at concentrations ranging from 0.005-2.5 mg/mL (Figure 
4.10).  
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Figure 4.10| MTT reduction by sinapic acid in a cell free system (24 
h) 
Statistical significant difference determined using One-way ANOVA and Bonferroni’s 
multiple comparison analysis compared to media control: ***p≤0.001, n=6 (only 
technical replicates) 
The results from this experiment showed a significant increase in absorbance 
readings at high concentrations of sinapic acid (1.0-2.5 mg/mL), suggesting 
a reduction of the MTT had taken place. No statistical significances were 
observed for the lower concentrations, however a trend towards a slightly 
higher absorbance is visible for most of them (Figure 4.10). Repeating 
statistical analysis excluding the highest 3 concentrations, revealed statistical 
significance also for 0.1, 0.25 and 0.5 mg/mL (Figure A9, p.450). This 
significance was lost in the initial graph due to the wide range of absorbance 
results. These results clearly showed that sinapic acid reduces MTT.  
At 5 mg/mL RSP extract, a sinapic acid concentration of 0.02 mg/mL (3.99 
µg/mg RSP extract, Table 3.5, p.171) is present. Although at that 
concentration sinapic acid alone is not expected to be responsible for the 
observed increase in absorbance (Figure 4.10), a combination of other 
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phenolics present in the RSP extract could synergistically have contributed to 
the observed effect. At the time of that experiment the high level of sinapine 
in the RSP extract was not known, which is why only sinapic acid was tested. 
Considering the higher concentration of sinapine in the extract, it could be 
responsible for the observed interference. More detailed analysis looking into 
sinapine’s reduction potential of MTT in a cell free-system could solve this 
uncertainty. 
However, due to the limited time available, the resazurin cell viability assay 
was used instead to determine cell toxicity of the extract. To avoid potential 
interference, wells without cells (prepared equally to cell containing wells) 
were analysed simultaneously.   
4.3.1.2 Resazurin assay 
The resazurin assay gave clearer results and agreed with the cell morphology 
observed under the microscope after treatment with RSP extract (Figure 4.11 
vs. Figure A10, p.449). Concentrations of up to 1.5 mg/mL of RSP extract 
showed no significant decrease in fluorescence intensity compared to the 
media control. Starting at 2.0 mg/mL, the measured fluorescence intensity 
significantly decreased compared to the media control (p<0.001). These 
results suggest a toxicity of the RSP extract towards SH-SY5Y cells starting 
between 1.5 and 2.0 mg/mL.  
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Figure 4.11| Resazurin cell viability assay using RSP extract (0.1-5.0 
mg/mL, 24 h treatment) 
Statistical significant difference determined using One-way ANOVA and Bonferroni’s 
multiple comparison analysis compared to media control: ***p≤0.001, n=3 
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Based on the resazurin toxicity results, subsequent experiments using RSP 
extract were done at concentrations of 1.0 mg/mL or less. Slightly higher 
concentrations could have been used (1.5 mg/mL, non-toxic), but this was 
avoided, because a small but insignificant decrease for the fluorescence 
intensity was observed at that concentration. In addition, the cell morphology 
started to change after 24 hours treatment with 1.5 mg/mL RSP extract 
concentration (Figure A10, p.449). Also, the addition of further stressors in 
combination with the extract could lead to increased toxicity, which is why a 
maximum of 1.0 mg/mL was chosen to be safe for future research. The IC50 
of the RSP extract was determined to be 2.75 mg/mL, which means 2.75 
mg/mL of the RSP extract eliminate 50% of the cell population (Figure A11, 
p.450). 
So far, no literature has been found to report on the cell toxicity of RSP 
extracts towards SH-SY5Y cells. Compared to other natural extracts, the cells 
show a higher acceptability towards the RSP extract. An ethanol extract of 
Bactris guineensis (L.) H.E. Moore (corozo fruit) for example showed reduced 
SH-SY5Y cell viability already at 0.15 mg/mL568. Similar was true for Agaricus 
blazei (almond mushroom) extract, even at small concentrations such as 0.05 
and 0.10 mg/mL showed a significant decrease in cell viability521. A greater 
tolerance towards the RSP extract is advantageous, as higher concentrations 
can be tested for the potential protection of cells from oxidative stress.  
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4.3.2 Protection of SH-SY5Y cells by RSP extract 
from ROS induced by H2O2 
Following the toxicity determination of the RSP extracts in the neuroblastoma 
cell line, the potential of RSP extract to alleviate the production of ROS after 
H2O2 induced oxidative stress was analysed. To achieve this objective, the 
potential of the RSP extract to produce ROS in SH-SY5Y cells was assessed 
and compared with ROS production (increased fluorescence) caused by H2O2 
(1 mM, 30 min, Figure 4.12). One-way ANOVA and Bonferroni’s multiple 
comparison analysis of the results (media control vs. treatment) showed a 
significant increase of ROS production upon treatment with H2O2 (1 mM, 30 
minutes). In contrast, the RSP extract (0.25-1.0 mg/mL) was not associated 
with a significant increase in ROS production after 24 hour treatment 
(p>0.05). 
m
ed
ia
H
2O
2
1.
0
0.
75
0.
50
0.
25
 
0
2
4
6
8
10
12
%
 f
lu
o
re
s
c
e
n
c
e
(a
t 
9
th
 d
e
c
a
d
e
 o
f 
1
s
t 
lo
g
)
***
RSP extract (mg/mL)
ns ns ns ns
 
Figure 4.12| ROS production in SH-SY5Y cells caused by H2O2 control 
(1 mM, 30 min) and different concentrations of RSP extract (0.25-1.0 
mg/mL) 
Statistical significant difference determined using One-way ANOVA and Bonferroni’s 
multiple comparison analysis compared to media control: ns-not significant; 
***p≤0.001, n=3 
However, in this set of data, the high fluorescence readings obtained for the 
H2O2 control skews the data. When taking a closer look, it appears as if the 
RSP extract is causing a slight concentration dependent increase in cellular 
ROS production. When removing the data obtained for the H2O2 control, the 
graph is less skewed (Figure A12, p.451). Although, One-way ANOVA with 
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Bonferroni’s multiple comparison does not show a significant difference in 
fluorescence between the treated and untreated cells a concentration 
dependent trend towards an increased ROS production at 1 mg/mL treated 
cells is visible. Since the increase was not significant all four concentrations 
were taken for further analysis. Especially as a minor increase in ROS 
production by the RSP extract treatment could trigger an antioxidant 
response on a molecular level in the cell, e.g. by activating Nrf2 (Figure 1.29, 
p.60) that could aid to decrease the oxidative stress caused by the addition 
of H2O2. 
In the following experiments, cells were pre-treated with RSP extract (0.25-
1.0 mg/mL) for 24 hours and then incubated with H2O2 (1 mM) for 30 minutes, 
to determine whether pre-treatment with the extract can decrease the 
amount of produced ROS in vitro. The results obtained (Figure 4.13, Figure 
A12 (p.451)- for example of raw data) clearly demonstrated the ability of the 
RSP extract to inhibit ROS production after H2O2 induced oxidative stress. 
Lower concentrations (0.25 and 0.5 mg/mL) showed a decreasing trend in 
fluorescence, hence a decrease in ROS production.  
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Figure 4.13| ROS production after pre-treatment with RSP extract 
(24 h) followed by treatment with H2O2 (1 mM, 30 minutes) 
Statistical significant difference determined using One-way ANOVA and Bonferroni’s 
multiple comparison analysis compared to H2O2 control: *p≤0.05; **p≤0.01; 
***p≤0.001, n=4 
Higher concentrations of RSP extract (0.75 and 1.0 mg/mL) show a statistical 
(One-way ANOVA and Bonferroni’s multiple comparison analysis) significant 
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decrease in fluorescence compared to the H2O2 control. This decrease in 
fluorescence implies a decrease of ROS production in the SH-SY5Y cells. Thus, 
the two highest concentrations (0.75 and 1.0 mg/mL) of the RSP extract are 
successful in significantly preventing ROS production as a result of H2O2-
induced oxidative stress. 
As previously described for the cell viability study, this is the first time, RSP 
extracts activity towards a decrease of ROS production in SH-SY5Y cells is 
reported. However, other plant extracts have previously shown similar effects 
in vitro520,569. In a paper by Park et al.520, a Liriope platyphylla extract (0.5-
50 µg/mL) deceased ROS concentrations measured in SH-SY5Y cells stressed 
with H2O2 (100 µM). Similarly, in a paper by Wang et al.569 phenolic extracts 
of Inula helenium, decreased ROS production at 0.5 and 5 µg/mL 
significantly. In contrast to these two papers, where pre-treatment with the 
extracts occurred for one and six hours respectively, we pre-treated the cells 
for 24 hours with the RSP extract. 
ROS are well known to cause oxidative stress (1.4.1 Oxidative stress, p.53 
ff.) within a cell system. This oxidative stress can amongst others lead to DNA 
strand breaks (nuclear). Following the above results, it was decided to extend 
the experiments to study whether (i) ROS generated by H2O2, can inflict SH-
SY5Y cellular DNA damage and (ii) RSP extract can provide cellular DNA 
protection from H2O2-induced DNA strand breakage using the comet assay. 
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4.3.3 Protection of SH-SY5Y cells by RSP extract 
from H2O2-induced DNA strand breakage-Comet 
assay 
To determine whether the RSP extract is not only able to protect pBR322 
plasmid DNA from oxidative stress induced damage (3.3.8 Inhibition of 
supercoiled plasmid DNA strand breakage, p.201 ff.) but also cellular nuclear 
DNA, here the comet assay was applied. In Figure 4.14 below an overview of 
the classes of comets scored during this experiment with SH-SY5Y cells, 
ranging from 0 (no DNA strand breaks) to 4 (significant amount of DNA strand 
breaks) is given. The scoring was done according to Collins541 (Table 4.5, 
p.234). The comets obtained from this cell line look very similar to those 
obtained from other cell lines, such as lymphocytes in Collins541. 
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Figure 4.14| Images of comet classes obtained for SH-SY5Y cells  
Score 0-4 (Leica DMRB microscope (100x) with Leica DFC 300FX camera (0.63x), size of 
pictures decreased to fit page) 
Comet score=0 Comet score=1 
Comet score=2 Comet score=3 
Comet score=4 
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Before conducting the experiments to study the protective properties of the 
extracts, the DNA strand breakages caused by different concentrations of 
H2O2 (100-1000 µM) were assessed first. Ideally a concentration of the 
stressor should be chosen that inflicts a significant amount of damage 
(arbitrary unit (AU) score between 200 and 300) but does not cause 
detrimental DNA damage and eventually cell death. In the SH-SY5Y cells, the 
controls had a mean score value of 6.9, when scoring 100 comets on 3 gels 
each and determining the mean (Figure 4.15). With increasing concentrations 
of H2O2, the comet score increases in a concentration dependent manner: 
100 µM 44.4 < 200 µM 197.7 < 300 µM 263.8 < 500 µM 360.4 < 1000 µM 
382.3. 
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Figure 4.15| Concentration dependent DNA strand breaks induced by 
H2O2 (30 minutes) 
Statistical significant difference using One-way ANOVA and Bonferroni’s multiple 
comparison analysis compared to media medium control: ***p≤0.001, n=3 
Based on the above results, the decision was made to use a concentration of 
300 µM H2O2 the protection study of RSP extract. At that concentration a 
significant amount of DNA damage (p<0.001) compared to the media control 
was observed, but the DNA is not a strongly damaged as for 1000 µM. Hence 
a protection study of the DNA by the extract is possible. In addition, another 
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H2O2 concentration of 1000 µM was used as in a previous experiment this 
concentration was able to induce ROS (4.3.2  Protection of SH-SY5Y cells by 
RSP extract from ROS induced by H2O2, p.241 ff.). RSP extract 
concentrations used in the comet assay were also based on the results of the 
ROS experiment, in which 1 mg/mL of the RSP extract showed the best 
inhibition of ROS production (Figure 4.13, p.242), so this concentration was 
taken forward for the comet assay. Figure 4.16 shows the results obtained 
for the comet assay, using both concentrations of H2O2 and comparing 
between media and RSP extract treated cells. 
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Figure 4.16| Cellular DNA protection from H2O2  induced DNA strand 
breaks  by the RSP extract (1mg/mL, 24 h preincubation) 
Protection from 300 µM H2O2 induced strand breakage (but not 1000µM), statistical 
significant difference using Two-way ANOVA and Bonferroni’s multiple comparison 
analysis compared with media control at the same level of H2O2 (**p<0.01), n=4 
As previously shown the media control shows little DNA damage (10.6). The 
same is true for the RSP treated control (no H2O2), with a mean comet score 
of 8.7. No significant difference between both were observed, indicating the 
presence of the RSP itself does not cause any DNA damage in SH-SY5Y cells. 
For the H2O2 treated cells comet scores showed increasing DNA strand 
breakage as previously determined (Figure 4.15, p.246). Here, 300 and 1000 
µM H2O2 gave comet scores of 266 and 351 respectively. When pre-treating 
cells with the RSP extract (1 mg/mL, 24 hr) followed by the addition of H2O2, 
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a significant (p<0.01) protection from DNA damage was observed for the 300 
µM H2O2 treatment (Figure 4.16, p.247). In contrast, no protection was 
observed for 1000 µM H2O2. The latter concentration led to severe stress 
(DNA strand breakage) that the protective properties of the extract were not 
effective to protect the cells from the DNA strand breaks. 
It is noteworthy to mention that this is the first study in applying RSP extract 
for the protection of cellular DNA from H2O2 induced DNA strand breaks. In 
general, there is limited supporting evidence in the literature for the use of 
natural compounds/extracts to prevent DNA strand breakage in SH-SY5Y 
cells.  
Kim et al.570 had previously demonstrated similar 
positive comet assay outcome by applying a pre-
treatment with phloroglucinol (1,3,5-
trihydroxybenzene). Phloroglucinol is a phenolic 
(phlorotannin) commonly found in in Ecklonia 
cava (brown algae) of the family Laminariaceae. 
In their paper phloroglucinol showed to be more 
toxic towards SH-SY5Y cells than the RSP extract. Concentration starting at 
40 µg/mL showed a decrease in cell viability in the MTT assay. However, they 
were also able to demonstrate that phloroglucinol can prevent high ROS 
levels, induced by H2O2 (0.8 mM). Similarly, to our findings, they were also 
able to show the protection from DNA strand breaks using 10 µg/mL 
(concentration found to be safe for cells). Also Ghosh et al.419 found DNA 
protective properties in the comet assay using boysenberry and blackcurrant 
extracts (phenolic or anthocyanin rich). However, they failed to detail the 
concentration of H2O2 used and for the comet assay they also switched cell 
lines from SH-SY5Y cells (toxicity/ROS) to HL-60 cell, for which no particular 
reason was given.  
DNA, as well as protein and lipid damage in neuronal cells (Figure 1.27, p.54) 
are known to play a key role in the development of neurodegenerative 
disease. Compounds able to protect DNA from strand breakage as well 
decreasing ROS levels when under oxidative attack, could be potential 
candidates for the prevention and treatment of these neurological disorders. 
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More studies into DNA protection of RSP extract are necessary, to determine 
the mode of action. One explanation for the protection of SH-SY5Y cells by 
RSP extract seen in both the ROS experiment and the comet assay is their 
direct antioxidant activity. However, the extracts could also provide cellular 
protection due to their potential indirect antioxidant activity through the 
activation of antioxidant pathways within the cell system (1.4.3 Exogenous 
antioxidants - natural products: direct and indirect antioxidant activity, p.58 
ff.). The literature suggests, that a number of different extracts/isolated 
compounds activate for example the Nrf2 pathway both in vitro and in vivo. 
Curcumin (turmeric), sulforaphane (broccoli) and resveratrol (grapes) are 
only some of the compounds known to activate Nrf2 expressions, followed by 
the activation of antioxidant and detoxification enzymes229,571. To further 
investigate the extracts effect in vitro, molecular analysis on the extracts 
effect on cell stress proteins was undertaken. 
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4.3.1 Study into the cell stress related protein 
expression induced by RSP extract using micro 
array technology 
As demonstrated in the ROS and comet assay, the RSP extract shows no 
significant increase in cellular stress (ROS) or DNA damage. To verify these 
observations at molecular levels, the human cell stress protein array was 
used. Media control cells were compared to cells incubated with RSP extract 
for 24 hours. All the cell stress proteins under investigation are listed in Table 
4.6. 
Table 4.6| Human cell stress proteins included in the protein array556 
Coordinate Colour Analyte/Control Alternative name 
A1, A2, A21, 
A22, E1, E2 
 Reference Spot / 
B3, B4  ADAMTS1 / 
C3, C4  HIF-2α EPAS1 
D3, D4  
Phospho-p38 
(T180/Y182) 
 
B5, B6  Bcl-2  
C5, C6  Phospho-HSP (S78/S82)  
D5, D6  Phospho-p53 (S46)  
B7, B8  Carbonic Anhydrase IX CA9 
C7, C8  HSP60  
D7, D8  PON1  
B9, B10  Cited-2  
C9, C10  HSP70  
D9, D10  PON2  
B11, B12  COX-2  
C11, C12  IDO Indoleamine 2,3-dioxygenase 
D11, D12  PON3  
B13, B14  Cytochrome c  
C13, C14  
Phospho-JNK Pan 
(T183/Y182) 
 
D13, D14  Thioredoxin-1  
B15, B16  Dkk-4  
C15, C16  NFκB1  
D15, D16  SIRT2 Sirtuin 2 
B17, B18  FABP-1 L-FABP 
C17, C18  p21/CIP1 CDNK1A 
D17, D18  SOD2 MnSOD 
B19, B20  HIF-1α  
C19, C20  p27 Kip1 
D19, C20  Negative control Control (-) 
Note(s): Colour coding in accordance with  Figure 4.17 schematic 
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Figure 4.17| Developed films of human cell stress protein arrays 
Comparing media control (left) to RSP extract treatment (right). Schematic on far right showed the analysed proteins colour coded in association 
with Table 4.6 
Media control RSP extract treated (1mg/mL) 
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The developed films (Figure 4.17, p.251) of the human cell stress protein 
array show a slight reduction in intensity for most of the investigated proteins. 
To verify the visual indication of a decrease in cell stress protein expression 
after RSP extract (1 mg/mL) treatment, the intensity of the spots was 
analysed and graphed (Figure 4.18). 
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Figure 4.18| Expression of human cell stress proteins in SH-SY5Y 
cells exposed to RSP extract (1 mg/mL, 24 h) in comparison to media 
control 
Values were normalized to the reference spots, statistical significant difference was 
determined using multiple t-test with Holm-Sidak correction (α=0.05), using adjusted 
p-values, **p≤0.01, ***p≤0.001, n=2 
As indicated by the visual observation, all the cell stress proteins except 
ADAMTS1 are slightly down regulated after RSP extract treatment. Only 
SIRT2 and SOD2 (white arrows in Figure 4.17, p.251)  were significantly down 
regulated. However, since the statistics were done using only two replicates 
for each condition, the results need to be taken carefully. Especially as the 
two replicates are not from independent experimental set-ups. To get a clear 
view on the effect of the extract on cell stress protein expression, 3 
independent experiments should be conducted. 
The enzyme SIRT2 (sirtuin2) is part of the histone deacetylase (HDAC) family 
of proteins that participate in a number of cellular functions and are important 
for aging, a major risk factor for many neurodegenerative diseases. In 
humans 7 sirtuins have been identified (SIRTT1-SIRT7)572, SIRT2 is a mostly 
cytoplasmic protein. In non-neuronal cells SIRT2 is associated with cell cycle 
regulation via the deacetylation of cytoplasmic substrates, including α-tubulin 
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(backbone for many cellular substructures like the mitotic and meiotic 
spindles and the intracellular cytoskeletal network573)574,575. Literature 
however found, that in neuronal cells microtubule acetylation is necessary for 
neuronal cell development and function. In addition, a number of well-known 
pathological issues in patients with neurological disorders (e.g. the 
accumulation of misfolded or aggregated proteins, abnormal mitochondrial 
trafficking and decreased synaptic connectivity) are microtubule-dependent 
cellular processes574. In Outeiro et al.572, the inhibition of SIRT2 has 
previously shown to rescue α-synuclein-mediated toxicity in in vitro and in 
vivo models of PD. Neuroprotection was also observed in a HD model by 
SIRT2 inhibition576. On the other hand, in a paper by Singh et al.577 over 
expression of SIRT2 in SH-SY5Y cells protected from rotenone 
(mitochondrial-) and diquat (cellular-) induced stress/cell death. In contrast 
to the papers given above, where SIRT2 inhibition showed positive effects in 
PD572 and HD576 models, Singh et al.577 demonstrated that SIRT2 inhibition 
enhanced α-synuclein aggregate formation in diquat or rotenone treated cells 
and overexpression reduced aggregation. The obtained different results are 
most likely due to the different treatments used to induce α-synuclein 
aggregates in Outeiro et al.572 A53T mutant α-synuclein overexpression 
directly aggregated in cellular and fly models whereas, in Singh et al.’s577 
study, α-synuclein aggregate formation was induced by oxidative stress577. 
Under basal conditions (no rotenone/diquat) no increase of aggregations was 
seen compared to the control. However, these varying results also show that 
a lot is still unknown regarding the importance of SIRT2 in neurodegenerative 
disease. 
Nevertheless, Wang et al.578 showed that SIRT2 expression is increased under 
caloric restriction as well as oxidative stress. As previously mentioned, SIRT2 
has deacetylation properties. When binding to FOXO3a, this leads to the 
reduced acetylation of this forkhead box O (FOXO) transcription factors, 
which increases FOXO DNA binding and so increased expression of its target 
genes, one of which is MnSOD (SOD2). This association is also seen in the 
protein array results. After treatment of the cells with RSP extract, both SIRT2 
and SOD2 protein expression were down regulated. 
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In humans 3 SOD enzymes exist (SOD1-3). SOD2 is a mitochondrial 
manganese-dependent superoxide dismutase (MnSOD), containing a single 
metal ion site579. It catalyses the reaction of superoxide (O2●-) to hydrogen 
peroxide (H2O2), before it can oxidize essential components such as DNA, 
proteins, or lipid (Figure 4.19)580. 
 
Figure 4.19|Reaction of superoxide to H2O2 catalysed by MnSOD 
(SOD2) 
Adapted from581,582 
SOD2 is generally upregulated under oxidative stress and is necessary to 
regulate levels of ROS. After the treatment with RSP extract the protein 
expression of SOD2 was decreased, which on the one hand means that the 
extract is not causing SOD2 related cell stress, which would otherwise lead 
to an increase of SOD2 expression. On the other hand, this downregulation 
could lead to increased damage when introducing oxidative stressors to the 
cells, as SOD2 is present in smaller amounts to counter act oxidative insult.  
To determine the cells reaction towards oxidative stress, it would be useful 
to analyse the cell stress proteins under e.g.  H2O2 -induced insult, when pre-
treated with RSP extract and in comparison, to the media control. An 
experiment like this could give an indication of which proteins are important 
for the protective effect of the RSP extracts in SH-SY5Y cells. In addition, 
further studies into the time dependent expression of these proteins could 
give a greater insight into the expression changes of stress related proteins. 
Currently the results only represent a single time point after RSP extract 
treatment (24h). Even though protein arrays are very useful in the detection 
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of several cell stress related proteins, they do not cover all the relevant 
cellular proteins which might be involved in the extracts potential to protect 
cells from oxidative stress induced damage. Since the extracts have 
previously shown in vitro antioxidant activity it would be interesting to 
determine the expression of a number of proteins involved in cellular 
antioxidant pathways. A few phytochemicals have previously been shown to 
not only have direct antioxidant activity but also indirect antioxidant activity, 
via the upregulation of endogenous antioxidant systems. One interesting 
pathway could be the Nrf2 (nuclear factor erythroid 2 [NF-E2]-related factor 
2)-Keap1 (Kelch-like ECH-associated protein 1)-ARE (antioxidant response 
element) pathway (1.4.3 Exogenous antioxidants - natural products: direct 
and indirect antioxidant activity p.58 ff.). This pathway is important in the 
cytoprotective responses to oxidative and electrophilic stress in cells583 and 
could be one pathway of action for the RSP extract.  
In general, the results obtained in this experiment should be taken cautiously. 
For the results obtained here, only two membranes for each condition were 
used. The cells used for all four membranes are from the same cell stock. No 
biological replicates were performed, using distinguished cell stocks. The 
replicates obtained here are technical replicates for the experimental set up 
rather than biological replicates. For verification of the results obtained here, 
the same experiment should be repeated additional two times, to have 3 
biological replicates with two technical replicates each. We also need to 
consider that neuroblastoma cells were used, not differentiated or primary 
neurons, which might show slightly different reactions towards the treatment 
with the RSP extract. However, this is still the first recorded study into the 
activation of cell stress related proteins after treatment with RSP extract and 
so enhances knowledge on the possible revalorisation of food “waste” for the 
potential treatment or prevention of neurodegenerative disease.  
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4.3.2 AChE inhibition study by RSP extract in SH-
SY5Y cells 
In chapter “3.3.6 AChE inhibition potential” (p.194) the inhibition of  the 
enzyme AChE by the RSP extract was clearly demonstrated in vitro. To 
determine whether such activity is observed at cellular level, neuroblastoma 
SH-SY5Y cells were used. The latter were treated with RSP extract (1 mg/mL) 
and positive control neostigmine (100 µM) for 24 hours and their AChE 
inhibition activity monitored. The neostigmine concentration (100 µM) was 
chosen after initial toxicity measurement using the MTT assay (Figure A14, 
p.452). The results obtained for the AChE activity in the cell samples are 
shown in Figure 4.20 below. 
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Figure 4.20| AChE activity in SH-SY5Y cells  
After treatment with RSP extract (1 mg/mL) and neostigmine (100 µM) for 24 hours, 
n=4 
Treatment of the cells for 24 hours with neostigmine, a known AChE inhibitor 
shows no significant difference in AChE activity within the assay. In contrast, 
an increase in AChE activity is observed after treatment with RSP extract. 
These results contradict the expectations. The hypothesis was to see a 
decrease in AChE activity for both treatments in comparison to the media 
control, as both had previously demonstrated AChE inhibition activity (Figure 
3.33, p.196). Literature research for a potential explanation of this 
phenomenon led to the finding of a review by Kračmarová et al.584 on the 
possibility of AChE overexpression in AD patients after treatment with AChE 
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inhibitors. Only measuring the AChE activity after 24 hour treatment could 
have led to the obtained results. Not many papers were found that analyse 
compounds AChE inhibition activity in a cell-based system, most research just 
employs simple in vitro methods such as described in chapter 3. In a study 
by Santillo and Liu585, cells were co-incubated with AChE inhibitors, including 
neostigmine, and the Amplex Red mix and ACh and the AChE activation 
measured immediately. A similar approach was taken by Li et al.586, where 
cells were left to attach overnight, treated for one hour and the reaction mix 
added thereafter for AChE activity measurement. Those experiments suggest 
that the AChE inhibition takes place well before the end of the 24 hours 
treatment undertaken in this study, suggesting shorter time points of 
treatment (e.g. 30 minutes to 2 hours) and the analysis of AChE activity 
thereafter would be more appropriate. In the experiments mentioned above 
cells were not lysed, the assay was conducted in the wells directly, where the 
cells were seeded, however, Li et al.586 suggested an interference with the 
culture media, which is why it was decided to use cell lysates instead. Using 
cell lysates makes it also possible to analyse data at the same protein 
concentration. By measuring the AChE activity in the well directly, the 
assumption is made that the same number of cells was present in all wells. 
Initially the 24 hours treatment were chosen to keep the experimental set up 
similar to the previously undertaken experiments discussed above. In 
hindsight this was the wrong decision. There is still the potential to see AChE 
inhibition by the extracts within the cell systems by applying shorter 
treatment time. 
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4.4 Conclusion/Future Work  
In this chapter we were able to demonstrate some of the RSP extracts in vitro 
cell activity. Initially the extracts toxicity towards SH-SY5Y neuroblastoma 
cells was found to have an IC50 of 2.75 mg/mL. Concentrations below 1.5 
mg/mL showed no significant cell toxicity compared to the media control. 
However, it was decided for subsequent experiments to work with extract 
concentrations of 1 mg/mL or below, for safety reasons, since at 1.5 mg/mL 
showed a slight trend towards lower cell viability (Figure A 10, p.449). Using 
1 and 0.75 mg/mL of RSP extract showed a significant protection of SH-SY5Y 
cells from H2O2-induced ROS production. Also, lower concentrations (0.25 and 
0.5 mg/mL) showed a trend towards cell protection from oxidative stress. In 
the comet assay the RSP extract (1 mg/mL) showed no increase in DNA 
damage compared to the media control. Induced DNA damage by H2O2 (300 
µM) was significantly reduced by pre-treatment with 1 mg/mL of the RSP 
extract. Higher levels of DNA strand breaks induced by 1000 µM H2O2 could 
not be prevented by the extract. When determining expression of cell stress 
proteins after treatment with RSP extract, a general down regulation of the 
analysed proteins was observed. This decreased expression was only 
significant for SOD2 and SIRT2 proteins. Overall these results indicate that 
the extract is not causing any harm towards the cells at concentrations of or 
below 1 mg/mL. Unfortunately, the AChE inhibition activity of the extract 
found in vitro was so far not verified in the cell based assay for the tested 
time point (24 hours). Additional studies need to investigate AChE activity at 
time points before 24 hours treatment. 
Further studies would include studying the concentration dependent DNA 
protection as well as DNA repair within the cells. Furthermore, different 
pathway of action, for the RSP extracts observed effect, should be 
investigated (e.g. Nrf2, NFκB, ERK1/2). The cell stress protein array showed 
the downregulation of some tested cell stress proteins, however, there is still 
the potential of the activation of other maybe antioxidant pathways such as 
those regulated by the Nrf-2 transcription factor, which might be responsible 
for the seen effect of the RSP extract. Further studies should also investigate 
sinapine, as the most abundant compound found in the extract, for its 
potential positive activity within the same cell line. To produce more 
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neurodegeneration significant output, it might also be advantageous to 
repeat the experiment on differentiated cells or primary neurons.  
Although cell based in vitro assays have the advantage over chemical assays 
to determine both direct and indirect antioxidant activity, however, they still 
have their limitations319 and are not representative for in vivo activity. For 
this reason, further in vivo studies were undertaken in the model organism 
C. elegans, to determine the potential application of RSP extracts for the 
treatment/prevention of neurodegenerative diseases.
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5 AN IN VIVO STUDY OF THE 
ANTIOXIDANT AND 
NEUROPROTECTIVE PROPERTIES OF 
RSP EXTRACT IN C. ELEGANS 
NEMATODE MODELS 
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This chapter covers the in vivo work undertaken using the RSP extract. The in vivo 
model of choice was the nematode C. elegans. After initial toxicity analysis of the 
RSP extract, its effect towards the phenotypes of one Machado-Joseph disease (MJD, 
SCA3) and three different Parkinson’s disease models was studied. To determine the 
mechanism of action of the RSP extract, two hypotheses were tested (i) the AChE 
inhibition and (ii) the antioxidant activity, using reporter and knock out strains.  
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5.1 Introduction  
5.1.1 C. elegans 
Model systems have become fundamental for the elucidation of mechanisms 
associated with complex neurodegenerative disease587. Currently, the most 
commonly used research organisms with a functional nervous system are 
rodents such as mice (Mus musculus) and rats (Rattus norvegicus) as well as 
the fruit fly (Drosophila melanogaster) and zebrafish (Danio rerio)506. In 
addition, there is one more organism whose impact has increased significantly 
over the last 40 years especially in the field of neuroscience, Caenorhabditis 
elegans (C. elegans), the organism of choice for this project. In the C. elegans 
research community, the nematode is often referred to as “the worm”, so 
following C. elegans is referred to as nematode, worm or animal.79 C. elegans 
research has increased so much, mainly due to the many advantages over 
other model organisms, some of which are highlighted in Figure 5.1 and will 
be further discussed throughout the chapter. 
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Figure 5.1| Advantages of C. elegans as research model organism 
Aadapted from Pohl79 
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5.1.1.1 General biological properties and genetic background of C. 
elegans  
Caenorhabditis elegans (scientific classification: Table 5.1) is a soil living non- 
hazardous, -infectious, -pathogenic and -parasitic soil living nematode 
(roundworm) found in many places of the world588–590.  
Table 5.1| Scientific classification of C. elegans 
Kingdom Wormia 
Phylum Nematoda 
Class Secernentea 
Order Rhabditida 
Family Rhabditidae 
Genus Caenorhabditis 
Species Caenorhabditis elegans 
Note(s): adapted from Wood588  
In the laboratory worms are fed with OP50, an uracil-requiring mutant of E. 
coli. This strain is used to prevent overgrowth of the bacterial lawn (limited 
uracil in the nematode growth media (NGM) media), which would obstruct 
the worms591. 
Just like other nematodes, C. elegans has a small, cylindrical body, consisting 
of only one segment, which becomes conical towards the head and tail region 
(Figure 5.2)592. There are two sexes, males (X0) and self-fertilising 
hermaphrodites (XX). The wild type (N2) hermaphrodite worms are between 
1-1.5 mm593 in length and about 80 µm in diameter once they reach adult 
age (~day 4 under normal laboratory conditions)588,591,593,594. Both sexes can 
be distinguished from each other via their size and tail shape at the adult 
stage. Hermaphrodites are slightly larger than males, but in comparison to 
males they lack the fan shaped tail (Figure 5.2 (arrows), p.264). One 
anatomical advantageous feature in the C. elegans, is its transparency, which 
is demonstrated in the brightfield microscopy images presented in Figure 5.2. 
This transparency is sustained throughout the whole life cycle of the worm79. 
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Figure 5.2| Microscopy images (bright-field illumination) and 
schematics of hermaphrodite and male C. elegans 
Indicating major anatomical features; Top: adult stage hermaphrodite producing 
progeny Bottom: adult male, bar =20 µm; Reprinted with permission from Sulston et 
al.595, with slight modifications 
By producing oocytes as well as sperm, hermaphrodites are able to reproduce 
by self-fertilisation (inbreeding). In addition, they can be fertilised by males, 
however, hermaphrodites are not able to fertilise each other588. Most often 
males occur through breeding (up to 50 %) whilst hermaphrodites through 
self-fertilization rarely produce male offspring. However, males offspring can 
occur, via meiotic non-disjunction of the X chromosome (0.1-0.2%), from the 
hermaphrodite animals596. During their reproductive life span, the self-
fertilising hermaphrodites can produce about 300 progenies. This number is 
regulated, by the limited supply of sperm in hermaphrodites. However, when  
fertilisation occurs through males, the number of progeny can rise to about 
1200-140079,588. In the laboratory and for most experiments, hermaphrodite 
C. elegans are employed. However, males are used regularly for breeding 
(crossing). Hence for the rest of this thesis, hermaphrodite C. elegans will be 
referred to as C. elegans while when referring to males, an indication of the 
sex will be given. 
Under optimal conditions (sufficient food availability), the life cycle (Figure 
5.3) of C. elegans takes only about 3-4 days from the fertilized egg to the 
adult stage; this is however dependent on the strain and temperature. The 
Hermaphrodite (XX) 
Male (X0) 
Chapter 5: An in vivo Study of the Antioxidant and Neuroprotective Properties of RSP 
Extract in C. elegans Nematode Models 
 265 Franziska Pohl 
embryonic development from the zygote (one cell) to the L1 larva (558 cells) 
only takes 12-14 hours. During that tima a total of 671 cells are generated 
some of which undergo controlled cell death. So, the L1 stage larva hatches 
with a total number of 558 cells 222 of which are neurons597. This complete 
cell lineage of the embryonic development was tracked from fertilization 
through hatching as early as 1983 by Sulston et al.598. To pass from the L1 
larva to the adult stage with 959 somatic nuclei only takes another 45-50 
hours post-hatching for wild type animals (room temperature).  
 
Figure 5.3| Complete life cycle of C. elegans  
From the egg to the adult stage, with the time the organism spends in every stage, 
reprinted with permission from WormAtlas592 
Thereafter, the worm is fertile for approximately 4 days and usually lives for 
another 10-15 days afterwards588, providing a general lifespan of about 20 
days for wild type C. elegans. However, there is also a facultative diapause 
stage called dauer larva, which the L1 larva can enter. This happens if the 
habitat is crowded, starved of food or when the temperature rises above the 
optimal conditions. They can survive in this dauer larva stage up to 4 
month.592 Of great advantage is also the worms (L1s and L2s) potential to 
survive a slow freezing process (-80°C or liquid nitrogen), this makes it 
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possible to undertake experiments on the same stock of worms, without the 
need for continuous culturing. 
The adult hermaphrodite consists of only 959 somatic cells, whilst the males 
are made up of 1031 cells (381 neurons). Of these 959 cells in a 
hermaphrodite, almost a third, that is 302, are neurons592. The anatomy and 
cell number of C. elegans are highly invariant, with each worm having the 
same number of cells599. 
The genome of C. elegans is diploid and consists of 5 pairs of autosomes 
(chromosome I-X), all of which have similar sizes, and one pair of x 
chromosomes (hermaphrodites, XX) or one x chromosome (males, X0)600.  
The whole genomic sequence was first published in 1998 with final changes 
up until 2002601. This made C. elegans the first completely sequenced 
multicellular organism.  
Genetic mutations are part of the natural course of life and so form part of 
natural selection. In the laboratory environment however they are 
exceptionally useful to decipher gene functions. In C. elegans, forward 
(genome-wide mutagenesis) and reverse (target-selected and gene-specific 
mutagenesis) genetic studies are possible602. These methods are used to 
create and find new mutations together with their phenotypic impact. They 
are also employed to create disease specific mutants, which can then be used 
for drug screenings (5.1.2 C. elegans disease models and their application in 
neurodegeneration). Before any such drug screenings, usually the toxicity of 
drug candidates is tested to determine safe working concentrations within the 
nematode model. The advantages and disadvantages for using C. elegans in 
toxicity tests are detailed following. 
5.1.1.2 C. elegans for toxicity screenings 
The current ‘gold standard’ for toxicity tests is still based on mammalian 
model organisms, however, even these do not always predict accurate and 
reliable toxic effects for humans. In addition, they are expensive and time 
consuming as well as ethically questionable. The aim of research in 
toxicology, is to find alternative methods, which can provide better 
predictions for human outcomes while reducing costs, time and use of 
mammals in toxicity assessments589. C. elegans in conjunction with many 
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alternative methods (cell culture, mathematical models or in silico) or non-
mammalian organisms could help to achieve this aim. 
C. elegans, unlike cell cultures, toxicity results come from a whole organism 
with an intact and metabolically active digestive, reproductive, endocrine, 
sensory and neuromuscular systems589. However, C. elegans also has its 
limitations as it lacks certain organs (e.g. heart, lungs and kidney) and the 
circulatory system found in mammals. Furthermore they lack an adaptive 
immune system (only have innate immune system), which allows for immune 
response in mammals.603 One additional concern in the C. elegans toxicity 
studies, is the worm’s drug uptake and the question of treatment methods. 
Different methods of treatment have been used in a variety of studies, hence 
making comparison amongst them difficult. The most commonly used  
treatment options and their drug uptake were studied by Zheng et al.604. 
Several more advantage and disadvantages of C. elegans in toxicity studies 
are summarised by Hunt589. Although toxicity read outs from C. elegans alone 
might not be ideal to determine safe concentrations of compounds in humans 
or other mammals, it is still valuable for determining toxicity within the 
species to obtain safe working concentrations for further studies in the model 
organism. To determine the toxicity of compounds in C. elegans, a number 
of different assays can be used. For lethality or developmental delay, the food 
clearance assay can be employed605. 
Food clearance assay for the determination of toxicity and 
developmental delay 
This assay determines toxicity using the feeding behaviour of developing C. 
elegans. Initially worm eggs or L1 larvae are coalesced with the OP50 food 
source and the drug/compound of interest in multi-well (96-) plates. To avoid 
metabolism of the drug by the E. coli, the latter are most often inactivated 
via UV radiation, freeze-thawing or heat. The nature of the OP50 solution 
(brown-yellowish in colour) leads to an optical absorbance of the final mixture 
(worms, OP50 and drug) at 595 nm. This optical density is then monitored 
for 7 consecutive days, to determine developmental delay as well as toxicity 
(Figure 5.4, p.268). Healthy developing animals will start consuming the 
OP50 food source, after hatching. During normal development, the OD of the 
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wells will start to decrease on day 3-4 (start at egg stage), where the worms 
reach their adult stage. This is followed with a significant drop on day 5 as 
seen for the s-media control and the 1% DMSO treated animals in Figure 5.4 
(  and  respectively). This drop on day 5 is associated with the worm’s 
production of progeny and their requirement for additional OP50. However, 
when increasing the DMSO concentration to e.g. 2% the curve has a slightly 
different trend ( ). At this DMSO concentration, the optical density 
decreases approximately 1 day delayed. The latter is due to developmental 
delay of the animals, they reach adulthood one day later and hence produce 
progeny later. This impact is even more obvious at 3% DMSO ( ). At this 
concentration an even stronger developmental delay of about 2.5 days can 
be observed. When increasing the concentration even further (e.g. 5% Figure 
5.22, p.312), the OD does not decrease over the 7 days, which indicates 
toxicity. 
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Figure 5.4| Food clearance assay example readout for DMSO toxicity 
test  
Adapted from Pohl79 
This assay is particularly valuable for toxicity analysis, as it determines 
toxicity and developmental delay within one experiment using a simple read 
out of optical absorbance. It is relatively easy to perform and avoids long 
scoring of dead or alive animals manually. By using multi-well plates, 
replicates as well as different drug concentrations can be analysed in the 
same experiment. Additional experiments will also look into other readouts 
of potential toxicity, such as motility and numbers of neurons (5.1.2 C. 
elegans disease models and their application in neurodegeneration studies).  
Chapter 5: An in vivo Study of the Antioxidant and Neuroprotective Properties of RSP 
Extract in C. elegans Nematode Models 
 269 Franziska Pohl 
5.1.2 C. elegans disease models and their 
application in neurodegeneration studies  
For C. elegans as a model organism in neuroscience, the same advantages 
over other model organisms (Figure 5.1 p.262) apply as for general use of 
the nematode in research. However, there are also some additional and 
important benefits that need to be emphasised. The nervous system of C. 
elegans is fully differentiated and consists of a constant number of 302 
neurons, including a large somatic nervous system (282 neurons) and a small 
pharyngeal nervous system (20 neurons)606. Of great advantage is also the 
unique position and identity of every single neuron, making them 
reproducible from worm to worm. A complete connectivity map for these cells 
is available79,607,608. Due to the worms’ transparency, protein inclusions as 
well as neuronal cell death can be visualized using microscopy techniques, or 
be measured/quantified via different optical techniques and software 
programmes116. Many human related neurodegenerative disease associated 
genes can and have been expressed in this model organism, including the 
creation of Huntington’s, Parkinson’s, Alzheimer’s as well as Machado-Joseph 
disease models609–611. The availability of such models together with its many 
other advantages (Figure 5.1, p.262) makes C. elegans very attractive and 
useful for drug discovery screenings as well as drug target analysis in 
neuroscience and aging. 
Several models of C. elegans have been created for most neurodegenerative 
diseases including AD, ALS, HD, PD and MJD, which were reviewed by Chen 
at al. in 2015610. Here in this project, the focus was on two neurodegenerative 
disease states namely, MJD and PD with the aim to determine the potential 
use of RSP extract in the treatment/prevention of such neurodegenerative 
diseases. The MJD model was chosen due to preliminary positive results  
obtained from the RSP extract in this disease79. In addition, we decided to 
expand our study in the use of RSP extract using PD models. In particular in 
PD oxidative stress has been associated with the course of the 
disease209,612,613 and so these models provide a good model for testing the 
activity of RSP extract in vivo. 
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5.1.2.1 C. elegans model of Machado-Joseph Disease (SCA3) 
The C. elegans model of MJD was established in 2011 by A. Teixeira-Castro 
et al.614. This model (AT3q130), expresses human ataxin-3, with 130 CAG 
(polyQ) repeats, in all neurons. In addition, two other models (AT3q14 and 
AT3q75) were created expressing shorter lengths of the CAG repeats (14 and 
75 respectively). The expression of the different length ataxin-3 proteins is 
controlled by the promoter of the F25B3.3 gene. This gene is a C. elegans 
ortholog of the Ca2+-regulated Ras nucleotide exchange factor (RasGRP), 
which is exclusively expressed in the nervous system. Normal length (q14) 
and mutant (q75/130) ataxin-3 were tagged at the C-terminus with the 
yellow fluorescent protein (YFP) for visualization of the protein within the 
model organism614. 
When comparing the three created models, both models with shorter polyQ 
sequences (AT3q14 and AT3q75), showed a diffuse neuronal distribution of 
ataxin-3, the AT3q130 model however is associated with the presence of 
discrete aggregates (foci) in some neurons but diffuse expression in other 
nerve cells (Figure 5.5). Also observed, was a decreased life span and 
lethargy of the worms, compared to the other two models (AT3q14 and 
AT3q75).614 
 
Figure 5.5|Comparison of AT3q14, AT3q75 and ATq130 C. elegans 
strain 
Showing heterogeneity as well as discrete foci for AT3q130 in certain neurons, whilst 
the other two show a diffuse distribution of ataxin-3 (arrows show foci formation in 
AT3q130 at ventral nerve cord (VNC, thin arrow), dorsal nerve cord (DNC, thick arrow) 
and pharyngeal nerve ring (arrow head)), scale bar 100 µm, reprinted with copyright 
agreement from Teixeira-Castro et al.614   
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In addition to the visible protein aggregation phenotype observed in the 
neurons, the MJD model (AT3q130) was also tested for neuronal dysfunction, 
using behavioural assays. In C. elegans neuronal dysfunctions are closely 
associated with motility, since innervations of muscle cells in the nematode 
require more than 60 neurons. In cases where ataxin-3 aggregations had led 
to neuronal dysfunctions, a reduced motility can be expected together with a 
lack of coordination. This was confirmed when testing the motility behaviour 
for AT3q130 animals using the classic motility assay by Teixeira-Castro et al. 
(Figure 5.6)614. 
 
Figure 5.6| Locomotion defect of AT3q130 in the classical motility 
assay 
Increase in polyQ-length is associated with a higher percentage of locomotion deficiency 
of age-synchronised young adult worms (day 4, post-hatching), reproduced with 
copyright permission from Teixeira-Castro et al.614 
When comparing AT3q130 with control animals (Q0) of the same age, a 
significant motility deficiency was observed, when using the classical motility 
assay as read out (5.2.2.5 AT3q130 strain methods; I Motility determination, 
p.306). The susceptibility to mutant ataxin-3 aggregations and toxicity was 
also found to be neuron-type specific, as seen in human MJD patients. These 
findings make this model exceptionally interesting for research in MJD, since 
the presence of those two phenotypical characteristics (aggregations and 
motility deficiency) strikingly recapitulates key aspects of polyQ diseases in 
human patients615. Having these two phenotypical read outs makes it possible 
to test compounds and determine their effect on either of them, increasing 
the amount of information gained for the tested compounds from this MJD 
model strain.  
Previous research in the same lab group616, employed this model to screen a 
library of over 1000 mainly FDA/EMA-approved small molecules, to identify 
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compounds which can supress the mutant ATXN3 pathogenesis in vivo. In 
that study citalopram (selective serotonin reuptake inhibitor) was found to 
achieve this aim. Citalopram was able to decrease the motility deficiency of 
the AT3q130 strain significantly in 4 day old animals. This improvement was 
continuously seen even for 6-14 day old animals. In addition to improving the 
locomotion defect, citalopram was also able to decrease the number of 
aggregates per total area in the disease strain. These effects caused by 
citalopram were shown to be due to its action on serotonergic 
neurotransmission and modulation of serotonin mediated signalling. To prove 
that the inhibition of serotonin transporter by citalopram was responsible for 
the observed effect with a potential target of citalopram being MOD-5 
(serotonin transporter orthologue of the vertebrate SERT). Both, 
pharmacological and pharmacogenetic inhibition of MOD-5 were shown to 
restore motility and decreased the aggregation load of AT3q130 via 
modulation of serotonin transmission616. Similar approaches can hopefully be 
applied to determine the mode of action for the RSP extract in the MJD model.  
  
5.1.2.2  C. elegans  models of Parkinson’s Disease 
As previously described, PD can be caused by a number of different genetic 
and environmental factors (1.3.3 Parkinson’s Disease (PD), p.47 ff.), however 
the exact pathogenic pathways are still under investigation617.  Just like for 
AD, ALS, HD and other polyQ disease, C. elegans has been widely employed 
to study the role of these genetic and environmental factors contributing to 
the pathology of PD as well as to find potential treatment options.  
Maulik et al.618 and Chege et al.206 summarize a number of commonly used 
C. elegans strains for PD research, including mutant and non-mutant strains 
(i) expressing human (wild type) α-synuclein in body wall muscles (e.g. 
NL5901, OW13), (ii) expressing wild type (UA44, BY273) or mutant (A53T) 
human α-synuclein (JVR107, JVR203)  in neurons, (iii) studying leucine-rich 
repeat kinase (LRRK) and putative kinase 1 (PINK1) mutations and their 
contribution (SGC851, SGC856, JVR104, BR3646) (iv) examining the 
involvement of PARKIN (PARK2; C. elegans homolog pdr-1, VC1024), (v) 
overexpressing of tyrosine hydroxylase (UA57)  and (vi) those using 
chemicals such as 6-OHDA, MPTP/MPP+, insecticides or different metals as 
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inducer for DAergic neuron loss (N2, BZ555, BY250). Most of the above 
models have one feature in common, the loss or defect of DAergic neurons. 
Out of the 302 neurons in C. elegans, 8 are DAergic neurons, 6 in the head 
and 2 in the tail region of the animal. They have ciliated dendrites, which 
contact the cuticle and likely convey mechanosensory information. Ablation 
of these neurons, using lasers, and genetic studies had linked them to 
foraging, movement and egg-laying behaviors619. In the head there are four 
cephalic sensilla (CEP) neurons, two dorsal (CEPDL/R (left and right)) and 
two ventral (CEPVL/R) both of which are bilaterally paired. Their dendrites 
extend to the tip of the nose (Figure 5.7). 
 
Figure 5.7| C. elegans CEP neurons 
A: schematic of CEP neurons, reprinted with permission from WormAtlas620, B: confocal 
image of BZ555 (egIs1 [dat-1p::GFP]) showing Brightfield image on top of fluorescent 
image taken of same worm in same position (A, anterior; P, posterior; D, dorsal; V, 
ventral) by Andreia Teixeira-Castro 
In addition to the four CEP neurons situated just anteriorly of the terminal bulb 
of the pharynx, there are also two bilaterally paired anterior deirid neurons. 
These are situated posteriorly to the terminal bulb of the pharynx (Figure 5.8). 
 
 
 
A 
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Figure 5.8| C. elegans ADE neurons 
A: schematic of ADE neurons, reprinted with permission from WormAtlas620 B: confocal 
fluorescent imaging of ADE neurons in BZ555 (egIs1 [dat-1p::GFP]) animals (A, 
anterior; P, posterior; D, dorsal; V, ventral) by Andreia Teixeira-Castro 
Besides the 6 DAergic neurons situated in the anterior, there are two posterior 
deirid neurons (PDE), positioned next to dorsal body wall muscle along the 
lateral side of the posterior body (Figure 5.9). 
 
Figure 5.9| C. elegans PDE neurons 
Schematic of both the left and the right PDE neurons (A, anterior; P, posterior; D, 
dorsal; V, ventral) , reprinted with permission from WormAtlas620 
These three classes of DAergic neurons (CEP, ADE and PDE) are 
mechanoreceptor neurons (MRNs) responsible for sensing the 
mechanosensory stimuli from the food source (e.g. bacteria) and facilitate 
the motor circuit for necessary behavioural changes i.e. basal slowing 
response (well fed animals). This behaviour change is dependent on intact 
CEP, ADE, and PDE neurons and dopamine synthesis621,622. At a molecular 
level, these neurons have all the essential components involved in dopamine 
neurotransmission, including the proteins responsible for dopamine 
biosynthesis (Figure 5.10), vesicular packaging, and inactivation. Males have 
6 additional DAergic neurons in the tail, mainly responsible for mating 
behaviour619,623. 
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Figure 5.10| DA biosynthesis 
These DAergic neurons are lost in PD and so form the focus of PD studies in 
C. elegans. Most of the models reported by Maulik et al.618 showed specific 
DAergic neuron damage or loss. This damage can be minor i.e. outgrowth or 
branching of the DAergic neuronal dendrites, or more significant i.e. blebbing 
of the dendrites or complete loss of DAergic neurons and their dendrites 
(Figure 5.11, p.276)624,625. The reason why this damage occurs in patients is 
not completely elucidated yet. However, in C. elegans significant DAergic 
neuron damage can be created using chemical induced or genetic models of 
PD, as described by Maulik et al.618. 
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Figure 5.11| DAergic neuronal damage observed in genetic (UA44 
and UA57) and chemical induced (6-OHDA) C. elegans models of PD  
Scale bar 30 µm, confocal imaging by Andreia Teixeira-Castro  
To study the effect of RSP extract in PD, three different C. elegans PD models 
were used, two genetic models; UA44, expressing human wildtype α-
synuclein in combination with GFP in DAergic neurons; UA57, overexpressing 
tyrosine hydroxylase in combination with GFP in DAergic neurons and one 
chemical included model employing BZ555, expressing GFP in DAergic 
Wild type looking CEP 
neurons: 
All 4 CEP neurons (arrows) + 
dendrites (arrow heads) 
 
Major damage  
Outgrowth  Branching  
Dendrite blebbing + 
Cell body rounding  
Neuron and dendrite 
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neurons treated with 6-OHDA.  Further details on all three strains and the 
conditions used in the experiments are discussed following. 
Chemically induced C. elegans PD model using 6-OHDA 
To induce PD like phenotypes i.e. DAergic neuronal loss in C. elegans the two 
commonly used chemicals are 6-OHDA and MPTP/MPP+, but also other 
chemicals e.g. metals such as methyl mercury (MeHg), manganese and 
aluminium206,626 or rotenone and paraquat have previously be reported to 
induce DAergic neuron loss. Here in our study 6-OHDA, a hydroxylated 
analogue of the natural neurotransmitter dopamine was used (Figure 
5.12)627. 
 
Figure 5.12| Chemical structure for 6-hydroxydopamine (6-OHDA) 
compared to dopamine (DA) 
Due to its structural similarities, 6-OHDA can be recognized by the DA 
reuptake transporter and be transported specifically into DAergic neurons. 
The exact chain of actions by which 6-OHDA is causing DAergic neurotoxicity 
and cell death is currently still under investigation. However, there are a few 
considerations on how 6-OHDA acts within the cells and oxidative stress is 
assumed to play a significant role. One of the theories is that 6-OHDA causes 
oxidative stress, due to the blocking of complex I of the respiratory chain627. 
In addition, it has also been shown that 6-OHDA reduces glutathione (GSH) 
and superoxide dismutase (SOD) enzyme activity628 while increasing the 
levels of malondialdehyde629, a marker for lipid peroxidation, often associated 
with cellular ROS. C. elegans exposed to 6-OHDA, have shown gradual 
DAergic neuronal  death619. Selective DAergic neurodegeneration manifests 
itself as blebbing of processes, cell body rounding and eventual disintegration 
of DAergic neuronal cell bodies and dendrites loss. Reasons and pathways of 
DAergic neuronal death induced by 6-OHDA are still under investigation619,630. 
Several factors have been identified which regulate 6-OHDA induced toxicity 
in C. elegans, including dopamine receptor modulation, autophagy 
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inactivation, and ER chaperone function. In addition, as previously mentioned 
6-OHDA also induces mitochondria disruption626. 
For easy visualization of DAergic neuron loss, BZ555 worms will be employed 
for this experiment. This strain expresses GFP in all DAergic neurons (using 
Pdat-1 promoter) allowing visualisation of the 8 DAergic neurons under 
investigation. For note, the expression of GFP alone does not cause significant 
DAergic loss626. 
Genetic α-synuclein C. elegans PD model (UA44) 
The UA44 (bal11, Pdat-1::alpha-syn, Pdat-1::GFP) model, co-expresses 
human wildtype α-synuclein and GFP in the dopaminergic neurons, using the 
dopaminergic neuron specific Pdat-1 promoter470,625. The observed neuronal 
loss in this strain is age dependent. Young larval-stage animals show little 
degeneration, whereas older worms (day 6 till 10) show significant neuronal 
(DAergic) damage625,631,632. This model was first described by Cao et al. in 
2005625, where they showed that the co-expression of TorsinA, reduced 
neurodegeneration. TorsinA is a human protein, expressed in DAergic 
neurons and a component of Lewy bodies, often associated with 
neurodegenerative disease. Since then, the same model has been used in 
other studies, to (i) identify neuroprotective genes633,634, (ii) show the 
importance of antioxidant enzymes (e.g. glutaredoxin 1 (Grx1))635 in 
preventing exacerbate neurodegeneration  and (iii) test  compounds for their 
neurodegeneration preventative properties e.g. spermidine470, alpha-linolenic 
acid636 and valproic aicd637. The DAergic neuron loss can be scored using 
fluorescence microscopy, due to the co-expression of GFP in the DAergic 
neurons. In some studies, the UA44 strain is used in conjunction with 6-
OHDA, which leads to an earlier onset of DAergic neuronal loss636. 
In addition to DAergic neuron loss, the UA44 strain also shows a decrease in 
basal slowing response. Wild type well-fed worms will slow down in their 
movement, once they enter a bacteria lawn. This behaviour is dependent on 
intact DAergic neuro signalling. The damage of DAergic neurons in the UA44 
strain leads to a loss of basal slowing response, which increases with age635. 
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Genetic tyrosine hydroxylase overexpressing C. elegans PD model 
(UA57) 
The UA57 (bals4, Pdat-1::GFP and Pdat-1::CAT-2) strain overexpresses 
tyrosine hydroxylase (CAT-2) which is a rate-limiting enzyme for the 
production of dopamine. CAT-2 performs hydroxylation of the aromatic ring 
of the amino acid tyrosine (highlighted red in Figure 5.10) to form L-DOPA. 
By increasing the concentration of CAT-2 this reaction is enhanced and leads 
to increased levels of DA. The strain co-expresses GFP in the dopaminergic 
neurons, using the same DAergic neuron specific Pdat-1 promoter as for the 
UA44 strain. This strain was first introduced in a study by Cao et al. in 2005625. 
Similar to the UA44 strain, UA57 animals show age dependent DAergic 
neurodegeneration, less than 25% of seven day old animals retain all four 
CEP neurons. In contrast to the positive results of torsin co-overexpression 
in the UA44 strain, there was no significant increase in worms with wild type 
CEP neurons in the double mutant torsin/UA57 strain625. 
Overexpression of CAT-2 leads to an increase in dopamine synthesis. Under 
normal conditions, DA is rapidly stored in vesicles by vesicular monoamine 
transporter 2 (VMAT2), where a lower pH stabilizes it, limiting the 
concentrations of cytoplasmic DA617,638. Increased production of DA can lead 
to excessive amount of cytoplasmic DA, which  can cause a diversion from 
the normal metabolic sequence (oxidation via MAO-A and ADH to generate 
non-toxic 3,4-dihydroxyphenylacetic acid and hydrogen peroxide) and 
generate intermediates (dopamine-o-quinone and (dop)aminochrome) and 
further metabolites (e.g. leukodopamineochrome-o-semiquinone radical) all 
of which are endogenous neurotoxins. The latter are able to reduce oxygen 
to superoxide anion radicals or impact mitochondria, via NADH oxidation or 
directly affecting mitochondrial complex I which can result in neuro 
toxicity188,617,638,639. Metal ions (e.g. copper(II) and iron (III)) can aid in the 
catalysis of cytoplasmic dopamine oxidation188,640. A paper by Chege et al.206 
gives a great overview of the issues associated with PD, including CAT-2, 6-
OHDA and α-synuclein. Previous research has employed this model to identify 
compounds that prevent or treat the observed DAergic neuronal loss in C. 
elegans e.g. extracts from Sorbus alnifolia (traditional medicine in Korea)641 
as well as Chondrus crispus (red seaweed)642 were tested.  
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5.1.3 Determination of potential pathways of 
action using C. elegans as model organism 
In chapters 3 experiments using the RSP extracts were carried out to study 
AChE inhibition, DNA plasmid protection and antioxidant activity. 
Furthermore, in vitro studies, at cellular level, had shown the ability of the 
RSP extract to (i) prevent ROS formation and (ii) protect DNA from oxidative 
damage. Previous preliminary experiments using two RSP extracts, had 
shown positive improvements of the C. elegans MJD motility phenotype79. 
These results led to the research question of  ‘How does the RSP extract 
induce these observed effects?’ To address this question, multiple hypotheses 
for the mode of action of the RSP extract were considered. Two of these were 
thoroughly studied in this project using the C. elegans model: 
1. “The extracts AChE inhibition activity is responsible for the observed 
effects” (5.1.3.1) 
2. “The extracts antioxidant activity is causing the positive results” 
(5.1.3.2) 
5.1.3.1 AChE neurotransmission 
ACh  is the most widely used neurotransmitter in the C. elegans nervous 
system643. Acetylcholine neurotransmission is stopped by enzymatic 
hydrolysis by AChE, in the synaptic cleft (Figure 3.10, p.147). The produced 
choline is transported back into the presynaptic neuron and is again available 
for the synthesis of further ACh (3.1.3 Acetylcholinesterase 
(AChE)/Acetylcholinesterase inhibitors). AChE inhibitors are used in the 
treatment of various disease to improve the neurotransmission by Ach. In 
chapter 3 (3.3.6 AChE inhibition potential, p.194 ff.) the AChE inhibition 
potential of both RSP extract and sinapine was discussed. To determine 
whether AChE inhibition can improve the MJD disease phenotype (motility 
deficiency), pharmacological and pharmacogenetic methods were employed. 
For the pharmacological option neostigmine, a known AChE inhibitor will be 
used to treat the disease MJD model, to determine whether pharmacologic 
treatment using AChE inhibitors can help to reduce the locomotion deficiency. 
The pharmacogenetic method employed two AChE C. elegans knock out 
strains (ace-1 and ace-2), which were crossed with the MJD disease model to 
discover if genetic deletion of either of the two genes responsible for most of 
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the production of AChE could alleviate the disease phenotype. At the end the 
results can be compared to the results of the pharmacological model to 
confirm or negate the first hypothesis. 
C. elegans has four so far known ace genes, ace-1 to 4, compared to only 
one gene encoding AChE in vertebrates. These four genes encode three 
different pharmacological classes of AChE (A-C)644,645. The gene ace-1 
encodes AChE class A and produces about half of the AChE activity in the 
nematode646,647. Ace-1 mutants (knock out, Figure A15, p.453 f.) were found 
to be developmentally and behaviourally indistinguishable from wild type 
animals (N2). The gene can be found 
towards the end of the X 
chromosome646 and has 42% identity 
with human AChEs645.  A second ace 
gene, ace-2, which is located on 
chromosome I (not linked to ace-1), is 
a structural gene for AChE class B. A 
homozygous deletion (Figure A16, 
p.455 f.) of ace-2 also produces 
normal coordinated animals, thus 
suggesting that ace-1 is partially 
redundant functionally with ace-2. A double mutant of ace-1;ace-2 however 
leads to an uncoordinated phenotype with approximate 98% decrease of 
AChE in worms648. The expression pattern for both ace enzymes is different, 
with ace-1 being expressed in muscle cells and a few neurons, whereas ace-
2 is mainly expressed in the neurons644.  
A third class of AChE, class C, in C. elegans is encoded by the third ace gene, 
ace-3, and is located on chromosome II. Ace-3 is thought  to account for less 
than 5% of AChE activity649. Worms homozygous for ace-3 have no obvious 
behavioural phenotype. Also, double mutants ace-1;ace-3 and ace-2;ace-3 
have shown little difference in their movement from the wild type animals 
(except slightly slower behaviour on backwards movement). However, the 
triple mutant ace-1;ace-2;ace-3, lacks all three AChE classes (A,B,C), 
resulting in paralysis and late embryonic or early larval lethality (after 
hatching).650 In conclusion, ace function in C. elegans seems to be essential, 
Figure 5.13| Genes for AChE (ace1-
4) in the C. elegans genome 
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at least ace-3 function is necessary for viability, whereas for intact motor 
function either ace-1 or ace-2 are necessary. A fourth ace-4 gene exists, 
located just ahead of the ace-3 gene. This gene is believed to encode a non-
functional protein (biochemically undetectable activity)645.  
The information found on these AChE knockout strains, had led to the decision 
that for crossings with the motility deficient MJD model only single mutants 
for ace-1 and ace-2 are viable options to determine if a genetic decrease of 
AChE activity is be able to alleviate the locomotion defective phenotype. This 
experimental set-up would assist in determining whether hypothesis 1 is a 
possible explanation for the effect of RSP extracts in C. elegans. The 
hypothesis will further be tested using various concentrations of neostigmine, 
a pharmacological AChE inhibitor, in the MJD model. 
5.1.3.2 Antioxidant and detoxification pathway 
It has been shown, that antioxidant molecules can act not only by simply 
scavenging free radicals, but also by modulating the activity and/or 
expression of endogenous antioxidants (indirect antioxidant activity), such as 
super-oxide dismutase (SOD), catalase (CAT) and glutathione peroxidase 
(GPX) as well as other genes related to the clearance of ROS and xenobiotics 
(1.4.3 Exogenous antioxidants - natural products: direct and indirect 
antioxidant activity, p.58 ff.). That way, antioxidants can improve the 
endogenous defence system against oxidative stress and exogenous toxins. 
To determine the indirect antioxidant activity of compounds/extracts in vivo 
in C. elegans, a few options are available. Due to its transparent and thin 
(~80 µm) nature, C. elegans is easily amenable to the use of fluorescent 
probes. These can help to visualize oxidative stress within the nematodes in 
vivo. When these fluorescent probes are bound to certain antioxidant genes, 
reporter strains are created. Those reporter strains make use of e.g. the 
green fluorescent protein (GFP651) to visualize gene expression patterns. 
These include amongst others the visualization of proteins associated with 
oxidative stress652.  
Although the anatomy of C. elegans is rather simple, it has a complex ROS 
biology including several redox-active enzymes, similar to other model 
organisms and humans. These include genes for superoxide dismutase (sod), 
catalase (ctl), glutathione-S-transferase (gst) and glutathione peroxidase 
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(gpx)653–655, responsible for detoxification and oxidative stress resistance. 
Reporter strains for 3 genes were employed for this project (gst-4, sod-3 and 
gcs-1) and are described in more detail following. 
Phase II metabolic enzyme glutathione S-transferases (GST-4) 
Glutathione S-transferases (GSTs) are a group of cellular detoxification 
enzymes (phase II). This multifunctional enzyme family helps to detoxify both 
exogenously and endogenously derived toxic compounds by catalysing the 
conjugation of various electrophiles with glutathione (GSH), an important 
antioxidant. After catalysis with GSH, less toxic and more hydrophilic 
molecules are obtained, which can be metabolised and excreted. Organisms 
usually express various GSTs, with different substrate specificity and 
localization, leading to specialized functions. Based on data base sequence 
comparison, C. elegans is thought to have over 50 GSTs656,657. 
The gene gst-4 (sequence K08F4.7), situated at the beginning of the second 
half of chromosome IV, induces a nematode specific GST, known to be 
upregulated under oxidative stress caused by e.g. paraquat658 or hyperbaric 
oxygen659. It is an antioxidant response element (ARE) containing gene and 
so a direct target of the transcription factor skn-1 (ortholog of Nrf2), which 
can upregulate the expression due to oxidative stress and reactive 
electrophilic compounds660. 
In 2002, Link and Johnson659, created a reporter strain for gst-4 called 
CL2166 by introducing an oxidative stress-inducible reporter transgene using 
GFP as fluorescence indicator. This reporter was used by Leiers et al.656 in 
2003 for further studies and showed increased fluorescence intensity after 
treatment with oxidative stressors plumbagin (200 µM), paraquat (100 mM) 
and juglone (200 µM)656. Although short time exposure of these compounds 
can induce gst-4 activation, exposure to high concentrations of plumbagin661, 
paraquat and juglone662 for longer time periods can be toxic or lead to 
developmental delay in the nematode. Thus, compounds that can induce the 
expression of gst-4 without having negative side effects are of significant 
interest for the treatment of oxidative stress related diseases. Literature 
review has shown that for example trans-cinnamaldehyde D-(+)-camphor, 
phytochemicals found in Cinnamomum osmophloeum, demonstrated 
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increased gst-4 expression along with antioxidant activity against juglone-
induced oxidative stress in C. elegans663. Similar results were reported for 
curcumin, found in turmeric664; coffee extracts665 and garlic-derived thioallyl 
compounds666. Some of these tested compounds/ extracts were also found to 
induce sod-3, one of the other antioxidant related genes of interest in this 
study. 
Antioxidant enzymes superoxide dismutase -3 
Superoxide dismutase (SOD) is another group of redox-active enzyme that 
protects against oxidative stress by catalysing the reaction of O2●- into H2O2, 
which can be further converted to H2O and O2 by catalase, glutathione 
peroxidase or other enzymes (Figure 4.19, p.254)667. C. elegans has five sod 
genes (sod-1-5). Sod-1, 4 and 5 express Cu/ZnSODs, whereas sod-2 and 3 
are mitochondrial MnSODs654. The sod-3 gene can be found in the end of the 
x chromosome.  
As previously seen for the gst-4, also for sod-3 a reporter strain was created  
(CF1553 (SOD-3::GFP)), for which the expression of GFP is controlled by the 
sod-3 promoter668. Overexpression of sod-3 three leads to increased 
catalyses of O2●-, which can lead to decreased oxidative stress. Sod-3 is a 
target gene of daf-16, a with aging and longevity associated gene669,670.Other 
natural extracts/ compounds have previously been shown to activate sod-3, 
epigallocatechin gallate (EGCG, found in tea) for example significantly 
increased SOD-3 expression in the sod-3 reporter strain model while also 
decreasing oxidative stress, as shown by Zhang et al.671. 
GCS-1, enzyme of the cellular glutathione (GSH) biosynthetic 
pathway 
Reduced glutathione (GSH), a linear tripeptide, is a very abundant non-
protein thiol in many organisms, known to be a potent reducing agent. Many 
other cellular functions have been recently ascribed to GSH, triggering 
intense scientific interest in its biological properties. Impaired GSH synthesis 
is associated with various disease and disorders, including neurodegeneration 
and aging. GSH depletion and increased levels of oxidative stress in the brain 
are common. However, currently no drugs are available to increase brain GSH 
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levels, which might be associated with the issue that e.g. orally dosed GSH is 
rapidly degraded in the gut. Also GSH administered through intravenous 
injection is rapidly oxidized (half-life of 2–3 min), making the treatment with 
GSH unsuccessful672,673. GSH is produced intracellularly from three amino 
acids through two consecutive steps catalysed by γ-glutamylcysteine ligase 
(GCL, also known as γ-glutamylcysteine synthetase GCS) and GSH 
synthetase (GS) (Figure 5.14).  
 
Figure 5.14| GSH synthesis from Glu, Cys and Gly catalysed through 
-GCS and GS  
Adapted from Franco et al. 674 
Due to its catalytic action, γ-GCS seems to play a key role in regulating GSH 
homeostasis and thus has an impact on the capacity of cells to cope with the 
potential detrimental effects of oxidative stress. Hence, compounds which 
have the potential to up regulate the expression and activity of γ-GCS are 
considered potential treatment options675 . In C. elegans, gcs-1, which is 
induced by SKN-1 (homologue of human transcription factor Nrf2), is the 
gene encoding γ-glutamyl-cysteine synthetase (heavy chain). Gcs-1 is 
expressed at low levels under normal conditions in the intestines and ASI 
neurons (set of two ciliated neurons), but it is upregulated strongly by 
oxidative stress676,677. Gcs-1 regulation (just like gst-4 and sod-3) can be 
visualized using a reporter strain in which the gcs-1 promoter drives 
expression of GFP (gcs-1p::GFP)207. Previous research has shown that  willow 
bark extract is able to induce gsc-1 expression in intestinal cells in a skn-1 
dependent manner678. 
The Potential Application of Rapeseed Pomace Extracts in the Prevention and 
Treatment of Neurodegenerative Diseases 
286  Franziska Pohl 
Use of knockout mutants for further pathway of action elucidation  
Using these three reporter strains will help to elucidate whether the RSP 
extracts activity observed in the model organism could be associated with its 
indirect antioxidant activity on either of those genes. Should one of these 
proteins be significantly increased due to overexpression on the gene level, 
knockout mutants for these genes can be employed to determine the 
necessity of these genes for the positive effect of RSP extract in the disease 
models. However, to be able to test whether the gene is necessary for the 
RSP extract effect, the potential knockout strains (Table 5.2) need to be 
crossed with the disease strains. Here in this to work, the knockout strains 
themselves need to have a wild type phenotype (no motility deficiency or 
DAergic neuron loss,) because this would interfere with the assay.  
Table 5.2| Potential knock out strains for sod-3, gst-4 and gcs-1 
Name gene Nucleotide change 
GA186 sod-3(tm760) X. 715 bp deletion 
RB1823 gst-4&msp-38(ok2358) IV. 1548 bp deletion 
VC337 gcs-1(ok436)/mIn1 [mIs14 dpy-10(e128)] II. 837 bp deletion 
Once the double mutant strains are created (e.g. sod-3(ko);AT3q130), the 
motility assay can be repeated, both under control (DMSO control) as well as 
RSP extract treatment. If the RSP extract would be mostly independent of 
sod-3 activation, the motility assay would show a significant improvement of 
motility behaviour for both strains (AT3q130 and sod-3(ko);AT3q130) when 
treated with the RSP extract (Figure 5.15 A). However, if the RSP extract is 
acting mostly through activation of sod-3, there would be no motility 
improvement in the double mutant, as the gene, that RSP extract is acting 
on, is absent and the pathway of action is disrupted (Figure 5.15 B).  
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Figure 5.15| Hypothetical results for the RSP extracts’ dependence 
on expression of sod-3 using double mutants (sod-3(ko);AT3q130)  
A: independent and B: dependent on sod-3 expression  
Chapter 5: An in vivo Study of the Antioxidant and Neuroprotective Properties of RSP 
Extract in C. elegans Nematode Models 
 287 Franziska Pohl 
5.1.4 Objectives 
The list below describes the final objectives set out for this project to 
determine the extracts potential in preventing or treating neurodegenerative 
disease: 
- Assess the extracts in vivo toxicity 
- Determine the extracts effect an MJD C. elegans model on the: 
o motility deficiency and 
o neuronal ataxin 3 aggregations 
- evaluate the extracts effect on three different models of PD (neuronal 
lose) 
- measure the extracts activity on antioxidant reporter strains  
- determine whether the AChE inhibition activity could be responsible for 
the seen activity via pharmacogenetic and pharmacological pathways 
- establish whether the knock out of the most activated reporter gene 
from the reporter strains can inhibit the extracts activity 
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5.2 Materials and Methods 
5.2.1 Chemicals and Equipment 
The following chemicals/kits (Table 5.3) and equipment (Table 5.4) was used 
in the aid of the experiments in this chapter. 
Table 5.3| Chemicals, reagents and kits 
Chemicals Provider 
NaC Sigma Aldrich 
KH2PO4 Sigma Aldrich 
Na2HPO4*7H2O Sigma Aldrich 
MgSO4*7H2O Sigma Aldrich 
Bleach (5% sodium 
hypochlorite, non-germicidal) 
Sainsbury’s/Pavão 
NaOH Sigma Aldrich 
DMSO Sigma Aldrich 
Nystatin Sigma Aldrich 
Penicillin-Streptomycin Sigma Aldrich 
Ethanol Sigma Aldrich 
Cholesterol Sigma Aldrich 
Bacto Peptone BD Bioscience 
Bacto Agar BD Bioscience 
Glycerol Evans Medical limited BD 
Proteinase K Thermo Scientific 
Agarose (molecular biology 
grade) 
GeneON for 50bp-50kb  
Tris base Sigma Aldrich 
Glacial acetic acid Sigma Aldrich 
EDTA Sigma Aldrich 
Levamisol Sigma Aldrich 
PCR master mix M750C Pomega  
GreenSafe Premium dye nzytech 
GelRed dye Fisher Scientific 
Bacto Tryptone BD Bioscience 
Bacto Yeast Extract BD Bioscience 
KCl Sigma Aldrich 
MgCl2 Sigma Aldrich 
Triton-X100 Acros Organics 
Tween-20 Fisher Scientific 
Gelatin BDH 
Tripotassium citrate Sigma Aldrich 
FeSO4*7H2O Sigma Aldrich 
Na2EDTA Sigma Aldrich 
MnCl2*4H2O Sigma Aldrich 
CuSO4*5H2O Sigma Aldrich 
Citric acid monohydrate Sigma Aldrich 
KOH Sigma Aldrich 
ZnSO4*7H2O Sigma Aldrich 
Sucrose Fisher Scientific 
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Bromophenol Sigma Aldrich 
 
 
Table 5.4| Equipment 
Equipment Manufacturer/Details 
Incubator SANYO 
Vacuum system Vacusafe Comfort, BS Integra 
Biosciences 
Centrifuge Thermo, Heraeus Multifuge 3L-
R 
Water bath Memmert, WNE22 
Plate reader Tecan Infinite 200; Tecan 
iControl software 
Agitator Shel Lab, SI Series 
Flow chamber (RGU) Microflow M51424/2 classII 
Microscope Olympus, SZX16 
Confocal microscope Olympus FV1000 
Shaking incubator (OP50) Shel Lab, SI series 
Shaker (RGU) Stuart SI1600 
Incubator (RGU) Panasonic MMIR-154-PE 
Thermocycler Eppendorf Mastercycler 
epgradient S 
Centrifuge Heraeus Pico 17 
Gel pouring chamber and tank Bio-RAD Sub-Cell GT 
Power pack Consort E835 (300V-500mA) 
PCR thermocycler (ICVS) Eppendorf mastercycler 
epgradient S 
PCR thermocycler (RGU) iCycler BioRad 582BR 
Gel camera/software BIO-RAD Gel Doc TM EZ 
Imager, software: Image lab 
4.1 bio-rad 
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5.2.2 Methods 
The methods employed in this chapter (Figure 5.16) were used to study the 
effect of RSP extract on the in vivo model organism C. elegans. Different 
disease models for both MJD and PD were employed, to evaluate the potential 
use of RSP extract for the treatment or prevention of neurodegenerative 
disease. 
 
Figure 5.16| Overview of methods used to determine the extracts 
activity in different C. elegans models  
5.2.2.1 General maintenance/Strains 
C. elegans strains (Table 5.5) were maintained on nematode growth medium 
(NGM, Table A5, p.457 f.) seeded with living E. Coli bacteria (OP50) as food 
source591, unless otherwise noted. The OP50 solution for seeding was 
obtained by inoculating LB with OP50 bacteria and culturing overnight (16 h 
at 37°C, 150 rpm). OP50 solution was immediately seeded onto dried NGM 
plates or stored at 4°C. After seeding the plates were dried for 2-4 days and 
then used for C. elegans maintenance or stored at 4°C.  The NGM plates with 
worms were maintained at 20°C (SANYO incubator), unless described 
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differently. Worms were transferred (3-6 adult animals) every 4-5 days for 
general maintenance.  Table 5.5 below lists the used stains, with 
abbreviations referred to throughout the thesis, their genotype and place of 
origin, whereas Table 5.6 lists the strains created via crossing during this 
project.  
List of strains 
Table 5.5| List of strains  
Name  Abbreviation  Genotype  origin 
Wild type N2 wt CGCa 
AM510  
(Teixeira- Castro 
et al., 2011)  
AT3q14  rmIs228[PF25B3.3::AT3
v1-1q14::yfp]  
ICVS made 
AM685  
(Teixeira- Castro 
et al., 2011)  
AT3q130  rmls263[PF25B3.3::AT3
v1-1q130::yfp]  II 
ICVS made 
Ace-1 Ace-1 NA CGCa  
(6x BC by F.Pohl) 
Ace-2 Ace-2 NA CGCa  
(6x BC by F.Pohl) 
BZ555 BZ555 egIs1 [dat-1p::GFP]  
UA44 UA44 baIn11[pdat-1::aSyn + 
pdat-1::GFP] 
Caldwell Labb 
UA 57 UA 57 baIs4 [dat-1p::GFP + 
dat-1p::CAT-2] 
Caldwell Labb 
RB1823 Gst-4(ko) gst-4&msp-38(ok2358) 
IV. 
CGCa (6x BC by F.Pohl 
and V. Lindsay) 
CF1553 Sod-3 muIs84 [(pAD76) sod-
3p::GFP + rol-
6(su1006)] 
CGCa 
LD1171 Gcs-1 ldIs3 [gcs-1p::GFP + rol-
6(su1006)] 
CGCa 
CL2166 Gst-4 dvIs19 [(pAF15)gst-
4p::GFP::NLS] III 
CGCa 
Note(s): aCGC, funded by NIH Office of Research Infrastructure Programs (P40 
OD010440); b Guy and Kim Caldwell, The University of Alabama 
Table 5.6| List of strains created 
Name  Created by 
AT3q130;ace-1 F.Pohl (ICVS) 
AT3q130;ace-2 F.Pohl, A.Teixeiro-Castro (ICVS) 
UA44;gst-4(ko) V. Lindsay (ICVS) 
All strains used, were outcrossed to N2 (Table 5.5) at least six times to avoid 
them carrying mutations in genes in addition to the gene of interest679. 
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5.2.2.2 Freezing and thawing of worm cultures 
Adult C. elegans (3-6, strain dependent) were picked onto new NGM plates 
(2-3) and left to have progeny (4 - 5 days) until their OP50 food source was 
just depleted, the plates had plenty of L1s and L2s as well as some eggs 
(plate has not been depleted too long) and no contaminations. Worms were 
washed off the plates using M9 (Table A5, p.457 ff.) solution into 15 mL falcon 
tubes, centrifuged (2000 x g, 1 min) the supernatant discarded, and the 
worms washed 2-3 more times until the supernatant was clear. After the last 
centrifuge step, all but 3 mL/4.5 mL (2/3 plates) of M9 solution were 
discarded. An equal amount of freezing solution (complete, Table A5, p.457 
ff.) was added, the vial agitated, to evenly distribute the worms, and the 
worm suspension aliquoted (1 mL each) into clearly labelled cryovials, which 
were cooled down slowly, using either a styrofoam or Mr. Frosty™ Freezing 
container in the freezer (-80°C). 
After one month, a test thaw for each frozen strain was undertaken until 
which the worms are continuously cultured under normal conditions. To thaw 
the worms and look for survival, the vials were thawed and then pipetted 
onto the NGM plates around the OP50 seeding. Plates were left to dry 
overnight and checked for survival the next day. Living worms were picked 
and placed onto new plates, to prevent contamination. If there were no 
surviving worms (unsuccessful freezing), the freezing process was repeated 
using the plates continuously cultured with the strains. 
5.2.2.3 Backcrossing and creation of double mutant strains-“worm 
crossings” 
Worm lysis 
Single or multiple worm lysis was undertaken by adding 10% Proteinase K 
(20mg/mL) to C. elegans lysis buffer (50 mM KCl, 10 mM Tris (pH 8.3), 2.5 
mM MgCl2, 0.45% NP-40/Triton-X100, 0.45% Tween-20, 0.01% gelatine). 
Depending on single or multiple worm lysis, 4 or 20 µL lysis buffer were 
pipetted into the lid of PCR tubes and 1 or 10 worms picked into the buffer 
respectively. PCR tubes were closed and then subject to a brief spin in the 
centrifuge to bring the solution and worms to the bottom of the tube, which 
were then frozen (-80°C) for 30 minutes. There after the tubes were placed 
in the thermocycler (Eppendorf Mastercycler epgradient S) using the following 
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lysis program: 65 minutes at 65°C, 15 minutes at 95°C followed by cool down 
to 4°C. Lysed worms were stored in the fridge (4°C) until needed for further 
experiments or it was immediately added to the PCR. 
Primer design and preparation for PCR 
For the back crosses (ace-1, ace-2 and gst-4 (ko)) and the intended crossings 
of ace-1 and ace-2 with AT3q130 worms, and gst-4 (ko) with UA44 worms, 
primers were needed, to determine the genotype of the crossed animals. 
These were created using the Primer3-PCR primer design tool680. The gene 
sequences of the ace-1 (VC505, ok663), ace-2 (RB1942, ok2545) and gst-4 
(ko) (RB1823, ok2358)  genes are shown in Figure A15 (p.453 f.), Figure A16 
(p.455 f.)and  Figure A17 (p.457 ff.) respectively. 
Table 5.7 shows the sequence of the three designed primers; one forward 
(for-1) and two reverse (rev-1 and rev-2), with primer rev-2 located in the 
middle of the allele deletion. The primers were obtained from STAB vida 
(Portugal) or Sigma-Aldrich (gst-4 (ko)).  
Table 5.7| Primers for crosses and back-crosses 
GENE PRIMER SEQUENCE (5’- 3’) 
ace-1 
for-1 TGTTGAAGAAGCATGCGAAA 
rev-2 TAGGGGTGTGAACATGCAAA 
rev-1 GAGATTGCCAACTGGTGGTT 
ace-2 
for-1 TGAAAAGTAGCCGCATCAAA 
rev-2 ACGATATCGGGATGGAGTTG 
rev-1 CAACAGCTTGCTCTTCGTTG 
gst-4 (ko) 
for-1 TTGGGCAAGAATTTCCAGAG 
rev-2 GGCTTCACTCACTTGGCTTC 
rev-1 AAAGATCTGGGGCAGTGATG 
 
Stock primers solutions (1 µg/µL) were prepared in milliQ water, based on 
the weight of primer obtained. From the respective stock solution, a working 
solution of 10 µM was prepared in milliQ water by considering the molecular 
weight of each primer. Working solutions and stock solutions were kept at -
20°C when not in use. 
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PCR optimization 
The following procedure describes the PCR reaction optimization for ace-1. 
The same process was repeated for ace-2 and gst-4 (ko). For the PCR 
optimization 3 PCR master mixes were prepared as described in Table 5.8. 
The amount of master mix prepared was adjusted, depending on the number 
of samples (e.g. x30, last column Table 5.8). For Mix 1 PCR master mix 2x 
(Pomega M750C) was mixed with milliQ water, primers for-1 and rev-2 (10 
µM) as well as worm lysate. In comparison, Mix 2 contained for-1 and rev-2 
and Mix 3 all three primers. The 3 different mixtures were prepared to 
determine if it would be necessary to run Mix 1 and Mix 2 for the following 
PCRs or whether Mix 3 itself would be sufficient.  
Table 5.8| PCR master mixes 
 Mix 
1 
(µL) 
Mix 
2 
(µL) 
Mix 
3 
(µL) 
 x30 for all samples, 
for each mix (µL) 
PCR master mix 2x 12.5 12.5 12.5 375 
For-1(10 µM) 0.5 0.5 0.5 15 
Rev-2 (10 µM) 0.5 - 0.5 15-0-15 
(Mix 1-Mix 2-Mix 3) 
Rev-1 (10 µM) - 0.5 0.5 0-15-15 
(Mix 1-Mix 2-Mix 3) 
Worm lysate 1.5 1.5 1.5 In PCR tubes 
Water milliQ 10 10 9.5 300-300-285 
(Mix 1-Mix 2-Mix 3) 
 
For the PCR optimisation eight different annealing temperatures (53.1, 54.2, 
55.0, 55.8, 56.7, 58.4, 59.1 and 59.8°C ) were tested within the following 
PCR program: 5 minutes 95°C, then 1 minute 95°C, 1 minute temperature 
gradient (8 different temperatures), 1.5 minutes 72°C which was repeated 
35 times, followed by 10 minutes 72°C and a cool down to 4°C using an 
Eppendorf thermocycler (Mastercycler epgradient S). The temperature and 
mixtures (Mix1+Mix2 or Mix3) found to give the best results (“5.3.3.2 
Pharmacogenetic approach using two C. elegans mutants (knock out) for the 
AChE gene”, p.325) was used for all subsequent PCRs. 
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Gel electrophoresis of PCR products 
For the gel electrophoresis of the PCR products, a 1% agarose gel (w/v) was 
prepared by dissolving an appropriate weight of agarose (molecular biology 
grade, GeneON for 50bp-50kb) in 1x TAE buffer (1960 mL deionized water 
and 40 mL 50x TAE buffer (242 g Tris base, 57.1 mL glacial acetic acid, 100 
mL EDTA (0.5 M, pH 8) made up to a total of 1000 mL with deionized water)) 
in the microwave. The gel was left to cool down till hand warm, green safe 
dye (3 µL/100 mL, nzytech Greensafe Premium) was added, mixed and then 
poured into the appropriate size gel tray fitted with combs and let to set for 
20-30 minutes. Thereafter the tray was immersed in the gel tank (BIO-RAD 
Sub-Cell GT) containing 1x TEA buffer. After the PCR run, 5 µL loading dye 
(20 g sucrose in 50 mL deionized water, with bromophenol for desired colour) 
were added to all the DNA samples obtained and 25 µL loaded into the wells. 
A DNA ladder (Gene Ruler TM DNA Ladder Mix: 100 µL DNA ladder, 100 µL 
6x loading dye, 400 µL dH2O; storage at -20°C) was run for DNA size 
determination. The gel was electrophorized at 125 V for about 90 min. The 
gels were visualized using a BIO-RAD Gel Doc TMEZ Imager and Image lab 
4.1 bio-rad software. 
The expected DNA lengths after PCR and gel electrophoresis for wild type, 
mutant and heterozygous worms for ace-1, ace-2 and gst-4 (ko) are 
presented in Table 5.9. 
Table 5.9|Expected DNA fragments for genotyped ace-1, ace-2 and 
gst-4 (ko) worms 
GENE WT MUT HETEROZYGOUS 
ace-1 263bp+1004bp 396bp 263bp+396bp+1004bp 
ace-2 243bp+1869bp 399bp 243bp+399bp+1869bp 
gst-4 (ko) 531bp+1983bp 435bp 531bp+435bp+1983bp 
 
Outcrossing 
Some of the strains, obtained from the CGC (ace-1, ace-2, gst-4 (ko)) were 
0 x backcrossed (BC). To avoid genes mutations in addition to the gene of 
interest they had to be backcrossed to N2 wors, before undertaking any 
further experiments or crosses with other strains (AT3q130 and UA444). The 
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following paragraph describes the process of backcrossing using ace-1 
animals, the same procedure was undertaken when backcrossing ace-2 and 
gst-4 (ko) worms. The gene for ace-1 is located on the x chromosome, which 
only hermaphrodites are diploid (x/x) for, males are haploid (x/0). 
For the first backcrossing 13 male N2 (genotype: wt/0), were placed onto 
OP50 seeded 60 mm NGM plates, together with three L4 stage hermaphrodite 
ace-1 worms (genotype: ace-1/ace-1) and left to breed at 15 °C for 2 days 
(Figure 5.17 (1xBC)).  Thereafter the three hermaphrodites (now around day 
five of development) were isolated onto three separate OP50 seeded 60mm 
NGM plates and left to lay eggs (2-3 days, 20°C). From these, one plate was 
chosen that contained a significant number of male worms as indicator for 
successful breeding. From this plate, 13 males (genotype: ace-1/0) were bred 
with three L4 stage N2 hermaphrodites (wt/wt) for 2 days at 15°C (Figure 
5.17 (2xBC)). There after the three hermaphrodites were again isolated onto 
separate 60mm plates and left to lay eggs (2-3 days at 20°C). One of these 
plates was selected (significant number of male progeny) and 10 
hermaphrodites (L4 stage) isolated. These 10 hermaphrodites can have the 
following genotypes: wt/wt (from self-fertilization) or ace-1/wt (occurred 
after successful breeding). The worms were left to lay eggs for 2-3 days. The 
10 isolated adults are then used for single worm PCR, to determine their 
individual genotypes. From one of the plates, that showed an adult with a 
heterozygous (ace-1/wt) genotype 16 hermaphrodites were isolated and left 
to lay eggs on 16 separate plates. Single worm PCR  was again undertaken 
to detect their genotype, which can be one of three: ace-1/ace-1, ace-1/wt 
or wt/wt  in the ratio 1:2:1 according to Mendel’s first law (law of segregation 
of genes681, Table 5.10). 
Table 5.10| Genetic cross of hermaphrodite self-fertilization 
 wt ace-1 
wt wt/wt wt/ace-1 
ace-1 wt/ace-1 ace-1/ace-1 
Note(s): heterozygous worms (wt/ace-1), on X-chromosome 
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Figure 5.17| Backcrossing schematic for ace-1 worms, deletion of 
ace-1 on  the X chromosome 
Three L4 stage hermaphrodites from one of the plates, which showed the ace-
1/ace-1 genotype, were then chosen to start the 3rd backcrossing, together 
with 13 N2 males, as previously described for the first backcrossing. The 3x 
and 4x as well as the 5x and 6x back crossing were conducted in the same 
way as the 1x and 2x respectively. Two-, four- and six times back crossed 
animals were frozen (5.2.2.2 Freezing and thawing of worm cultures p.292), 
to secure the different stages of back crossing. 
Crossing 
To explain the crossing between two C. elegans mutants, the example of 
crossing ace-1 worms with AT3q130 is presented, the other crosses (ace-2 
(6xBC)xAT3q130 and gst-4(ko)(6xBC)xUA44 were undertaken using the 
same crossing method (Figure 5.18, p.300). For the first crossing 13 male N2 
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(wt/0 for ace-1; wt/wt for AT3q130) were transferred onto 60 mm NGM plates 
and left to breed with three L4 stage hermaphrodite AT3q130 animals (wt/wt 
for ace-1; q130/q130 for AT3q130) (2 days, 15 °C). Thereafter the three 
hermaphrodites (now around day 5 of development) were isolated onto 3 
separate 60 mm plates and were left to lay eggs (2-3 days, 20°C). From one 
of the three plates, containing a significant number of males, 13 males (wt/0 
for ace-1; wt/q130 for AT3q130) were bred with 3 ace-1 L4 stage 
hermaphrodites (ace-1/ace-1 for ace-1, 6xBC; wt/wt for AT3q130) for 2 days 
at 15°C. There after the hermaphrodites were isolated again onto 60 mm 
plates and left to lay eggs (2-3 days at 20°C). One of the plates, containing 
a significant number of males, was selected and 3 L4 stage hermaphrodites, 
showing YFP fluorescence when observed using a fluorescent microscope, 
were isolated. This confirms the successful crossing and provides the 
following genotype for the three chosen hermaphrodites: wt/ace-1 for ace-1 
and wt/q130 for AT3q130. The three isolated worms were left to lay eggs (2-
3 days, 20°C). Following, from one of the three plates 24 hermaphrodites (L4) 
were isolated, showing both low and high intensity fluorescence, both 
wt/q130 and q130/q130 (for AT3q130) genotype worms were selected (Table 
5.11, both  and  respectively), for the chance of picking an ace-1/ace-1 
genotype (bold in Table 5.11).   
Table 5.11| Genetic cross for progeny of the 24 isolated animals* 
Note(s):* heterozygous for both genes: genotype wt/ace-1|wt/q130 green 
highlighted genotypes showed YFP fluorescence (bright for      homozygous  and less 
bright for heterozygous animals); genotypes needed for further experiments are 
highlighted with red/orange boarder 
 
ace-1|q130 ace-1| wt wt|q130 wt|wt 
ace-
1|q130 
ace-1/ace-1 
| q130/q130 
ace-1/ace-1 
| 
wt/q130 
wt/ace-1 | 
q130/q130 
wt/ace-1 | 
wt/q130 
ace-1| wt 
ace-1/ace-1 
| q130/wt 
ace-1/ace-1 | 
wt/wt 
wt/ace-1 | 
q130 /wt 
wt/ace-1 | 
wt/wt 
wt|q130 
ace-1/wt | 
q130/q130 
ace-1/wt | 
wt/ q130 
wt/wt | 
q130 / 
q130 
wt/wt |  
wt/ q130 
wt|wt 
ace-1/ wt | 
q130/ wt 
ace-1/ wt | 
wt / wt 
wt / wt | 
q130 / wt 
wt/ wt | 
wt / wt 
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The probability of obtaining the desired double mutant (genotype ace-1/ace-
1|q130/q130) was 1:16, and 1:12 after selecting for fluorescence. To 
enhance the probability of picking the ace-1/ace-1 genotype, a total number 
of at least 24 worms were isolated and left to lay eggs for 2-3 days (20°C). 
Thereafter all the parental worms were genotyped for the ace-1 gene, using 
single worm PCR, to identify the parents, homozygous for the ace-1 gene. 
These would also produce homozygous offspring for this gene. 
The plates with homozygous (ace-1) parental worms were then observed 
using fluorescence microscopy, to determine plates with exclusively 
fluorescent worms. Plates with only fluorescent worms, verify, that the parent 
had the required genotype for the ataxin-3 gene (q130/q130), thus giving 
the wanted double mutant genotype of ace-1/ace-1|q130/q130 (Table 5.11 
) to all of their offspring. In addition, the wild type (ace-1) homozygous 
AT3q130 worms (wt/wt|q130/q130) were isolated (Table 5.11 ). The 
acquired newly created worms were cultured (5.2.2.1 General 
maintenance/Strains, p.290 f.) and frozen (5.2.2.2 Freezing and thawing of 
worm cultures, p.292), to secure the positive outcome of the crossing, and 
their use in future experiments. 
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Figure 5.18| Schematic depicting the crossing for ace-1 (on 
chromosome X) x AT3q130 (on chromosome II) worms for the 
creation of double mutants 
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5.2.2.4 Toxicity assay/Food clearance assay 
To evaluate toxicity of the RSP extract towards C. elegans the food clearance 
assay was applied. The latter was performed in liquid culture using a 96-well 
format as previously described605,616 with minor modifications. The steps 
adopted for the toxicity evaluation are depicted in Figure 5.19 (p.302). and 
described following (I.-III.). 
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Figure 5.19| Food clearance assay/Toxicity assay for evaluating the toxicity of the RSP extract in C. eleagans 
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I. Preparation of inactivated OP50 solution 
Inactivated OP50 solution was prepared by growing the OP50 bacteria in Luria 
Broth (LB, Table A5, p.457) media (overnight (16 h) at 37°C and 150 rpm). 
The solution was aliquoted into falcon tubes (50 mL) and pelleted by 
centrifugation (4000 x g, 30 min). The supernatant was discarded and the 
OP50 pellet inactivation via 2 cycles of freeze (liquid nitrogen)/thawing (water 
bath, 70°C). For storage, pellets were frozen in liquid nitrogen and stored at 
-80°C. On the day of the assay, the pellet/s was/were thawed and re-
suspended in s-medium complete (Table A5, p.457) containing 0.08% 
cholesterol (5 mg/mL), 0.5% streptomycin/penicillin and 0.5% nystatin 
(100x). The optical density (OD) of the diluted OP50 pellet was adjusted to a 
final OD between 0.6-0.7 at 595 nm (20 µL OP50 plus 40 µL s-media in 96-
well plate). 
II. Preparation of synchronised C. elegans egg population 
To screen the RSP extract for toxicity, the Bristol strain (N2) was employed. 
Four days prior to the setup of the toxicity experiment, three to four gravid 
adult N2 animals were picked onto a new OP50 seeded NGM plates. The 
number of plates was adjusted depending on the number of toxicity assays 
(eggs needed). 
On the day of the experiment, early progeny of the picked animals had grown 
into gravid adult C. elegans. The plate/s were washed using M9 (Table A5, 
p.457 f.) solution and animals collected in falcon tubes (15 mL) and worms 
left to settle to the bottom (5 min). The M9 solution was carefully removed 
by aspiration using flame sterilised glass pipette attached to a pump 
(Vacusafe Comfort, BS Integra Biosciences). The worms were then treated 
using alkaline hypochlorite (bleaching) solution (Table A5, p.457 f.), until the 
adult worms had dissolved (4-6 min) to obtain an age synchronised egg 
population. After the bleaching process, the bleaching solution was carefully 
removed after centrifugation (2000 x g, 1 min) with the eggs at the bottom 
of the falcon tube and M9 was added for washing. The eggs were again 
centrifuged (2000 x g, 1 minute) and the washing process repeated twice 
more. After removing the M9 following the last wash, the eggs were re-
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suspended in s-medium complete (Table A5, p.457 f.) to an appropriate 
number of eggs (15-20 eggs in 15 µL). 
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III. Preparation of RSP extract and DMSO controls 
The extract was dissolved in DMSO to create a stock solution (100 mg/mL). 
This stock solution was diluted using filtered water to obtain different 
concentrations of RSP extract stock solutions at 20 % DMSO, which were 
further diluted to obtain final concentrations of the extract between 0.024-12 
mg/mL, each at 2.4% DMSO. Aliquots of these solutions were stored at -20°C 
until further use. The final concentration of DMSO in all the RSP extract 
samples was 1% and final extract concentrations tested ranged from 0.01-5 
mg/mL (see well set-up below and Figure 5.19, p.302). A 2.4% and 12% 
DMSO control were prepared in addition for final concentrations of 1% 
(vehicle/solvent control) and 5% (toxic condition) DMSO respectively. 
In addition, neostigmine and sinapine were tested in the toxicity assay. 
Stocks were made up with DMSO, using similar procedures as described for 
the RSP extract. Using final DMSO concentration of 1% and neostigmine and 
sinapine concentrations ranged from 0.01-10 mM and 0.001-1.0 mg/mL 
respectively. 
IV. Set-up of 96-well plate for toxicity assay 
After the preparation of all the solutions, 15 µL of the egg solution (15-20 
eggs) together with 20 µL inactivated OP50 bacteria and 25 µL of the RSP 
extract or DMSO control solutions were added to the wells (5 wells for each 
condition) of a 96-well plate (clear flat bottom). To avoid interference from 
the absorbance of the RSP extract at 595 nm, one well per condition was used 
as drug control.  These were filled with 35 µL s-media complete and 25 µL of 
the RSP extract or DMSO control solutions. The outside wells of each plate 
were filled with filtered water to avoid dehydration of the plate throughout 
the time of the experiment (7 days). After the preparation of the 96-well 
plate, the initial optical density (day 0) at 595 nm was measured and the 
plates wrapped into moist paper towels (avoid dehydration) and aluminium 
foil (avoid light). The eggs/worms in the 96-well plates were grown at 20°C 
and 180 rpm (Shel Lab) for 7 days. The optical density (595 nm) was 
measured daily to monitor the rate by which the OP50 food suspension was 
consumed, as a read out for worm growth and development, survival and 
fecundity. 
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5.2.2.5 AT3q130 strain methods 
I. Motility determination 
For the motility assay N2, AT3q14 (NC7) and AT3q130 (RSP extract treated 
and DMSO control treated (1%)) worms were grown in liquid culture using 
inactivated OP50 as food source as described above (5.2.2.4 Toxicity 
assay/Food clearance assay) with minor modifications. The optical density 
was increased to between 0.9-1.0 at 595 nm, to ensure the availability of 
enough OP50 for the duration of 4 days. In addition, the number of eggs used 
per well was adjusted per strain (N2 20-30, AT3q14 30-40 and AT3q130 40-
60). A total number of 6 wells were used per condition on each 96-well plate. 
On day four of incubation (20°C and 180 rpm (Shel Lab)) worms (gravid 
adult) were transferred from the wells to unseeded NGM plates, equilibrated 
to 20°C. Plates were allowed to dry for approximately one hour, before 
conducting the motility assay as previously described614. Briefly, worms (3-
10) were picked and transferred into the middle of an evenly seeded (OP50) 
NGM plate (30 mm). The worms were given 1 minute to crawl, worms that 
had not crawled out of a circle 10 mm in diameter were scored as motility 
deficient (Figure 5.20, p.307). The circle was kept constant by using a circle 
drawn onto a lid of a 30 mm plate, which was put underneath the seeded 
NGM plate before transferring worms into the middle. The motor behaviour 
assays were run in quintuplicate (n=5) with at least 50 animals per condition 
in each experiment, giving a total n≥250 per tested genotype and/or extract 
concentration. 
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Figure 5.20| Schematic of the motility assay of N2 and AT3q130 
worms 
II. Confocal microscopy 
For confocal dynamic imaging and quantification of ataxin-3, animals 
(AT3q130) were mounted onto 3% agarose pads (agarose prepared in M9) 
on microscopy slides and treated with levamisole (10 mM, antihelmintic), 
covered with a cover slip and all four sides sealed with 3% agarose to avoid 
dehydration. Slides were left at 20°C for ~two hours for the levamisole to 
immobilize the worms for confocal imaging. All images were captured on an 
Olympus FV1000 (Japan) confocal microscope, under a 60x oil (NA= 1.35) 
objective. Z-series images were acquired for vehicle (1% DMSO)- and 
extract-treated (4 mg/mL) animals, using a 515/514 nm laser excitation line 
for YFP. The pinhole was adjusted to 1.0 Airy unit of optical slice, and a scan 
was acquired every ~0.5 µm along the z-axis. The quantification of the 
aggregates was performed as previously described by Teixeira-Castro et 
al.614,616. Two parameters were measured: area of aggregates/total area and 
number of aggregates/total area in 3 repeated experiments (n=3). Values 
shown are the mean (normalized to vehicle treated control) of ten or more 
animals per group. 
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5.2.2.6 PD strain methods 
For the experiments using the PD strains, DMSO controls (1%) as well as RSP 
extract treated worms were analysed for the prevention of DAergic neuron 
loss in one chemical induced model of PD, using 6-OHDA and BZ555 animals, 
and 2 genetic models (UA44, UA57). For the extract a concentration of 4 
mg/mL was chosen (explanation see 5.3.2 Machado-Joseph disease C. 
elegans model). For all PD models, treatment was performed on NGM plates. 
I. Preparation of OP50 seeding with treatment  
The seeding  for C. elegans treatment on NGM plates was prepared by 
thawing the for the drug assay (in liquid media) prepared inactivated OP50 
pellets (5.2.2.4 I. Preparation of inactivated OP50 solution, p.303) and adding 
approximately 4 mL of s-media complete (Table A5, p.457 f.) containing 
streptomycin/penicillin and nystatin. To this, 50 µL of concentrated vehicle 
control (DMSO) or RSP extract were added and the solution made up to a 
total of 5 mL for final concentrations of 1% DMSO and 4 mg/mL RSP extract. 
Dried unseeded NGM plates (60 mm) were seeded with 200 µL of the 
prepared seeding and allowed to dry in the flow chamber for 20-30 minutes 
in the dark. Treatment plates were used immediately after or stored for use 
(4°C) for up to two days. All plates seeded with treatment, with or without 
worm populations, were stored in the dark to prevent potential light sensitive 
compounds from decomposition. 
II. Exposure to 6-OHDA (BZ555) 
An age synchronized egg population was obtained via bleaching for BZ555 
worms, as described before (5.2.2.4 II. Preparation of synchronised C. 
elegans egg population p.303). About 200 eggs were put onto freshly vehicle 
(1% DMSO) and RSP extract (4 mg/mL) OP50 seeded plates (day 0, Figure 
5.21, p.309). Approximately 48 hours later worms (between L2-L3 stage of 
development) were washed off the plates and washed in filtered deionized 
water (supplemented with 1 % LB) 2-3 times until the washing liquid was 
clear (no more OP50 present). Worms were redistributed in approximately 
500 µL filtered deionized water (1% LB). In a 12 well plate, 250 µL 6-OHDA 
(final concentration 10 and 25 mM), 250 µL ascorbic acid (final concentration 
2 and 5 mM respectively, antioxidant) and 500 µL of the worm solution were 
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incubated for one hour (20°C, ~50 rpm). After one hour, the worms were 
diluted and washed (2-3) times with filtered deionized water (1% LB). 
Thereafter worms were transferred back onto respective vehicle or RSP 
extract OP50 seeded plates. On day 5 approximately 72 hours after 6-OHDA 
treatment worms were prepared for confocal imaging, as described previously 
(5.2.2.5 II. Confocal microscopy, p.307). DAergic neurons in 10-12 animals 
were counted and representative pictures taken for all conditions. The 
experiment was repeated 3 times (n=3), with a total number of n≥30 worms 
scored. 
 
Figure 5.21|6-OHDA induced PD model experimental setup using 
BZ555 animals 
Comparing treated (4 mg/mL RSP extract ) to vehicle treated (DMSO (1%)) animals 
using two different concentrations of 6-OHDA (10 and 25 mM) in conjunction with 
ascorbic acid (AA-ascorbic acid, 1 and 5 mM respectively) 
 
III. Age dependent neurodegeneration (UA57, UA44) 
To determine age dependent neurodegeneration in PD models of C. elegans, 
BZ555 (control for DAergic neurons), UA44 (alpha-syn.) and UA57 (CAT-2) 
age synchronised egg populations were obtained, through synchronisation via 
egg laying, by picking 10 gravid animals onto freshly seeded vehicle (1% 
DMSO; BZ555, UA57, UA44) and RSP extract (4 mg/mL; UA57, UA44) seeded 
plates. They were left to lay eggs and then taken off, for only the eggs to 
remain.  Starting on day three/four, adult worms were transferred onto 
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freshly seeded plates (treated/untreated) each day until about day 7, when 
the egg laying slowly decrease and worms were only transferred once before 
the end of the experiment on day 10. Worms (10-12) were prepared for 
confocal microscopy on day 7 and 10 as described above (5.2.2.5 II. Confocal 
microscopy, p.307) and DAergic neurons were counted, and representative 
pictures of each condition taken. The experiment was repeated 3 times (total 
number of worms scored n≥30).  
5.2.2.7 Reporter strains/Fluorescence microscopy 
An age synchronised egg population was obtained via egg laying methodology 
as described before (5.2.2.6 III. Age dependent neurodegeneration (UA57, 
UA44) p.309). Ten gravid adults from each strain (CL2166, CF1553, LD1171) 
were picked onto three freshly vehicle and RSP extract seeded plates (5.2.2.6 
I. Preparation of OP50 seeding with treatment, p.308) and left to lay eggs. 
The plates were seeded fresh on the day of the egg laying. After about 1-2 
hours (~50 eggs), the adult worms were removed and only the eggs 
remained. On day four (96 hours later), the worms were prepared for 
fluorescence microscopy as previously described (5.2.2.5 II. Confocal 
microscopy, p.307) using sodium azide (2 mM), to anesthetize the worms. 
On the slide, the worms (10-12) were orientated facing the same direction, 
using an eyelash. Excess azide was removed and the worms covered with a 
cover slide and sealed as previously described. Bright field (1.662 ms 
exposure time, ISO1600) images and fluorescence (ISO1600, GFP filter) 
images were taken for both, the vehicle and RSP extract treated animals with 
the same settings. However, fluorescence exposure time was set to a 
different value for each strain (CL2166, CF1553, LD1171), so that vehicle 
treated worms were barely visible; the same settings were used to analyse 
the RSP extract treated worms, to distinguish between their difference in 
intensity. Exposure time of the same strain in different experiments varied. 
Fluorescence intensity of each worm was measured using Fiji (ImageJ, 
1.51n), divided by the total area of the respective animal. Statistical analysis 
was undertaken on the raw data, and after normalized to the mean of the 
vehicle treated worms for graphical representation. The results of one 
representative experiment are shown. A total of three biological replicates 
(n=3) with a total of ≥30 animals were analysed per strain. 
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5.2.2.8 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 7. Specific methods 
used for statistical comparison of each experiment are detailed in the results 
section. At least 3 independent experiments (n) were analysed per assay, 
unless otherwise stated and results shown as mean ± standard deviation. P-
values below 0.05 were considered significant. 
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5.3 Results and Discussion 
5.3.1 Toxicity/Food clearance assay 
To test the extracts potential toxicity towards C. elegans the food clearance 
assay was employed. This assay had previously been used to test a whole 
library of individual compounds616 as well as plant extracts331. The RSP extract 
was tested with concentrations ranging from 0.01-5 mg/mL, together with 
two DMSO controls, 5%, known to be toxic to the worms and 1%, known to 
not cause any developmental delay or toxicity. The final concentration of 
DMSO in all RSP extract samples was similarly equal to 1%. Previously, the 
safe working concentration of DMSO (≤1%) was determined using the same 
food clearance assay79. The results obtained for the toxicity determination of 
the RSP extract in C. elegans (Figure 5.22) show that the extract is not toxic 
up to the tested maximum concentration of 5 mg/mL.  
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Figure 5.22| Toxicity assessment of RSP extract (0.01-5.0 mg/mL) 
using the food clearance assay, DMSO as negative (1%) and positive 
(5%) control  
The optical density curves for all the tested concentrations are consistent with 
the 1% DMSO control (▬), known to be safe for the animal79. The food is 
being cleared in the expected manner, starting on day 2-3 where worms are 
between L3 and L4 of development. Further decrease in optical density on 
day 4 is associated with an increased number of worms in the wells, due to 
the number of progenies. The 5% DMSO control shows no clearing of the well, 
with an optical density around 0.75 throughout the entire experiment, 
confirming its toxic effect towards the model organism. 
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For the solvent DMSO, both mammalian cells and C. elegans nematodes 
showed similar susceptibility at concentrations over 1%. Hence, less than or 
equal to 1% DMSO is used as solvent. In contrast, the RSP extract was found 
to be less toxic in C. elegans than in SH-SY5Y cells (Figure 4.11 p.239). The 
use of immortalized cell line such as SH-SY5Y have previously shown false 
positives and negatives for toxicity determination and can often not be used 
to predict a response at the organism level589,682. C. elegans, when compared 
to the SH-SY5Y cell line, provides an insight into in vivo toxicity, with the 
advantage of an intact and metabolically active digestive, endocrine, sensory, 
reproductive and neuromuscular system. In addition, some similarities in the 
mode of toxicity have been observed between C. elegans and mammals, e.g. 
the toxicity of organophosphate pesticides is liked to AChE inhibition589,683. 
Although C. elegans also has its limitations as model organism for drug 
screenings (5.1.1.2 C. elegans for toxicity screenings, p.266), the toxicity 
evaluation was necessary to determine a safe working concentration for the 
RSP extract within the C. elegans model. Based on the toxicity results, all the 
subsequent experiments using RSP extract were performed using 
concentrations up to 5 mg/mL.  
Other natural compounds/extracts have previously been tested for toxicity 
using the food clearance assay. Tsai et al.684 for example tested the toxicity 
of betulin, a naturally occuring triterpen found in the outer bark of birch trees 
with various biological activities. Concentrations up to 0.5 mM (0.22 mg/mL) 
were found to not cause developmental delay or toxicity in the model 
organism, when starting treatment in the L1 stage of development. In 
contrast, 2.5 mM (1.1 mg/mL) showed significant toxicity. In a report from 
Chalorak et al.685 the extracts from Holothuria scabra were found to be safe 
up to the highest tested concentration of 0.5 mg/mL. For different solvent 
extracts of the roots and leaves from Damnacanthus officinarum (Yang et 
al.686) 0.8 mg/mL were found to be acceptable as a safe concentration. One 
difference, between the food clearance assays undertaken in those references 
and our study, was the stage of development in which the assay was initiated, 
whilst Tsai et al.684, Chalorak et al.685 and Yang et al.686 all used L1s for the 
start of the experiment, in our study the treatment started in the egg stage 
of development. Personal preliminary analysis of different compounds using 
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both egg and L1 stage of development as starting point for the food clearance 
assay had indicated slight variations for some of the tested compounds when 
starting at different stages of development. Some compounds which were 
safe at certain concentrations showed developmental delay when starting the 
assay in the L1 stage, none of them however, showed extreme toxicity79. Due 
to the fact that the following experiments would start treatment in the egg 
stage, the toxicity was also tested starting at the same stage of development. 
In general, the results indicate that C. elegans is tolerant towards the RSP 
extracts and all the tested concentrations can be taken forward for further 
experiments using the disease models. 
5.3.1.1 Toxicity of sinapine and neostigmine in C. elegans 
After identifying sinapine as one of the most abundant compounds in the RSP 
extract, also the toxicity of sinapine was tested in the food clearance assay, 
ranging from concentrations between 0.001 to 1.0 mg/mL. The toxicity of 
sinapine was determined, to identify safe concentrations for further studies 
on its effect in the disease model/s. Similar to the RSP extract, no toxicity of 
sinapine towards the model organism was found (Figure 5.23), even at double 
the concentration (1 mg/mL) of sinapine present in 5 mg/mL RSP extract 
(545.5 µg sinapine/5 mg RSP extract. For the following experiments (e.g. 
motility assay), concentrations of up to at least 1.0 mg/mL could be tested. 
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Figure 5.23|Toxicity assessment of sinapine (0.001-1.0 mg/mL) 
using the food clearance assay, DMSO as negative (1%) and positive 
(5%) control  
So far there is limited research in the toxicity evaluation of sinapine in model 
organisms. As previously indicated, research using sinapine has been 
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undertaken in Asian countries, using rodent cerebral homogenate and blood 
serum as well as in the Drosophila model, but toxicity values were not 
provided401,403. In the Drosophila model 10 and 50 mg/L (0.01 and 0.05 
mg/mL respectively) of sinapine had shown increased longevity.  In the 
rodent cerebral homogenate and blood serum also low concentrations showed 
ACHE inhibition (3.66 µM (1.13 µg/mL) and 22.1 µM (6.86 µg/mL) 
respectively). Both studies used much smaller concentrations of sinapine than 
the concentration (1 mg/mL) tested here. In a different much older study in 
1987, sinapine was found to have no depressive effect on the digestive and 
metabolic utilization in the diet of rats and did not show signs of toxicity 
towards the latter687. 
Furthermore, also neostigmine in form of neostigmine bromide was subject 
to toxicity studies in C. elegans, for further investigations into the extract’s 
potential mechanism of action, i.e. AChE inhibition.  Neostigmine is a 
currently used drug (AChE inhibitor) for the treatment of myasthenia gravis, 
concentrations tolerated in patients are well known. Oral administration of 
15-30 mg are commonly used for adults, that can be repeated for a total daily 
dose of between 75-300 mg. Subcutaneous injections or intramuscular 
injection use lower doses of between 1.0-2.5 mg, which are repeated to 
usually total daily doses of 5-20 mg (adults)688. 
Just like for the extract and sinapine, all the tested concentrations (0.01-10 
mM; 0.03-3.0 mg/mL) showed no toxicity towards the N2 animals (Figure 
5.24). As no toxicity or developmental delay was observed, following 
concentrations up to 10 mM will be tested in the MJD model (AT3q130). 
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Figure 5.24| Toxicity assessment of neostigmine (0.01-10 mM) using 
the food clearance assay, DMSO as negative (1%) and positive (5%) 
control  
In a paper by Kalinnikova et al.689, toxic effects of neostigmine were seen in 
worms’ in form of paralysis only at very high concentrations of neostigmine 
(≥6 mM). This toxic effect was assessed using the worms’ motility ability. The 
food clearance assay in comparison assesses toxicity via the development of 
the nematode, using food consumption as read out. During this experiment 
the worms are not assessed on the motility behaviour. The slightly different 
toxicity results in our and Kalinnikovas study can be explained by the two 
different methods used. In general, both studies agree that very high 
concentrations of neostigmine are necessary to show toxic effects in C. 
elegans. To verify the findings by Kalinnikova et al.689 all concentrations 
(0.01-10 mM) were take forward for further studies in the MJD model. This 
might verify an increased locomotion defect, when using high concentrations 
of neostigmine, which was not detected using the food clearance assay, with 
the latter determining toxicity via development and fecundity.  
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5.3.2 Machado-Joseph disease C. elegans model 
The first neurodegenerative disease model used to assess the potential of the 
RSP to prevent/treat neurodegenerative disease was the MJD model. 
Preliminary studies using the same model and RSP extracts (SOX and UAE-
ethanol/water 95/5%, 2012 RSP harvest) had shown improvement in the 
motility deficient phenotype using an automated system, to track the 
movement of worms in liquid media (swimming behaviour)79. To determine if 
the same positive outcome could be repeated when assessing the worms 
crawling behaviour, here the manual motility assay was employed and 
AT3q130 animals treated with the RSP extract. In addition, also the impact 
of the RSP extract on the ataxin-3 aggregation load in the neurons was 
assessed. 
5.3.2.1 Motility assessment of RSP extract treated AT3q130 strain 
Since the concentrations of RSP extract up to 5 mg/mL were found to be safe 
for C. elegans in the toxicity assay, RSP extract concentrations ranging from 
0.1 to 5 mg/mL were used to determine their effect on the MJD model. All 
but the smallest concentration (0.1 mg/mL) tested showed a positive dose 
dependent improvement of the motility deficient phenotype (Figure 5.25).  
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Figure 5.25| RSP extract improves locomotion defective behaviour of 
MJD (AT3q130) animals 
Comparison between treated (RSP extract 0.1-5.0 mg/mL) and untreated animals (1% 
DMSO solvent control) in comparison to wild type (N2) and AT3q14 controls (1% 
DMSO). Statistical significant difference was determined using One-way ANOVA and 
Bonferroni’s multiple comparison analysis compared to AT3q130 control: ***p≤0.001, 
**p≤0.01, *p≤0.05, n=5  
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The highest RSP extract concentrations (1.0-5.0 mg/mL) showed the best 
motility improvement with p≤0.0006. At the lower concentrations (0.25, 0.5 
and 0.75 mg/mL RSP extract) this significance was reduced as expected 
(p<0.05 but p>0.001). At 0.1 mg/mL the significance was lost (p>0.05), 
however a slight improvement in motility was still observed for the mean 
values i.e. untreated 49.31% compared to 40.76% for 0.1 mg/mL RSP 
treated animals.  
To determine whether the presence of sinapine within the RSP extract could 
be responsible for the seen motility improvement, concentrations of sinapine 
ranging from 0.001 to 1.00 mg/mL sinapine were tested in the motility assay 
using the MJD (AT3q130) model (Figure 5.26). 
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Figure 5.26| Sinapine shows limited positive effect in MJD strain 
(AT3q130) 
Locomotion defective behaviour of AT3q130 animals, comparison between treated 
(sinapine 0.001-1.00 mg/mL) and vehicle treated (DMSO (1%) solvent control) animals 
in comparison to wild type (N2) and AT3q14 controls (1% DMSO). Statistical significant 
difference was determined using One-way ANOVA and Bonferroni’s multiple comparison 
analysis compared to AT3q130 control: *p≤0.05, ***p≤0.001 , n=5 
Only two of the tested concentrations of sinapine (0.75 and 0.50 mg/mL) 
showed a significant improvement of the phenotype. This improvement 
however was not as significant as some of the RSP extract concentrations i.e. 
p≤0.05 (e.g. 0.5 mg/mL sinapine) compared to p≤0.001 (e.g. 4 mg/mL RSP 
extract) (Figure 5.25, p.317). Interestingly, the tested concentrations that 
showed significant difference (0.50 and 0.75 mg/ mL) are equivalent to 4.58 
and 6.87 mg/mL of RSP extract respectively. This is comparable to the results 
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seen with the RSP extract where significant motility improvement was 
demonstrated at 4.0 and 5.0 mg/mL concentrations. RSP extract 
concentrations above 5.0 mg/mL were not tested, due to lack of toxicity data. 
These results indicated that the sinapine within the RSP extract could be 
partially responsible for the positive activity in the MJD model. The lower 
improvement (p>0.01) from sinapine when compared with the RSP extract, 
may be due to the presence of other compounds within the RSP extract 
contributing to the activity. Further studies into the identity of compounds, 
whether already known (3.3.3 LC-MS/MS analysis of final RSP extract, p.170 
ff. or  3.3.4 Additional secondary metabolite analysis, p.175 ff.) or not would 
be necessary to fully elucidate the mode of action of the RSP extract.  
Only limited research information is available on this MJD model since this 
strain is not currently available from the CGC. However, a few other 
compounds have shown to improve the locomotion defective phenotype. In 
Teixeira-Castro et al.614 both valproic acid (6 mM) and 17-
(dimethylaminoethy- lamino)-17-demethoxygeldanamycin (17-DMAG (1 and 
10 µM), induces heat shock response) showed improvement of the 
phenotype. Valproic acid from 71.75% to 37.9% on day 10 of adulthood and 
17-DMAG from around 40% to 20% in 4 day old animals. In a more recent 
study by the same group a commercially available compound library, 
containing mainly FDA/EMA-approved drugs, was screened for potential drug 
candidates for MJD in C. elegans. Throughout that study 48 compounds, with 
different specific pharmacological activity, such as modulators of 
neurotransmission (adrenergic 14%, serotonergic 14%, cholinergic 4%, 
dopaminergic 4% and histaminergic 5%), anti-infectious (14%), 
cardiovascular (9%), anti-inflammatory (9%), analgesic (4%), hormone-
related (7%) and other actions, were found to induce more than 50% 
improvement616. With an improvement from a mean of 49.31% for the 
AT3q130 model to 22.29% for AT3q130 animals treated with 4 mg/mL of RSP 
extract, improvement of the locomotion defect was more than 50% and so 
fits into the above mentioned criteria.  
To determine whether the effect from the RSP extract was disease specific, 
also N2 (WT) and AT3q14 (AT3WT, normal length of q repeats in ataxin-3) 
animals were treated with the RSP extract (Figure 5.27), at a concentration 
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(4 mg/mL) that showed the best results in the MJD model (Figure 5.25 p. 
317).  
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Figure 5.27| RSP extracts effect on MJD strain is disease specific 
Comparison of locomotion defective behaviour of N2, AT3q14 and AT3q130 untreated 
(1% DMSO vehicle control) and RSP extract treated (4 mg/mL) animals. Statistical 
significant difference determined using One-way ANOVA and Bonferroni’s multiple 
comparison analysis compared to AT3q130 control: ***p≤0.001, *p≤0.05, n=6  
The results obtained, show that neither the wt animals (p>0.999) nor the 
AT3q14 (p= 0.761) animals are significantly affected by the presence of the 
RSP extract, whereas the MJD model is (p<0.001). Therefore this observation 
leads to the conclusion, that the effect is disease specific, targeting mutant 
ataxin-3 mediated pathogenesis as described in Teixeira-Castro et al.616 
regarding their hit compound citalopram. To determine whether the observed 
motility improvement is associated with a decrease in the number or the area 
of ataxin-3 aggregations, animals were also studied using confocal 
microscopy methodology as discussed following. 
5.3.2.2 Ataxin-3 aggregation load after RSP extract treatment of 
AT3q130 animals  
To determine if the observed positive activity of the RSP extract is related to 
a change in the number or the area of protein aggregations in AT3q130 
neurons in vivo, confocal microscopy imaging was undertaken. The results 
obtained are presented in Figure 5.28 (p.321). In this study no significant 
changes in either number or the area of ATXN3 aggregates (per total area) 
were observed. This suggests that the RSP extract has a different mode of 
action when compared to e.g. citalopram in the identical model, where a 
decrease in number and/or area of aggregates was reported together with 
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and increased ATXN3 solubility (assessed by biochemical fractionation). 
However, these changes were not associated with an overall change in protein 
levels of ATXN3616. 
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Figure 5.28| No changes in the ataxin-3 aggregation load induce by 
RSP extract in the MJD model 
Aggregation load (number and area of aggregation) of AT3q130 animals upon 
treatment with RSP extract (4 mg/mL) compared to solvent control (1% DMSO). For 
aggregate quantification: n≥10 number of animals per experiment, n=3 number of 
experiments, no significant difference, p>0.05 (ANOVA, Bonferroni’s multiple 
comparisons test). Data normalized to the 1% DMSO control. Confocal microscopy 
pictures are representative for the three independent experiments; confocal imaging 
by Andreia Teixeira-Castro. 
Considering the previously undertaken in vitro studies (“3. Phytochemical 
Characterisation and Neuroprotective Properties of RSP Extract”, p.133 ff.), 
other potential modes of action can be identified and tested in the C. elegans 
model system. Previously, the RSP extract for example showed antioxidant 
and radical scavenging activity indicating their direct antioxidant activity 
(3.3.2 Antioxidant activity of final RSP extract, p.168 ff.). In addition the 
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extract might also exhibit indirect antioxidant activity (through the  activation 
of Nrf2/skn-1, followed by phase II enzymes see 1.4.3 Exogenous 
antioxidants - natural products: direct and indirect antioxidant activity, p.58 
ff. and 5.1.3 Determination of potential pathways of action using C. elegans 
as model organism, p.280 ff.), as previously shown for other  natural 
products54,224,690. This hypothesis was further investigated in “5.3.5 In vivo 
study of antioxidant activity: the indirect antioxidant activity pathway 
theory”. In addition, in vitro analysis also indicated AChE inhibition activity 
by the extract/sinapine, which could also be responsible for the seen motility 
improvements and this was further investigated as discussed following. 
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5.3.3 AChE inhibition hypothesis 
Two different approaches were initiated (pharmacological and 
pharmacogenetic) to verify the AChE inhibition hypothesis (5.1.3 
Determination of potential pathways of action using C. elegans as model 
organism p.280 ff.). The pharmacological approach used the treatment of 
AT3q130 worms with neostigmine (AChE inhibitor), whereas the 
pharmacogenetic model employed AChE knock out strains crossed with the 
AT3q130 model.  
5.3.3.1 Pharmacological approach using neostigmine as AChE 
inhibitor in vivo 
For this approach neostigmine was employed, to evaluate whether AChE 
inhibition could be responsible for the observed motility improvements with 
the RSP extract in the AT3q130 model. Neostigmine is a well-known AChE 
inhibitor used in the clinic for the treatment of myasthenia gravis, and was 
also applied as positive control in the in vitro analysis of AChE inhibition 
activity  of the RSP extract (3.3.6 AChE inhibition potential, p.194). The food 
clearance assay (Figure 5.24, p.316) showed no toxicity of neostigmine 
towards C. elegans up to 10 mM. Therefore, neostigmine concentrations from 
0.01 to 10 mM were applied in the motility assay initially (Figure 5.29, p.323). 
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Figure 5.29| Locomotion defective behaviour of AT3q130 animals 
after neostigmine treatment 
Comparison between treated (neostigmine 0.01-10 mM) and untreated animals in 
comparison to wild type (N2) and AT3q14 controls. Statistical significant difference 
determined using One-way ANOVA and Bonferroni’s multiple comparison analysis 
compared to AT3q130 control: ***p≤0.001, **p≤0.01, *p≤0.05, ***p≤0.001 (increase 
of motility deficiency, worsening of phenotype) n=5 
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Although 10 mM neostigmine did not show to have an effect on the worm’s 
development and fecundity (Figure 5.24), there is a significant increase in 
locomotion defect when treating AT3q130 animals with this concentration. 
The locomotion defect increases significantly from 49.32±2.32% ( ) to 
83.37±8.28% (  p<0.0001). A worsening effect on the phenotype is also 
visible for 5 mM ( 73.27±7.58%, p=0.0004)). Similar results were obtained 
by Kalinnikova et al.689, where 6, 12, 24 mM neostigmine (90 minute 
exposure) showed increasing uncoordinated behaviour while swimming, after 
mechanical stimulus) due to aldicarb-like toxic effects.  
Interestingly at lower neostigmine concentrations (0.1-1.0 mM) non-
significant difference between treated and untreated animals was observed. 
Only at 0.01 mM ( ) a significant (p=0.0225) positive improvement of the 
locomotion behaviour was observed. Due to the improving phenotype at the 
lowest concentration of neostigmine, further studies were initiated that 
included 10 µM (0.01 mM), 1 µM and 0.1 µM (Figure 5.30).  
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Figure 5.30| Locomotion defective behaviour of AT3q130 animals 
after lower concentrations ofneostigmine treatment  
Locomotion defective behaviour of AT3q130 animals, comparison between treated 
(neostigmine 0.1-10 µM) and untreated animals in comparison to wild type (N2) and 
AT3q14 controls. Statistical significant difference determined using One-way ANOVA 
and Bonferroni’s multiple comparison analysis compared to AT3q130 control: 
***p≤0.001, **p≤0.01, n=5 
The results obtained for the lower neostigmine concentrations demonstrated 
significant motility improvement of the AT3q130 model for all 3 tested 
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concentrations (0.1, 1.0 and 10.0 µM). However, this improvement (ATq130 
59.55% compared to between 37.0-40.2% for the neostigmine treatment) is 
not as significant as seen for the RSP extract treatment (Figure 5.25, p.317). 
Literature research on the potential use of AChE inhibitors for the treatment 
of MJD is very limited. In a small (21 participants) double‐blind, triple‐
crossover trial of oral physostigmine in inherited ataxias, published by Kark 
et al. in 1981691, physostigmine showed to be more effective than the 
placebo. More than half of the patients (13) showed statistically significant 
responses to physostigmine. However, the results were not consistent, 
certain aspects of ataxia improved in some patients, whereas other aspects 
improved in other patients. This report was a follow up on a study published 
in 1977 by the same lead Author, where similar positive results were 
observed692. In contrast, in a later study (1997) using physostigmine, by 
Wessel et al.693, no significant effect on cerebellar symptoms were detected 
when using a transdermal system (patch). Of note, in both studies by Kark, 
oral administration was used. Those results seem to be contradicting and no 
further research into other AChE inhibitors was found during literature review. 
Considering the outcome of our C. elegans study here, the hypothesis, that 
the RSP extract’s AChE inhibition activity could be responsible for the 
improved motility phonotype, cannot be negated. To further shed light on this 
hypothesis, also a pharmacogenetic approach was employed, which is 
described following. 
5.3.3.2 Pharmacogenetic approach using two C. elegans mutants 
(knock out) for the AChE gene 
The two strains (ace-1 and ace-2), used to determine whether the extract’s 
AChE inhibition potential might be responsible for the motility improvement 
in the MJD model of C. elegans, were obtained from the CGC (Table 5.5). The 
strains acquired from the CGC had to be back crossed, before crossing them 
with the AT3q130 model. To perform either of the crosses, the PCR protocol 
had to be optimized, so the genotype of backcrossed animals could be 
identified. The results for the PCR optimization for ace-1 and ace-2 (short), 
the outcrossing and the crossing with the AT3q130 disease strain are detailed 
in the appendix (subsection A5, p.458 ff.) 
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Motility analysis 
After successful crossing of AT3q130 and ace-1 and ace-2 mutant strains, 
motility testing was conducted to either proof or disproof the AChE hypothesis 
through pharmacogenetics methodology. Figure 5.31 represents the motility 
results obtained for the motility assays with (A) AT3q130;ace-1 and (B) 
AT3q130;ace-2 double mutants. 
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Figure 5.31| Locomotion defective behaviour of AT3q130 animals 
compared to double mutant  
A: AT3q130;ace-1, B: AT3q130;ace-2 treated (RSP extract (4 mg/mL)) and untreated 
(DMSO (1%)), including controls (WT, ace-1/2 6xBC (treated and untreated)). 
*AT3q130;wild type animals for ace-1 gene obtained after crossing, #ace-1/2 mutants 
(6xBC). Statistical significant difference determined using One-way ANOVA and 
Bonferroni’s multiple comparison analysis: ***p≤0.001, **p≤0.01, *p≤0.05, n=5  
The results for the motility assays, done using the AT3q130/ace-1/2 cross, 
are inconclusive. The improvement for the AT3q130;wt to the RSP extract 
treated animals is still significant for both experiments and verifies previously 
obtained results (Figure 5.25, p.317). However, the difference between the 
AT3q130;wt animals and the AT3q130/ace-1/2 worms is not significant (ns), 
suggesting that knock out of the ace-1 gene, which is responsible for 
approximately half of the AChE production in C. elegans, or ace-2 does not 
have a significant effect on the AT3q130 motility deficiency. However, 
although the difference is not significant, there is a visible trend towards 
reduced motility impairment, with e.g. mean values of 50.12% and 42.11% 
for AT3q130;wt and AT3q130;ace-1 respectively, which could indicate a 
minor involvement of AChE activity in the phenotypic behaviour 
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improvement. When treating the double mutants with the RSP extract also 
no significant difference was detected compared to the untreated control 
(DMSO (1%)). This is most likely due to the relatively large standard 
deviation seen for most of the strains/conditions e.g. the AT3q130;ace-1 
animals (42.11 ± 8.895%). To test whether the ace-1/2 worms have a 
motility deficient phenotype themselves, they were also tested, treated and 
untreated. Statistical analysis comparing WT (N2) to ace-1 and ace-2 worms 
did not show any significant difference in locomotion behaviour (p>0.9999) 
in our assay, although Melstrom and Williams649 had previously suggested a 
decrease in the rate of movement for ace-1 animals. This might be due to the 
sensitivity of the used experiment. Here a manual motility assay was used 
(5.2.2.5 I Motility determination, p.306) whereas in Melstrom and Williams a 
tracking system was used which can monitor 50-80 worms simultaneously to 
determine the average distance of movement per worm per second in µm.  
Furthermore, as previously shown for WT and AT3q14 animals, the RSP 
extract is not able to significantly improve the motility behaviour of the 
mutants (ace-1 and ace-2) motility behaviour. The AT3q130;wt, obtained 
after the crossing with ace-1, shows the same phenotype as the AT3q130 
used in the previous experiments, with means and standard deviations of 
50.12 ± 6.75% and 49.31±5.351% (Figure 5.25, p.317) respectively. This 
suggested that for further experiments the regular AT3q130 worms could be 
used.  For the ace-2 motility assays the AT3q130 and not the from the back 
crossing obtained AT3q130;wt was used, because the stain was lost during a 
freezer shut down. To verify the results with the back crossed version, further 
crosses (AT3q130xace-2) will be initiated and the motility assay repeated, to 
verify the results.  
In general, the results obtained from both these motility assays using the 
double mutant strains together with the neostigmine data are inconclusive. 
Although neostigmine showed a significant improvement of the motility 
deficient phenotype (Figure 5.30, p.324), both double mutants showed a 
lacked of significant changes (Figure 5.31, p.326). However, the fact that in 
both cases a slight trend towards motility improvement was observed led to 
the conclusion that AChE might play a role in the effect observed by the RSP 
extracts but further investigation is required. No comparison to previous 
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literature can be done, as this is the first study looking into the importance 
of AChE inhibition via drug treatment and decreased expression via gene 
knockout in the context of MJD. 
To further investigate our hypothesis, it would be useful determine if the RSP 
extract can actually decrease the AChE activity in vivo within the MJD model 
as well as in wild type (N2) animals. To do so either the Amplex Red Assay 
kit or the Ellman’s assay could be employed, after lysis of worm pellets to 
determine the AChE activity in worms untreated (DMSO (1%)) compared to 
treated (RSP extract) animals in conjunction with control animals treated with 
an AChE inhibitor (e.g. neostigmine) or the mutant strains. Different time 
point of treatment should be considered, as previously mentioned (4.3.2 
AChE inhibition study by RSP extract in SH-SY5Y cells, p.256). The Ellman 
assay has previously been used to determine AChE activity in C. elegans by 
Shashikumar et al.636. The latter used the assay to show that induced 
inhibition of AChE activity by 6-OHDA, can be recovered by co-incubation with 
alpha-linolenic acid. Similarly the AChE activity Amplex Red Kit has been used 
previously694. In addition, it would be interesting to create triple mutants of 
both AT3q130;ace-1 and AT3q130;ace-2 animals with ace-3. The addition of 
knocking out an extra gene encoding approximately 5% more AChE645, in C. 
elegans, might lead to an additional improvement which could turn out to be 
significant. In contrast, the creation of a triple mutant using AT3q130, ace-1 
and ace-2 would most likely not be useful, due to the fact that the double 
mutant (ace-1;ace-2) are relatively uncoordinated648 and so might interfere 
with the already motility impaired AT3q130 model. 
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5.3.4 Parkinson’s disease C. elegans model  
To determine the activity of RSP extract in an additional model of 
neurodegenerative disease in C. elegans, three PD models were selected. One 
was chemically induced (6-OHDA) and two were genetically induced, age 
dependent, models (UA57(CAT-2) and UA44(α-syn)). All three can be 
characterised by a significant loss of dopaminergic neurons compared to 
control strains (BZ555). The results obtained from these strains after 
treatment with RSP extract (4 mg/mL, Figure 5.25 p.317) together with 
untreated (1% DMSO, solvent control) conditions are presented following. 
5.3.4.1 Chemical induced PD model using 6-OHDA 
For the investigation of dopaminergic (DAergic) neuronal loss the mutant 
BZ555 strain was employed, in which the DAergic neurons can be visualized 
using fluorescence microscopy, due to their co-expression of GFP in 
combination with the Pdat-1 promoter. This C. elegans model, treated with 
6-OHDA (chemical inducer of DAergic neuronal loss), has previously been 
used in a number of publications. Reports show varying conditions of 
treatment (i) different concentrations of 6-OHDA, (ii) different treatment 
times and (iii) the presence or absence of ascorbic acid618,684,695,696. Due to 
these varying protocols, the assay first had to be optimized (data not shown). 
The use of both 10 and 25 mM 6-OHDA together with ascorbic acid, 2 and 5 
mM respectively, exhibited a significant phenotype for the loss of DAergic 
neuron (Figure 5.32 F and G). In conclusion, these concentrations were used 
for further analysis of the RSP extracts potential to prevent the induced 
neuronal loss.  
The results obtained for the study on the RSP extract’s DAergic neuron 
protection potential are presented in Figure 5.32 (p.331), showing confocal 
imaging (A-E) as well as graphical representation of the three independent 
experiments (F andG). The graph represents an overview of the mean values 
for each of the independent experiments for each strain/condition.  
For each experiment 10 or more animals were scored per strain and 
treatment (F and G). The left graph (F) in Figure 5.32 shows the total number 
of DAergic neurons (total of 8: 4 CEP, 2 ADE and 2 PDE) found in control 
animals treated with the control solvent (DMSO (1%) ), in comparison to 
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the animals treated with both concentrations of 6-OHDA (  10 mM and  
25 mM). Looking at these three bars reveals a clear dose dependent DAergic 
neuronal loss after 6-OHDA induced stress. This phenotype was rescued, 
when pre- and post-treating the animals with the RSP extract (4 mg/mL) for 
both concentrations of 6-OHDA (  10 mM and  20 mM). A similar effect 
was seen when only looking at the four CEP neurons (G Figure 5.32). In both 
cases the effect is more significant when introducing higher concentrations of 
6-OHDA (25 mM). To determine whether even higher concentrations of 6-
OHDA would show an increased DAergic loss, 30 and 50 mM were tested in 
the initial optimization process, but either of them led to developmental delay 
or morphological changes of the worms. Counting the DAergic neurons in 
these worms would not have been reliable, as the absence of DAergic neurons 
could be due to the 6-OHDA treatment or the developmental delay or 
morphological changes. In comparison, at the chosen 10 and 25 mM the 
animals developed normally in comparison to control animals. The most 
obvious DAergic loss after treatment with 6-OHDA was observed in the CEP 
neurons, together with the loss of CEP neuron dendrites, which are 
highlighted by the arrow in Figure 5.32 (A-E, p.331). To verify this 
observation graphicly the percentage of animals with intact CEP, ADE and 
PDE neurons are plotted in Figure 5.33 (p.332). The biggest differences were 
seen when animals were treated with 25 mM 6-OHDA, where 78% (mean) of 
worms still showed intact ADE and PDE neurons, but only 37% exhibited 
intact CEP neurons. Already Nass et al.619 identified the higher sensitivity of 
CEP neurons towards 6-OHDA (CEP>ADE>>PDE), showing earliest and most 
detected morphological changes occurring in the CEP processes/dendrites. 
Both, the dendrite and cell body loss of CEP neurons were prevented with 
RSP extract treatment (Figure 5.32, p.331). 
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Figure 5.32| Protective effects of RSP extract on the DAergic 
neurodegeneration in C. elegans  
GFP expression of treated/untreated transgenic strain BZ555 (Pdat-1::GFP) (A)-(C) 1% DMSO 
(solvent control) treated BZ555 with; A 0 mM 6-OHDA and 0 mM AA, B 10 mM 6-OHDA and 2 mM 
AA, C 25 mM 6-OHDA and 5 mM AA. (D)-(E) 4 mg/mL RSP extract pre- and post- treated BZ555; 
D 10 mM 6-OHDA and 2 mM AA, E 25 mM 6-OHDA and 5 mM AA. The fluorescence signals of 
DAergic neurons (CEP and ADE) were photographed using confocal fluorescence microscopy. (F) 
Total number of DAergic neurons and (G) total number of CEP neurons in treated/untreated 
transgenic strain BZ555. Significant differences were determined by One-way ANOVA and 
Bonferroni’s multiple comparison analysis, # p<0.05, ###p<0.001 compared with vehicle alone 
(no 6-OHDA), *p<0.05, **p<0.01 and ***p<0.001 compared with respective 6-OHDA control, 
n≥10 for each independent experiment (n=3). Scale bar 50 µm in all represented pictures;  confocal 
imaging and neuron counting by Andreia Teixeira-Castro.  
10 mM 6-OHDA 25 mM 6-OHDA 
1% DMSO, control 
4 mg/mL RSP extract  
A B C 
D E 
1% DMSO, control 
10 mM 6-OHDA 25 mM 6-OHDA 
1% DMSO, control 
4 mg/mL RSP extract  
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Figure 5.33| DAergic neuron loss is dependent on 6-OHDA 
concentration as well as class of DAergic neurons 
Same data as in  Figure 3.37 F and G, distinguishing between the three classes of 
DAergic neurons and their susceptibility to 6-OHDA 
As with previous results so far, there has been no literature evidence that 
identifies the positive effects of RSP extract on PD models of C. elegans. 
However, this model was used with other natural extracts/compound and 
they showed similar effects as the RSP extract. Li et al.696 for example 
observed, that polysaccharide from Astragalus membranaceus, a Chinese 
medicine, were able to decrease 6-OHDA (50 mM and 10 mM AA) induced 
neurotoxicity (DAergic neuron loss) in the same model of C. elegans (BZ555). 
Similar positive results were also found for (i) alpha-linolenic acid (ALA)636, a 
plant-derived dietary polyunsaturated fatty acid (using UA44 animals in 
conjunction with 6-OHDA), (ii) methanolic extracts of red seaweed (Chondrus 
crispus, using UA57 animals in conjunction with 6-OHDA)642 and (iii) 
betulin684, a triterpene found in the outer bark of birch trees for 6-OHDA 
induced PD model and for (iv) a methanol extract from Sorbus alnifolia641 in 
a MPP+ induced PD C. elegans model. A very interesting recent article by 
Chalorak et al.685 also used the BZ555 6-OHDA model (50 mM). They were 
able to show that Holothuria scabra (sea cucumber, found in the Indo-Pacific 
region including Thailand) extracts also presented the potential to protect 
DAergic neurons from 6-OHDA induced damage. Three (whole body-butanol, 
whole body-ethyl acetate, body wall-ethyl acetate) of their six extracts 
showed this protection. Even more interesting however is the fact that they 
also employed Levodopa, a common used drug to treat PD in human patients. 
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Levodopa provided the best protection from 6-OHDA induced damage. 
Levodopa increases the concentration of dopamine in the cells and might so 
lead to a decreased uptake of 6-OHDA into C. elegans DAergic neurons. 
These very positive results from the RSP extract in the chemical induced PD 
model then led to further investigation into the effect of the RSP extract on 
two additional genetic models, the results of which are described following. 
5.3.4.2 Two genetic Parkinson’s disease C. elegans models  
The two additional C. elegans PD models UA44 and UA57 (5.1.2.2  C. elegans  
models of Parkinson’s Disease, p.272) used in this project, are age dependent 
phenotypes, with DAergic neuron loss occurring towards the middle of their 
life. Both strains showed a significant DAergic neuron loss phenotype on day 
7 (Figure 5.34, p.335, A7). The same analysis was repeated for day 10 old 
animals (Figure 5.34, p.335 A10). In this case, again both strains show a 
decreased number of DAergic neurons when compared to the BZ555 control. 
For easier visualization of data, all the worms from the 3 independent 
experiments were drawn together with n≥30 animals per strain and One-way 
ANOVA with Bonferroni’s multiple comparison was used to determine 
significant differences between the strains. When analysing the results, while 
taking replicates and independent experimental trials into consideration, two-
way ANOVA also showed a significant statistical difference between the strain. 
However, this difference was not seen for all the independent trials 
(Bonferroni’s multiple comparison analysis). The lack of significant difference 
for each trial is probably due to the very small and limited number of DAergic 
neurons. Thus, this experiment was repeated three times.  
Surprisingly there does not seem to be a big difference between the number 
of surviving DAergic neurons on day 7 compared to day 10 (Figure A18, 
p.463). This may be due to the fact that it was not possible to analyse the 
same animals on day 7 and 10. In addition, this is also the time of C. elegans 
life span, when worms are starting to die due to their natural life cycle a 
limited number of worms is available. Another explanation for this 
phenomenon was the fact that potentially worms scored on day 10 were 
healthier (survival till day 10), which might be associated with a smaller loss 
of DAergic neurons. Taken together, this could explain why there is no 
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significant difference between day 7 and day 10 old animals (Figure A23, 
p.466). 
When treating both strains from the start of their development (egg stage) 
till day 7 (Figure 5.34, p.335 B7), the RSP extract treated animals showed a 
decreased loss of DAergic neurons. Again, for easier graphical presentation, 
the total number of worms were plotted and analysed together, with n≥30 per 
treatment condition. The RSP extract treatment was significant for both 
strains, UA44 (p≤0.05) and UA57 (p≤0.001). As mentioned previously when 
analysing the results grouped for trials and treatment, two-way ANOVA 
showed a significant treatment effect. Which was not present in each trial 
separately, which is why we decided to run 3 independent experiment.  
In contrast, when treating the animals till day 10, both strains show a 
significant difference between vehicle and RSP extract treated worms of 
p≤0.001 (Figure 5.34, B10). This is most likely cause by the lower standard 
deviation of the results on day 10.  
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Figure 5.34| Effect of RSP extract treatment in genetic C. elegans PD 
strains 
Dopaminergic neuron cell count for BZ555 (control), vehicle treated (1% DMSO) as well 
as UA 44 and UA57, vehicle (1%DMSO) and RSP extract (4 mg/mL) treated on day 7 
(top) and 10 (bottom). Data are expressed as the mean ± std. of all worms (n≥30) 
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with results obtained from three independent experiments (n≥10 each). A7+10: 
comparison between the three strains indicates age dependent neuronal loss for UA44 
and UA57 on day 7 and 10, B7+10: comparison between untreated (1% DMSO) and 
treated (4 mg/mL RSP extract) disease strains (UA44 and UA57). Right (C7+10): 
Confocal microscopy pictures, showing CEP neurons, the pictures are representative for 
the three independent experiments. Blue arrows indicating dendrite loss, blebbing and 
abrupt gaps. Scale bar 50 µm in all represented pictures. Significant differences 
between the three strains (A7+A10) were determined by One-way ANOVA and 
Bonferroni’s multiple comparison analysis. For statistical analysis of the treatment 
unpaired t-test (two-tailed) was undertaken for each strain, *p<0.05 and **p<0.01, 
***p<0.001. Confocal imaging and neuron counting by Andreia Teixeira-Castro. 
The same can be observed for both time points in the confocal images (Figure 
5.34 C7+10). BZ555 animals clearly showed the presence of the four CEP 
neurons with their dendrites intact. In contrast both UA44 and UA57 animals 
had lost some of the CEP neurons and dendrite, showed blebbing and abrupt 
gaps or breaks in the dendrites on day 7 (top) and 10 (bottom). The animals 
pre-treated with the RSP extract show less CEP neuron and dendrite loss.  
It is noteworthy to mention that this is the very first reported evidence that 
demonstrates the use of RSP extract to alleviate PD related DAergic neuron 
loss in C. elegans strains. However, other natural compounds have previously 
been tested and shown positive results. For example in a paper by Büttner et 
al.470 spermidine (polyamine), was found to show DAergic neuron protection 
in the α-synuclein strain (UA44). In addition, it also showed positive effects 
in a α-synuclein Drosophila melanogaster model of PD. Also, valproic acid 
(synthetic compound) has been found to induce DAergic neuron protection in 
the UA44 strain. In general, reported literature on the UA44 strain is limited, 
probably partially due to the fact that this strain is not available through the 
CGC, but can only be obtained from the laboratory where the strain was 
created (Caldwell lab). Although the UA57 strain is available through the CGC, 
research using natural compound in this model is nevertheless still limited 
but a few studies were found in the literature. For example, methanoic plant 
extracts from Sorbus alnifolia641 and Chondrus crispus642 (red seaweed, using 
UA57 animals in conjunction with 6-OHDA) showed protective properties. In 
a very recent study by Manalo and Medina697, caffeine was found to protected 
DAergic neurons against degeneration promoted by excessive dopamine 
production through over expression of tyrosine hydroxylase.  
In previous experiments (5.3.3 AChE inhibition hypothesis) it was shown that 
the AChE inhibition hypothesis cannot be negated in the MJD model, however 
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results were not positive enough to evaluate the same AChE inhibition 
hypothesis in the PD model. In addition to its AChE inhibition activity 
however, the RSP extract also possesses valuable direct antioxidant activity 
in vitro and was able to reduce ROS production in H2O2 stress induced SH-
SY5Y neuroblastoma cells, which can be associated with its antioxidant 
activity. This led to the second hypothesis (5.1.3 Determination of potential 
pathways of action using C. elegans as model organism, p.280 ff.), that the 
observed positive effect of the RSP extract on the disease strains, may be 
caused by its antioxidant property. 
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5.3.5 In vivo study of antioxidant activity: the indirect 
antioxidant activity pathway theory 
To test the hypothesis whether the RSP extracts antioxidant activity is 
responsible for all or at least some of the observed positive phenotypical 
improvements in the 4 different disease models (1 MJD, 3 PD) two methods 
were employed. One made use of reporter strains, which show increase GFP 
fluorescence in association with increased expression of certain genes of 
interest (5.3.5.1 C. elegans reporter strains). The second method entails the 
use of a knockout strain, in which one of the important genes necessary for 
oxidative stress resistance and detoxification (gst-4(ko)) is knocked out. The 
latter was crossed with the genetic disease model (UA44) to determine 
whether the gene in question (gst-4) is required for the activity of the RSP 
extract. 
5.3.5.1 C. elegans reporter strains for antioxidant related genes 
Antioxidant activity can either be direct or indirect (1.4.3 Exogenous 
antioxidants - natural products: direct and indirect antioxidant activity p.58 
ff.). The RSP extract has previously demonstrated direct antioxidant activity 
in several in vitro experiments (3.3.2 Antioxidant activity of final RSP extract, 
p.168 ff.). To determine whether the extract also exhibits indirect antioxidant 
activity in vivo, three C. elegans reporter strains for stress response genes 
(sod-3, gst-4 and gcs-1) were employed. Worms were treated with the 
extract from the egg stage till adulthood and were then analysed using 
fluorescence microscopy while comparing to vehicle treated (DMSO (1%)) 
control animals. Fluorescent imaging and the intensity analysis of one of the 
independent experiments are depicted in Figure 5.35 (p.339). 
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Figure 5.35|RSP extract treatment activats antioxidant pathways 
gst-4 and sod-3 in C. elegans 
Graphical results of the fluorescence intensity divided by the total area of each worm 
(n≥9) normalized to the respective pathway 1% DMSO control, statistical comparison 
via Two-way ANOVA and Bonferroni’s multiple comparisons test. The graph shows one 
representative example of the three experimental replicates. The pictures and the 
graph presented are from the same experimental day and represent all three pathways, 
gst-4, sod-3, gcs-1. A:bright field image of 1% DMSO control, B:GFP fluorescence 
picture of 1%DMSO control, C:bright field image of 4 mg/mL RSP extract treated 
animals, D:GFP fluorescence pictures of 4 mg/mL RSP extract treated animals. 10x 
objective, ISO 1600, exposure time set according to DMSO control (worm outlines 
barely visible), scale bar (bottom right corner in light microscopy pictures) 100 µm, 
*for better representation depicted in larger size in the appendix (Figure A24, p.467) 
The graph (top left) in Figure 5.35 presents the results obtained for the 
reporter strains, each strain normalized to its respective DMSO control. The 
results are shown for one of the three independent experiments. The 
additional two experiments showed very similar results. The graph as well as 
the microscopy pictures (gst-4 B compared to D) indicate a significant 
(p≤0.001) activation of gst-4 in the reporter strain in comparison to the DMSO 
(1%) control. The fluorescence intensity is more than 3 times higher. Also 
sod-3 is significantly activated after treatment with the RSP extract, however 
the activation is not as visual as for the gst-4 reported. In the fluorescent 
microscopy pictures for sod-3 (Figure 5.35 bottom righ and Figure A24, 
gcs-1 
sod-3 gst-4 
A 
A 
A 
B 
B B* 
C 
C C 
D 
D D* 
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p.467) a slight activation can be observed in the tail and head region of the 
animals. In contrast to gst-4 and sod-3, no activation of gcs-1 was observed. 
These results suggest that the RSP extract not only has direct antioxidant 
properties but can also exert indirect antioxidant activity, via the activation 
of antioxidant pathways in vivo within C. elegans. However, only certain 
pathways appear to be significantly activated (sod-3 and gst-4). Similarly 
curcumin (20 µM) has been shown to increase the expression of gst-4, 
however it did not significantly induce sod-3664. The same was true for garlic-
derived thioallyl compounds S-allylcysteine (SAC) and S-
allylmercaptocysteine (SAMC) as reported by Ogawa et al.666. Also coffee 
extracts showed an increase in the expression of gst-4 reporter strain in 
Dostal et al.665. When using a different reporter strain (MJCU032 {kEx32 [gst-
4p::gfp, pDP#MM016B]}), Hasegawa et al.698 showed that also allyl 
isothiocyanate, found in wasabi can induce gst-4 expression. Although some 
of the previously mentioned compounds were not able to induce sod-3 
expression there are other natural compounds that do, e.g. flavonoids 
quercetin, kaempferol and naringenin also found in the RSP extract699. 
Naringenin was tested for its direct antioxidant activity in the FRAP an the 
DPPH assay in this project and was found to have no or very little activity 
(2.3.11 Determination of antioxidant activity of single compounds within the 
extract as well as their mixtures, p.127 ff.), suggesting that compound do 
not necessarily need to have direct antioxidant activity to show indirect 
activation of antioxidant pathways. However, some compounds and extracts 
appear to have both direct and indirect activity700,701. 
For better understanding of these antioxidant pathways it is important to 
know, that harmful compounds such as juglone, paraquat and H2O2 can 
activate these pathways. However, at high concentrations these compounds 
can be harmful for the organism. In contrast, the RSP extract can induce 
these pathways without causing adverse effects, e.g. not toxicity and 
negative impact on fecundity or motility behaviour were observed (Figure 
5.22, p.312, Figure 5.25, p.317). Furthermore, the RSP extract even 
improves the observed devastating phenotypes (motility deficiency and 
DAergic neuronal loss). Further studies are necessary to determine exactly 
which compound/s in the extract is/are responsible for the activation of the 
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gst-4 and sod-3 antioxidant genes. The first compound that should be tested 
in this endeavour is sinapine, as it is the most abundant compound in the RSP 
extract. Fu et al.396 had shown that sinapine from Brassica rapa var. rapa L 
was able to increase SOD/CAT activation after a decrease caused by carbon 
tetrachloride (CCl4, hepatotoxin) in mice.  
The strong expression increase of gst-4, suggests the importance of this gene 
for the RSP extracts activity. To further investigate whether gst-4 activation 
is necessary to observe the positive effect of the RSP extract treatment, 
further studies using a gst-4 knock out (ko) strain were undertaken, which 
are described following. 
5.3.5.2 Determination of the significance of the gst-4 gene on the 
RSP extracts effect using a gst-4 knock out strain 
After determining the activation of gst-4 and sod-3 using the reporter strains 
above, the aim of the subsequent experiment was to determine whether the 
modulation these genes are necessary for the positive effect in the disease 
models after RSP extract treatment. Due to the fact that the gst-4 activation 
was more significantly increased than the sod-3 activity the decision was 
made to test the importance of gst-4 first. To do so a gst-4 knockout (gst-4 
(ko)) strain was obtained from the CGC (5.1.3.2 Antioxidant and 
detoxification pathway, p.282). The received strain was not back crossed and 
had to go through the same procedure as ace-1 and ace-2 previously (5.3.3.2 
Pharmacogenetic approach using two C. elegans mutants (knock out) for the 
AChE gene, p.325 ff.) using the method described in “5.2.2.3 Backcrossing 
and creation of double mutant strains-“worm crossings”” (p.292 ff.). After 
obtaining the 6xBC gst-4(ko) strain, it was crossed (Figure 5.18, p.300) with 
the UA44 (PD) disease model, to obtain double mutants, lacking the gene for 
the expression of gst-4. This double mutant strain was thereafter tested for 
DAergic neuronal morphology with the treatment of RSP extract and under 
control conditions (1% DMSO). 
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DAergic neuron loss and its prevention using RSP extract in 
UA44;gst-4(ko) double mutants 
To determine whether gst-4 expression is necessary for positive effect of the 
RSP extract in the PD model, animals were treated as previously described 
on NGM plates. In addition to the BZ555 (control) and the UA44 (control for 
DAergic neuron loss) this time also the double mutant was analysed for 
DAergic neuronal loss under vehicle (DMSO (1%)) treated conditions. Both 
UA44 and UA44;gst-4(ko) were  also treated using the RSP extract (4 mg/mL) 
(Figure 5.36). 
 
Figure 5.36| Conditions and strains used to determine the RSP 
extracts dependence on gst-4 in the UA44 strain 
In the previous experiment, when assessing the DAergic neuron loss of both 
UA44 and UA57, there was no significant difference between day 7 and day 
10 old animals, therefore only day 7 old animals were assessed following 
(Figure A23, p.466). 
Figure 5.37 (p.343) presents the results obtained as mean±standard 
deviation off the total number of worms (n≥24), collected from 2 independent 
experiments (n≥12 each). The number of experiments was reduced, due to 
the high significance observed after only 2 independent experiments. The 
knockout of the gst-4 gene however does not appear to have an impact on 
the neuronal phenotype of the UA44 strain, hence no significant difference 
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was observed between UA44 and UA44;gst-4(ko)  DMSO (1%) treated 
animals. As previously shown, the RSP extract treatment is able to reduce 
the DAergic neuronal loss significantly in the UA44 strain (p≤0.001). In 
contrast, when treating UA44;gst-4(ko) animals with the RSP extract, the 
number of DAergic neurons is not significantly higher than the number of 
DAergic neurons for the vehicle treated animals (Figure 5.37). 
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Figure 5.37| Protection of DAergic neurons in UA44 strain dependent 
on gst-4 activation  
DAergic neuron loss in BZ555, UA44 and UA44;gst-4(ko) animals comparing treated 
(RSP extract (4 mg/mL) and untreated (DMSO (1%)). Top: 2 independent experiments 
(n) were conducted with 12 replicates per strain each. For statistical analysis all 24 
worms per condition were accumulated. Statistical significant difference was 
determined using One-way ANOVA and Bonferroni’s multiple comparison analysis: 
***p≤0.001. Bottom: confocal imaging of DA neurons, scale bar 30 µm. Confocal 
imaging and neuron counting by Andreia Teixeira-Castro, experimental set-up by 
Victoria Lindsay. 
BZ555::1% DMSO UA44::4 mg/mL RSP ext. UA44::1% DMSO 
UA44;gst-4(ko)::1% DMSO UA44;gst-4(ko)::4 mg/mL RSP ext. 
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These results clearly suggest the strong dependence of the DAergic neuronal 
protection of the RSP extract on the activation of gst-4. In the absence of the 
gene, no protection is observed. Further studies using an AT3q130;gst-4(ko) 
double mutant are currently under investigation, to determine if gst-4 
activation is also necessary for the improved motility in the MJD model. 
Literature research indicated a lack of current knowledge in this area, no 
publications were found indicating the activation of gst-4 by RSP extracts or 
the importance of gst-4 activation as the pathway of action of PD/MJD medical 
treatment. Hence, these findings are extremely interesting, as they do not 
only present the potential application of RSP extract in the prevention or 
treatment of neurodegenerative disease, but they also indicate the 
importance of antioxidant/detoxification pathways in neurodegeneration. This 
could lead to the search of additional gst-4 activators with the potential to 
treat/prevent PD/MJD or even other neurodegenerative disease, since 
oxidative stress has been associated with most of them192,702.  
Further research is required to investigate through which pathway gst-4 is 
activated in C. elegans by the RSP extract. Although gst-4 is often associated 
with the activation of transcription factor skn-1 (Nrf2, Figure 1.29, p.60) there 
are however other potential pathways by which it can be activated e.g. 
through the epidermal growth factor (EGF) signalling pathway that was 
responsible for activation of gst-4 by royalactin (Figure 5.38, p.345) as 
presented by Detienne et al.660.  
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Figure 5.38|Activation pathway of gst-4 through epidermal growth 
Factor (EGF) signalling by royalactin  
Reprinted with permission from Taylor and Francis from Detienne et al.660 
Additional quantitative real-time PCR of the genes of interest or western blot 
analysis of protein expression could shed further light on the issue of pathway 
elucidation. One paper by Chege et al.206 elegantly summarizes most of the 
results obtained throughout our project for the PD models, in written as well 
as in graphical form (Figure 5.39). They highlighted the three different PD 
models (6-OHDA, CAT-2 and α-synuclein ) used here and how they induce 
DAergic neuronal damage through the production of ROS followed by lipid, 
protein and DNA/RNA damage. In addition, some mechanisms of potential 
counter action are presented, one of which is activation of GST (Figure 5.39), 
but also includes correct metal homeostasis. In vitro studies of the RSP 
extract showed its copper chelating properties, which might add to the 
extracts activity in vivo by keeping copper homeostasis in check. 
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Figure 5.39| Oxidative stress and metal homeostasis implications in 
PD 
Reprinted (minor modifications) with permission by corresponding author Gawain 
McColl from Chege and McColl206 
  
 
 
GST 
? 
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5.4 Conclusion/Future Work  
The in vivo experiments, using C. elegans, regarding the RSP extract 
treatment have shown very interesting and promising results. Whilst 
indicating no toxicity towards the model organism up to 5 mg/mL, the RSP 
extract was able to partially rescue the motility deficient phenotype of MJD 
as well as the DAergic neuron loss in three different PD models. These results 
indicate that the RSP extract might not only be able to help to prevent one 
single neurodegenerative disease but has the potential to prevent 
neurodegeneration in general. In particular, since the extract showed to 
prevent disease phenotypes related to protein aggregations (ataxin-3 (MJD) 
and α-synuclein (PD)), exogenous toxins (6-OHDA) and endogenous toxin 
production (CAT-2). All these different mechanisms have been closely 
associated with neurodegeneration in other neurodegenerative disease, e.g. 
AD, ALS and MS. Therefore, these results provide a solid basis for further 
studies into the potential use of the RSP extract to prevent and treat other 
neurodegenerative disease. As indicated previously, there are several 
additional C. elegans models for all the different neurodegenerative diseases, 
including AD, ALS, HD as well as prion related disease610. All these models 
present different behaviours or show phenotypical changes, which can be 
assessed to give additional valuable insights into the RSP extracts potential 
in neurodegenerative research. Due to the observed potential of the RSP 
extract to reduce Aβ42 aggregation in vitro (Figure 3.35), one interesting 
model would be either of the Aβ42 AD C. elegans models, e.g. strain CL4176 
(Pmyo-3::Aβ42), in which the Aβ42 is inducible via temperature upshift. This 
model has previously been used to show that coffee665, as well as tea seed 
pomace (Camellia tenuifoliacan) extracts238 can reduce the by Aβ42 induced 
paralysis.  
In addition, we also showed the importance of the indirect antioxidant activity 
of the extracts with the activation of gst-4 and sod-3 in the reported strains. 
This activity could be investigated further by (i) including reporter strains for 
other antioxidant/detoxification pathways e.g. CAT, GSH GPx and other 
SODs/GSTs or (ii) determining the expression increase on a genetic level i.e. 
quantitative real-time PCR of mRNA expressions after RSP extract treatment 
(work in progress, data not shown).  
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Crossing the gst-4(ko) strain with the UA44 PD model, to create the double 
mutant, revealed the significant importance of the RSP extracts on the 
presence of  the intact gst-4 gene. In the absence of the gene, the RSP extract 
does not show the decreased DAergic neuronal loss. Further studies could on 
the one hand identify if additional antioxidant genes are necessary for the 
observed effect. Sod-3 for example was also significantly upregulated in the 
reporter strains and could be another important gene of interest. On the other 
hand, as gst-4 has already been shown to be of significant interest, further 
studies should determine through which pathway it is activated. Most often 
gst-4 is described to be dependent on skn-1 (Nrf2) activation. However, 
further research has suggested the potential dependence on epidermal 
growth factor (EGF) and EOR-1 signalling in C. elegans. So was royal actin 
treatment for example skn-1 independent but eor-1 dependent660. The skn-1 
dependence of the RSP extract effect can be determine by (i) using rt-qPCR, 
(ii) use of reporter strains (LD1) or (iii) the use of knockout strains skn-1 
(zu67) and eor-1(cs28)660. 
The overview in Figure 5.39 (p.346) describes the downstream detrimental 
effects caused by the production of ROS (lipid, protein and DNA/RNA 
damage), which then lead to the DAergic neuronal loss. To better understand 
the background of the used models (MJD and PD), further studies should 
initially determine the effect that the endogenous and exogeneous toxins 
have on the ROS production and the cellular components (DNA/RNA, proteins, 
lipids). As previously indicated to determine ROS levels in C. elegans, the 
same dye, used for the SH-SY5Y cell line, can be employed and ROS be 
analysed in N2 compared to the disease strains, to determine whether the 
genetic modification or the external stressors (6-OHDA) induce increased 
levels of ROS. In addition, the disease models can be analysed, comparing 
treated to untreated, to determine if the RSP extract treatment is able to 
decrease ROS production in vivo as well as in vitro. 
To determine lipid damage, one of the most widely studied compounds is 
malondialdehyde (MDA), a lipid peroxidation product. MDA can be detected 
via HPLC703, the thiobarbituric acid (TBA) method704 or assay kits696. Also 
other lipid peroxidation products can be determined, such as lipid 
hydroperoxides and 4-hydroxynonenal206. Furthermore, the level of DNA 
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damage could be determined in the different PD and the MJD models. To 
determine whether the extract is able to prevent DNA damage in vivo, the 
comet assay705 or a number of stressors known to induce DNA damage can 
be employed706. These stressors e.g. UV irradiation, γ-IR, hydroxyurea, 
camptothecin or nitrogen mustard (HN2) can induce different DNA lesions, 
which have a negative impact on embryonic viability and larva lethality, which 
can be measured by observation of the progeny706. Overall the so far obtained 
results for the RSP extract in C. elegans look very promising and grant further 
research into their potential use for the treatment or prevention of 
neurodegenerative disease, especially when being able to determine the 
active component or components. 
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6 OVERALL CONCLUSION ON 
THE POTENTIAL OF THE RSP 
EXTRACT 
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Neurodegenerative diseases are on the rise and currently no cures are 
available. Thus, with the constantly growing world population, the issues 
associated with these diseases will further increase. Research into these 
diseases with the aim to find drug treatments has become increasingly 
important. However, so far research has been unsuccessful in determining 
the RSP extracts molecular mechanisms behind these diseases and to find 
successful cures. In this project, we aimed to find potential 
treatments/preventions using an extract obtained from a natural waste/by-
product called rapeseed pomace (RSP). The decision was made to employ a 
food by-product that is currently being used only as animal feed. Because of 
the growing world population, the need for food resources has been 
increasing and so the use of food products themselves to extract natural 
products from to treat diseases is not a desirable undertaking. However, 
using food production by-products has many advantages that include: (i) 
reduces the amount of waste accumulated, (ii) does not impact the amount 
of food available for consumption and (iii) adds extra value to the by-product. 
During this project the Soxhlet extraction method was found to produce the 
most antioxidant active RSP extract, with practical handling properties (dry 
powder sample). The 95% aqueous ethanolic extract, obtained from defatted 
(petroleum ether extraction) RSP, showed in vitro antioxidant activity in a 
number of different assays in addition to acetylcholinesterase inhibition 
activity, plasmid DNA protection under oxidative stress, copper chelating 
properties and the prevention of self-mediated β-amyloid aggregation. To 
determine whether the extract would show similar positive results in a cellular 
system, SH-SY5Y neuroblastoma cells were employed. Here the extract 
showed low toxicity (non-toxic till 1.5 mg/mL), the protection of cells from 
hydrogen peroxide induced ROS production as well as the prevention of DNA 
strand breakage. Investigation of activity of the extract at the molecular 
protein level, showed that SIRT2 and SOD2, associated with cell stress, were 
down regulated after RSP extract treatment of the cells. 
Although all these promising results showed potential for the RSP extract to 
aid in the prevention of neurodegeneration associated with oxidative stress, 
further in depth in vivo studies were necessary to explore the extract’s full 
potential. Thus, the Machado-Joseph disease (MJD) C. elegans model was 
applied where the extract significantly improved the motility deficient 
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phenotype. However, this improvement in motility was not related to a 
decrease in number or area of ataxin-3 aggregations within the C. elegans  
MJD model system. To determine whether the RSP extract was selective in 
ameliorating MJD, we also employed three Parkinson’s disease C. elegans 
strains, all of them demonstrated typically PD associated dopamine(DA)ergic 
neuron loss. Once treated with the RSP extract, this DAergic neuronal loss 
was significantly decreased. Hence, the neuroprotective effect of RSP extract 
does not appear to be specific to a certain neurodegenerative disease but 
seems to affect neurodegeneration in general. Further studies using other 
disease strains would support this conclusion. Additional studies, using C. 
elegans, were initiated to determine the mechanism of action of the RSP 
extract. Whilst the results for the AChE inhibition hypothesis were 
inconclusive, investigations into the importance of antioxidant response 
genes appeared very promising. In the C. elegans reporter strains, GFP 
expression increase for sod-3 and gst-4 and subsequent studies using gst-4 
knockout strains, suggested the importance of the gst-4 gene for the show 
positive effect seen with the RSP extract. 
Overall this study investigated the chemical composition of the RSP extract 
together with its in vitro and in vivo activity. However, before the extract can 
enter clinical trials, a number of further experiments are necessary. These 
include more detailed studies into the pathway of action, as well as studies 
determining a potential active ingredient (e.g. sinapine) which is responsible 
for the observed activity. Furthermore, studies using mammalian models 
(e.g. mice or rats) would give a second input on toxicity data and determine 
whether the RSP extract is active in other models of neurodegenerative 
diseases. If positive activities of the extract as a total or potentially isolated 
compounds can be shown, then the extract/compounds would have good 
chances of getting into clinical studies or could be used as food additive with 
positive impact on neuro protection such as seen previously for gingko biloba. 
However, very often, when moving up the ladder of model complexity, the 
positive activity of drugs is lost. Even if this were the case, further studies 
into determining why the RSP extract is only active in certain model 
organisms could enhance the knowledge of neurodegenerative disease and 
might help to create better animal model for future drug testing. In general, 
the RSP extract shows overall promising potential for the 
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treatment/prevention of neurodegenerative disease and further research is 
recommended. 
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This last section forms the appendix. It contains information, important for the 
project which didn’t fit into the context of the chapters above. The Appendix is 
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Hence each subsection in this appendix contains information important for the 
chapter indicated e.g. A2 “Secondary Metabolite Composition and Antioxidant Activity 
of Rapeseed Pomace Extracts – comparison between 2 harvest years and 3 extraction 
techniques” contains information relevant for Chapter 2.  
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A2 Secondary Metabolite Composition and Antioxidant Activity of Rapeseed Pomace 
Extracts – Secondary Metabolite Composition and Antioxidant Activity of Rapeseed 
Pomace Extracts – comparison between 2 harvest years and 3 extraction 
techniques 
Table A1| Explanation of various extraction techniques used for plant and plant by-products, food waste/food 
production waste (adapted from various sources245,247,252,258,273,707,708 ) 
Extraction 
technique 
explanation advantages disadvantages used 
in  
maceration Soaking of plant material in 
solvent containing stoppered 
container at room temperature 
for long period (at least 3 days) 
with agitation, followed by 
straining and filtering, “cold 
extraction” 
- Easy 
- No expensive equipment 
- Flexible choice of 
solvents/mixtures 
- cheap 
- Time consuming 
- Amount of solvent  
- Choice of container 
(resistance to 
solvent for long 
time, take up of 
compounds to be 
extracted, 
contamination for 
following extraction) 
249,709 
Infusion Similar to maceration; boiling 
water/oil/alcohol is placed over  
sample remains suspended in 
solvent for a shorter amount of 
time (minutes), usually 
prepared for immediate use. 
- Easy 
- No expensive equipment 
needed 
- Cheap 
- Made for immediate use 
- Amount of solvent 
- High temp. Might 
impact on 
metabolites 
- Solvent choice 
limited if used 
immediately 
320,710 
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Digestion Form of maceration, using 
gentle heat throughout the 
extraction process with solvent, 
used when higher temperatures 
are not objectionable, increasing 
solvent efficiency 
- Easy  
- Cheap 
- Better extraction via heat 
- No expensive equipment 
 711 
Percolation Starting material is moistened 
and left for a few hours, the 
packed into the percolator, more 
solvent added and  the 
percolator left to macerate for 
about 1 day and then the outlet 
is opened, and the extract left to 
drip out into the collection 
vessel slowly, additional solvent 
can be added. The process is 
finished by filtration or 
decanting. 
- Easy  
- Cheap 
- Percolator necessary 
- High amount of 
solvent 
249 
Decoction Plant material is placed in cold 
water and the boiled for certain 
amount of time, sometimes with 
a specific volume of water to 
sample ratio (1:4 or 1:16 
sample:water); and the water 
evaporated to parts of its 
original volume, the extract is 
then cooled a strained/filtered. 
Used for water soluble, heat 
stable compounds. 
- Easy  
- Cheap 
- Water as solvent 
- Only for heat 
resistant compounds 
249,712 
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Soxhlet 
(traditional and 
automated) 
Sample is placed in a cellulose 
thimble, which is placed into the 
solvent, extraction can be done 
using different temperatures 
and times, solvent is partially 
evaporated and used for rinsing 
the sample within the 
automated system. 
- Can be automated 
- Easy 
- Solvent can be re-used, as it 
is collected in reservoir 
- Reduced extraction time due 
to heat and automated 
system 
- Rinse cycle displaces the 
transfer equilibrium 
- Amount and 
temperature of 
solvent 
- Soxhlet equipment 
needed  
- Extraction time can 
be long 
- Volume of solvent 
 
249,262,35
3 
Microwave- 
assisted 
Sample extraction is facilitated 
using microwave energy, which 
interacts polar and polarizable 
materials, such as polar 
solvents, causing them to heat 
up; a vapour pressure within the 
cell can be generated which can 
break cell walls to release 
compounds of interest. 
- Reduced extraction time due 
to microwave radiation (fast) 
- Less solvent use possible 
- Energy efficient, uniform 
heating 
- Easy to handle 
- Microwave 
equipment needed 
- Thermal degradation 
possible of e.g. 
tannins and 
anthocyanins 
- Selective for polar 
compounds 
 
713–715 
Ultra sound-
assisted/ 
sonication  
(bath or probe) 
Uses ultra sound in the range of 
20kHz to 2000kHz, which 
increases the surface contact 
between solvent and sample via 
acoustic cavitation. Disruption 
of plant cell walls can facilitate 
compound release.  
- Reduced extraction time and   
   solvent amount 
- Relatively cheap 
- Sonic bath available in most  
   Laboratories 
- Safe to use (atmospheric 
pressure) 
- Temperature changeable 
 
- High ultra sound 
energy can have 
effect on 
phytochemicals  
- Filtration required 
after processing 
 
255,715,71
6 
Counter-current A wet raw material is pulverized 
to obtain a slurry, it is brought 
in contact with the solvent in a 
cylindrical extractor in which the 
slurry is mixed with the solvent 
and then separated through 
different outlets. 
- Efficient 
- Quick 
- No high temperatures 
- Less solvent  
- Equipment 
necessary 
 
717,718 
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Accelerated 
solvent/ 
pressurized 
fluid  
Uses the help of pressure to 
reduce the needed temperature 
for extraction, samples are 
packed within layers of inert 
material such as sand and filters 
in an extraction cell. The solvent 
is passed through the cell under 
high pressure and relatively low 
temperature and the extract 
collected. 
- Very efficient extraction 
- Can be automated 
- Very low amount of solvent 
- Lower temperature possible 
due to high pressure 
- Short extraction time 
- No filtering required 
- High cost of 
equipment 
- Sample preparation 
in cells time 
consuming 
276,719 
Supercritical  
fluid 
A technique using supercritical 
fluid, such as CO2 at their 
respective supercritical fluid 
temperature and pressure 
(<31.1°C and 7380kPa for CO2). 
Supercritical fluids behave like 
gasses but show solvating 
characteristics of liquid. Also, 
Argon can be used as solvent. 
- Very efficient 
- No organic solvent needed 
- CO2 low cost and toxicity 
- Less heat required 
- Fast 
- High cost of 
equipment 
- Polarity limitations 
of CO2, addition of 
organic solvents can 
counter-act issue 
- Number of 
parameters to 
optimise 
720,721 
Steam  Often used for the extraction of 
essential oils from plant 
material, using steam, which is 
passed through the plant 
material, vaporized compounds 
travel to the condenser and are 
collected after separation from 
water. 
Isolation of volatile compounds 
(essential oils, amines, organic 
acids) 
- High energy 
consumption 
- High temperatures 
- System need to be 
set up 
722,723 
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Enzyme-
assisted 
This method uses enzymes, 
which work as catalysts, to 
enhance the extraction; they 
can also break cell walls and 
membranes, helping to release 
compounds of interest 
- Eco-friendly 
- Specificity and 
regioselectivity 
- Use of mild processing 
conditions 
- Lower amount of solvent 
- Can be assisted by other 
techniques such as 
microwave 
- Need of enzymes 
- Enzymes usually 
have an optimal 
temperature, 
change from this 
can impact 
extraction efficiency 
724,725 
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Table A2| Comprehensive secondary metabolite composition of 6 RSP extracts.  
  
 
2012 2014 
 
2012 2014 
 
2012 2014 
 
  
FA 
 
ALK 
 
ACD 
 
  
mean std mean std t-test mean std mean std t-test mean std mean std t-test 
Benzoic Acids benzoic acid 5.081 0.083 3.888 0.728 * 9.219 1.201 12.531 0.373 * 7.008 1.069 7.266 1.090 
 
salicylic acid 0.238 0.031 0.420 0.156 
 
0.239 0.055 0.286 0.035 
 
0.536 0.055 0.757 0.067 * 
m-hydroxybenzoic acid 0.573 0.089 0.498 0.041 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
p-hydroxybenzoic acid 3.843 0.066 5.201 0.888 
 
4.209 0.411 6.049 0.566 * 8.473 0.154 6.824 0.227 *** 
2,3-dihydroxybenzoic  
acid 
0.100 0.001 0.121 0.007 ** 0.181 0.007 0.228 0.018 * 0.404 0.019 0.437 0.017 
 
2,4-dihydroxybenzoic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
2,5-dihydroxybenzoic  
acid 
0.460 0.014 0.481 0.082 
 
0.000 0.000 0.000 0.000 
 
3.704 0.228 2.375 0.078 *** 
2,6-dihydroxybenzoic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
protocatechuic acid 2.521 0.040 5.396 0.812 ** 16.543 3.762 24.116 1.203 * 17.143 0.534 17.423 0.935 
 
3,5-dihydroxybenzoic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
o-anisic acid 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
m-anisic acid 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
p-anisic acid 0.585 0.046 1.016 0.110 ** 1.310 0.127 2.682 0.146 *** 0.208 0.010 0.313 0.020 ** 
gallic acid 0.000 0.000 0.838 0.066 *** 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.259 0.016 *** 
vanillic acid 1.826 0.162 2.551 0.336 * 1.608 0.192 2.275 0.123 ** 14.737 0.353 13.770 0.344 * 
syringic acid 2.386 0.039 5.658 1.032 ** 1.195 0.151 1.320 0.066 
 
4.864 0.245 4.500 0.121 
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3,4-dimethoxybenzoic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Benzaldehydes p-hydroxybenzaldehyde 0.217 0.016 0.153 0.027 * 0.715 0.101 0.849 0.073 
 
0.604 0.048 0.560 0.024 
 
protocatachaldehyde 2.141 0.067 2.463 0.349 
 
19.539 5.718 23.332 2.033 
 
11.956 0.700 12.066 0.712 
 
3,4,5-trihydroxy- 
benzaldehyde 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.159 0.144 
 
0.000 0.000 0.000 0.000 
 
vanillin 0.714 0.003 0.536 0.078 * 1.682 0.209 1.825 0.063 
 
1.201 0.128 1.269 0.092 
 
isovanillin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
syringin 0.965 0.011 0.746 0.107 * 1.841 0.228 2.049 0.003 
 
1.826 0.282 1.812 0.215 
 
3-methoxy- 
benzaldehyde 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
3,4-dimethoxy- 
benzaldehyde 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.028 0.002 0.027 0.004 
 
3,4,5-trimethoxy- 
benzaldehyde 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Cinnamic Acids cinnamic acid 2.512 0.053 1.366 0.174 *** 0.489 0.015 0.490 0.033 
 
0.450 0.013 0.488 0.021 
 
o-coumaric acid 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
m-coumaric acid 0.145 0.252 0.000 0.000 
 
0.080 0.139 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
p-coumaric acid 2.162 0.008 1.933 0.340 
 
10.754 6.601 6.842 5.163 
 
0.249 0.009 0.285 0.028 
 
caffeic acid 5.538 0.119 7.540 1.275 
 
13.427 0.769 20.661 2.090 ** 6.510 0.381 6.759 0.339 
 
ferulic acid 12.251 0.302 9.570 1.627 * 64.554 39.367 38.645 2.074 
 
1.527 0.166 1.232 0.056 * 
sinapic acid 224.235 3.577 161.400 25.548 * 917.650 43.784 1072.136 32.380 ** 11.312 1.378 10.540 1.249 
 
3-methoxycinnamic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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4-methoxycinnamic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
3,4-dimethoxycinnamic  
acid 
0.066 0.006 0.051 0.011 
 
0.381 0.035 0.926 0.019 *** 0.000 0.000 0.000 0.000 
 
3,4,5-trimethoxycinnamic  
acid 
0.031 0.003 0.025 0.003 
 
0.131 0.019 0.284 0.013 *** 0.000 0.000 0.000 0.000 
 
Phenylpropionic acids phenylpropionic acid 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
1.871 0.091 1.548 0.216 
 
2-hydroxyphenyl- 
propionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
3-hydroxyphenyl- 
propionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
4-hydroxyphenyl- 
propionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
3,4-dihydroxyphenyl- 
propionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
1.243 0.048 1.309 0.040 
 
4-hydroxy-3-methoxy- 
phenylpropionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.113 0.195 
 
0.291 0.039 0.282 0.025 
 
3-methoxyphenyl- 
propionic acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Benzenes phenol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.821 0.062 1.020 0.172 
 
1,2-hydroxybenzene 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
1,3-hydroxybenzene 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
1,2,3-trihydroxy- 
benzene 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Acetophenones 4-hydroxyaceto- 
phenone 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.031 0.005 0.034 0.004 
 
4-hydroxy-3-methoxy- 
acetophenone 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.088 0.009 0.077 0.005 
 
4-hydroxy-3,5-dimethoxyaceto- 
phenone 
0.125 0.009 0.088 0.018 * 0.257 0.045 0.336 0.021 
 
0.308 0.060 0.277 0.020 
 
3,4-dimethoxyaceto- 
phenone 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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3,4,5-trimethoxyaceto- 
phenone 
0.00
0 
0.00
0 
0.00
4 
0.00
1 
*
* 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
Phenylacetic acids phenylacetic acid 0.56
2 
0.03
1 
0.43
3 
0.05
2 
* 1.18
7 
0.11
0 
1.322 0.05
9 
 
0.115 0.00
2 
0.124 0.00
2 
** 
3-hydroxyphenyl- 
acetic acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
4-hydroxyphenyl- 
acetic acid 
0.37
6 
0.08
0 
0.60
8 
0.12
1 
 
3.27
8 
0.29
3 
4.052 0.39
0 
 
1.794 0.18
5 
2.747 0.84
4 
 
3,4-dihydroxyphenyl- 
acetic acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
4-hydroxy-3-methoxyphenyl- 
acetic acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
4-methoxyphenyl- 
acetic acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
Mandelic Acids mandelic acid 0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
3-hydroxymandelic 
acid 
0.12
2 
0.01
3 
0.09
6 
0.00
6 
* 2.92
3 
0.43
6 
3.938 0.21
4 
* 2.350 0.32
0 
3.049 0.13
8 
* 
4-hydroxymandelic 
acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
3,4-dihydroxymandelic 
acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
4-hydroxy-3-methoxymandelic 
acid 
0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
Phenypyruvic 
Acids 
phenylpyruvic acid 0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
4-hydroxyphenylpyruvic 
acid 
1.67
4 
0.26
2 
7.46
3 
3.97
9 
 
7.88
5 
4.03
7 
17.92
1 
1.56
2 
* 13.57
0 
0.32
5 
13.86
2 
2.49
1 
 
Phenyllactic Acids phenyllactic acid 0.80
2 
0.06
2 
0.57
2 
0.05
1 
*
* 
0.48
6 
0.01
7 
0.235 0.01
3 
**
* 
0.534 0.05
1 
0.192 0.03
9 
**
* 
4-hydroxyphenyllactic 
acid 
0.53
1 
0.03
8 
0.58
5 
0.06
6 
 
0.40
8 
0.06
0 
0.447 0.07
1 
 
0.558 0.09
2 
0.611 0.25
6 
 
Phenolics Others anthranilic acid 0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.22
9 
0.06
0 
0.454 0.01
3 
** 0.000 0.00
0 
0.043 0.00
7 
**
* 
quinadilic acid 0.00
0 
0.00
0 
0.00
0 
0.00
0 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
chlorogenic acid 0.99
0 
0.19
4 
1.02
0 
0.09
4 
 
0.00
0 
0.00
0 
0.000 0.00
0 
 
0.000 0.00
0 
0.000 0.00
0 
 
0-hydroxyhippuric acid 0.01
6 
0.00
2 
0.01
1 
0.00
2 
 
0.06
4 
0.00
4 
0.073 0.00
3 
* 0.000 0.00
0 
0.000 0.00
0 
 
  
4
3
3
 
F
ra
n
z
is
k
a
 P
o
h
l 
A
p
p
e
n
d
ic
e
s
 
A
p
p
e
n
d
ic
e
s
 
 
 
ethylferulate 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
4-hydroxyl 3-methoxyl benzyl alcohol 0.030 0.005 0.057 0.010 * 0.012 0.010 0.013 0.003 
 
0.039 0.022 0.019 0.002 
 
p-cresol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
4-ethylphenol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
4-methylcatechol 0.000 0.000 0.000 0.000 
 
0.004 0.001 0.000 0.000 *** 0.012 0.001 0.014 0.002 
 
tyrosol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
hydroxytyrosol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Phenolic Dimers ellagic acid 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
ferulic dimer  
(5-5 linked) 
0.000 0.000 0.000 0.000 
 
3.744 3.481 0.383 0.042 
 
0.000 0.000 0.000 0.000 
 
ferulic dimer  
(8-8 linked) 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
ferulic dimer  
(8-5 linked) 
0.000 0.000 0.000 0.000 
 
1.852 1.562 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Hydrogenated Ferulic 
Dimer H5-5 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
reservatrol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
indole 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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Indoles indole-3-acetic acid 0.117 0.010 0.105 0.006 
 
0.211 0.023 0.326 0.020 ** 0.112 0.031 0.123 0.012 
 
indole-3-acrylic acid 0.000 0.000 0.000 0.000 
 
0.014 0.003 0.019 0.002 
 
0.000 0.000 0.000 0.000 
 
 
indole-3-propionic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
indole-3-carbinol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
indole-3-carboxylic  
acid 
0.824 0.026 0.609 0.056 ** 0.967 0.178 1.314 0.090 * 0.097 0.034 0.074 0.005 
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indole-3-pyruvic  
acid 
3.040 0.392 53.540 87.112 
 
76.168 131.927 197.678 37.956 
 
381.396 71.970 223.575 123.479 
 
indole-3-methyl 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
indoe-3-lactic  
acid 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Amines spermine 0.016 0.003 0.012 0.001 
 
0.015 0.002 0.017 0.002 
 
0.013 0.002 0.014 0.001 
 
spermidine 3.796 0.691 3.669 0.126 
 
2.742 0.012 2.666 0.111 
 
2.583 0.097 2.422 0.209 
 
tyromine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
pyrollidine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
histamine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
piperidine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
cadaverine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
putresine 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
5-OHtryptophan 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Flavanoids/Coumarins Coumarin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Psoralen 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.006 0.000 0.000 0.000 *** 
8-methylpsoralen 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Bergapten 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Tangeretin 0.008 0.001 0.003 0.000 ** 0.003 0.001 0.003 0.000 
 
0.003 0.000 0.002 0.000 ** 
Cyanidin-3- 
Galactoside 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Peonidin-3- 
Glucoside 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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Petunidin-3- 
Glucoside 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Malvin-3- 
Glucoside 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Coumesterol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Catechin 0.000 0.000 0.000 0.000 
 
0.497 0.861 0.341 0.226 
 
0.000 0.000 0.000 0.000 
 
Epicatechin 0.000 0.000 0.091 0.033 ** 0.986 1.493 0.456 0.385 
 
0.000 0.000 0.000 0.000 
 
Gallocatechin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Epigallocatechin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Epigallocatechin  
Gallate 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Isoliquiritigenin 0.012 0.007 0.000 0.000 * 0.004 0.004 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Phloretin 0.011 0.004 0.021 0.004 * 0.004 0.003 0.007 0.001 
 
0.009 0.001 0.006 0.006 
 
Imperatorin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Eriocitrin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Naringenin 0.052 0.007 0.034 0.008 * 0.053 0.011 0.211 0.078 * 0.023 0.002 0.031 0.002 ** 
Naringin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Hesperitin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Kaempferol 0.193 0.010 0.754 0.527 
 
0.105 0.008 0.195 0.013 *** 141.301 6.773 152.623 5.535 
 
Morin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Quercetin 0.103 0.035 0.072 0.012 
 
0.453 0.403 0.397 0.086 
 
3.678 0.299 5.496 0.300 ** 
Myricetin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Quercetin-3-Glucoside 0.137 0.032 0.443 0.116 * 0.114 0.009 0.562 0.203 * 0.000 0.000 0.000 0.000 
 
Taxifolin 0.000 0.000 0.000 0.000 
 
0.121 0.073 0.131 0.037 
 
0.475 0.211 0.374 0.062 
 
Genstein 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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Scopoletin 0.017 0.029 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.028 0.049 0.011 0.019 
 
Umbelliferone 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
7,8-dihydroxy-6- 
methyl coumarin 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Neohesperidin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Hesperidin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Quercitrin 0.012 0.013 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Biochanin A 0.018 0.011 0.000 0.000 
 
0.005 0.005 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Poncirin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Didymin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Phloridzin 0.090 0.002 0.084 0.012 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Daidzein 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Galangin 0.218 0.238 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.073 0.007 *** 
Luteolin 0.596 0.070 0.305 0.377 
 
0.189 0.021 4.353 6.836 
 
0.043 0.014 0.168 0.190 
 
Equol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Fisetin 0.048 0.027 0.000 0.000 * 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Luteolinidin 0.055 0.049 0.000 0.000 
 
0.071 0.004 0.064 0.004 
 
0.034 0.004 0.032 0.003 
 
Neoeriocitrin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Isorhamnetin 1.213 0.386 0.718 0.027 
 
0.601 0.327 0.491 0.015 
 
15.737 0.413 18.571 1.166 * 
Formononetin 0.008 0.001 0.000 0.000 *** 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Apigenin 1.273 1.960 0.039 0.029 
 
0.139 0.200 0.124 0.192 
 
0.025 0.010 0.020 0.002 
 
Gossypin 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.235 0.027 0.128 0.112 
 
Glycitein 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
2OHBAlc 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
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coniferyl alcohol 0.000 0.000 0.000 0.000 
 
1.848 0.371 2.057 0.536 
 
0.000 0.000 0.000 0.000 
 
BCA 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BGCA 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BGDCA 0.010 0.017 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BGUDCA 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BGChDCA 0.009 0.015 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BTCA 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BTDCA 0.007 0.012 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BTUDCA 0.002 0.004 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BTChDCA 0.007 0.013 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
BDCA 0.319 0.124 0.228 0.094 
 
0.172 0.021 0.088 0.063 
 
0.264 0.014 0.040 0.069 ** 
BChDCA 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
seco 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
mata 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
e-diol 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
e-lac 0.078 0.017 0.039 0.014 * 0.061 0.005 0.006 0.000 *** 0.045 0.004 0.000 0.000 *** 
syrg 1.234 0.072 0.559 0.485 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
pino 0.486 0.069 0.000 0.000 *** 0.238 0.074 0.000 0.000 ** 0.000 0.000 0.000 0.000 
 
lari 0.475 0.026 0.154 0.071 ** 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
OH-mata 0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
0.000 0.000 0.000 0.000 
 
Note(s): Statistical significance determined without correction for multiple comparisons, with alpha=0.05%. Each row was analysed individually, 
without assuming a consistent SD, multiple t-test, analysing each extraction separately, GraphPad Prism 
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FRAP assay spectrum example
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Figure A1 | Example absorbance measurement for FRAP assay (350-
800 nm) 
Determining 593 nm as absorbance maximum and wavelength used for the experiment 
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Figure A2 | Absorbance spectra for DPPH  assay  
Solution before and after reaction with a radical scavenger (SA) and the methanol 
negative control 
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Table A3 | Secondary metabolite composition of various Brassica 
plants  
Secondary 
metabolite 
cabbage 
kale broccoli cauliflower 
RSP 
 red white 2012 2014 
Sinapic acid 2891 445.3 2001 134.9 34.42 1153 1244 
Coumaric 
acid 
m 
372.0 / 8.195 
na na 
 
0.226 
/ 
o 2.575 3.767 / / 
p 2.632 5.673 13.17 9.059 
Ferulic acid 185.7 4.724 106.4 50.10 6.545 78.33 49.45 
Benzoic acid 2.846 3.805 7.728 5.987 5.445 21.31 23.69 
quercetin 6.039 0.8761 125.8 / / 0.012 / 
kaempferol / / / 19.88 0.1466 141.6 153.6 
p-
hydroxybenzoic 
acid 
20.88 2.385 12.03 4.618 9.464 16.53 18.07 
indol-3-pyruvic 
acid 
/ / / / / 460.6 474.8 
Note(s): Concentrations for all the samples given in mg/kg dry weight plant material 
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A3  Phytochemical Characterisation and 
Neuroprotective Properties of RSP Extract 
Phytochemical Characterisation and 
Neuroprotective Properties of RSP Extract in 
vitro 
sinapinemix 1unknown
FRAP
6.53%
48.45%
45.03%
DPPH
8.42%
73.16%
18.42%
FC
47.23%
7.32%
45.45%
ORAC
14.99%
35.26%
49.75%
 
Figure A3| Comparison of sinapine and phenolic acid mixture (mix1) 
contribution to antioxidant activity of the extract in %, highlighting 
the unknown fraction 
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Figure A4| DAD spectra of GLS standards compared to DAD spectra 
of RSP extract at same retention time 
Glucoraphanin 
Glucoraphenin 
RSP extract 
RSP extract Gluconapin 
Glucobrassicanapin 
RSP extract 
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Figure A4| continued  
Glucotropaeolin 
RSP extract 
Glucobrassicin 
RSP extract 
Gluconastartiin 
RSP extract 
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Figure A5| Comparison of chromatogram obtained for the RSP extract 
(red) and the RSP (blue), arrows indicating where the standards 
would be 
 
𝐁𝐚𝐜𝐤 𝐜𝐚𝐥𝐜𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐆𝐋𝐒𝐬 𝐢𝐧 𝐜𝐨𝐥𝐝 𝐩𝐫𝐞𝐬𝐬𝐞𝐝 𝐑𝐒𝐏 𝐟𝐫𝐨𝐦 𝐆𝐋𝐒 𝐜𝐨𝐧𝐭𝐞𝐧𝐭  
𝐨𝐟 𝐑𝐒𝐏 𝐞𝐱𝐭𝐫𝐚𝐜𝐭 𝐨𝐧 𝐞𝐱𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐏𝐫𝐨𝐠𝐨𝐢𝐭𝐫𝐢𝐧: 
𝑦𝑖𝑒𝑙𝑑 = 76 𝑚𝑔 𝑒𝑥𝑡𝑟𝑎𝑐𝑡/1𝑔 𝑅𝑆𝑃 
𝑃𝑟𝑜𝑔𝑜𝑖𝑡𝑟𝑖𝑛 𝑖𝑛 𝑅𝑆𝑃 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 = 2.197 𝑚𝑔/𝑔 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 
2.197 𝑚𝑔 𝑝𝑟𝑜𝑔𝑜𝑖𝑡𝑟𝑖𝑛/1𝑔 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 = 0.167 𝑚𝑔 𝑝𝑟𝑜𝑔𝑜𝑖𝑡𝑟𝑖𝑛/ 76 𝑚𝑔 𝑅𝑆𝑃 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 
0.167 𝑚𝑔 𝑝𝑟𝑜𝑔𝑜𝑖𝑡𝑟𝑖𝑛/76 𝑚𝑔 = 0.167 / 1𝑔 𝑅𝑆𝑃 
Figure A6| Calculation of GLS in RSP from results obtained in RSP 
extract, using the extraction yield 
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Figure A7| AChE inhibition activity of RSP extract at 1 mg/mL 
together with sinapine, a mixture of sinapine and phenolic acids and 
the phenolic acids at the extract specific concentration 
 
 
Table A4|Emission values for the self-mediated β-amyloid 
experiment 
sample Mean excitation control 
Corrected 
mean 
significance 
Peptide  
146.9 
28.43# 140.5 ± 19.74  174.9 
185.0 
curcumin 
64.21 
28.43 33.9 ± 2.154 *** 59.99 
62.85 
Extract (0.0455 
mg/mL) 
145.8 
28.39 108.6 ± 7.873 * 134.87 
130.52 
Extract (0.455 
mg/mL) 
126.91 28.43# 95.44 ± 7.475 ** 
115.35    
129.34 73.68 50.19 ± 7.475 *** 
Note(s): Excitation wavelength 446 nm and emission wavelength 490 nm, #same ThT 
control; statistical significant difference analysis via One-way ANOVA and 
Bonferroni’s multiple comparisons analysis between the β-amyloid control and 
treatments, p≤0.05*, P≤0.01**, p≤0.001*** 
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Figure A8| 96-well plate iron chelating 
(1) EDTA calibration curve (5-50 µg/mL), (2) positive control (green tea), (3) RSP 
extract 1 mg/mL, (4) RSP extract 0.5 mg/mL, (5) sinapine 120 µg/mL, (6) sinapine 60 
µg/mL and (7) negative control 
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A4 Cell Protective Properties of RSP Extract in 
SH-SY5Y Neuroblastoma Cell Line 
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Figure A9| MTT reduction by sinapic acid in a cell free system 
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Figure A10 | Morphology of cells under treatment with RSP extract 
Concentrations 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0 and 5.0 mg/mL from top left to 
bottom right (40x magnification, picture size adjusted to fit page)
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Figure A11| IC50 determination of the RSP extract 
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Figure A12| Raw data obtained from flowcytometry, showing Events 
(number of cells) related to their fluorescence intensity on a 
logarithmic scale (FL1 LOG) 
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Figure A13| ROS production in SH-SY5Y cells caused by different 
concentrations of RSP extract (0.25-1.0 mg/mL) 
Statistical significant difference determined using One-way ANOVA and Bonferroni’s 
multiple comparison analysis compared to media control: no significant differences, 
n=3 
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Figure A14|MTT assay neostigmine, no significant differences 
between all tested concentrations 
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A5 An in vivo Study of the Antioxidant and 
Neuroprotective Properties of RSP Extract in 
C. elegans Nematode Models 
 
Gene: ace-1 
Chromosome: X 
Variation type of mutant: allele deletion (608bp) 
red = mutation  
actg = flanking sequence view wild type, with 250 bp flanks 
green = chosen primer region 
 
>ok663 wild type, with 250 bp flanks 
gttcctagttttgctcaacgtagatatcatgttcaaatagaatcgcatataaaataaaataaaataaaacgaaatcac
ctattcttatgatcatatttttctttttgattttcgattttttcgttgtttccttgtcaccttgcgtcatcgtttcccttggtttata
cttggcccagatggtgaaaaaggccattaggatcaagacgtcacatttttccacatgtgtggctgctggacccggga
aaaatctgaaatttgtttatatttttagatcgcaaaatatacacaatctgcgaaattccttcttgtgatctacagctctcc
cggcggtccaaacgattatgatttgttgaagaagcatgcgaaattccttactattcttcatttttctgccttcggtaaatt
tttctttgattttgcattttaaattggcatttgatttatttaatatttttttaacatttaagcaaaaatacactcataatgatc
caaaacaaccaAATATCATAATAAAACACTCCTAAAAGATTTTTCATAATATCCTGTCAAAATT
TTGAAAAATAAGAACTTTTGAGGAAATCCAAAGCAGTTTTGCATGTTCACACCCCTACAAT
GTTTTAATGAATGAATAAGTAAAACAAAATTAAAGTATAAAAAATGTAGGAAAAAATTTTT
TTTGGTCGACTTCCAAAATTATGAGCTTCAAAAACTGAGTAATTATCACTTTTTGACAGTA
AATAAAAAATTTTCGAAATTTTTAAGAAACGTTTTATTATGATATTCGGTCATTTTGGCACT
ATAGAAATAGTTTAAAACAGTTTCCCCACTGGCGCTACCCCACCTTTGAAAAAAATTTAGA
AATTTTCTGGTAAGCGAAAATTAAATACACTAGTTTTTTTGGCAACAAACTTCTAAATTATA
TTGGAAACTAATTTGATAATTGTTTAAAATTTAAGATGTTTCTAAATGTTCAATGACTTTTT
TTGCAAATTTTCGAAAAAGTTTAAAATTTTAAATTTCTAACTGCGATCGAAATTAAACCATA
TATAAATACTGTTTATTGAATTTTTTGGTTTTTTGATTTAAAAATTCTTTTGAGTACATATGT
agtattatacataaatagcaaatactcttttcaaaaatcacactaatttgagtttgaaattgttttgattattttaaaaat
atataaacgtttttttttctgtttcagacgatattagctgttgatctcattcacctccatgatggctccccactttttggcga
agaagttttatcacaaaccggtaaaccattgacaaggtttcaaggtattccatttgcagaaccaccagttggcaatct
caggtacatttcttatatgcatgcgcaaactcattgtatcatttttgcaggtttaaaaaaccgaaaccaaagcaaccat
ggagaatacctttgaatgcgacaactccaccgaacagttgtattcagagtgaggacacttactttggagacttttatg
gttccactatgtggaatgccaacactaaattatccgaagattgtctgtatttgaatgtgtatgtgcctggaaaagtgg
acccaaataagaaattggctgta 
>ok663 ok663 with 250 bp flanks 
gttcctagttttgctcaacgtagatatcatgttcaaatagaatcgcatataaaataaaataaaataaaacgaaatc
acctattcttatgatcatatttttctttttgattttcgattttttcgttgtttccttgtcaccttgcgtcatcgtttcccttggtt
tatacttggcccagatggtgaaaaaggccattaggatcaagacgtcacatttttccacatgtgtggctgctggacc
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Figure A15|ace-1 molecular details (sequence reported on (+) 
strand) 
 
cgggaaaaatctgaaatttgtttatatttttagatcgcaaaatatacacaatctgcgaaattccttcttgtgatctaca
gctctcccggcggtccaaacgattatgatttgttgaagaagcatgcgaaattccttactattcttcatttttctgccttc
ggtaaatttttctttgattttgcattttaaattggcatttgatttatttaatatttttttaacatttaagcaaaaatacactc
ataatgatccaaaacaacca|agtattatacataaatagcaaatactcttttcaaaaatcacactaatttgagtttg
aaattgttttgattattttaaaaatatataaacgtttttttttctgtttcagacgatattagctgttgatctcattcacctc
catgatggctccccactttttggcgaagaagttttatcacaaaccggtaaaccattgacaaggtttcaaggtattcc
atttgcagaaccaccagttggcaatctcaggtacatttcttatatgcatgcgcaaactcattgtatcatttttgcaggt
ttaaaaaaccgaaaccaaagcaaccatggagaatacctttgaatgcgacaactccaccgaacagttgtattcaga
gtgaggacacttactttggagacttttatggttccactatgtggaatgccaacactaaattatccgaagattgtctgt
atttgaatgtgtatgtgcctggaaaagtggacccaaataagaaattggctgta 
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Gene: ace-2 
Chromosome: I 
Variation type of mutant: allele deletion (1470bp) 
red = mutation  
actg = flanking sequence view wild type, with 250 bp flanks 
green = chosen primer region 
>ok2545 wild type, with 250 bp flanks 
accaatttcagtgatgttatttgtgaataaattatcgattttttattgaaaattaaaaaagttcttgattgtttgttttaa
gaacatacaatttcttgaaaacatatcaatctattgataaaaattatatttttcataagatgtatttttattgattttcca
tagaaaacaaaaaaaatgtatttcaaattattgattttcatgaaaaatatcaatttttgtcataaactaatcgataaa
tttgtttaaaaattaacgatttttttggaaattttcggaaaaaatatggtagaaaaaagtgaaaagtagccgcatca
aatccctcaaaaacattttttttttacatttttcctgatatttttcagaatttctgatcaatcgatttttaaatacaaatact
ccaagcaatatctcacctgtaggtaaagtagtacatataaacatttccaaaaatgttatccgatatcaaatcagcaa
aatcaataagagagcaagtaaaaAACAAGTCTCCCAAGAATCGAGCAACTCCATCCCGATATC
GTTCTTCAGGTACATTACTAGTCGATACATGCTCATAAGAATTCATAAATGCATTCAATA
CAAGTTTCGAACCAGCAAAATATGGCATGAATGCTCTCATTGATTCTTCATAATGATCTC
GTGTAATCAGGGCTCGATTATGAGGATCTTCAGCCGATATTGTGTGATTGAATGCAAAT
CCATATTTGGGAAGTGACATGTAATAGGGTAGCCAGTATGTTCCTTCGTCTTTTACACTT
CCGAATATTATGTTCACGTCTTTTTTGAATTGCTTATTCGCCAGTTTTTGGAATACGTCG
CCCTGAAAATGTTTACGCATAGTAGGAATAATGGTAGAGTATTACGGGAACTCAAAATT
CTGAAAATCCGTACTGCACAACATATTTGACGCGCATAATATCTCGTAGCGAAAACTAC
AGTAATTCTTTAAATGTTTACTTTAGCGCTTGTGTCGATTTACCGGCTCCGATTTTCATC
GAATAAACGAATTAACGAATGAAAAAAAAACCATTAAAAATAGAGCCCGTAAATCGACA
CAAGCTCTACAGTTGTCATTTCAAGAAATACTGTAGTTTTCGCTACGAGATATTTTGCGA
GTCAATTATGTTGCGCAATACGCATTTTCAAAATTTTGAGTTCCTATGAAAACATCGCAA
AAAATTCAATATACCAGTTCTAAAAGTAGAATAATTATAGAATTTTTTTTCCAAAATTTTC
TATGATTTTTTAAAAACTCTACCGCAAAAAAATTGGCAAGACTGAATTTTTTTTTTGAATT
CCAGCGAAAATGAATGAGTTTCAATAATCAATTGCAAAATTTTTTTTTCGAAAAATGAAT
TTTCATACACTTTTGTGAAAAAAAAATGTTGAAAAAATGTTAAATTACCAATTTTCAGAAA
AGACGTAGTTCAACTCTCCAACCCCGTTAAACTTTTTTTGAGTATTTTTTTAACTTTTGAC
TTTTTTTTGTCCTTTTTTGGCCGTTTTTTAATGAAACTTTTTGACCCAATTTCGGGATGTC
CTATTTTTGCTGATTTTTTGTGTGTTTTTTCCTTTTTTCTCATTTTTTCTGGATTTTTTGAA
ATTTCTGGGAATTTCTCTTTTCTCTTGTTTTCTCCCTGCACTAACTAAACATAAGCTTAAG
CCTCGGCCTAAGCCTAAGCCTTAGCCTTTTCTTTTTCTTTACCTGGAAGAAATTGGCGTC
CGACGAAACAGGAACGTATGCAAATGTCATCGGTGGCCCAATATCTCCAGAAATATTAT
CAGCTTCTGCTTGAACTAGATGTGCTGGAACACTTCGAAGACACTTGACAATTGCATTC
ATATCCGGTGAGCTACAGTTCACTTTTTTCGCGAGACGAAACGAAAGATCAAGCATTGT
TGGTGGAGTTGCTGATGCCCATGAGTTGATTATTGAGCCACTCTTAAAAgtgttagagagtg
ataattggaaaattgatggtgtaaacctttgcaataatatttctaaaatatttatgtgaattcggggcaaacagatg
agcagtcgtcgaggcggatccagctgattctccgaacaaagtgacccgtgaccgatcgcctccgaatgctccgat
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Figure A16 | ace-2 molecular details (sequence reported on (+) 
strand) 
 
attctcgtgaacccaacgaagagcaagctgttgatccattaagcccatgtttccttgaatcggagaatcatctcc
gaagtagagaaatccgaatgggcccagcctgaaaaaaaatgcgtacgaagttcaggcttagaaggagatcg
gtgctcatgaataggaaacttggccacaagttctaatagtaagtttgcaaattgcaggtataaaattcttatattt
ttttgttctaaaatcatcccactgaaaatgagaaaactgcctatatttctctcaaagaaacactgctaggcaggc
aagtacgcctgtctatcattagagcctaacctaacatt 
>ok2545 ok2545 with 250 bp flanks 
accaatttcagtgatgttatttgtgaataaattatcgattttttattgaaaattaaaaaagttcttgattgtttgttttaa
gaacatacaatttcttgaaaacatatcaatctattgataaaaattatatttttcataagatgtatttttattgattttcca
tagaaaacaaaaaaaatgtatttcaaattattgattttcatgaaaaatatcaatttttgtcataaactaatcgataaa
tttgtttaaaaattaacgatttttttggaaattttcggaaaaaatatggtagaaaaaagtgaaaagtagccgcatca
aatccctcaaaaacattttttttttacatttttcctgatatttttcagaatttctgatcaatcgatttttaaatacaaatact
ccaagcaatatctcacctgtaggtaaagtagtacatataaacatttccaaaaatgttatccgatatcaaatcagca
aaatcaataagagagcaagtaaaa|gtgttagagagtgataattggaaaattgatggtgtaaacctttgcaataa
tatttctaaaatatttatgtgaattcggggcaaacagatgagcagtcgtcgaggcggatccagctgattctccgaa
caaagtgacccgtgaccgatcgcctccgaatgctccgatattctcgtgaacccaacgaagagcaagctgttgatc
cattaagcccatgtttccttgaatcggagaatcatctccgaagtagagaaatccgaatgggcccagcctgaaaaa
aaatgcgtacgaagttcaggcttagaaggagatcggtgctcatgaataggaaacttggccacaagttctaatagt
aagtttgcaaattgcaggtataaaattcttatatttttttgttctaaaatcatcccactgaaaatgagaaaactgccta
tatttctctcaaagaaacactgctaggcaggcaagtacgcctgtctatcattagagcctaacctaacatt 
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Gene: gst-4, msp-38 
Chromosome: IV 
Variation type of mutant: allele deletion (1548 bp) 
red = mutation  
actg = flanking sequence view wild type, with 250 bp flanks 
green = chosen primer region 
 
>ok2358 wild type, with 250 bp flanks 
aatttgatttcaaagatttgaattcttccctactgactcgaaaatcttcaaacgaaacatctcccagataaaacaatt
gtctgatgacttcacctaatcctcgaacatcgaaacacatcagtttatagtgaaccatttttgcagactaaaaataa
ctactctgccagtgtttaatttatagatgcaatttgtcactattttcattttatatcgaccaacccattcacacttcacta
atcgtgttaaaactcaattagtggaaaatttgaaattctatgaaactttcatttgcgacaaaagattgttgttttcttc
aaaccaaaaatttatcaatgggaaaatgagatagacaagaactgggaaaaaagtcgaggttaataatttaaag
aaatattgaatattcggcgccataatattaacgaaaataaccaaaatatgcccaattattatccaaaaagattaga
agttggcaaaccttgggcaagaatttccagagattgCACTAAAGTTGTAGCCAAGTTTGATCCAACT
TTATCCAATCTTTTACTAAAATTATCCTTAAGACTATTTAAATTTTAGATAGAGAATTGGC
GAGAGTTAGATCCCACTTGGATATGACTTATAGTTAGCCTAACCTGAAGCTATTGCTTG
CTTGATCATTTGGTTTATCGCTTTGCTACTTGGATAACCAGCTCCAATAGTTGTTATTTT
TGCTTTTGTCATCATTTTTCCACGATTTACACTCTCAAGTGAAACCAACTGTTCTTTGAT
GCCAGACGATGACATTACACTTGATAAGAAAATATATATAAACTGGAATTAAAAACAAT
TGATACATCGATTCAATTACTGAATTCTAATTATGCCAAACTATAAGCTATTGTATTTTG
ATGCTCGTGCTCTTGCTGAGCCAATCCGTATCATGTTTGCAATGCTCAATGTGCCTTAC
GAGGATTATAGAGTTTCAGTGGAAGAATGGTCAAAGCTGAAGCCAAGTGAGTGAAGCC
ATGATTATTTTTATAACAATTTTCAACTTTTCAAATTTCCAGCGACTCCATTTGGCCAGC
TTCCCATTTTACAAGTCGATGGAGAACAATTCGGTCAGTCAATGTCTATCACAAGATAC
TTGGCAAGAAAATTTGGTAAGGTTTTGTTGTTTTTCTTTTTAAAATGTTTAAACATCTAG
GACTCGCTGGAAAAACTGCAGAGGAAGAAGCTTACGCTGATTCAATTGTAGATCAATA
CAGAGATTTCATATTCTTTTTCCGTCAATTCACTTCTTCCGTTTTCTATGGAAGTGACGC
TGATCATATTGTAAGCATTCTTAAAATAGCATCTTAATTTGGGTATCCTATTCTAGAACA
AAGTACGTTTTGAAGTTGTTGAACCAGCCCGTGATGATTTCTTGGCAATAATCAATAAG
TTCCTGGCCAAGAGTAAATCAGGATTCCTCGTTGGAGACTCATTGACTTGGGCTGATAT
TGTGATTGCTGACAATTTGACAAGTCTCCTGAAGAATGGATTCTTAGATTTCAACAAAG
AAAAGAAGTTGGAAGAGTTCTATAACAAGATTCATTCAATTCCAGAAATTAAGAATTAC
GTGGCAACAAGAAAGGATAGTATTGTTTAAAATCGAATTATTTAAGTCTGAATTATGTA
TGTAGTAAAATAATATCGTTCCTATCACGTCTCCCAGAGAGCGTAATAAATTATTATTAT
GTGTTTATCCTGAAGCACCGAACTATCTAATTATCAAATATCTTTGAAAATATTAAAATG
TTATTCTTAAAGATCCAGTTTGGGAAAAACTATGGCAGTGACAGAAAGTGGCAGGATTT
GAGTAATTGGCATTTTATTTTTATTATTATACAAAACTTGTTCGCTTGAGTCTTAATAAAT
ATTCAATCTGCAGATTAAAACAGAAAAACAGAACATATACTTGGAAAAAGTTTATTGTTT
AGAAACCCAGTTCACACATCCTATGGATTGTACTCGATTGGAAGGTTCTTGCGACGAAC
CATACCGTCTCCTTGGAACCATTCACGACGgaattgtttggcagcgccatccggggtgttggtccac
tcaacagtgatacggtcgttgttggtatcctcttgtccgaaggcaaaagcatcgcaggaaacagcaagaagcac
agcttcctttgggtcgaaaactccacatggtggatcaactccaagtctcttcatattggtggtcttgataccatatcc
aatacgacgagccgatgagttgatcaccttgatgtggtcggtgtgcttgtcatcgtatggagcattgaagacaatc
ttggtacccggttgggtttggatgtctcctggtgggacggattgggccatggcgacttgttgaaggagttatgaga
actcgcactgaagattatgacaaaatctgcccaatttatagcaagcttctcatcactgccccagatctttgttctaga
tttgtcatgtagagttcacagaaaaatggaaaatagttatttagaataatgatgaatttgatttattctagaaactc
gtta 
 
>ok2358 ok2358 with 250 bp flanks 
aatttgatttcaaagatttgaattcttccctactgactcgaaaatcttcaaacgaaacatctcccagataaaacaatt
gtctgatgacttcacctaatcctcgaacatcgaaacacatcagtttatagtgaaccatttttgcagactaaaaataa
ctactctgccagtgtttaatttatagatgcaatttgtcactattttcattttatatcgaccaacccattcacacttcacta
atcgtgttaaaactcaattagtggaaaatttgaaattctatgaaactttcatttgcgacaaaagattgttgttttcttc
aaaccaaaaatttatcaatgggaaaatgagatagacaagaactgggaaaaaagtcgaggttaataatttaaag
aaatattgaatattcggcgccataatattaacgaaaataaccaaaatatgcccaattattatccaaaaagattaga
agttggcaaaccttgggcaagaatttccagagattg|gaattgtttggcagcgccatccggggtgttggtccactc
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Figure A17 | gst-4 (ko) molecular details (sequence reported on (+) 
strand) 
 
Table A5| Recipes for C. elegans maintenance 
Solution Compound 
Weight/ 
Volume 
Nematode Growth Media (NGM) 
-1 L 
NaCl 3.0 g 
Bacto peptone 2.5 g 
Bacto agar 17 g 
NGM complete 
(for pouring plates) 
~1 L 
Autoclaved NGM 1.0 L 
KH2PO4 (1 M, pH 6, 0.2 µm 
filtered) 
25 mL 
Cholesterol (5 mg/mL in 
ethanol) 
1.0 mL 
MgSO4 (1 M, 0.2 µm filtered) 1.0 mL 
CaCl2 (1 M, 0.2 µm filtered) 1.0 mL 
s-medium (basal) 
-1 L 
NaCl 5.85 g 
K2HPO4 1.0 g 
KH2PO4 6.0 g 
Cholesterol (5 mg/ml in 
ethanol) 
1.0 mL 
Trace metal solution 
-500 mL 
FeSO4*7H2O  0.346 g 
Na2EDTA  0.93 g 
MnCl2*4H2O  0.098 g 
CuSO4*5H2O  0.012 g 
ZnSO4*7H2O 0.144 g 
Potassium citrate (1M) 
-100 mL (pH 6) 
Citric acid monohydrate 21.01 g 
KOH (for pH) ~17 g 
s-medium (complete) 
-40 mL 
s-medium (basal) 
38.96 
mL 
MgSO4 (1 M, 0.2 µm filtered) 120 µL 
CaCl2 (1 M, 0.2 µm filtered) 120 µL 
Trace metal solution  400 µL 
Potassium citrate 400 µl 
Luria Broth (LB) 
-1 L 
Bacto tryptone 10 g 
Bacto yeast 5.0 g 
NaCl 10 g 
M9 
-1 L 
Na2HPO4*7H2O 5.8 g 
KH2PO4 3.0 g 
NaCl 5.0 g 
MgSO4*7H2O 0.25 g 
Freezing solution 
-100 mL 
NaCl  0.58 g 
KH2PO4 (1 M, pH 6, 0.2 µm 
filtered) 
5 mL 
Glycerol 24.0 mL 
aacagtgatacggtcgttgttggtatcctcttgtccgaaggcaaaagcatcgcaggaaacagcaagaagcacag
cttcctttgggtcgaaaactccacatggtggatcaactccaagtctcttcatattggtggtcttgataccatatccaat
acgacgagccgatgagttgatcaccttgatgtggtcggtgtgcttgtcatcgtatggagcattgaagacaatcttg
gtacccggttgggtttggatgtctcctggtgggacggattgggccatggcgacttgttgaaggagttatgagaact
cgcactgaagattatgacaaaatctgcccaatttatagcaagcttctcatcactgccccagatctttgttctagattt
gtcatgtagagttcacagaaaaatggaaaatagttatttagaataatgatgaatttgatttattctagaaactcgtt
a 
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Made up to 100 mL with 
water 
~ 
Freezing solution  
(complete, prepare on day of 
freezing) 
Freezing solution 100 mL 
MgSO4 (1 M, 0.2 µm filtered) 30 µL 
Bleaching Solution 
-10 mL 
Bleach 2.0 mL 
 NaOH (1M) 2.5 mL 
 dH2O 5.5 mL 
Note(s):NGM and LB were autoclaved; all other solutions are filtered (0.2 µm, 
Corning™ filter system) to sterilize, all solutions were thereafter handled using sterile 
techniques (flame/flow chamber) 
 
PCR optimization for ace-1/ace-2 C. elegans strain 
For the ace-1 PCR optimization, a usable mix of primers and the optimal 
annealing temperature for the PCR had to be determined. For this, three 
different PCR primer mixes were used initially (Mix 1: for_1 and rev_2; Mix 2 
for_1 and rev_1; Mix 3 for_1, rev_2 and rev_1), to determine if it would be 
possible to use a mixture of all three primers in the PCR. To determine the 
optimum annealing temperature, gradient temperatures from 53.1-59.8°C 
were tested.  
The lowest temperatures from 53.1-56.7°C show too much unspecific binding 
(extra bands at 300 bp and below 250 bp on top gels Figure A18). At 
annealing temperatures, 59.1 and 59.8°C the heterozygous band at 396 bp 
started to lose its intensity, which initiated the continuation of further PCRs 
with 58.4°C as annealing temperature. Furthermore, the latter two 
temperatures were also omitted due to the appearance of a contamination 
visible in the gels blank (B), thus making the validity of the gel questionable. 
Table A 6.1 shows the expected bp lengths for the three genotypes and for 
each mix. At for example 54.2°C, in Mix 1 bands occur for the mutant strain 
(-) at about 400 bp (expected) as well as below (~300 and 200bp), the latter 
were not expected. These nonspecific bands disappeared with an increase in 
annealing temperature. Starting at 58.4°C the anticipated bands for Mix 1 
and 2 were present (Table A 6.1). For Mix 3 however the 1004 bp band was 
missing for both, the wt (+) and the heterozygous (+/-) animals. That had 
prompted further PCRs using both Mix 1 and Mix 2, and not Mix 3 (containing 
all three primers) on its own. At annealing temperatures, 59.1 and 59.8°C 
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the heterozygous band at 396 bp started to lose its intensity, which initiated 
the continuation of further PCRs with 58.4°C as annealing temperature. 
Furthermore, the latter two temperatures were also omitted due to the 
appearance of a contamination visible in the gels blank (B), thus making the 
validity of the gel questionable. 
Table A 6.1| Expected DNA length* for the three different genotypes 
MIX WT (+) MUT (-) HET (+/-) 
1 263 - 263 
2 1004 396 396, 1004 
3 263, 1004 396 263, 396, 1004 
Note(s): *all lengths given in bp 
  WT= wild type for the ace-1 gene 
  MUT= mutant, knock out for ace-1, 
  HET= heterozygous for the ace-1 gene 
The same procedure was adopted with the primers obtained for ace-2, using 
only Mix 1 and Mix 2, to save time and master mix. The obtained DNA gels 
also showed some nonspecific binding for the lowest annealing temperature 
(53.1°C), while all the other temperatures showed the expected bp lengths 
for the respective genotypes. To be able to run the PCR tubes of ace-1 and 
ace-2 crosses together in one thermocycler (time saving), the same 
annealing temperature as for ace-1 (58.4°C) was chosen for ace-2. The gel 
obtained during PCR optimization for this temperature is depicted in Figure 
A19. 
After optimising the primer mixtures and the PCR annealing temperature, the 
same settings were used for all the subsequent PCRs for the backcrosses 
(ace-1 and ace-2) as well as for the crosses between the two different 
mutants (ace-1/2 with AT3q130). 
 
Backcrossing of mutant strains (ace-1/2) 
As described (5.2.2.3 Backcrossing and creation of double mutant strains-
“worm crossings”) mutants (ace-1 and ace-2) obtained from the CGC were 
first back crossed with N2 animals. After the second backcross (2xBC, Figure 
5.17, p.297), first the heterozygous animals had to be identified. The two 
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DNA gels obtained after the PCR amplification and gel electrophoresis are 
shown in Figure A20. In the gels, the bands obtained for single worms 1-9 
(10 was lost in agar) are presented as well as blank controls (B) and controls 
for all possible genotypes (WT, mut and het). As can be seen in Figure A20, 
all 9 animals were found to be heterozygous, this is due to the fact that the 
ace-1 gene is located on the X-chromosome in C. elegans. For the ace-2 
mutants all three genotypes were found and one heterozygous plate was 
chosen. In the case of ace-1 (Figure A20) it was decided to pick one of the 
plates with progeny from worm 5-9 due to contamination found on gel A in 
the blank (B1).   
From the chosen plate (e.g. #5), 16 or more worms (L4) were isolated onto 
new seeded NGM plates (60 mm) and left to produce progeny. The parental 
worms were then again subject to single worm lysis, PCR and gel 
electrophoresis, to find a plate with 2x back crossed homozygous ace-1 
mutant worms (Figure A21). 
In the case of the first back cross (2xBC) of ace-1 the following plates were 
identified to be homozygous ace-1 mutants: plate number 1, 9 and 20 (Figure 
A21). Worms of one of the latter were picked onto fresh NGM plates for 
freezing/maintenance and 3 L4 were chosen for the second round of back 
crossings (3x and 4x BC). The same procedure was repeated twice more to 
obtain 6x back crossed ace-1 and ace-2 worms.  
Crossing of two mutants (ace-1/2 with AT3q130) 
After the final back crossing of both strains (ace-1 and ace-2), they were 
ready to be crossed with the AT3q130 strain (Figure 5.18 p.300), to 
determine whether a knockout of either of the two ace genes could improve 
the motility deficient phenotype. After crossing 13 N2 males with 3 
hermaphrodite AT3q130 animals (2 days, 15°C) and isolation of the latter (2-
3 days 20°C), 13 males were selected again from one of the plates (wt/wt; 
q130/wt) and crossed with 3 hermaphrodite, 6xBC ace-1 L4s (ace-1/ace-1; 
wt/wt). Again the 3 hermaphrodites were separated and left to have progeny 
for 2-3 days with the possible genotypes shown in Table A 6.2. 
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Table A 6.2| Genotypical outcome of crossing male optained from first 
cross (wt/wt; AT3q130/wt) with ace-1 hermaphrodite (ace-1/ace-1; 
wt/wt) 
 ace-1|wt 
wt|q130 ace-1/wt | 
q130/wt 
wt|wt ace-1/wt | 
wt/wt 
 
From one of the plates with a significant number of males, 3 hermaphrodites 
(L4) showing fluorescence ( ) under the fluorescence microscope are 
selected and isolated to produce progeny. After another 2-3 days 24 worms 
of one of the plates were isolated. Worms showing both bright 
(AT3q130/q130 ) and less bright (q130/wt ) fluorescence, were picked, 
to reduce the number of potential genotypes to 12 (Table 5.11, excluding 
animals which did not carry the AT3q130 gene), but still maintain good 
chances of having an ace-1/ace-1 genotype in one of the 24 animals. The 24 
isolated worms were left (2-3 days) to produce progeny and were then 
subject to single worm PCR and gel electrophoresis to determine their ace-1 
genotype (Figure A22).  
After determining the homozygous mutant ace-1/ace-1 genotype in the 
parent generation (plate#: 2, 6, 9, 17, 18 and 20, Figure A22) as well as the 
homozygous wt/wt genotype (1, 4, 5, 8, 13, 15) after crossing, the plates 
were observed using fluorescence microscopy. The aim of this was to identify 
plates with 100% fluorescent worms as these were homozygous mutant 
strains for the ataxin-3 gene. Plates with a mixed culture of bright, less bright 
and non-fluorescent worms were discarded (heterozygous parental worm). 
Plates found with the appropriate genotypes (ace-1/ace-1 | q130/q130 and 
wt/wt | q130/q130), were maintained, frozen and used for future motility 
assays. Wt/wt | q130/q130 worms were used as back crossed AT3q130 
control, because the crossing with the ace mutant worms could have induce 
a variation in other genes, which might change the motility behaviour.  The 
same crossing process was undertaken for ace-2 worms with AT3q130.
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Figure A18| DNA gels for PCR annealing temperature gradient and master mix optimization procedure 
 
L B 
Mix 1  Mix 2  Mix 3  Mix 1  Mix 2  Mix 3  
53.1°C 54.2°C 
L B 
Mix 1  Mix 2  Mix 3  Mix 1  Mix 2  Mix 3  
L B 
Mix 1  Mix 2  Mix 3  Mix 1  Mix 2  Mix 3  
L B 
Mix 1  Mix 2  Mix 3  Mix 1  Mix 2  Mix 3  
55.0°C 55.8°C 
56.7°C 58.4°C 59.1°C 59.8°C 
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Figure A19| DNA-gel after PCR of ace-2 gene, showing the chosen 
temperature (58.4°C) with the expected bands (ladder same as in 
Figure ) 
 
Figure A20| DNA gels depicting initial isolated hermaphrodites after 
second backcros 
Gel A: blank 1 (B1), worms 1-4, WT-wild type control and mut- mutant ace-1 control, 
gel B: blank 2 (B2), worms 5-9 and het-heterozygous control (ladder same as in Figure 
5.31 and 5.32)
58.4°C 
+  -  +/-  
Mix    1       2      1      2      1       2   
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Figure A21| DNA gels depicting single worm PCR of worm isolation 
after the second backcross, to identify homozygous 2xBC animals 
Gel A: mut- mutant ace-1 control, worms 1-8, blank 1 (B1); gel B: WT-wild type control, 
worms 9-16 blank 2 (B2); gel C het-heterozygous control, worm 17-24 and blank 3 (B3) 
 wt          9           10         11        12         13         14         15        16       B2      
mut         1          2           3           4          5          6           7           8       B1             
 het         17        18          19         20        21          22         23         24       B3      
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Figure A22 | DNA gels depicting single worm PCR of second worm 
isolation after crossing (ace-1) with AT3q130 animals, to identify 
homozygous ace-1 animals 
Gel A: worms 1-6, WT-wild type control; gel B: worms 7-12, mut- mutant ace-1 control; 
gel C worm 13-28, het-heterozygous control; gel D: worms 19-24 and blank (B); ladder 
same as in Figure A18/21 
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Figure A23 |Comparison between day 7 and day 10 old animals 
(BZ555, UA44 and UA57) 
Statistical significant difference determined using Two-way ANOVA and Bonferroni’s 
multiple comparison analysis:*p≤0.05, 3 independent experiments with n≥10 animals 
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Figure A24| Fluoresecence imaging of sod-3 reporter strain after RSP 
extract treatment (see Figure Figure 5.35) 
Top: DMSO (1%) and bottom RSP extract (4 mg/mL)  
